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A b s t r a c t
A b s tr a c t
Inflammation is a physiological response to injury, trauma or infection. The initial phase o f  
inflammation, the acute phase response (A P R ), is characterised by changes in levels o f  serum 
acute phase response proteins (APPs). These APPs are synthesised primarily by hepatocytes 
in response to several inflammatory cytokines, including interleukin-1 ( IL -1 )  and interleukin- 
6 (IL -6 ). Expression o f APP genes is known to be regulated by the C C A A T  Enhancer 
Binding Protein (C /E B P ) fam ily o f  transcription factors, which consists o f six members (a -Q . 
Several studies have implicated C /EB P 6 as an important regulator o f APP gene transcription  
during inflammation. Additionally, a number o f  cytokines and other inflammatory mediators 
modulate the expression/activity o f  C /E B P 6 during the APR. Unfortunately, the mechanisms 
by which cytokines regulate the expression o f  C /EBP5 remain poorly understood. 
Understanding these mechanisms could potentially aid in the development o f therapeutic 
strategies aimed at combating inflam m atory disease. Therefore the objective o f this project 
was to delineate the molecular mechanisms governing C /EB P5 expression in response to IL-1 
and to a lesser extent, IL -6 .
Initial investigations were designed to determine the effects o f various inflam m atory  
mediators on C /EB P5 expression in hepatocytes focusing on IL -1 , with the aim o f delineating  
the regulatory elements in the human C /EB P 5 gene promoter that were responsible for gene 
expression in response to this cytokine, and to identify the nuclear factors regulating this 
response. However, unlike endogenous C /E B P 5 m R N A  and protein expression, both o f  
which were induced by IL -1 , the activity o f  the human C /EBP8 gene promoter was not 
stimulated by this cytokine, despite being responsive to IL -6  action. Sim ilar results were also 
obtained when the actions o f  IL-1 and IL -6  on the murine C /EB P5 gene promoter were 
examined. Using the same transfection system, studies were also initiated to determine i f  the 
human C /EBP5 gene was subject to auto-regulation, as this mode o f  control is likely to play a 
significant role in regulating C /EB P6 gene expression during the A PR  and because this was a 
novel area o f investigation. Results from these studies showed, for the first time, that the 
human C /EBP8 gene is subject to auto-regulation, potentially via an indirect mechanism and 
the cw-acting elements responsible for this response were identified to within approxim ately  
200 base pairs o f the transcriptional initiation site.
Therefore, as a consequence o f  our initial findings, we adopted an alternative strategy 
for determining the mechanisms by which C /EB P 5 expression was induced by IL -1 . This  
involved investigating the signal transduction pathways involved in the actions o f  IL-1 on the 
expression o f this gene and characterising the critical components o f these pathways. 
Simultaneously, some investigations were also carried out to identify the transcription factors 
regulating endogenous C /EBP5 gene expression by IL -6 , given that this was also a novel area 
o f investigation.
With the use o f a range o f com m ercially available pharmacological inhibitors, our 
initial investigations led to the identification o f casein kinase 2 (C K 2 ), c-Jun N -term inal 
kinase (JNK) and nuclear factor-kappa B (N F -k B) as potential regulators o f  IL -1-induced  
C/EBP8 expression. The exact role o f these pathways was then further investigated using 
several independent approaches. Western blot analysis and associated kinase activation 
assays revealed that JNK is activated by IL-1 in hepatocytes, a novel finding. W ith  the use o f  
RN A  interference, /ram -activation assays and electrophoretic m obility shift assays, our 
investigations led to the identification o f  N F -k B as a key regulator o f the IL-1-induced  
C/EBP8 expression, also a novel finding. In association with this finding, we also 
investigated a role for C K 2 and JNK  in the regulation o f N F -k B activation by IL -1 .
Finally, our studies have also revealed a critical role for the S T A T  (Signal Transducer 
and Activator o f  Transcription) fam ily o f  transcription factors in the regulation o f  human 
C/EBP6 gene expression by IL -6 . Consistent w ith this finding, we also show that IL -6  action 
leads to the activation o f both STAT1 and S T A T 3  in hepatocytes.
To summarise, the studies presented here have revealed that the human C /E B P 8  gene 
is subject to transcriptional regulation by auto-activation and in response to IL-1 and IL -6  
action is induced by N F -k B and STA Ts, respectively. These studies have provided novel 
insights into the molecular mechanisms by which C /EB P5 is regulated during the A P R .
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P/CAF p300/CBP-associated factor
Pa Pascals
PAGE Polyacrylamide gel electrophoresis
PAI Plasminogen activator inhibitor
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PDGF Platelet derived growth factor
PEI Polyethylenimine
pen/strep Penicillin/streptomycin
phospho Phosphorylated
PI3K Phosphoninositide 3-kinase
PIAS Protein inhibitors of activated STATs
PIC Pre-initiation complex
Pit-1 Pituitary specific transcription factor 1
PKA Protein kinase A
PKB Protein kinase B (Akt)
PKC Protein kinase C
PKR dsRNA-dependent protein kinase/protein kinase R
PMA Phorbol 12-myristate 13-acetate
PMSF Phenylmethanesulphonyl fluoride
Pol Polymerase
PPAR Peroxisome proliferator-activated receptor
Pu Purine
PVDF Polyvinylidene fluoride
Rac Ras-related C3-botulinum toxin substrate
Raf Rous sarcoma associated factor
RANK Receptor activator of N F-kB
RANTES Regulated upon Activation, Normal T-cell Expressed and Secreted
Rap Receptor associated protein
Rb Retinoblastoma protein
RD Regulatory domain
RISC RNA-induced silencing complex
RNA Ribonucleic acid
RNAi RNA interference
RNase Ribonuclease
rpm Revolutions per minute
RPMI-1640 Roswell Park Memorial Institute-1640
rRNA Ribosomal RNA
RSV Rous sarcoma virus
RT Reverse transcriptase
RT-PCR Reverse transcriptase polymerase chain reaction
Runx-2 Runt-related transcription factor 2
s Seconds
A b b r e v ia t io n s
S6K Ribosomal protein S6 kinase (p70)
SAA Serum amyloid A
SAPK Stress activated protein kinase
SD Standard deviation
SDS Sodium dodecyl sulphate
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
SEK SAPK/ERK kinase
SH2 Src homology 2 (domain)
SHP2 Src homology 2-containing tyrosine phosphatase
siRNA Small interfering RNA
SMC Smooth muscle cell
SOCS Suppressor of cytokine signalling
SOS Son of sevenless
Sp Specificity protein
SRC-1 Steroid receptor coactivator-1
STAT Signal transducer and activator of transcription
SUMO Small ubiquitin-related modifier
SUV39H1 Suppressor of variegation 3-9 homolog 1
SV40 Simian virus 40
SW1/SNF Switching deficient/sucrose non-fermenting
TAB TAK1-binding protein
TAF TBP-associated factor
TAK1 Transforming growth factor beta activated kinase 1
TANK TRAF (TNF receptor-associated factor) family member associated NF-kB 
activator
TBB 4, 5, 6, 7-tetrabromobenzotriazole
TBE Tris-borate-ethy lenediam inetetracetic acid
TBP TATA-binding protein
TBS Tris-bufTered saline
TE Tris-ethy lened iam i netetracet ic ac id
TEMED N, N, N \N , tetramethylenediamine
TF Transcription factor
TGF Transforming growth factor
T1R Toll-interleukin receptor domain
TNF Tumour necrosis factor
Tollip Toll interacting protein
TRAF6 Tumour necrosis factor-alpha associated factor 6
TRE TPA responsive element
TRF TBP-related factor
tRNA Transfer RNA
Tyk Tyrosine kinase
U Units
UN Untreated
USF Upstream stimulating factor
uv Ultra-violet
V Volts
v/v Volume/volume
w/v Weight/volume
Xg x gravity
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Inflammation is the physiological response to tissue injury, trauma or infection 
designed to combat further tissue damage, destroy invading pathogens and activate 
cellular repair processes. Although inflammation acts as a defence mechanism, 
aberrant inflammation contributes towards the pathophysiology o f many diseases 
including atherosclerosis, asthma, inflammatory bowel disease and auto-immune 
conditions such as rheumatoid arthritis. The inflammatory response is orchestrated by 
a group o f regulatory proteins collectively known as cytokines. Cytokines exert 
multiple actions on a variety o f tissues principally by inducing changes in cellular 
gene expression. Understanding the signalling pathways by which cytokines 
modulate gene expression could potentially aid the development o f therapeutic 
strategies aimed at combating inflammatory diseases, in addition to providing a more 
in depth understanding o f the molecular mechanisms that govern the regulation o f 
gene expression. Therefore, the focus o f this thesis is the investigation o f signalling 
pathways by which the major pro-inflammatory cytokines interleukin 1 (IL-1), and to 
a lesser extent, interleukin 6 (IL-6) regulate the expression o f CCAAT Enhancer 
Binding Protein 6 (C/EBPS), a key transcription factor implicated in the regulation o f 
gene expression associated with the inflammatory response.
This introduction w ill start with an overview o f eukaryotic gene transcription and its 
regulation. A description o f the C/EBP family o f transcription factors, their biological 
actions and a discussion o f their roles in inflammation w ill follow. Finally, the signal 
transduction pathways by which the cytokines, IL-1 and IL-6 mediate their affects 
w ill be considered.
1.1 T r a n s c r ip t io n
RNA polymerase II is one o f three RNA polymerases present in eukaryotic cells. It is 
responsible for the transcription o f messenger RNA (mRNA) and most small nuclear 
RNAs. As RNA polymerase II regulates the production o f mRNAs which are 
subsequently translated into proteins, this section w ill be restricted to a discussion o f 
the regulation o f transcription, as mediated by this particular polymerase (Latchman 
1998).
RNA polymerase II driven gene expression is a tightly controlled process involving 
several stages, all o f which are subject to regulation. These stages include the
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transcription o f DNA into mRNA, modification o f the mRNA, export o f the m RNA 
from the nucleus to the cytoplasm and finally, translation o f the mRNA into a specific 
protein. In addition, it should be noted that regulation o f gene expression is subject to 
the affects o f other parameters, such as mRNA and protein stability. It is necessary 
for gene expression to be a tightly regulated process because it controls the 
development and differentiation o f an organism, it is the terminating point o f many 
signal transduction pathways and it continually reshapes the cell in response to 
metabolic needs and environmental stimuli.
RNA polymerase II driven gene transcription is dependent on the co-ordinate 
interaction o f specific regulatory proteins (/ram-acting factors) with numerous DNA 
sequence elements (c/.v-acting elements). These DNA sequence elements are usually 
located in the 5' region o f a gene upstream from the transcriptional initiation site. The 
DNA sequences involved include the promoter region, which consists o f  core 
promoter and upstream regulatory elements and the enhancer and silencer regions that 
often function distally from the gene to induce or inhibit gene transcription, 
respectively (see Roeder 1996; Smale and Kadonaga 2003 for reviews). The 
influence o f enhancer/silencer elements is blocked by boundary/insulator elements 
(Blackwood and Kadonaga 1998; West el al. 2002). Tram-acting factors or 
transcription factors act by binding to specific cA-acting elements and subsequently 
influence transcription by interacting directly or indirectly with RNA polymerase II 
(or the associated machinery, see section 1.1.3). RNA polymerase II driven gene 
expression is supported by a group o f transcription factors often termed the general 
transcription factors. These transcription factors function by binding the core 
promoter o f a class II gene (genes transcribed by RNA polymerase II) and associate 
with RNA polymerase II in initiating transcription. Regulatory transcription factors 
function by binding cis-acting elements located upstream or downstream, proxim ally 
or distally from the core promoter and control transcription driven by RNA 
polymerase II associated with the general transcription factor machinery (see 
Orphanides el al. 1996; Roeder 1996 for reviews).
1.1.1 T h e  RNA p o l y m e r a s e  I I  c o r e  p r o m o t e r
The core promoter elements have been defined as ‘minimal DNA elements that are 
necessary and sufficient for accurate transcription initiation by RNA polymerase II in
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reconstituted cell-free systems' (Roeder 1996). The core promoter contains the 
transcriptional start site o f a gene and typically extends -35 nucleotides upstream or 
downstream from this site. There is a considerable amount o f variability in the DNA 
elements that constitute the core promoter region o f many class II genes. The core 
promoter can contain the TA T A  box, the TF1IB recognition element (BRE), the 
initiator (Inr) and the downstream promoter element (DPE) and these sequence 
elements can be found in various combinations in this region o f class II genes (Figure
1.1) (Roeder 1996; Kadonaga 2002; Smale and Kadonaga 2003). Apart from these 
core promoter elements, other motifs have also been associated with gene promoters 
such as CpG islands (Smale and Kadonaga 2003).
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■37 to -32 -31 to -26 -2 to +4 +28 to +32
BRE TA TA Box Inr DPE
TF1IB Initiator Downstream Core
Recognition
Element A G TATA AA
f f l  A
G T
Drosophila TCA T
Promoter Element
GGG
CGCC
T A T C
A AC G
i n  a
CCA T
Mammals PyPyAN PyPy 
A
G A 
G T T  C
F ig u r e  1.1 A schematic representation of the RNA polymerase II core promoter motifs (adapted from Smale and Kadonga 2003). The
diagram represents some o f the sequence elements that can contribute to basal transcription from a core promoter. Each o f these sequence motifs 
can be found only in a subset o f core promoters. A particular core promoter may contain some, all, or none o f these sequences. The TATA box is 
functional in the absence of the BRE, Inr and DPE motifs. Conversely, the DPE motif requires the presence of an Inr motif. The BRE is located 
immediately upstream in a subset o f promoters containing a TATA box. The DPE consensus was determined with Drosophila core promoters. 
The Inr consensus is displayed for both mammals and Drosophila. The arrow depicts the transcriptional start site, Py indicates a pyrimidine base 
and N denotes any base.
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1.1.2 T r a n s c r ip t io n  in i t i a t io n  a n d  t h e  g e n e r a l  t r a n s c r ip t io n  f a c t o r s
Transcription initiation is mediated through the binding o f RNA polymerase II to the 
core promoter region o f a gene, through the coordinated association o f six general 
transcription factors namely, TF II-A , -B, -D, -E, -F and -H (Orphanides et al. 1996; 
Roeder 1996). In its simplest form, eukaryotic transcription can be divided into a 
series o f ordered steps:
1) Recognition o f the core promoter elements by TFIID.
2) Recognition o f the TFIlD-promoter complex by TFIIB.
3) Recruitment o f a TFIIF/RNA polymerase II complex.
4) Binding o f TFIIE and TFIIH  to complete the pre-initiation complex.
5) Promoter melting resulting in the formation o f an ‘open’ initiation complex.
6) Synthesis o f the first phosphodiester bond o f the nascent mRNA.
7) Release o f RNA polymerase II contacts with the promoter ( ‘ promoter 
clearance’ ).
8) Elongation and termination o f the mRNA transcript (Orphanides et al. 1996).
The only general transcription factor not to be included in this assembly is TF IIA , 
which can be recruited to the complex at any stage follow ing the binding o f TFIID , it 
functions to stabilise the assembly (Orphanides et al. 1996).
Two models have been proposed and supported by various studies for the formation 
o f the pre-initiation complex (PIC). In vitro reconstitution studies support the model 
for the ordered step-wise assembly o f the pre-initiation complex, whilst more recent 
studies support the ‘ pre-formed or holoenzyme’ model o f the RNA polymerase II 
transcriptional complex. Both these models w ill be discussed briefly, together with 
more recent findings regarding RNA polymerase II driven transcription.
1.1.3 S te p w is e  a s s e m b ly  o f  t h e  p r e - in i t i a t io n  c o m p le x
1.1.3.1 Binding of T F IID  at the core promoter
The binding o f TFIID  to the TA TA  box is the first stage in the assembly o f the PIC. 
TFIID is a multi-protein complex; it comprises o f TATA-binding protein (TBP) and 
multiple TBP-associated factors or TAFs. It is the TBP subunit o f TFIID  that is 
responsible for TATA  box recognition (Hernandez 1993). TFIID  (specifically the
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TAFn250 subunit) possesses both histone acetyltransferase (HAT) and kinase 
activities (Tansey and Herr 1997). The kinase activity regulates auto-phosphorylation 
o f TFIID. TF IIA  and TFIIF are also like ly substrates for the TFIID kinase (Dikstein 
et al. 1996; Solow et al. 2001). The auto-phosphorylation function o f TFIID  is likely 
to play a regulatory role in transcription (Wassarman and Sauer 2001). HAT activity 
o f TFIID may regulate changes in chromatin structure to facilitate binding o f other 
general transcription factors to the PIC (Tansey and Herr 1997).
1.13.2 Binding of T F IIA  and T F IIB
The interaction between TBP and the TA T A  element is stabilised by the binding o f 
TFIIA and TFIIB  to the complex. T F IIA  binds to the TBP-DNA complex and 
increases the affin ity o f TBP for the TA T A  box. TFIIB  is important in providing a 
physical link between TFIID  and the RNA polymerase II/TFIIF complex at the core 
promoter. Additionally, some eukaryotic core promoters contain the BRE which is 
reported to stabilise the interaction between TBP and TFIIB on DNA (Orphanides et 
al. 1996; Smale and Kadonaga 2003).
1.133 Recruitment of RNA polymerase I I /T F IIF  to the PIC
The binding o f TFIID  and TFIIB at the core promoter is a prerequisite for RNA 
polymerase II recruitment to the PIC. However, RNA polymerase II cannot stably 
associate with the TF IID /TFIIB /TFIIA  subassembly without TFIIF. TFIIF increases 
the specificity and efficiency o f RNA polymerase II transcription. Specifically, TFIIF 
prevents spurious initiation by inhibiting the binding o f RNA polymerase II to non- 
promoter sites on DNA (Orphanides et al. 1996; Roeder 1996).
1.1.3.4 Binding of T F IIE  and T F IIH  completes the PIC
RNA synthesis is only initiated when TFIIE  and TFIIH  are recruited to the PIC. 
TFIIE can enter the PIC following the recruitment o f RNA polymerase II and TFIIF, 
although it is likely to jo in  the PIC simultaneously with RNA polymerase II and 
TFIIF. Once TFIIE is stably associated, TF IIH  is recruited to the promoter. TFIIH  is 
a complex multi-subunit general transcription factor, with kinase and DNA helicase 
activity required for transcription initiation (Orphanides et al. 1996; Roeder 1996;
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Reese 2003). Once TFIIE and TFIIH  are recruited to the PIC, RNA polymerase II can 
initiate transcription.
1.1.4 T h e  h o lo e n z y m e . A c h a l l e n g e  t o  t h e  s te p -w is e  m o d e l o f  PIC
FORMATION
The ordered, step-wise assembly o f the PIC in the model described above has been 
challenged by the discovery o f ‘ holoenzyme’ complexes. Essentially, holoenzyme 
complexes consist o f a subset o f general transcription factors that can exist in 
association with RNA polymerase II in a preassembled form. These complexes can 
potentially bind to a promoter in a single step, rather than in a step-wise fashion 
detailed above (Bjorklund and Kim  1996; Li et al. 1996; Orphanides et al. 1996; 
Malik and Roeder 2005). Holoenzyme complexes were originally identified in yeast 
by Young and co-workers (Koleske and Young 1994; Koleske and Young 1995) and 
Kim et al. (1994). A multi-protein complex termed ‘ Mediator,’ was found in 
association with RNA polymerase II and TFIIF.
The discovery o f yeast holoenzyme complexes prompted extensive research in this 
field and it is now generally accepted that the Mediator complex is universally 
required for the expression o f almost all genes expressed in yeast (Holstege et al. 
1998). Further research eventually led to the discovery o f mammalian holoenzyme 
and Mediator complexes also (see Orphanides et al. 1996; M alik and Roeder 2005 
and references therein). The mammalian Mediator complex is believed to consist o f 
at least 28 subunits, many o f which are orthologs o f yeast Mediator subunits. Like the 
yeast Mediator complex, little is known about the detailed mechanism by which 
mammalian Mediator regulates RNA polymerase II gene transcription. However, 
what is clear is that the mechanism involves a complex network o f interactions 
between components o f the Mediator, transcriptional activators (and repressors; see 
section 1.1.8.1), RNA polymerase II, the general transcription factors and co-factors 
(Section 1.1.8.2) (Malik and Roeder 2005).
1.1.5 CELL AND TISSUE TYPE-SPECIFIC PICs
Until recently, the components o f the basal transcription machinery (that make up the 
PIC) described above, were thought to be unvarying between different cell types o f an 
organism. However, recent studies have challenged this theory and have resulted in
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the identification o f cell type-specific components o f the core transcriptional 
machinery. Specifically, cell type-specific and in some cases gene-specific homologs 
o f basal transcription factors have been identified in higher eukaryotes. Investigations 
have led to the characterisation o f T A T A  box-binding protein (TBP)-like proteins, 
known as TBP-related factors (TRFs) and a number o f tissue-specific homologs o f the 
TAF components o f TFIID  (see Hochheimer and Tjian 2003 and references therein). 
Therefore, it is now evident that complex eukaryotes contain cell/tissue-specific 
components o f the basal transcriptional machinery, increasing diversity and 
complexity o f transcription.
1.1.6 T r a n s c r ip t io n  in it ia t io n
The first stage o f transcriptional initiation requires the separation o f the D N A double 
helix, thus permitting RNA polymerase II access to the necessary promoter sites o f 
the gene to be transcribed. This process is described as ‘ promoter melting’ and is 
followed by the formation o f the first phosphodiester bond o f the nascent mRNA. 
The continuing extension o f the RNA transcript eventually disrupts RNA polymerase 
II contacts at the site o f PIC formation, in the process o f ‘promoter clearance.’ 
Promoter clearance is followed by the elongation stage o f transcription, which 
involves the continual extension o f the mRNA transcript along its D NA template. 
The transition from the ‘ initiation’ stage to the ‘elongation’ stage o f transcription is 
accompanied by covalent modification o f RNA polymerase II. Specifically, the 
carboxy-terminal domain (CTD) o f RNA polymerase II is a target for 
phosphorylation. Initiation o f RNA synthesis is accompanied by extensive 
phosphorylation o f the CTD o f RNA polymerase II. The unphosphoylated form o f 
RNA polymerase II is preferentially recruited to the PIC, whilst RNA polymerase II 
engaged in elongation is heavily phosphorylated (Orphanides et al. 1996; Roeder 
1996). As mentioned briefly before, TFIIH  possesses an ATP-dependent helicase 
activity and a protein kinase activity specific for the CTD o f RNA polymerase II. The 
helicase activity o f TFIIH is responsible for the unwinding o f DNA in the ‘ promoter 
melting’ stage o f initiation, although this also requires the presence o f TFIIE  and ATP 
(Orphanides et al. 1996; Svejstrup et al. 1996). Both TFIIE and TFIIH have also been 
implicated in ‘promoter clearance,’ although the precise role o f these general 
transcription factors in both ‘promoter clearance’ and ‘promoter melting’ has been 
disputed (see Orphanides et al. 1996 and references therein).
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1.1.7 RNA POLYMERASE II ELONGATION AND TERMINATION
In recent years it has become apparent that transcript elongation is not simply a 
process that describes the addition o f ribonucleoside tri-phosphates to the growing 
mRNA chain. On the contrary, the process is a dynamic, highly regulated stage o f 
transcription which can control multiple stages required for the maturation o f mRNA. 
These processes include; pre-mRNA capping, splicing, 3’ -end processing (addition o f 
a poly-A tail), and mRNA export. Pre-mRNA processing events are believed to be 
coupled with the elongation process itself, for which the CTD o f RNA polymerase II 
is required (Shilatifard 1998; Sims et al. 2004; Hirose and Ohkuma 2007).
Transcriptional termination is defined as cessation o f RNA synthesis, where the RNA 
polymerase II elongation complex dissociates from the DNA template to release the 
newly transcribed mRNA. Transcription termination is necessary for maintaining 
active cellular RNA polymerase II pools and to prevent erroneous transcription o f 
downstream genes from the elongating RNA polymerase II. The exact molecular 
mechanisms governing the termination process are still under investigation (Sims et 
al. 2004; Gromak et al. 2006).
1.1.8 DNA SEQUENCE ELEMENTS AND TRANSCRIPTION FACTORS INVOLVED IN THE  
REGULATION OF TRANSCRIPTION
As described previously (Section 1.1.1), ‘ the core promoter sequence elements are 
sufficient to direct accurate transcription initiation by RNA polymerase II in 
reconstituted cell-free systems’ (Roeder 1996). This type o f transcription is not 
dependent on the presence o f regulatory transcription factors (e.g. activators; section
1.1.8.1) and is often referred to as ‘ basal’ transcription (Orphanides et al. 1996). 
However, in vivo the situation is quite different. This is mainly because in a cell, 
DNA is packed into chromatin and this generally results in transcriptional repression. 
Transcription is triggered by regulatory transcription factors that bind to specific DNA 
sequences (distinct from the core promoter) and interact with the RNA polymerase II 
general transcription factor machinery (bound at the core promoter) to induce the 
expression o f a gene. Therefore transcription that occurs in a cell is referred to as 
‘activated transcription’ . Hence, ‘ basal’ transcription does not occur in vivo, but is a 
term used to describe transcription in vitro  (Orphanides et al. 1996).
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The additional DNA sequence elements, also briefly mentioned in section 1.1, 
involved in the regulation o f transcription are represented in Figure 1.2. It is worthy 
o f note that these sequences bind transcription factors that have both positive and 
negative influences on transcription.
SILENCER INSULATORENHANCER PROMOTER GENE
FIGURE 1.2 R egulatory c/s-acting elements involved in the control o f eukaryotic  
gene transcrip tion . Broken lines indicate activating (+++) or repressive (— ) 
influence on gene transcription by enhancer or silencer elements respectively, often 
located distally from the promoter o f a class II gene. Insulator/boundary elements are 
thought to function as transcriptionally neutral DNA elements that insulate/block 
(indicated by thick vertical lines) the spreading o f the positive or negative influences 
o f enhancers and silencers respectively. The arrow indicates gene transcription from 
the transcriptional initiation site.
Proximal to the transcriptional start site, a number o f sequence elements make up the 
promoter region o f a gene. This region contains the core promoter elements and also 
upstream promoter elements. The upstream promoter elements (approximately -50 to 
-200bp relative to the transcriptional start site), contain multiple binding sites for a 
range o f different transcription factors. By binding to their specific sequence 
elements, these transcription factors regulate gene transcription by influencing the 
formation o f the PIC at the core promoter (see below, section 1.1.8.1) (Latchman 
1998).
Enhancers were originally identified as DNA sequence elements that positively 
influence gene transcription in a manner that is independent o f their orientation and 
distance, relative to the transcriptional start site o f the gene (Khoury and Gruss 1983). 
Like the promoter region, enhancers are composed o f DNA motifs that bind 
transcription factors. Regulatory transcription factors that bind to enhancer elements 
are able to interact with protein complexes formed at the promoter and thus positively 
influence gene transcription (Latchman 1998). Interactions between enhancer-bound 
transcription factors and those bound at the promoter are important because they 
influence whether the enhancer acts at the correct gene promoter, as enhancers often 
act over a large stretches o f DNA. These interactions are particularly significant
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when the enhancer must only act on one o f many promoters in its immediate vicin ity. 
Blackwood and Kadonaga (1998) proposed two possible mechanisms by which 
enhancer-promoter selectivity may be achieved. In the first model, it was suggested 
that there may be selective interactions between enhancer bound transcription factors 
and those bound at the promoter o f the gene which is to be transcribed. In the second 
model, they propose that boundary/insulator elements could negatively influence 
unwanted promoter-enhancer interactions. Silencer elements act in a similar fashion 
to enhancers but as the name suggests these elements negatively influence gene 
transcription (Jackson 1991).
1.1.8.1 Regulatory transcription factors-activators and repressors
The general transcription factors and their role in RNA polymerase II-mediated 
transcription have been discussed in some detail above. Although the general 
transcription factors are important in regulating RNA polymerase II-mediated gene 
transcription, other transcription factors also known as transcriptional activators and 
repressors are vital for the control o f cell/tissue-type specific and regulated gene 
transcription.
Activator proteins can regulate the synthesis o f an mRNA molecule by a number o f 
different mechanisms (Orphanides et al. 1996);
1) By removing repressor molecules from promoter DNA.
2) By recruiting general transcription factors/RNA polymerase II to a promoter.
3) By inducing conformational changes w ithin the PIC.
4) By inducing covalent modifications o f proteins in the PIC.
5) By stimulating promoter clearance and elongation.
Transcriptional repressors can be classified as ‘ active’ or ‘passive’ repressor proteins 
(Thiel et al. 2004). Active transcriptional repressor proteins directly target chromatin 
assembly/organisation. Specifically, active repressors (e.g. retinoblastoma protein) 
can recruit histone deacetylases to a gene promoter and histone deacetylation results 
in subsequent gene silencing. Others can induce gene silencing via histone 
methylation by histone methyltransferases (e.g. SUV39H1) and heterochromatin 
formation. By contrast, passive repressor proteins do not possess an intrinsic 
repressive activity. Rather, these proteins inh ib it RNA synthesis by competing with
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activators for DNA binding. They can act as dominant-negative inhibitors (e.g. 
inducible cAMP early repressor-ICER) by forming inactive heterodimers w ith 
transcriptional activators, essentially neutralising the positive effect o f the activator by 
inhibiting its DNA binding or trans-achvalion potential. Passive repressor proteins 
can also sequester co-activator molecules, preventing them from binding to the 
cognate activator proteins. Hence, passive repressor proteins act by regulating D N A- 
or protein-protein interactions (see Thiel et al. 2004 and references therein).
1.1.8.2 Co-factors. Accessory proteins to transcription factors
Co-factors are accessory proteins that interact w ith DNA-bound transcription factors 
and play a critical role in the action o f these transcription factors. Transcriptional co- 
factors can be subdivided into co-activators, which mediate gene activation and co- 
repressors, which inhibit gene transcription (Latchman 1998). A variety o f other co­
activator molecules exist to facilitate activator-dependent transcription such as CBP 
(CREB-binding protein). CBP was orig inally defined as a co-activator pivotal for 
cyclic AMP-mediated activation o f the transcription factor, CREB (cAMP responsive 
element binding protein). Subsequently, it has been demonstrated that CBP and p300 
(a close relative o f CBP) are essential co-activators for a variety o f other transcription 
factors such as myogenic differentiation antigen (MyoD), activator protein-1 (AP-1), 
p53 and the C/EBPs (Latchman 1998; Kovacs et al. 2003). CBP is believed to 
activate gene transcription by recruiting basal transcription machinery (TFIIB , TBP 
and RNA polymerase II), through modifying chromatin structure via histone 
acetylation and also by recruiting other histone acetyltransferases such as steroid 
receptor coactivator-1 (SRC-1) and p300/CBP-associated factor (P/CAF) (see Kovacs 
et al. 2003 and references therein). Additionally, a variety o f co-repressor molecules 
have also been identified and characterised. NCoR is an example o f a nuclear 
receptor co-repressor and is involved in recruiting histone deacetylases to induce gene 
silencing (Burke and Baniahmad 2000).
1.1.9 C la s s i f ic a t io n s  o f  t r a n s c r ip t io n  f a c t o r s
On the basis o f the structure and their DNA-binding domains, it has been possible to 
classify transcription factors into families (Harrison 1991; Pabo and Sauer 1992; 
Latchman 1998). The DNA-binding motifs that define these families are the helix- 
tum-helix m otif (e.g. X repressor, catabolite activator protein), the related POU
13
C h a p t e r  o n e  G e n e r a l  I n t r o d u c t io n
domain (e.g. Pit-1, Oct-1 and Oct-2), the zinc finger m otif (e.g. T F IIIA , steroid 
receptors, Spl), the helix-loop-helix m o tif (e.g. E12/E47 and myogenic regulatory 
factors including MyoD) and the basic leucine zipper m otif or bZIP (e.g. C/EBP, AP- 
1 and CREB). DNA-binding motifs can be used to classify major groups o f 
transcription factors, however not all transcription factors can be categorised this way. 
For example, the major transcription factors p53 and NF-kB contain similar DNA- 
binding motifs that are structurally distinct from those mentioned above (Latchman 
1998).
This next section w ill discuss the family o f regulatory transcription factors belonging 
to the bZIP classification, namely the C/EBPs. Their structure, function and 
regulation w ill be detailed, with particular emphasis on their role in the regulation o f 
gene expression during inflammation, before establishing the aims o f this study.
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1.2 C C A A T E n h a n c e r B inding P ro te in s
The first C/EBP family member was identified by McKnight and co-workers in 1988 
(Landschulz et al. 1988). Two members o f his team were working to purify what was 
then believed to be two independent transcription factors, isolated from rat liver 
tissue. As the projects matured, it emerged that both these transcription factors co- 
purified to the level o f a single polypeptide (Graves et al. 1986; Johnson et al. 1987). 
Interestingly, what was thought to be the discovery o f two very different transcription 
factors, one o f which bound to cis-acting elements containing a CCAAT motif, 
common to many RNA polymerase II promoters and the other that bound to enhancer 
core elements o f SV40, murine sarcoma virus and polyomavirus, led to the 
identification o f the same protein, now designated C/EBPa (Cao et al. 1991; 
McKnight 2001). A further five other members o f the C/EBP family were identified 
by 1992, all o f which contained the conserved bZIP domain at their C-terminus (Akira 
et al. 1990; Chang et al. 1990; Descombes et al. 1990; Poli et al. 1990; Roman et al. 
1990; Cao et al. 1991; W illiams et al. 1991; Ron and Habener 1992). The discovery 
o f these transcription factors prompted extensive investigations into their function and 
it has now emerged that the C/EBPs regulate various cellular responses including; 
growth and differentiation, aspects o f metabolism, immune and inflammatory 
processes.
There are six members o f the C/EBP family designated C/EBPa-C/EBP^ by Cao and 
co-workers (Cao et al. 1991). However, because these transcription factors have been 
identified and characterised in a number o f different species, from different 
laboratories, they have often been designated alternative names. To avoid confusion, 
the detail o f alternative nomenclature for each C/EBP family member is listed in 
Table 1.0, together with the different species from which the genes have been cloned.
15
C h a p te r  o n e : G e n e r a l  In t r o d u c t io n
T a b l e  1.0 Alternative nomenclature o f C/EBPs and the species from which they 
have been cloned.
C/EBP FAMILY ALTERNATIVE SOURCE AND REFERENCES 
MEMBER
IDENTITY
C/EBPa C/EBP, RcC/EBP-1 rat, mouse, human, chicken, bovine, Xenopus laevis, Rana 
catesbeiana, zebra fish, Podocoryne carnea
(Landschulz et al. 1989; Cao et al. 1991; Williams et al. 1991; 
Xu and Tata 1992; Chen et al. 1994; Antonson and 
Xanthopoulos 1995; Calkhoven et al. 2000; Lyons et al. 2001; 
Seipel et al. 2004; Lo et al. 2007)
C/EBPp NF-IL6, IL-6DBP, LAP, 
CRP2, NF-M, AGP/EBP, 
ApC/EBP
rat, mouse, human, chicken, bovine, Xenopus laevis, 
Aplysia, zebra fish, Paralichthys olivaceus
(Akira et al. 1990; Chang et al. 1990; Descombes et al. 1990; 
Poli et al. 1990; Cao et al. 1991; Williams et al. 1991; Katz et 
al. 1993; Alberini et al. 1994; Kousteni et al. 1998; Lyons et 
al. 2001; Tucker et al. 2002; Lo et al. 2007)
C/EBPy lg/EBP-1 rat, mouse, human, chicken, zebra fish
(Roman et al. 1990; Lyons et at. 2001)
C/EBP6 NF-IL6P, CRP3, CELF, 
RcC/EBP2
rat, mouse, human, Rana catesbeiana, bovine, ovine, 
zebra fish, Xenopus laevis
(Cao et al. 1991; Kageyama et al. 1991; Williams et al. 1991; 
Kinoshita et al. 1992; Chen et al. 1994; Davies et al. 2000; 
Lyons et al. 2001; Ikuzawa et al. 2005; Lo et al. 2007)
C/EBPe CRP-1 rat, mouse, human, ovine, Paralichthys olivaceus
(Williams et al. 1991; Antonson et al. 1996; Chumakov et al. 
1997; Yamanaka et al. 1997a; Sabatakos et al. 1998a; Tucker 
et al. 2002)
C/EBP; CHOP-10, G A D D I53 rat, mouse, human, hamster
(Luethy et al. 1990; Park et al. 1992; Ron and Habener 1992)
(adapted from Ramji and Foka 2002)
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1.2.1 St r u c t u r a l  f e a t u r e s  o f  C/EBPs
The DNA-binding m otif o f bZIP fam ily members is bipartite, consisting o f a 
dimersiation interface ‘ leucine zipper’ and a DNA binding region or ‘basic region.’ A 
consensus sequence for C/EBP binding has been determined as RTTG CG YAAY 
(R=A or G and Y=C or T) (Osada et al. 1996). A ll C/EBP proteins contain a C- 
terminal bZIP domain and with the exception o f C/EBPy, also contain activation 
and/or negative regulatory domains at their N-terminus. The C-terminus leucine 
zipper consists o f a heptad o f leucine repeats that interdigitate with the equivalent 
repeats o f the dimer partner, together assuming a coiled-coil configuration o f a- 
helices. It is the electrostatic interactions between amino acids along the dimerisation 
interface that determine the specificity o f  dimer formation. Importantly, dimerisation 
is a prerequisite o f D NA binding and D NA binding is mediated through a basic 
stretch o f amino acids (approximately 20), immediately upstream o f the leucine 
zipper, which also adopt an a-helical configuration (Figure 1.3). Specificity o f DNA 
binding is mediated by three amino acids that lie along the DNA-protein contact 
surface (see Lekstrom-Himes and Xanthopoulos 1998; Ramji and Foka 2002 and 
references therein). The spacing between the basic and leucine zipper regions is 
critical for binding activity, w ith alterations abolishing activity (Agre et al. 1989).
In contrast to the highly conserved C-terminal bZIP domain, the N-termini o f C/EBP 
proteins are quite divergent (less than 20% sequence identity in common), except for 
certain regions identified as activation domains. Functionally, the activation domains 
interact with various components o f the basal transcription apparatus and stimulate 
transcription (Nerlov and Z i f f  1994; W illiams et al. 1995; Williamson et al. 1998; Ji 
et al. 2003). N-termini o f the C/EBP proteins have also been proposed to contain 
‘negative regulatory domains,’ the precise details o f which are still under 
investigation (Pei and Shih 1991; W illiamson et al. 1998; Angerer et al. 1999; Tang 
and Koeffler 2001). However, a more recent study by Kim et al. (2002a) suggests 
negative regulatory domains o f C/EBPs are targets for sumoylation (see section 
1.2.5).
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FIGURE 13 Schematic representation o f C/EBP dimer formation (adapted from 
Wedel and Ziegler-Heitbrock 1995). ZIP represents the leucine zipper domain; b 
indicates the basic DNA-binding domain and AD the activation domain.
1.2.2 C/EBP HOM O- AND HETERODIM ERISATION AND INTERACTIONS W ITH  OTHER  
BZIP TRANSCRIPTION FACTORS
The numbers o f transcription factors containing a C/EBP component in various 
tissue/cell types can be considerably diverse. There are a number o f contributing 
factors that allow this phenomenon to occur. Firstly, this is partly because certain 
C/EBPs may exist as several isoforms, as is the case with C/EBPa, C/EBPp and 
C/EBPe (see section 1.2.6 and Figure 1.4). C/EBPa can exist as two isoforms o f 
42kDa and 30kDa in size, with the 42kDa protein possessing a higher activation 
potential than the shorter 30kDa protein (Lin et al. 1993; Ossipow et al. 1993). 
Similarly, C/EBPp exists as three iso forms; 38kDa (LAP*-liver-enriched 
transcriptional activator protein), 35kDa (LAP) and 20kDa (LIP-liver-enriched 
inhibitory protein), with LAP and LIP predominating in cells. LAP contains both 
bZIP domain and activation domains, whereas LIP only possesses the bZIP domain 
(Descombes and Schibler 1991; Xiong et al. 2001). C/EBPe exists as at least four 
different isofoms (32kDa, 30kDa, 27kDa and 14kDa) and the activation potential o f
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the 32kDa is greater than that o f the 30kDa isoform, whereas the smallest isoform 
(14kDa) lacks an intact activation domain (Yamanaka et al. 1997a) (Figure 1.4).
C/EBPa
C TB Pp
C /FJfy
C/F.BP* 
C LBPt
|>42
pJO
LAP
LAP
I IP
pJ2
pJH
All AD KD AD B ZIP
lllll
lllll
l l l l
] H I
r
c k b p :
p!4
m u
FIGURE 1.4. A schematic representation o f the C/EBPs w ith the ir various 
isoforms (taken from Ramji and Foka 2002). The leucine zipper o f the bZIP 
domain is depicted in yellow, with black vertical lines representing the leucine 
residues. The basic region o f the bZIP domain is blocked in red. The positions o f the 
activation domains (AD) and negative regulatory domains (RD) are shown in green 
and blue respectively. A RD is also suggested to exist in C/EBP5 (Kim  et al. 2002a), 
although this domain is not depicted in the above figure. ? indicates that the N- 
terminus o f C/EBP£ is reported to contain an activation domain but its exact position 
remains to be determined (Ron and Habener 1992; Ubeda et al. 1996). The 
mechanisms by which the various polypeptides o f C/EBPa -p  and -e are formed are 
discussed in section 1.2.6.
Secondly, given that C/EBPs must dimerise in order to regulate gene transcription, it 
is not surprising that they are capable o f forming dimers in all interfamilial 
combinations. This generates combinations o f family members with varying 
properties o f DNA binding and /ra/7S-activation potential (Akira et al. 1990; Chang et 
al. 1990; Descombes et al. 1990; Poli et al. 1990; Roman et al. 1990; Cao et al. 1991;
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Williams et al. 1991; Ron and Habener 1992; Rorth and Montell 1992; Ramji and 
Foka 2002). For example, C/EBPy and the LIP form o f C/EBPp act as dominant- 
negative inhibitors o f C/EBP function through heterodimerisation with other fam ily 
members (Descombes and Schibler 1991; Cooper et al. 1995; Parkin et al. 2002). 
This is because both these isoforms have a functional bZIP permitting 
heterodimerisation but lack trans-activation domains. Hence, heterodimers 
containing these isoforms are able to bind to their cognate promoters, owing to the 
presence o f an intact bZIP domain but are unable to positively influence transcription. 
However more recently, a role for C/EBPy (as a heterodimer with C/EBPp) in the 
positive regulation o f IL-6 and interleukin 8 (IL-8) genes has been suggested, 
although this effect is only observed in a cell type-specific manner (Gao et al. 2002).
C/EBP^ contains two proline residues in the basic region o f its bZIP domain, which 
disrupt the normal a-helical structure. The consequence o f this is that, C/EBP^ can 
readily dimerise with other C/EBP fam ily members, owing to the presence o f an intact 
leucine zipper, but these heterodimers cannot bind to cognate sequences in the 
promoters o f target genes (Ron and Habener 1992). However, C/EBP^/C/EBP 
heterodimers can bind to an alternative consensus sequence 
[PuPuPuTGCAAT(A/C)CCC, where Pu is a purine] found in the promoter regions o f 
a subset o f genes that are induced under conditions o f cellular stress and subsequently 
activate gene transcription (Ubeda et al. 1996). Therefore, C/EBP^ can either act as 
an activator or inhibitor o f gene transcription, depending on the cellular state.
C/EBPS readily heterodimerises w ith C/EBPa and C/EBPP and has a tram -activation 
potential comparable to C/EBPa and C/EBPp (Cao et al. 1991; Kinoshita et al. 1992). 
C/EBPe is also reported to heterodimerise with other C/EBP family members, 
including C/EBPS and - C, (Chumakov et al. 1997; Chumakov et al. 2007).
Furthermore, C/EBP proteins can also heterodimerise with other bZIP transcription 
factors. The existence o f heterodimers formed between members o f the C/EBP family 
and the CREB/ATF family o f bZIP transcription factors (e.g. ATF-2, ATF-3, ATF-4, 
C/ATF and CREB) has been reported (Valle jo et al. 1993; Shuman et al. 1997; 
Wolfgang et al. 1997; Ross et al. 2001). For example, C/EBPy and C/EBPe dimerise 
with ATF4 (Vinson et al. 1993; Chumakov et al. 2007) and C/EBPa and -p can 
dimerise with C/ATF (Vallejo et al. 1993). Cross-dimerisation o f this nature results
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in changes in the binding specificity o f these transcription factors. C/EBP-ATF 
heterodimers bind to a ‘C/EBP-ATF composite site’ in promoters o f regulated genes. 
Heterodimers bind to an asymmetric sequence composed o f one consensus half-site 
for each monomer (Shuman et al. 1997). Heterodimerisation between C/EBPs and 
members o f the Fos/Jun family o f bZIP transcription factors has also been reported. 
Dimerisation o f C/EBPp with Fos or Jun directs binding away from conventional 
C/EBP consensus sites towards AP-1 sites (Hsu et al. 1994). Additionally, an 
interaction between c-Jun and C/EBPP is required for the regulation o f the tumor 
necrosis factor-a (TNF-a) gene expression in myelomonocytic cells (Zagariya et al. 
1998).
1.2 J  I n t e r a c t io n s  b e t w e e n  C/EBPs a n d  n o n  bZ IP  t r a n s c r ip t io n  f a c t o r s
C/EBP proteins have also been reported to interact with a number o f different non- 
bZIP transcription factors and various co-activators. Protein-protein interactions 
between C/EBPa, -P, -6, -e and NF-kB proteins (p50, p65/RelA) have been reported 
previously (LeClair et al. 1992; Matsusaka et al. 1993; Stein and Baldwin 1993; Stein 
et al. 1993; Chumakov et al. 2007). Interactions between C/EBPp and the 
glucocorticoid receptor have also been reported to synergistically activate the ai-acid 
glycoprotein gene promoter (Nishio et al. 1993). More recently, it has been reported 
that C/EBPp and C/EBPS physically interact with the SMAD transcription factors 
during a transforming growth factor P (TGF-p)-mediated signalling pathway in 
NIH3T3 cells (Choy and Derynck 2003). Liu and co-workers (2003) have revealed 
there to be a physical interaction between Spl with C/EBPp or C/EBPS that is 
enhanced upon lipopolysaccharide (LPS) treatment o f the murine macrophage cell 
line RAW264.7. This interaction between Spl with C/EBPS has also recently been 
confirmed (Chiang et al. 2006). Additionally, the product o f the proto-oncogene c- 
myb (c-Myb) has been demonstrated to interact with C/EBPP (Tahirov et al. 2002). 
Furthermore, the zinc finger transcription factors GATA-2 and GATA-3 have been 
shown to interact with C/EBPa and -p . The interaction between GATA and C/EBP 
factors is critical for GATA-mediated suppression o f adipocyte differentiation (Tong 
et al. 2005). A physical association between the p53 tumour suppressor and C/EBPp 
has been shown to be important for regulating negative cross-talk between these 
transcription factors during the differentiation o f human endometrial stromal cells 
(Schneider-Merck et al. 2006).
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The C/EBPs also interact with various transcriptional co-factors. C/EBPa and 
C/EBPp recruit the chromatin remodelling complex SWI/SNF as a mechanism o f 
mediating transcription (Kowenz-Leutz and Leutz 1999; Pedersen et al. 2001). 
Furthermore, the co-activators p300 and CBP are involved in regulating C/EBPa-, 
C/EBPp- and C/EBPS-driven transcription (Oelgeschlager et al. 1996; M ink et al. 
1997; Erickson et al. 2001; Schaufele et al. 2001; Kovacs et al. 2003). C/EBP 
recruitment o f CBP and p300 has also been shown to induce the phosphorylation o f 
these co-factors through a yet undetermined mechanism (Kovacs et al. 2003; 
Schwartz et al. 2003). Recently, p300-mediated acetylation o f C/EBPp has been 
suggested to be important for its transcriptional activation in 3T3-F442A 
preadipocytes (Cesena et al. 2007). Additionally, p300-mediated acetylation o f 
C/EBP6 is reported to be one o f the mechanisms by which the expression o f the 
cyclooxygenase-2 (COX-2) gene is regulated in response to epidermal growth factor 
(EGF) (Wang et al. 2006). Moreover, the elongation factor CA150 has been shown to 
act as a transcriptional co-repressor o f  C/EBPs. Over-expression o f CA150 inhibits 
/r<ms-activation mediated by C/EBPa and reverses the enhancing effect o f p300 on 
C/EBPp-mediated trans-activation (McFie et al. 2006).
1.2.4 P h o s p h o r y l a t io n  o f  C/EBPs
The phosphorylation status o f the C/EBP proteins can not only determine their 
function, but their trans-activation potential, DNA-binding and translocation 
properties. Therefore, understandably, phosphorylation o f C/EBP proteins is key in 
their regulation.
Mahoney et al. (1992) were the first to hypothesise that phosphorylation o f C/EBPa 
may regulate its DNA binding activity. Specifically, they observed that C/EBPa was 
efficiently phosphorylated by protein kinase C (PKC) but not protein kinase A  (PKA). 
PKC-mediated phosphorylation o f serine299 attenuated the sequence-specific DNA 
binding activity o f C/EBPa by 80%, at least in vitro. Additionally, insulin action has 
been implicated in regulating the phosphorylation status o f C/EBPa. Insulin sensitive 
phosphorylation sites in C/EBPa have been identified and insulin action was 
suggested to result in the dephosphorylation o f  C/EBPa (Ross et al. 1999). C/EBPa
222  • 226  • 230phosphorylation sites were identified as threonine , threonine and serine (Ross 
et al. 1999). Phosphorylation o f these threonine residues is regulated by glycogen
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synthase kinase 3 (GSK3). As GSK3 activity is inhibited by insulin action, a possible 
mechanism for the insulin-mediated dephosphorylation o f C/EBPa was suggested 
(Ross et al. 1999; Roesler 2001). However, results from a recent study suggest that 
phosphorylation o f threonine222 and threonine226 in C/EBPa is not inhibited by insulin 
action, at least in hepatocytes-H411E cells (L iu  et al. 2006d). Results from this study 
also revealed that mutating threonine222 and threonine226 phosphorylation sites in 
C/EBPa has no effect on C/EBPa activity in hepatocytes, questioning the functional 
significance o f this phosphorylation. Furthermore, data also suggested that C/EBPa 
was a poor substrate for GSK3 and that insulin does not regulate threonine222 and 
threonine226 phosphorylation through the inhibition o f GSK3 in hepatocytes. 
Nevertheless, preliminary results suggested that phosphorylation o f threonine222 and 
threonine226 residues in C/EBPa may negatively regulate the activity o f this 
transcription factor in 3T3L1 pre-adipocytes, and that the phosphorylation status o f 
these residues may be regulated through GSK3 as modulated by insulin, consistent 
with the prediction by Ross et al. (1999). Collectively, these results suggest that 
phosphorylation o f C/EBPa may regulate its activity in a cell/tissue-specific manner.
Phosphorylation o f C/EBPa is also associated with its inactivation in acute 
myelogenous leukemia (A M L) cell lines. Thirty percent o f A M L  cases are associated 
with mutations in the FLT3 receptor tyrosine kinase gene. Mutations result in 
constitutive activation o f the receptor and aberrant activation o f downstream 
pathways, including the extracellular signal-regulated kinase (ERK1/2) mitogen- 
activated protein kinase (M APK). C/EBPa expression/activity is important for 
normal myeloid cell differentiation (Section 1.3) and its inactivation is associated with 
various types o f leukemia, including A M L. It has recently been shown that FLT3- 
ERKl/2-mediated phosphorylation o f C/EBPa (serine21) inactivates C/EBPa in A M L  
patients and cell lines, blocking granulocytic differentiation (see Radomska et al. 
2006 and references therein).
Phosphorylation o f CEBPP plays a key role in modulating the activity o f this 
transcription factor. PKC regulates the phosphorylation o f C/EBPp in its activation 
domain (serine105) and this increases its /ram-activation potential (Trautwein et al.
1993). By contrast, phosphorylation o f  C/EBPp (serine240) by PKC inhibits its D NA 
binding activity in vitro (Trautwein et al. 1994). In an effort to identify the region in 
C/EBPp important for gene activation by phosphorylation o f serine105, further
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experiments were carried out by Trautwein and colleagues (Trautwein et al. 1995). 
Results from these experiments indicate that an acidic region located between amino 
acids 21 and 105 o f C/EBPp is important for trans-activation.
It has also been proposed that C/EBPp is a ‘ repressed’ transcription factor with 
concealed activation potential. Phosphorylation is believed to play a unique role to 
‘derepress’ rather than to enhance the trans-activation potential o f C/EBPp. Negative 
regulatory domains normally mask the trans-activation domains o f C/EBPp, but 
residues in the repression domain can be phosphorylated to unmask the activation 
domains and alleviate repression (Kowenz-Leutz et al. 1994; Williams et al. 1995).
Phosphorylation o f  murine C/EBPp at serine276 by a Ca2+-calmodulin-dependent 
protein kinase (C aM KII), increased its trans-activation potential (Wegner et al. 1992). 
The Ras/MAPK pathway has also been shown to phosphorylate human C/EBPP
" J ' lC
(threonine ), leading to significant activation o f  this transcription factor (Nakajima 
et al. 1993). Another study has demonstrated that treatment o f 3T3-F442 fibroblasts 
with growth hormone rapidly induces binding o f C/EBPp to its cognate site on the c- 
fos gene promoter. This effect seemed to be mediated through the dephosphorylation 
o f C/EBPp, through a unidentified residue (Liao et al. 1999). Phosphorylation o f 
C/EBPp has also been implicated in the control o f other cellular activities. For 
example, phosphorylation o f C/EBPP (threonine271) by p90 ribosomal S kinase has 
been found to be critical for rescuing stellate cells from apoptosis in a model o f liver 
injury (Buck et al. 2001b).
Regulation o f C/EBPp translocation (cytoplasm-nuclear shuttling) is mediated, at least 
in part through phosphorylation. Forskolin treatment o f rat PC 12 cells causes 
phosphorylation o f C/EBPp and its translocation into the nucleus from the cytoplasm 
(Metz and Z if f  1991). PKA-dependent phosphorylation o f C/EBPp is also responsible 
for its nuclear translocation in antioxidant-treated DKO-1 cells (Chinery et al. 1997). 
TNF-a action in hepatocytes is believed to regulate translocation o f C/EBPP and there 
is some evidence to suggest that this process is regulated through phosphorylation o f 
this factor (Yin et al. 1996; Buck et al. 2001a).
Streams o f recent studies implicate the ERK1/2 M APK pathway as a regulator o f 
C/EBPp phosphorylation by a variety o f  extracellular mediators, including the 
cytokine interferon-gamma (IFN-y). ERKl/2-mediated phosphorylation o f C/EBPp is
24
C h a p t e r  o n e  G e n e r a l  I n t r o d u c t io n
reported to regulate both trans-activation and translocation o f this transcription factor 
in a variety o f cellular systems, depending on the target residue o f phosphorylation 
(Piwien-Pilipuk et al. 2002; Meng et al. 2005; Ghosh et al. 2006; Raymond et al. 
2006; Bezy et al. 2007; Koria and Andreadis 2007).
Phosphorylation o f C/EBP8 also plays a role in modulating its DNA binding and 
activation function. Ray and Ray (1994a) showed that phosphorylation enhances 
activation o f C/EBP8, w ith only the phosphorylated form able to bind to the C/EBP 
site o f the serum amyloid A promoter during the acute-phase response (APR) (Section 
1.3.1). Dephosphorylation severely impaired the DNA binding activity o f C/EBP8. 
Preliminary data indicate a potential role o f ERK1 MAPK in phosphorylation- 
mediated regulation o f C/EBP5 (Ray and Ray 1994a). Similar results were obtained 
in a separate study where expression o f the a 1-acid glycoprotein gene was analysed. 
C/EBP8 trans-activates this gene in response to inflammatory stimuli and its 
phosphorylation enhances its activating potential (Ray and Ray 1994b). In a model o f 
turpentine-induced APR, both C/EBP-p and -5 were found to bind the promoter 
region o f rat a-2-macroglobulin gene and binding was dependent on their 
phosphorylation status (M ilosavljevic et al. 2002).
Data presented by Osada et al. (1996) also suggested that C/EBP5 is indeed a 
phospho-protein. The group showed that phosphorylation o f C/EBP6 by casein kinase 
2 (CK2) increased the DNA binding capability o f this transcription factor by 
approximately 3-fold. Previous studies have shown that CK2 phosphorylates serine 
residues located in acidic regions o f proteins (Krebs et al. 1988). Five serine residues 
exist in the DNA binding domain o f  C/EBP6, with serine227 located within an acidic
• 227  •stretch o f amino acids. However, it remains to be elucidated as to whether serine is
indeed phosphorylated by CK2 in vivo and in vitro (Osada et al. 1996).
Recent evidence suggests that C/EBPe is also a phospho-protein. C/EBPe is 
phosphorylated on multiple serine and threonine residues and can be a target for 
phosphorylation by a number o f kinases. Threonine is part o f a consensus M APK 
site within the trans-activation domain o f  C/EBPe, and is phosphorylated by p38 
MAPK. Phosphorylation o f this residue results in enhanced transcriptional activity 
and increased DNA-binding o f this transcription factor (W illiamson et al. 2005).
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During cellular stress, C/EBP^ undergoes inducible phosphorylation o f serine79 and
• g |  •serine , via a p38 M APK pathway. This in turn enhances the trans-activation 
potential o f the factor (Wang and Ron 1996). It has also been shown that association 
between C/EBP£ and CK2 results in the phosphorylation o f its amino terminal trans- 
activation domain. This phosphorylation results in impaired transcriptional activity o f 
the factor (Ubeda and Habener 2003).
1.2.5 SU M O YLA TIO N  OF C/EBPS
A novel post-translational modification, termed sumoylation has more recently been 
described. Covalent modification o f cellular proteins by a ubiquitin-like protein 
SUMO (small ubiquitin-related modifier) regulates various cellular processes, 
including nuclear transport, signal transduction, stress response and cell cycle 
progression (M u lle r et al. 2001).
Sequence analysis revealed that C/EBPa, -p, -6 and -e all contain a conserved 
transcriptional regulatory region that can act as a negative regulatory domain. This 
domain contains a five-amino acid motif, o f which a conserved lysine residue is a 
target for sumoylation. Sumoylation o f C/EBPe is reported to relieve the inhib itory 
effect o f the negative regulatory domain and improves its /ram-activating capability. 
Moreover, mutation o f the conserved lysine into an alanine residue in C/EBPe also 
ablates transcriptional repression, indicating that this conserved residue is important 
for negative regulatory domain function (K im  et al. 2002a). In a similar study, Eaton 
and Sealy (2003) demonstrated that the largest isoform o f C/EBPp, C/EBPP-1 
(equivalent to LAP*) was also sumoylated, however the related isoform C/EBPp-2 
(equivalent to LAP) was not. These results indicate that the integrity o f the N- 
terminal amino acids present in C/EBPP-1 but absent in C/EBPP-2, are important for 
targeting C/EBPP-1 for sumoylation. A conserved lysine residue [lysine173 - 
equivalent to the lysine residue as specified by Kim  et al. (2002a)] was determined as 
the target for sumoylation in C/EBPP-1. Previous studies from this laboratory 
demonstrate that C/EBPp-2, but not C/EBPp* 1 can activate the cyclin D1 promoter 
(Eaton et al. 2001). As the K im  et al. (2002a) study suggested that the conserved 
lysine residue in the C/EBPs is critical for negative regulatory domain function, the 
authors assessed whether mutation o f the equivalent residue, lysine173 o f human 
C/EBPp, was responsible for preventing C /EBPp-1 from activating the cyclin  D1
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promoter. Mutation o f this site in C/EBP(3-1 caused this isoform to behave sim ilarly 
to the C/EBPp-2 isoform, with respect to its ability to activate the cyclin D1 promoter 
(Eaton and Sealy 2003).
C/EBP6 is also a target for sumoylation and sumoylation o f this transcription factor 
plays an important role in the regulation o f COX-2 gene expression in A431 epithelial 
cells (Wang et al. 2006). C/EBP6 regulates both basal and EGF-stimulated COX-2 
gene expression. Sumoylation at lysine120 o f human C/EBP6 attenuates the activation 
o f the COX-2 gene promoter, whereas acetylation at the same residue (as mediated by 
p300) increases COX-2 gene promoter activation. Therefore, it seems that 
sumoylated-C/EBPS and acetylated-C/EBP6 are involved, respectively, in the 
silencing and activation o f COX-2 gene transcription (Wang et al. 2006).
1.2.6 M o l e c u l a r  b io lo g y  o f  t h e  C/EBPs
1.2.6.1 C/EBPa
The human C/EBPa gene is a single copy, intronless gene and its locus assigned to 
chromosome 19q 13.1 (Hendricks-Taylor et al. 1992). Expression patterns for 
C/EBPa are similar in both mouse and human tissues and cell types, with measurable 
levels in the liver, adipose tissue, intestine, lung, adrenal gland, peripheral blood 
mononuclear cells and placenta (Cao et al. 1991; Williams et al. 1991; Antonson and 
Xanthopoulos 1995; Lekstrom-Himes and Xanthopoulos 1998). In the liver and 
adipose tissue, increased levels o f C/EBPa mRNA are present in the term inally 
differentiated cells o f the tissue (Cao et al. 1991; W illiams et al. 1991; Lekstrom- 
Himes and Xanthopoulos 1998).
Transcriptional control o f the C/EBPa gene is important for its regulation. Although 
various transcription factors have been implicated in regulating C/EBPa gene 
expression, auto-regulation o f the C/EBPa gene plays a significant role in modulating 
its expression (Legraverend et al. 1993; Timchenko et al. 1995; Kockar et al. 2001). 
Both C/EBPa and to a lesser extent, C/EBPP are involved in auto-regulation o f  the 
murine C/EBPa gene (Legraverend et al. 1993). A  mechanism o f indirect auto­
activation is proposed for the regulation o f  the human C/EBPa gene (Timchenko et al. 
1995). Unlike its murine counterpart, the human C/EBPa gene promoter does not 
contain a C/EBP czs-acting element. Instead, C/EBPa stimulates upstream stimulating
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factor (USF) to bind to a consensus element w ith in the C/EBPa promoter, thereby 
activating gene transcription. Therefore, C/EBPa indirectly regulates the expression 
o f its own gene by recruiting USF. In contrast, the C/EBPa gene from Xenopus 
laevis, is subject to direct auto-regulation (Kockar et al. 2001).
Two isoforms o f C/EBPa are generated from a single mRNA by a ieaky ribosomal 
scanning mechanism.’ As mentioned in section 1.2.2 and depicted in Figure 1.4, the 
full length protein is 42kDa in size. However, a fraction o f ribosomes are unable to 
recognise the first two AUG codons from the mRNA and instead initiate translation at 
the third AUG, 351 nucleotides downstream o f the first initiation codon. This 
generates a protein o f 30kDa that retains its dimerisation and DNA binding domains 
but has a shorter N-terminus compared to its 42kDa counterpart (Lin et al. 1993; 
Ossipow et al. 1993; Calkhoven et al. 1994).
1.2.6.2 C/EBPp
The human C/EBPp gene, like C/EBPa is intronless, and has been assigned to 
chromosome 20 between q 12-q 13.1 (Hendricks-Taylor et al. 1992). Constitutive 
expression o f C/EBPp is highest in liver, intestine, lung and adipose tissue but is also 
detectable in kidney, heart and spleen (Descombes et al. 1990; Cao et al. 1991; 
Lekstrom-Himes and Xanthopoulos 1998).
Transcriptional control o f the C/EBPp gene has also been described and CREB is one 
o f the transcription factors known to regulate its expression (N iehof et al. 1997). The 
murine C/EBPp gene is subject to direct auto-regulation during the APR (Chang et al.
1995) and two cAMP responsive elements w ithin the rat C/EBPP gene promoter play 
an important role in auto-regulation (N iehof et al. 2001a). Interactions between 
C/EBPp and members o f the CREB or NF-kB family enhances C/EBPP gene auto­
regulation in response to different stimuli in a tissue specific manner (N iehof et al. 
2001a). Auto-regulation o f chicken and Xenopus laevis C/EBPp genes has also been 
described (M ink et al. 1999; Foka et al. 2001). The transcription factor STAT3 
(signal transducers and activators o f  transcription-3) is reported to regulate the 
transcriptional induction o f the C/EBPP gene during the APR by IL-6 (N iehof et al. 
2001b). Transcriptional induction o f  C/EBPp can also be regulated by an enhancer 
element found 3’ downstream o f the protein coding region o f the human C/EBPp gene 
in response to amino acid deprivation (Chen et al. 2005b).
28
CHAPTER ONE GENERAL INTRODUCTION
As with C/EBPa, C/EBPp proteins are translated from a single mRNA and at least 
three isoforms are generated by alternative use o f translation initiation codons 
(Descombes and Schibler 1991; Ossipow et al. 1993). The initiation o f translation at 
the first or second AUG, results in the generation o f LAP* and LAP isoforms, both o f 
which contain activation and bZIP domains. LIP however, is translated from the third 
in frame AUG and possesses only the bZIP domain (Xiong et al. 2001) (Section 1.2.2 
and Figure 1.4). A mechanism involving proteolytic cleavage o f fu ll length C/EBPp 
has also been proposed to generate various isoforms (Welm et al. 1999).
Post-transcriptional/translational regulation o f  C/EBPp has also been described. LPS- 
induced APR in mouse liver leads to an increase in expression o f the LIP isoform o f 
C/EBPp. The 5’ region o f C/EBPp mRNA has been shown to be involved in the 
regulation o f LIP translation, through the action o f RNA-binding proteins. One o f 
these proteins (a CUG repeat binding protein), CUGBP1 has been shown to physically 
interact with the 5' region o f C/EBPp mRNA. The binding activity o f CUGBP1 is 
induced upon LPS stimulated APR in mouse liver and this is accompanied by 
increased binding o f this protein to polysomes. It seems that this RNA-binding 
protein regulates the translation o f LIP during the APR, as CUGBP1 
immunoprecipitated from LPS-treated mouse livers can sustain translation o f LIP in 
an in vitro cell-free translation system. Increased production o f LIP through this 
mechanism has been suggested to mediate inhibition o f C/EBPa gene transcription 
during the APR (Timchenko et al. 1999; Welm et al. 2000), although these results 
should be interpreted with some caution (see section 1.3.1.3 for details).
Although transcriptional regulation o f C/EBPP gene expression has been described, 
the main mode o f regulation by which C/EBPP activity is controlled is post- 
translational and as described in section 1.2.4, phosphorylation is key in its regulation.
1.2.6.3 C/EBPy
The C/EBPy gene itself is short, intronless and generates an mRNA that is 
ubiquitously expressed. The highest expression levels have been noted in non- 
differentiated progenitor cells. The protein encoded by C/EBPy is 16.4kDa, possesses 
an intact dimerisation and DNA binding domain, although it lacks /r<ms-activation 
domains (Figure 1.4) (Cooper et al. 1995).
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1.2.6.4 C/EBP6
The mouse C/EBP5 gene has been assigned to chromosome 16, with the human 
counterpart at 8ql 1 (Cleutjens et al. 1993; Jenkins et al. 1995). Putative binding sites 
for AP-2, USF, Spl, STAT, NF-kB and CREB transcription factors have been 
identified in the promoter region o f the gene (Yamada et al. 1997; Davies et al. 2000). 
Like previous members o f the C/EBP fam ily, the C/EBP6 gene is intronless 
(Kinoshita et al. 1992; Cleutjens et al. 1993). Constitutive expression o f C/EBP6 has 
been detected in lung, adipose tissue, intestine, spleen, with lower levels in the liver 
and brain (Cao et al. 1991; Alam et al. 1992; Kinoshita et al. 1992).
Transcriptional regulation o f the C/EBP6 gene is well documented. The Runt domain 
factor (Runx)-2 is implicated in C/EBP8 gene transcription in osteoblasts. Mutation 
o f a Runx-2 binding sequence in the rat C/EBP5 gene promoter dramatically reduces 
promoter activity. Moreover, co-transfection experiments with an anti-sense Runx-2 
expression plasmid attenuated C/EBP5 gene promoter activity, whereas over 
expression o f wild-type Runx-2 activated the promoter (McCarthy et al. 2000). 
Recently, a role for NF-kB in the transcriptional regulation o f C/EBP5 expression has 
been demonstrated in response to LPS and peptidoglycan in murine macrophages (L iu  
et al. 2006b; Huang et al. 2007).
Transcription o f C/EBP5 is also induced in growth-arrested mammary epithelial cells, 
the involuting mammary gland and in IL-6-induced, growth-arrested LNCaP prostate 
cancer cells (Sabatakos et al. 1998b; Hutt et al. 2000; Sivko et al. 2004; Sanford and 
DeWille 2005). Activation o f C/EBP5 gene transcription is mediated by the 
transcription factor STAT3 in growth-arrested mammary epithelial cells and in IL-6- 
induced growth-arrested LNCaP cells, as demonstrated by transfection analysis using 
C/EBP6 gene promoter-reporter D NA constructs (Hutt et al. 2000; Sivko et al. 2004; 
Sanford and DeWille 2005), although a role o f STAT3 in the regulation o f 
endogenous C/EBP5 gene transcription is yet to be confirmed. However, a detailed 
analysis o f the murine C/EBP6 gene promoter in mammary epithelial cells revealed 
several insights into the factors regulating C/EBP5 transcription in growth-arrested 
and exponentially growing epithelial cells. Chromatin-immunoprecipitation (ChIP) 
assays demonstrated that phosphorylated-STAT3 and Spl interact and bind to the 
transcriptionally active C/EBP5 promoter. ChIP assays also showed that in
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exponentially growing (C/EBPS non-expressing) cells, the C/EBPS gene promoter 
was bound with the factors; Spl, CREB, TBP and RNA Polymerase II. In contrast, 
under growth-arrested (C/EBPS expressing) conditions ChIP analysis detected 
phosphorylated-STAT3, Spl, SRC1, CBP/p300, phosphorylated-CREB, TBP and 
phosphorylated RNA polymerase II, at the C/EBPS gene promoter. Furthermore, 
chromatin remodelling experiments demonstrated that the ATPase component o f the 
SWI/SNF was also required for C/EBPS transcription. Additionally, C/EBPS 
expression was shown to be repressed in proliferating mammary epithelial cells by c- 
Myc (Zhang et al. 2007b). STAT3 is also required for the IL-6-mediated induction o f 
mouse and rat C/EBPS gene transcription during the APR (Yamada et al. 1997; 
Cantwell et al. 1998). Furthermore, IL-6 action induces the expression o f myelin 
gene expression in rat embryonic dorsal root ganglia cultures and in murine 
melanoma cells through its induction o f C/EBPS, possibly through a similar pathway 
involving STAT3 as mentioned above (Kamaraju et al. 2004).
Activation o f STAT3 by IL-6 for example, is short-lived. However, C/EBPS 
expression is prolonged in comparison with levels o f C/EBPS detected for up to 24h 
following IL-6 stimulation o f hepatocytes (Ramji et al. 1993a; Yamada et al. 1997; 
Cantwell et al. 1998). In response to LPS, IL-1 or IFN-y, C/EBPS expression is also 
induced and similar to its induction by IL-6, LPS, IL-1 or IFN-y treatment o f various 
cell types leads to prolonged expression o f C/EBPS over several hours (Alam et al. 
1992; Juan et al. 1993; Cantwell et al. 1998; Granger et al. 2000; Tengku-Muhammad 
et al. 2000). This is achieved, at least in part, through auto-activation o f the gene 
(Yamada et al. 1998; O'Rourke et al. 1999a; Davies et al. 2000). Species-specific 
mechanisms have been described to account for auto-activation o f the C/EBPS gene. 
Auto-regulation o f the rat C/EBPS gene is regulated by two C/EBP binding sites 
found at the 3’ end o f the gene (Yamada et al. 1998), whereas the 5’ promoter region 
o f the gene is sufficient for regulating auto-activation o f the murine and ovine genes 
(O'Rourke et al. 1999a; Davies et al. 2000). Ovine C/EBPS gene auto-activation is 
proposed to be mediated by an indirect mechanism as no putative C/EBP binding site 
was identified in the promoter region o f this gene (Davies et al. 2000). In contrast, 
the murine gene is thought to be regulated by a direct mechanism o f auto-activation as 
putative C/EBP binding sites were identified in the region o f C/EBPS gene promoter. 
Presently, no study has sought to determine whether the human C/EBPS gene 
promoter is also subject to auto-regulation.
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1.2.6.5 C/EBPe
The human gene (localised to chromosome 14q 11.2) contains two introns, two exons 
and five AUG initiation codons. Isoforms are produced by use o f alternative 
promoters in combination with differential splicing o f mRNA (Yamanaka et al. 
1997a; Yamanaka et al. 1997b; Yamanaka et al. 1998; Tang and Koeffler 2001). 
Expression o f C/EBPe has been reported to be primarily limited to cells o f the 
myeloid and lymphoid lineages (Chumakov et al. 1997; Yamanaka et al. 1997a; 
Yamanaka et al. 1997b; Lekstrom-Himes 2001). Isoforms are translated into at least 
four proteins (32kDa, 30kDa, 27kDa and 14kDa), all o f which harbour identical bZIP 
domains but d iffe r in their /ram-activation domains (Figure 1.4). The C/EBPe gene is 
transcribed by two alternative promoters pa and pp. This promoter area is similar to 
those o f several other myeloid-cell-specific genes in that it has no TA TA A  box, but 
contains a number o f purine-rich stretches, harbouring multiple sites for the factors o f 
the Ets family o f transcriptional regulators (Chumakov et al. 1997). The promoter 
also contains a functional retinoic acid-response element that regulates inducibility by 
the corresponding ligand (Park et al. 1999).
1.2.6.6 C/EBP^
C/EBP^ was originally cloned from hamster as a gene that was induced by D NA 
damage and then aptly named growth arrest and DNA damage inducible gene 
(G A D D I53) (Fomace et al. 1989). The human gene has been cloned and its location 
assigned to 12q 13.1 -q 13.2 (Park et al. 1992). The gene contains four exons and is 
expressed ubiquitously. Sequence analysis indicated that the human promoter region 
is relatively GC-rich and contains putative binding sites for multiple transcription 
factors, including recognition sites for T A T A - and CAAT-binding proteins, six S p l- 
binding sites, an AP-1 recognition element, an E-26-specific sequence-binding 
protein-1 DNA binding site and four IL-6 response elements (Park et al. 1992). 
C/EBP^ gene expression is induced by a variety o f growth-arresting, oxidative stress 
and DNA-damaging agents. The C/EBP^ gene promoter is strongly activated by 
methyl methanesulfonate, hydrogen peroxide and ultra-violet (UV) irradiation 
(Luethy et al. 1990). The AP-1 element in the C/EBP^ gene promoter is necessary for 
C/EBP£ gene transcription in response to UV-C  or oxidant treatment (Guyton et al.
1996). Messenger RNA and protein levels o f  C/EBP£ are also induced by glucose
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and amino-acid deprivation (Carlson et al. 1993; Bruhat et al. 1997). C/EBP^ gene 
transcription is also induced in response to endoplasmic reticulum stress (ER-stress) 
and the promoter region responsible for conferring this response has been mapped 
(Ubeda and Habener 2000).
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1.3 B io l o g ic a l  r o l e s  o f  t h e  C /E B P s
The action o f the C/EBPs has been investigated extensively, leading to the 
identification o f pivotal roles o f family members in a number o f biological processes. 
These include the differentiation and proliferation o f various cell types, aspects o f 
metabolism and o f particular relevance to this thesis, the inflammatory response. 
Since a discussion o f the C/EBPs in the context o f biological processes other than 
inflammation is beyond the scope o f this thesis, the reader is directed to a number o f 
informative reviews covering various aspects o f C/EBP function, as presented in 
Table 1.1.
T a b le  1.1 M a jo r biological roles o f the C/EBPs
B io l o g ic a l  r o l e R e f e r e n c e ( s)
Adipocyte differentiation Darlington et al. (1998), Rosen et al. (2000), 
Ramji and Foka (2002)
Myeloid cell differentiation Yamanaka et al. (1998), Ramji and Foka 
(2002), Rosmarin et al. (2005)
Epithelial cell differentiation Zahnow (2002), Ramji and Foka (2002)
Cell cycle control Nerlov (2007)
Liver cell regeneration Diehl (1998), Ramji and Foka (2002), Schrem 
et al. (2004)
Metabolic regulation Croniger et al. (1998), Roesler (2001), Ramji 
and Foka (2002)
1.3.1 I n f l a m m a t io n  a n d  t h e  a c u t e  p h a s e  r e s p o n s e
During the aftermath o f injury, trauma or infection o f a tissue a complex series o f 
reactions are carried out by the host in an effort to prevent ongoing tissue damage, 
destroy invading pathogens and activate repair processes which are necessary to 
return the organism back to normal function. Collectively, these series o f reactions 
can be defined as the inflammatory response, with the early and immediate set o f 
inducible reactions known as the acute phase response or APR (Baumann and Gauldie
1994). Characteristic features o f the systemic acute phase response are; fever, 
neutrophilia, alterations in lipid metabolism, decreased serum levels o f zinc and iron,
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increased gluconeogenesis, increased muscle protein catabolism and amino acid 
transfer from muscle to liver, activation o f the complement and coagulation pathways, 
hormonal changes and production o f acute phase response proteins (Moshage 1997).
The APR is part o f the body’s innate immune defence against microbial infection or 
injury. Innate immune responses are initiated by chemical structures that are 
presented by invading microbes (e.g. endotoxin, teichoic acid, polysaccharides and 
mannans) or revealed by damage to the host. These structures are recognised by the 
body’s ‘pattern recognition’ molecules or receptors. Engagement o f these receptors 
initiates the inflammatory response that is the APR (Suflredini et al. 1999). Table 1.2 
displays details o f pattern recognition molecules o f the innate immune response.
T a b le  1.2 M a jo r pattern recognition molecules o f the innate immune system
T y p e
Humoral
N a m e
C-reactive
protein
Serum amyloid 
P
Mannose 
binding protein
LPS binding 
protein
soluble CD 14
L o c a t io n
Primarily synthesised in the 
liver; part of APR
Primarily synthesised in the 
liver
Primarily synthesised in the 
liver
Primarily synthesised in the 
liver; induced production 
by APR
Plasma protein; presumed 
shed from myelomonocytic 
cells
L ig a n d
Microbial
polysaccharides
Extracellular 
matrix proteins; 
microbial cell 
wall
saccharides
Microbial cell 
wall
saccharides
Complement 
factor 3 (C3)
Primarily synthesised in the 
liver; induced by APR
Catalytically 
transfers LPS 
to CD 14 and 
from CD 14 to 
serum 
lipoproteins
LPS and 
numerous 
microbial cell 
wall
components
Forms ester 
linkage to OH
F u n c t io n
Activates
complement;
enhances
phagocytosis
Enhances
phagocytosis;
stabilises
extracellular matrix 
components
Activates
complement;
promotes
phagocytosis;
regulates CD 14-
induced cytokine
production
Enhances sensitivity 
to LPS; system for 
LPS inactivation
Enhances sensitivity 
to LPS; complex 
with LPS binds to 
receptor on 
endothelial cells and 
leukocytes, 
including 
macrophages
Attachment of 
ligands for
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Cellular Mannose
receptors
(macrophage
mannose
receptor and
CD205)
Tissue macrophages; 
hepatic endothelial cells; 
dendritic cells; thymic 
epithelium
groups on 
carbohydrates 
and proteins
Carbohydrates
and
glycoproteins
complement 
receptors C D 21 and 
CD35
Potentially targets 
antigens to class II 
loading 
compartment
Scavenger
receptors
LPS receptor 
(CD14)
Toll receptors
Complement CD35 
receptors
CD2I
Tissue macrophages; 
endothelial cells
Monocyte-macrophages 
and other leukocytes
Lymphoid tissue and 
monocyte-macrophages
Monocyte-macrophages;
lymphocytes
B lymphocytes; follicular 
dendritic cells
Bacteria and 
yeast cell wall
LPS and other 
microbial cell 
wall
components
LPS;
heat shock 
proteins; 
viral dsRNA; 
flagell ins
C3b, C4b
iC3b, C3dg, 
C3d
Clearance of LPS 
and microbes
LPS sensitivity; 
clearance of 
microbes; pro- 
inflammatory 
cytokine production
Induce production 
of cytokines 
including IL-1, IL-6  
and IL-8
Enhances C3b and 
C4b cleavage
Augments B cell 
activation by 
antigen
CD1 lb/CD 18 monocyte-macrophages; iC3b, LPS and Adhesion and LPS
natural killer cells and other fibrinogen clearance
______________________________leukocytes___________________________________________________
(Adapted from SufTredini et al. 1999)
Activated immune cells including macrophages, release a variety o f inflammatory 
mediators such as IL-1, IL-6 and TNF-a that are essential for regulating the APR. In 
response to inflammatory stimuli, major changes in liver physiology occur. This is 
characterised by dramatic changes in the expression and synthesis o f liver APR 
proteins (APPs). Examples and functions o f APPs are given in Table 1.3.
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T a b l e  13 Acute phase response proteins and the ir functions
E x a m p l e (s) F u n c t io n (s)
C-reactive protein Enhances phagocytosis; complement
activation; immunomodulation
Serum amyloid A
a 1-Antitrypsin
a2-Antiplasm in
Ceruloplasmin
Transferrin
Haptoglobin
Complement C2-C5 and C9
Prothrombin, fibrinogen, von Willebrand 
Factor, Factor V I I I ,  antithrombin III
Plasminogen
Plasminogen activator inhibitor-1 
Fibronectin 
a 1-Acid glycoprotein 
a 1 -Antichymotrypsin
Hemopexin
a2-Macroglobulin
Transthyretin (prealbumin)
(Adapted from Suffredini et al. 1999)
Leukocyte activation; chemotaxis; 
phagocytosis; cholesterol transport
Serine protease inhibitor; major inhibitor o f  
elastase and trypsin
Serine protease inhibitor; major inhibitor o f  
fibrinolysis
Copper transport
Iron transport
Haemoglobin scavenger
Complement activation
Clot formation
Activation o f fibrinolysis, complement and 
clotting
Inhibits fibrinolysis
Cell attachment; fibrin clot
Transport protein; steroid binding
Serine protease inhibitor; inhibits chymases 
and cathepsin G
Haem scavenger
serine-, cysteine-, aspartic- protease inhibitor; 
inhibitor o f coagulation
Carrier o f  thyroxine and retinol
The APPs can be distinguished into two major groups depending on whether their 
expression is induced or reduced during the APR. The so-called positive APPs (e.g. 
hemopexin, C-reactive protein (CRP), haptoglobin and a 1-acid glycoprotein) whose 
plasma levels increase during inflammation and the negative APPs (e.g. prealbumin
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and transferrin) whose concentrations decrease. Serum concentrations o f some 
positive APPs can increase up to 1000-fold w ith onset o f the APR, as is the case for 
CRP. For other positive APPs (e.g. a 1-antitrypsin), the induction is more modest with 
a two- to threefold increase in concentration (Ramji et al. 1993b; Gruys et al. 2005).
Four major classes o f factors regulate APP production; the IL-6-type cytokines (e.g. 
IL-6 and oncostatin M), IL-1-type pro-inflammatory cytokines (e.g. IL-1 and TNF), 
growth factors (e.g. insulin and hepatocyte growth factor) and glucocorticoids. The 
cytokines act as primary stimulators o f APP production by inducing APP gene 
transcription, whereas the glucocorticoids and growth factors act as regulators o f 
cytokine action (Baumann and Gauldie 1994).
Natural termination o f the APR involves up-regulation o f cytokines such as IL-4, IL- 
10 and IL -13, enhanced expression o f soluble decoy receptors o f TNF and IL-1 or IL- 
1-receptor antagonist, and endogenous production o f glucocorticoids (Koj 1998).
13.1.1 Cytokines
Cytokines are small, regulatory proteins (<30kDa in size) with pleiotropic actions, 
particularly in the regulation o f the inflammatory response. Leukocytes secrete 
numerous cytokines, although the vast majority o f other cells in the body are also 
capable o f synthesising these proteins (Dinarello 2000). Typically (but not always), 
cytokines act over short distances and their binding to specific cell surface receptors 
triggers signalling events that ultimately result in alterations in the pattern o f gene 
expression in target cells.
On the basis o f their structural features it is possible to group cytokines into various 
families. Families include: interleukins (e.g. IL-1 and IL-18); interferons (e.g. IFN-a, 
IFN-P, IFN-a) and IFN-y); chemokines (chemotactic cytokines e.g. IL-8); tumour 
necrosis factors (e.g. TNF-a); transforming growth factor-p family (e.g. TGF-p and 
bone morphogenetic proteins); and other growth factors [e.g. platelet-derived growth 
factor (PDGF) and EGF] (Table 1.4) (V ilcek 2003).
Functional redundancy among the different cytokines is common and even those that 
are structurally very distinct often exhibit sim ilar or overlapping effects [e.g. TNFa 
and IL-1 (Zhao et al. 2003)]. There are also some examples o f cytokines acting
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synergistically [e.g. TNF-a and IFN-y in the regulation o f lipoprotein lipase gene 
expression (Tengku-Muhammad et al. 1998); IL-6 and TNF-a or IL-1 in the induction 
o f serum amyloid A  gene expression (Hagihara et al. 2004)] or antagonistically [e.g. 
IL-6 and TNF-a in the regulation o f haptoglobin gene expression (Mackiewicz et al. 
1991); TNF-a and TGF-(3 in the regulation o f type I collagen gene expression 
(Verrecchia and Mauviel 2004)].
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T a b l e  1.4 Categorisation o f cytokines into families based on structural features
F a m il y E x a m p l e s
IL-1 IL-1 a  
IL-1 p
IL-1 receptor antagonist 
1L-I8
IL-1F5-F10*
1L-33*
1L-10 IL-10
1L-19
IL-20
IL-22
IL-24
IL-17 IL-17
IL-25
IL-2/IL-4 IL-2
IL-4
IL-5
GM-CSF
IL-6/IL-12 IL-6 
IL-12
Interferons IFN-a
lFN-0
IFN-w
IFN-y
IFN-t
IFN-X(l-3)
TGF-(3 TGF-P
bone morphogenetic proteins
Inhibins
Activins
Tumor necrosis factors TNF-a
LT-a (TNF-p) 
LT-P
Fas ligand 
CD40 ligand
Chemokines IL-8
MCP-I
M IP -la
(Adapted from Vilcek 2003; Harvey 2006)
Abbreviations: GM-CSF, granulocyte-macrophage colony-stimulating factor; MCP-1, monocyte 
chemoattractant protein-1; LT, lymphotoxin; M IP -la , macrophage inflammatory protein 1 alpha; IL- 
1F, interleukin-1 family. * IL-1 F5-F10 and 1L-33 represent newest members of the IL-1 family of 
cytokines (Barksby et al. 2007).
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Another way to group cytokines is in terms o f their action during the inflammatory 
response. Some cytokines clearly promote inflammation and are thus termed pro- 
inflammatory cytokines (e.g. IL-1 and TNF-a), whereas other cytokines attenuate the 
activity o f pro-inflammatory cytokines and are therefore named anti-inflammatory 
(e.g. IL-4 and IL-10). However, d iv id ing cytokines into these two broad categories 
should be done with some caution, because cytokines can function differentially 
depending on the biological process. For example, IL-4, IL-10 and IL-13 are all 
potent activators o f B lymphocytes, but by virtue o f their ability to suppress genes for 
pro-inflammatory cytokines such as IL-1, they are regarded as anti-inflammatory 
(Dinarello 2000). Another example o f a pleiotropic cytokine is IL-6, which has long 
been considered as pro-inflammatory because it is induced by IL-1, TNF-a and LPS. 
In addition, this cytokine is also a potent activator o f the APR. However, there is also 
considerable evidence to suggest that IL-6 has anti-inflammatory properties also, as 
studies w ith IL-6 knock-out mice have revealed (X ing et al. 1998). Furthermore, IL-6 
has the ability to inhibit the synthesis o f a number o f pro-inflammatory cytokines 
including IL-1, TNF, GM-CSF and IFN-y and it promotes the expression o f IL-1 
receptor antagonist and soluble TNF receptor, inhibitors o f IL-1 and TNF action 
respectively (see Opal and DePalo 2000 and references therein).
13.1.2 C/EBPs and the liver APR
The C/EBPs are one o f the major groups o f transcription factors responsible for 
regulating APP gene expression. Numerous APP genes contain functional C/EBP 
binding sites in their gene promoters. These include, hemopexin, haptoglobin, a l-  
acid glycoprotein, a2-macroglobin, serum amyloid A l,  A2 and A3, complement C3, 
CRP, plasminogen and plasminogen activator inh ib itor-1 (PAI-1) (see Poli 1998 and 
references therein; M ilosavljevic et al. 2002; Bannach et al. 2004; Dong et al. 2005).
APP genes can be divided into two classes according to their pattern o f 
responsiveness to cytokines. Class I genes require a combination o f both IL-1 and IL- 
6, and sometimes the addition o f glucocorticoids, for maximal induction (e.g. 
hemopexin and haptoglobin). In contrast, class II genes are responsive to IL-6 and 
related cytokines, either alone or in combination with dexamethasone (e.g. a2- 
macroglobulin). Functional C/EBP binding sites [originally known as type I IL-6- 
responsive elements (IL-6REs)] have been identified in most promoters o f class I
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genes, often in association with IL-1-responsive elements (IL-lR Es), containing 
binding sites for NF-kB for example. Conversely, genes responsive to IL-6 (class II) 
often contain type II IL-6REs in their promoters, which are characterised as binding 
sites for the cytokine-inducible STAT1 and STAT3 transcription factors. Type II IL- 
6-REs are also found in gene promoters o f  class I genes (Poli 1998).
In addition, the activity and/or expression levels o f C/EBP family members is 
regulated by a number o f inflammatory stimuli including LPS and a variety o f 
cytokines during the APR (see Ramji and Foka 2002 and references therein). Indeed, 
C/EBPP was originally discovered as an IL-6 and IL-1 inducible factor in human 
hepatoma cells and in a glioblastoma cell line respectively (Akira et al. 1990; Poli et 
al. 1990). Subsequently, it was discovered that C/EBP6 as well as C/EBPp were 
induced by numerous inflammatory stimuli not only in hepatocytes, but in a range o f 
cell types (A lam  et al. 1992; Ramji et al. 1993a; Magalini et al. 1995; Cardinaux et al. 
2000; Granger et al. 2000; Tengku-Muhammad et al. 2000; M ilosavljevic et al. 2003; 
Dinic et al. 2004). Conversely C/EBPa expression is down-regulated under 
inflammatory conditions (Alam et al. 1992; Tengku-Muhammad et al. 2000; 
Milosavljevic et al. 2003). C/EBP^ is also induced during the APR by C/EBPp, 
although its precise role in the process is yet to be fu lly  elucidated, but it may be 
involved in curtailing the inflammatory response (Sylvester et al. 1994).
Several studies have investigated the transaction between the C/EBPs at the promoters 
o f liver APP genes. A  general trend has emerged, where in the resting state; the 
majority o f promoters are ‘ loaded’ w ith C/EBPa homodimers or C/EBPa:C/EBPP 
heterodimers. However, upon APR induction, the C/EBPa dimers are rapidly 
replaced by C/EBPP and -6  homo-/heterodimers, although the exact composition o f 
these complexes varies w ith different experimental models used for study (Alam et al. 
1993; Chen and Liao 1993; Juan et al. 1993; Ray and Ray 1994a; Ray and Ray 
1994b; Poli 1998; Milosavljevic et al. 2003). These results collectively suggest that 
C/EBPP and C/EBP6 are principally involved in regulating APP gene expression 
during the inflammatory response and that C/EBPa is involved in regulating 
constitutive expression o f these genes, although a critical role for C/EBPa in the 
regulation o f neonatal APR has been shown (see section 1.3.1.5).
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1.3.1.3 Regulation of the C/EBPs in hepatocytes during the APR
As mentioned previously in section 1.2.2 to 1.2.6 the C/EBPs are regulated at multiple 
levels and the situation is quite the same during the APR.
Transcriptional suppression o f the murine C/EBPa gene occurs in response to LPS 
during the APR (Welm et al. 2000). As mentioned in section 1.2.6.2 this 
transcriptional inhibition is suggested to occur in response to increased binding o f the 
inhibitory LIP form o f C/EBPp to the promoter region o f the murine C/EBPa gene 
(Welm et al. 2000). However, a study by Baer and Johnson (2000) has shown that 
truncated C/EBPP isoforms can be produced by in vitro proteolysis during the 
isolation o f tissue/cellular extracts, thereby suggesting that any data generated in 
relation to gene regulation by LIP should be interpreted with caution and confirmed 
using in vivo studies. In human hepatoma cells, suppression o f C/EBPa gene 
transcription occurs by a novel mechanism whereby auto-activation o f the C/EBPa 
gene is suppressed in the presence o f IL-6 (Foka et a l 2003).
Regulation o f  C/EBPp can occur at a number o f  levels; including gene transcription, 
translation, protein-protein interactions and phosphorylation-mediated changes in 
DNA-binding activity, activation potential and nuclear localisation (see sections 
1.2.2-1.2.4 and 1.2.6.2). Furthermore, sumoylation o f C/EBPp has been described 
and this novel post-translational modification has also been implicated in the 
regulation o f C/EBPP activity (Section 1.2.5).
In relation to the APR, CRE-like sequences in the promoter region o f rat C/EBPP 
gene are required for IL-6 mediated induction o f C/EBPp transcription in hepatocytes 
by a mechanism involving the tethering o f STAT3 to a DNA-bound complex. 
Additionally, C/EBPp mRNA levels were increased in liver extracts from mice treated 
with IL-6, compared to controls, indicating transcriptional regulation o f this gene in 
vivo (N iehof et al. 2001b). Auto-regulation o f the C/EBPP gene may also regulate its 
transcriptional expression during the APR (see section 1.2.6.2 and N iehof et al. 
2001a).
As previously mentioned, post-transcriptional regulation o f LIP translation has also 
been described as a mechanism o f C/EBPp regulation during the APR (Welm et al.
2000). Furthermore, TNF-a stimulation o f  hepatocytes results in rapid accumulation
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o f C/EBPP in the nucleus. However, this cytokine was reported to have no effect on 
the expression levels o f this transcription factor, indicating that TNF-a regulates 
C/EBPp at the post-transcriptional/-translational level (Y in et al. 1996).
Regulation o f C/EBPP is mainly controlled in a post-translational manner. Early 
studies first indicated this because it was observed that IL-6 treatment o f human 
hepatoma cells, resulted in increased D NA binding and enhanced fram-activation 
potential o f C/EBPp, but this cytokine had a minimal effect on the expression levels 
o f this transcription factor (Poli and Cortese 1989; Poli et al. 1990; Ramji et al. 
1993a). Phosphorylation-mediated changes in C/EBPp activity play a predominant 
role in C/EBPp regulation (Section 1.2.4). For example, regulation o f the rat a2- 
macroglobulin gene during the APR is dependent on the phosphorylation status o f 
C/EBPp (M ilosavljevic et al. 2002). As detailed in section 1.2.4 a number o f protein 
kinases have been implicated in controlling the phosphorylation status o f C/EBPp. In 
murine hepatocytes, IL-6-mediated regulation o f plasminogen gene expression is 
mediated by C/EBPp as determined by electrophoretic mobility shift assays (EMSAs) 
and this response was suggested to be regulated by the ERK1/2 M APK (Bannach et 
a l 2004). Although, no experiments were carried out in this study to determine at 
what level the ERK1/2 kinase was involved in the regulation o f C/EBPp, a plethora o f 
studies have suggested a role for this pathway in the regulation o f the phosphorylation 
status o f C/EBPp (see section 1.2.4). More recently, it has been shown that IL-1 
induces the phosphorylation o f C/EBPP and its subsequent activation by a ceraminde- 
and ER K1/2-dependent pathway in primary rat hepatocytes (G iltiay et al. 2005). 
Furthermore, the orphan nuclear receptor-1 iver receptor homolog 1 has been shown to 
act as a negative regulator o f the hepatic APR, by antagonising C/EBPp action 
potentially through regulating its post-translational modification (Venteclef et al.
2006).
A number o f different transcription factors have been shown to physically and 
functionally interact with C/EBPp and this dictates regulation through protein-protein 
interactions (see sections 1.2.2 and 1.2.3). O f particular relevance to the APR, are 
interactions between C/EBPp and members o f the NF-kB family (Agrawal et al.
2001). Adjacent C/EBP and NF-kB binding sites have been located in the promoters 
o f many APP class I genes, which require both the actions o f IL-1 and IL-6 for 
maximal induction. Synergistic activation o f  APP genes, mediated through C/EBP
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and NF-kB activity are well documented. O f the genes regulated in this manner, 
serum amyloid A l ,  A2, A3 and a 1-acid glycoprotein are o f particular relevance 
during the APR (see Poli 1998 and references therein).
Furthermore, in relation to the regulation o f  the APR, protein-protein interactions 
between peroxisome proliferator activated receptor a (PPARa) and C/EBPp may also 
be significant (Mouthiers et al. 2005). Recently, a role o f PPARa in the hepatic APR 
has been associated with a decrease o f APP gene expression. Exposure o f rodents to 
peroxisome proliferator ligands results in the down-regulation o f many positive APR 
genes including fibrinogen, a 1-acid glycoprotein, a 1-antitrypsin, ceruloplasmin and 
serum amyloid A (Corton et al. 1998; Anderson et al. 1999; Mouthiers et al. 2005). 
This effect seems to be mediated mainly by PPARa as transcriptional repression o f 
these genes is abolished in PPARa knock-out mice (Anderson et al. 1999). More 
recent studies have shown that PPARa regulates transcriptional repression o f liver 
APP genes by interfering with C/EBP action. For example, PPARa has been shown 
to repress fibrinogen gene expression by interfering with C/EBPp action in 
hepatocytes (Gervois et al. 2001). Similarly, PPARa inhibits dexamethasone-induced 
a 1-acid glycoprotein gene expression by physically associating with C/EBPp and 
preventing its binding to the a 1-acid glycoprotein gene promoter (Mouthiers et al. 
2005).
Regulation o f APP genes by C/EBP5 is to a large degree dependent on transcriptional 
activation o f the gene itse lf (Ramji et al. 1993a; Yamada et al. 1997; Cantwell et al. 
1998). However post-translational modifications, o f which phosphorylation-mediated 
changes in C/EBPS activity are particularly significant during the APR, have also 
been described (Ray and Ray 1994a; Ray and Ray 1994b; Milosavljevic et al. 2002).
Although little  is known about the exact mechanisms by which the C/EBPS gene is 
regulated during the APR, work by Yamada et al. (1997) and Cantwell et al. (1998) 
has successfully identified transcription factors that induce C/EBPS expression in 
response to IL-6 in cultured hepatocytes. These studies have implicated the 
transcription factors STAT3 in regulation o f C/EBPS gene expression, mainly with the 
use o f transfection based assays utilising C/EBPS gene promoter-reporter constructs 
and electrophoretic mobility shift assays (EMSA). Similar findings have now been 
confirmed in relation to the regulation o f the human C/EBPS gene promoter in
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response to IL-6, albeit in a prostate cancer cell line, LNCaP (Sanford and DeW ille 
2005). Cantwell et al. (1998) determined the positions o f STAT3 and Spl binding 
sites in the mouse C/EBP6 gene promoter and demonstrated that both sites were 
necessary for IL-6 responsiveness. It was concluded that Spl synergises with STAT3 
in regulating C/EBP6 gene promoter activity, induced by IL-6. Interestingly, STAT3 
also confers IL-6 responsiveness in the C/EBPp gene (see above), implicating it as 
major transcription factor in the regulation o f IL-6 signalling pathways. However, 
Alonzi and co-workers (2001) have shown that overall induction o f C/EBPp and 
C/EBP6 genes (as mediated by IL-6 or LPS) in mouse livers was only minimally 
defective in STAT3 deficient mice. This suggests that other signalling pathways, 
independent o f  STAT3 activation, can lead to the transcriptional activation o f C/EBPp 
and C/EBP8 genes during the IL-6 induced APR in vivo.
Several studies have reported that C/EBP8 expression is induced and maintained 
several hours fo llow ing treatment o f cells w ith pro-inflammatory stimuli, including in 
hepatocytes (Alam et al. 1992; Juan et al. 1993; Ramji et al. 1993a; Cantwell et al. 
1998; Granger et al. 2000; Tengku-Muhammad et al. 2000). It is generally accepted 
that this effect is attributed to auto-activation o f the C/EBP5 gene as discussed in 
section 1.2.6.4 (Yamada et al. 1998; O'Rourke et al. 1999a; Davies et al. 2000; 
Tanabe et al. 2000). Auto-regulation o f the C/EBP5 gene is therefore likely to bare 
significance in modulating its expression during the APR.
Phosphorylation mediated changes in C/EBP5 activity have also been suggested to 
contribute to its regulation during the APR (Section 1.2.4). Additionally, synergistic 
interactions between C/EBPp and C/EBP5 has been demonstrated to control the 
expression o f the IL-6 gene and sim ilar interactions are likely to be involved in 
regulating expression o f a number o f acute phase genes (Kinoshita et al. 1992; Ray 
and Ray 1994a; Ray and Ray 1994b; Poli 1998).
1.3.1.4 A model of action for C/EBPp and —8 in APP gene regulation
A sequential model o f APP gene induction involving C/EBPp and C/EBP5 was 
proposed by Valeria Poli (1998). The model proposed that cytokine-activated 
transcription factors like NF-kB and STAT3 (activated rapidly but transiently in 
response to inflammatory stimuli) mediate in itia l transcription o f APP genes. Their 
activity is then, at least partially, replaced by the action o f C/EBPp and C/EBP8, in
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the later stages o f the APR. In this scheme o f events, inflammatory stimuli such as 
IL-1 and IL-6 would first trigger the activation o f NF-kB and STAT3 respectively. 
Both STAT3 and NF-kB would initiate transcription o f class I and class II APP genes. 
STAT3 and other yet unidentified transcription factors would also induce 
transcription o f C/EBPp and C/EBP6 genes. Synthesis o f new C/EBPp and C/EBP6 
proteins would lead to /ram-activation o f additional class I APP genes, substituting 
the activity o f STAT3, NF-kB and other ‘early’ transcription factors. As the 
expression o f C/EBPp and C/EBP5 is maintained sometime after their initial 
induction, it is like ly that this gene transcription is continued through auto-regulation 
o f these genes. The increasing pools o f C/EBPp and C/EBP8 would then act to 
support APP gene transcription during the later stages o f the APR. Constitutive 
C/EBPP pools may also be activated by phosphorylation during the initial stages o f 
inflammation and therefore contribute to ‘ early’ and ‘ late’ APP gene transcription. A 
schematic representation o f this model is shown in Figure 1.5.
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F i g u r e  1.5. A model for the induction of APP genes by IL-1 and IL-6 (adapted 
from Poli 1998). Inflammatory cytokines (IL-1 and IL-6) bind to cognate receptors 
and activate respective signalling pathways. IL-1 is known to activate M APK 
pathways and the translocation o f NF-kB (see section 1.4 for details). Activated NF- 
kB can induce the transcription o f class I APP genes. IL-1 is also known to increase 
the expression o f C/EBPp and C/EBP6 genes, although the exact mechanisms are still 
unclear and therefore this is not depicted in the schematic. IL-6 activates the JAK 
(Janus kinases)-STAT pathway and also M APK pathways. JAK stimulation results in 
STAT3 activation but M APK may also be required for the process (flagged with ?) 
(see section 1.5 for details). Activation o f  STAT3 leads to the transcription o f class I 
and II APP genes. A t the same time activated STAT3 also induces transcription o f 
C/EBPp and C/EBP6 genes. MAPK-dependent phosphorylation o f C/EBPp can also 
activate constitutive pools o f this transcription factor, resulting in transcription o f 
class I APP genes. This phase is represented as ‘ EAR LY .’ Newly synthesised 
C/EBPp and C/EBP6 may be able to maintain their expression during the APR 
through auto-regulation mechanisms (although this is not depicted in the schematic). 
C/EBPp and C/EBP6 can bind and trans-activate class I APP gene promoters (in 
various combinations), either functionally replacing other ‘early’ transcription factors 
or synergising with them, depending on the gene promoter. This is the latent phase o f 
APP gene induction (LATE). It is worthy o f note that this scheme only illustrates a 
model proposed for the coordinated role o f the transcription factors NF-kB, STAT3, 
C/EBPp and -6  in APP gene regulation. This is not meant as an exhaustive 
description o f all possible activators o f these factors. ‘ P’ denotes phosphate group. 
See text for further details.
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13.1.5 Abnormalities of the APR in C/EBP knock-out mice
A critical role for C/EBPa in the regulation o f neonatal APR was demonstrated in a 
study by Burgess-Beusee and Darlington (1998). C/EBPa null neonatal mice fail to 
mount a hepatic APR reaction in response to LPS or IL-1. Expressions o f a 1-acid 
glycoprotein, ^-fibrinogen, haptoglobin and serum amyloid A were all severely 
impaired in C/EBPa-/- mice compared to C/EBPa +/+ controls, stimulated with LPS. 
This is in spite o f the fact that C/EBPp, -6 and NF-kB are all induced in C/EBPa -/- 
mice at a level comparable to controls under the same conditions. Collectively, these 
data suggest that C/EBPa is critical for the neonatal APR in vivo.
Expression profiling data for mRNAs o f APP genes in C/EBPp -/- mice has revealed 
that not all APP genes responsive to this C/EBP are regulated in a similar manner 
(Cappelletti et al. 1996). Induction o f both hemopexin and haptoglobin mRNA is 
normal in C/EBPp -/- mice. Conversely, induction o f serum amyloid A and P 
mRNAs is reduced, w ith induction o f complement C3 totally impaired. C/EBPP-/- 
mice are able to induce expression o f serum amyloid (A  and P) and ai-acid 
glycoprotein during the initial phases o f the APR, w ith levels comparable to their w ild 
type counterparts. However follow ing the initia l induction, mRNA levels begin to 
decrease in C/EBPp -/- mice, dropping to basal levels w ithin 24h at which point w ild  
type mice display maximal induction. Therefore, the role o f C/EBPp in the regulation 
o f such genes appears to be in the maintenance o f their expression, rather than 
initiating the induction (Poli 1998). Furthermore, to account for the normal levels o f 
other APP gene mRNAs in C/EBPp -/- mice, it is possible that other C/EBP family 
members functionally compensate for its loss. Indeed redundancy amongst the 
C/EBPs has been demonstrated in their regulation o f IL-6 and MCP-1 gene expression 
in P388 lymphoblasts (Hu et al. 1998).
Results from a recent study in C/EBP6-/- mice reveal a role for C/EBP6 in the 
regulation o f endotoxin-induced disseminated intravascular coagulation or DIC 
(Slofstra et al. 2007). DIC is characterised by systemic activation o f blood 
coagulation factors that eventually lead to the formation o f intravascular micro­
thrombi and impaired organ perfusion. Ongoing activation o f coagulation can result 
in depleted levels o f platelets and coagulation factors, resulting in excessive bleeding.
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O f relevance, the liver is one o f the key organs that is susceptible to- and responsible 
for the initiation o f organ failure during DIC or related sepsis (Slofstra et al. 2007).
One o f the triggers for DIC is the presence o f excessive amounts o f pro-inflammatory 
cytokines such as IL-6 and TNF-a in the system. Interestingly, systemic levels o f IL- 
6 and TNF-a were significantly reduced in LPS-challenged C/EBP6-/- mice compared 
to their equivalent controls. Markers for kidney and liver failure were also compared 
between the two groups. Markers for kidney injury (creatinine and blood urea 
nitrogen) were significantly lower in LPS-challenged C/EBP5-/- mice compared to 
controls, indicating that C/EBPS deficient mice were protected against kidney damage 
mediated by endotoxin-induced DIC. In contrast, makers for liver injury were 
increased in LPS-challenged C/EBPS-/- mice compared to controls, suggesting that 
absence o f C/EBPS may actually aggravate hepatic damage in these mice.
Therefore, consistent w ith its role during the inflammatory response and given that 
C/EBPs have been implicated in the regulation o f cytokine gene expression (see 
below), the observation that TNF-a and IL-6 are present in reduced amounts in 
C/EBPS-/- LPS-challenged mice, emphasises a key role for C/EBPS in the regulation 
o f the inflammatory response in vivo. The fact that C/EBPS deficiency may cause 
endotoxin-induced liver dysfunction is consistent with its role in the APR. As 
mentioned above, many o f the APP genes are induced by C/EBP5, including 
haptoglobin, C3 and CRP. These proteins are known to affect the pro-coagulant and 
anti-fibrinolytic state and function to lim it tissue damage. C/EBPS deficiency could 
impair the production o f these proteins and therefore make the liver more susceptible 
to injury induced by potent inflammatory stimuli (Dhainaut et al. 2001; Slofstra et al.
2007). The observation that C/EBPS-/- mice are protected against DIC-mediated 
kidney damage is more d ifficu lt to explain, although discrepant responses between 
organs are a recurring theme in sepsis and may be reflected by varying sensitivities 
and responses to injury-inducing stimuli in different cell types (Mahidhara and B illia r 
2000; Slofstra et al. 2007).
Given the significance o f both C/EBPp and C/EBP5 activity during the APR and the 
potential existence o f functional redundancy amongst these family members, it would 
be o f interest to create C/EBPp and C/EBPS double knock-out mice for study.
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Although such a strain has been generated, mice are perinatal lethal and therefore 
prove d ifficu lt to study (Tanaka et al. 1997).
1.3.1.6 C/EBP regulation of other genes relevant to inflammation
The C/EBPs play a significant role in controlling hepatic APP gene expression but 
they also regulate the expression o f a plethora o f other genes relevant to the 
inflammatory response. Far from being liver specific, the expression o f C/EBPa, -P 
and -6  is modulated during the inflammatory response in a range o f cell types, 
including cells o f the myelomonocytic lineages, mesangial cells and astroglial cells. 
Notably, the expressions o f various C/EBPs are also differentially modulated during 
myeloid cell differentiation (Table 1.1). Therefore, it is not surprising that the 
C/EBPs are able to regulate multiple genes expressed in these cell types. O f note, 
genes for multiple cytokines and their receptors (e.g. IL-6, IL - lp , TNF-a, IL-8, IL -12, 
MCP-1 and GM-CSF receptor) and genes encoding proteins necessary for 
macrophage or granulocytic functions (e.g. COX-2, inducible nitric oxide synthase, 
lysozyme, myeloperoxidase and neutrophil elastase), all contain C/EBP binding 
motifs in their regulatory regions, many o f which have been shown to be necessary for 
their trans-activation (see Poli 1998; Ramji and Foka 2002 and references therein).
A role for the C/EBPs in the inflammatory response is further confirmed by studies in 
knock-out mice. Defects in the inflammatory response and in the development and 
function o f various immune cells are apparent in knock-out mouse models for 
C/EBPa, -P and -£. Some o f the experimental findings from published studies are 
summarised in Table 1.5.
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T a b l e  1.5 C/EBP knock-out mice w ith  phenotypic abnormalities relevant to the 
inflammatory response
K n o c k -o u t  m o d e l P h e n o t y p ic  a b n o r m a l it ie s R e f e r e n c e ( s)
C/EBPa Lack mature granulocytes 
Unresponsive to G -CSF
Zhang et al. (1997)
Disrupted macrophage 
development
Heath et al. (2004)
C/EBPp M ajor defects in bactericidal and 
tumoricidal activities o f  
macrophages
Tanaka et al. (1995)
Lymphoproliferative disorder 
associated with defects in 
macrophage activation 
Impaired IL -12 production
Screpanti et al. (1995)
Curtailed inflammatory response 
in reaction to cerebral ischemia
Kapadia et al. (2006)
C/EBPe Immunodeficient
Produce morphologically atypical
granulocytes
Yamanaka et al. (1997b)
Lack mature macrophages 
Impaired production o f M CP-3, 
C D  14, PA I-2, IL -6  and IL -1 2
Tavor et al. (2002)
Abbreviations: G-CSF, granulocyte-colony stimulating factor; ICAM1, intercellular adhesion molecule 
1; MCP-3, monocyte chemotactic protein-3; PAI-2, plasminogen activator inhibitor-2.
The above sections have highlighted the critical role o f the C/EBPs in regulation o f 
the inflammatory response, in particular during the APR. It is evident from the 
discussion that aspects o f C/EBP regulation in response to cytokine action remain 
largely unknown. In particular, the mechanisms by which C/EBP8 is transcriptionally 
up-regulated during the inflammatory response are elusive. As already mentioned, 
IL-1 and IL-6 are major inflammatory cytokines that regulate several key aspects o f 
the APR and are known to induce C/EBP5 expression. Therefore, this next section 
aims to provide an account o f the signalling pathways by which these cytokines are 
known to mediate their effects before establishing the aims o f this study.
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1,4 IL -1  SIGNALLING PATHWAYS
IL-1 is a potent, pro-inflammatory cytokine with the ability to produce countless 
biological effects. Its effects include induction o f fever and the APR (as mentioned 
above), leukocyte activation and stimulation o f cytokine production (e.g. IL-6). The 
three primary members o f the IL-1 gene superfamily are IL-1 a, IL - ip  and IL-1 
receptor antagonist (IL -IR a ) (Table 1.4). Studies in knock-out mice have revealed 
that IL - lp  is the critical IL-1 isoform required to mediate the APR (Zheng et al. 
1995). IL-1 a and IL - ip  are both agonists, whereas IL-IR a is a specific receptor 
antagonist for IL-1 a and IL-1 p. When IL -IR a  occupies the IL-1 receptor, it prevents 
both IL-1 a and IL - ip  from binding the receptor and thus there is no biological 
response to IL-1. IL-1 a and IL - lp  are both synthesised as precursors and their 
conversion to ‘mature’ forms requires enzymatic processing. The IL-1 a precursor is 
functionally active, although the IL - lp  precursor must be processed into its mature 
form to be biologically active. IL -IR a  can exist as a secreted (sIL-IRa) protein or as 
an intracellular form in cells (Loppnow et al. 2001; Dinarello 2002).
1.4.1 IL-1 RECEPTORS
The two IL-1 isoforms and IL -IR a  bind two receptors, aptly named type I and type II 
IL-1 receptors (IL-1RI and IL-1RII). These receptors are encoded by two separate 
genes and belong to the immunoglobulin (Ig)-like receptor family. They contain three 
extracellular Ig-like domains, a transmembrane domain and a cytoplasmic portion. 
The cytoplasmic segment o f IL-1RI contains a T o ll-IL -IR  (TIR) domain that is 
common to the superfamily o f To ll-like receptor/ IL-1 receptors whose other members 
are also involved in regulating aspects o f defence and immunity. The IL-1R II is also 
part o f this superfamily o f receptors although it does not contain the TIR  domain. Its 
cytoplasmic segment is substantially shorter than that o f IL-1RI and therefore does 
not accommodate this domain. A ll three Ig-domains are required for high affin ity 
binding to the IL-1 ligand, whereas only two o f these domains are required for IL -IR a 
binding. Owing to the absence o f the TIR  domain in IL-1RII, that is required for IL-1 
signalling, IL-1R II cannot transduce a signal by IL-1, despite being able to bind the 
ligand. It therefore serves as a decoy receptor and together with IL -IR a  probably 
serves to lim it IL-1 action. Both receptors can also be found as soluble forms, 
produced as a result o f enzymatic shedding from cell surfaces and these soluble
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receptors also serve to neutralise the action o f IL-1. For IL-1 responsiveness another 
TIR containing ‘ receptor’ is required for IL-1 signalling, the IL-lR-accessory-protein 
(IL-lRAcP). Despite sharing a similar structure with IL-1RI, IL-lRAcP does not 
physically bind IL-1 on its own and thus is not a true IL-1 receptor. Rather, it appears 
to function to increase the affinity o f IL-1RI for IL-1 by forming a heterodimeric 
complex with this receptor. IL-1 binding may induce a conformational change in IL- 
1RI that recruits IL-lRAcP to the complex (Dinarello 1996; Loppnow et al. 2001; 
Dinarello 2002; Martin and Wesche 2002; Dunne and O'Neill 2003). Figure 1.6 
illustrates the various IL-1 receptors and their functions.
T h e  IL-1 RECEPTORS
Extracellular
IL -IP
IL-1R I
Soluble I H R  I 
(neutralization)
I L l R A c P
IL-1R II
Soluble IL -1R  II  
+
IL -1R  AcP
No Signal
Signal
No Signal
Cytoplasm
FIGURE 1.6 The IL-1 receptors (adapted from  Dinarello 2 00 2 ). IL-1RI binds IL- 
ip  and this complex recruits IL-lRAcP and signalling is initiated. Conversely, when 
IL -lp  binds IL-1 RII, there is no signal transduction as it lacks a complete cytoplasmic 
domain comparable to IL-1 RI. Soluble IL-1 RII can also bind IL-1 (3 and this 
interaction serves to neutralise IL-1 action. Additionally, the soluble IL - lR II- IL - lp  
complex may bind to the IL-lRAcP, depriving the IL-1RI o f its co-receptor and thus 
also dampening IL-1 action.
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IL-1-mediated gene transcription is known to be regulated by the activity o f the 
transcription factor, NF-kB. Therefore, N F-kB has been the focus o f much attention 
in studies attempting to delineate IL-1-dependent signalling pathways. Furthermore, 
studies have concentrated on the regulation o f NF-kB activity because it is well 
established that NF-kB is a key regulator o f inflammatory gene expression (O 'Neill 
2000; O 'Neill 2002). In addition to the activation o f NF-kB, the other major 
signalling pathways activated by IL-1 are dependent on MAPK activation. Signalling 
events leading to the activation o f both NF-kB and the MAPKs are discussed below.
1.4.2 I L - 1 - d e p e n d e n t  s i g n a l l i n g  e v e n t s  l e a d i n g  t o  t h e  a c t i v a t i o n  o f  NF- 
kB AND MAPKs
A number o f  proteins are involved in IL-1-mediated activation o f NF-kB and 
MAPKs, and proteimprotein interactions play a crucial role in the signalling process. 
Upon binding IL-1, IL-1RI and IL -lR A cP  form a signalling complex presumably 
through the close spatial association o f the two TIR domains. This allows the 
recruitment o f the adapter proteins, myeloid differentiation protein 88 (MyD88) and 
Tollip. The MyD88 adapter protein contains a C-terminal TIR domain and an N- 
terminal death domain. MyD88 associates w ith the TIR domains o f the receptor 
signalling complex, possibly as a dimer and thus introduces the death domains at the 
active receptor complex. The IL-lR-associated kinase-1 (IRAK-1), which is pre­
associated w ith Tollip, rapidly translocates to the active receptor complex and 
interacts w ith MyD88 with its N-terminal death domain. This interaction is likely to 
cause dissociation o f To llip  from IRAK-1, thus liberating IRAK-1, which is anchored 
to the active receptor via death domain proteinrprotein interactions with MyD88 
(Martin and Wesche 2002; Dunne and O 'Neill 2003). Subsequently, IRAK-1 
becomes in itia lly  phosphorylated by another IRAK, IRAK-4 as more recently 
described (Suzuki et al. 2002; Li et al. 2002a), although the significance o f IRAK-4 in 
IL-1 signalling has been disputed (Qin et al. 2004). In the present model, IRAK-4 is 
believed to be recruited to the active receptor complex via an adapter protein, possibly 
by To llip  (Qin et al. 2004).
Following the initia l phosphorylation, IRAK-1 can catalyse multiple auto­
phosphorylations and this event may trigger its release into the cytoplasm (Martin and 
Wesche 2002). It has been reported that at this stage IRAK-1 can interact w ith novel
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scaffold proteins called Pellinos, although their precise role in the signalling process is 
still unclear (Schauvliege et al. 2007). IRAK-1 also interacts with the downstream 
adapter protein TNF-a receptor associated factor 6 (TRAF6) and in parallel IRAK-1 
also makes transient contact with the membrane-associated TAB2, an adapter protein 
for the M A P K K K , TGF-P-activated kinase 1 (TAK1). TAB2 serves as an adapter by 
linking TRAF6 to TAK1 and its other adapter protein TAB1 (Martin and Wesche 
2002; Dunne and O’N eill 2003). More recently however, a new TAK1 adapter 
protein has been identified, TAB3 (Cheung et al. 2004). Two distinct TAK1 
containing complexes were identified in cells, where TAK1 is complexed with TAB1 
and either TAB2 or TAB3, with both these forms activated by IL-1.
Chen and co-workers (Deng et al. 2000; Wang et al. 2001) showed that protein 
ubiquitinylation plays a key role in TRAF6-mediated TAK1 and inhibitor-icB kinase 
(IK K ) activation. TRAF6 has been shown to function as an E3 ubiquitin ligase and 
TRAF6 itse lf is a target for ubiquitinylation. O f relevance, IL-1 stimulation triggers 
ubiquitinylation and oligomerisation o f TRAF6, indicating that this process is 
required for signal transduction events (Martin and Wesche 2002; Dunne and O 'Neill 
2003; Yao et al. 2007). By a yet unresolved mechanism, polyubiquitinylated TRAF6 
directly facilitates fu ll activation o f TAK1 which can activate itse lf by auto­
phosphorylation in its activation loop (Kishimoto et al. 2000). TAK1 activation can 
lead to the activation o f NF-kB and/or the subsequent activation o f the MAPKs, both 
o f these processes w ill be discussed separately below (Sections 1.4.3 and 1.4.4).
The molecular switch to turn o ff the signalosome is the proteolytic degradation o f 
hyperphosphorylated IRAK-1 (Yamin and M ille r 1997). It has been speculated that 
degradation o f IRAK-1, results in the dissociation o f the proteins centring around 
TRAF6 and this lim its the duration o f the IL-1 response (Martin and Wesche 2002).
The sequence o f events detailed above is essentially the scheme o f events described 
during IL-1 signalling as reviewed by Martin and Wesche 2002 and Dunne and 
O’Neill 2003. However, it should be noted that although other groups have proposed 
very similar schemes, some models o f IL-1 signalling deviate slightly from the one 
described above, particularly in terms o f describing the translocation o f various 
signalling components involved in the process (Qin et al. 2004; Yao et al. 2007).
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1.4.3 I L - 1 - d e p e n d e n t  a c t i v a t i o n  o f  NF-kB
There are five proteins o f the NF-kB fam ily; NF-kB1 (p50 and its precursor p i05), 
NF-kB2 (p52 and its precursor p i00) and the Rel subfamily, RelA/p65, RelB and c- 
Rel. A ll members contain a conserved Rel-homology domain which consists o f a 
DNA-binding motif, a dimerisation region and a nuclear localisation signal. 
Additionally, members o f the Rel subfamily contain a trans-activation domain that is 
required for target gene activation (Wietek and O'Neill 2007).
Pro-inflammatory cytokines like IL-1 activate the ‘ classical’ or ‘ canonical’ NF-kB 
pathway which results in the activation o f mainly the p50:p65 NF-kB heterodimer. 
This involves the phosphorylation and subsequent ubiquitinylation-mediated 
degradation o f inhibitor kB proteins ( IkB), which are bound to NF-kB protein dimers 
in the cytoplasm o f unstimulated cells. Degradation o f IkB (normally IkBcl), unmasks 
the nuclear localisation signal on NF-kB proteins and allows translocation o f NF-kB 
from the cytoplasm to the nucleus where it can regulate the transcription o f target 
genes (W ietek and O 'Neill 2007).
The regulatory event in this pathway is the phosphorylation o f IkBs. This process is 
regulated by the iKB-kinases (IKKs). IK K  is a large multimeric complex consisting 
o f two kinase subunits, IK K a (IKK1), IK K p (IK K 2) and a regulatory subunit IK K y or 
NEMO (for N F -kB  essential modifier). In the classical pathway, IKKp 
phosphorylates IkBgi at two key residues serine and serine , marking it for 
ubiquitinylation and subsequent degradation. IKKs also have substrates outside the 
IkB fam ily, most notably the p65 subunit o f  N F-kB . Activation o f the IK K  complex 
is regulated by its phosphorylation. M ultip le upstream kinases have been suggested to 
act as IKK-kinases (Dunne and O 'Neill 2003; Hayden and Ghosh 2004). In IL-1 
signalling, both TAK1 and the extracellular signal-regulated kinase kinase kinase 3 
(M EKK3) have been implicated in this process (Wang et al. 2001; Yao et al. 2007). 
Additionally, the Toll/IL-1 pathway specific adapter protein ECSIT (evolutionary 
conserved signalling intermediate in Toll pathways) has been described to interact and 
activate MEKK1 resulting in N F-kB  activation (Kopp et al. 1999).
NF-kB (p50:p65), activation is also regulated by phosphorylation-mediated changes 
in trans-activation potential o f mainly the p65 subunit and by its recruitment o f co­
factors such as p300 or CBP. p65 NF-kB is phosphorylated at a number o f serine
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residues in its trans-activation domain and generally phosphorylation has been shown 
to enhance the fraAw-activation potential o f p65 (Wietek and O 'Neill 2007). IL-1 
stimulates the phosphorylation o f p65 as a number o f studies have indicated. Kinases 
involved in this reaction have been reported as casein kinase 2 (CK2), IKKa, -P and 
the two non-canonical kinases IKKe (IK K i) and TANK-binding kinase 1 (Bird et al. 
1997; Buss et al. 2004).
1.4.4 I L - 1 - d e p e n d e n t  a c t i v a t i o n  o f  MAPKs
IL-1 is reported to activate all three M APK modules; the ERK1/2 M APK and the 
stress activated protein kinases, c-Jun N-terminal kinase (JNK) and p38 (a, p, y and 5) 
(Dunne and O 'Neill 2003). MAPKs modulate gene expression by regulating the 
activity o f a wide range o f transcription factors (Yang et al. 2003) and by regulating 
mRNA stability (particularly in the case o f p38 M APK) (Clark et al. 2003). MAPKs 
denote an entire class o f protein kinases that share several fundamental features. 
Principally they are regulated by threonine and tyrosine phosphorylation and are 
organised into a hierarchical cascade o f kinases. The MAPKs are phosphorylated at a 
threonine-x-tyrosine motif. Both threonine and tyrosine phosphorylations are 
catalysed by dual-specificity protein kinases generically termed M APK kinases 
(M APKKs). These enzymes are in turn phosphorylated (at serine/threonine residues) 
and activated by a third class o f enzymes the M APKK kinases (M APKKKs) (Kyriakis 
and Avruch 2001).
Precise details o f the upstream regulation o f the MAPKs by IL-1 are not fu lly  
determined, although some details have been established. As mentioned previously, 
IL-1 activates TAK1. TAK1 is a M A P K K K  and is reported to activate the M APKK, 
M KK6 and this in turn activates both the p38 and JNK M APK modules (Wang et al. 
2001). Raf-1 is another upstream kinase o f the M APK cascade and it too is activated 
by IL-1 (Huw iler et al. 1996). IL-1 is also reported to activate the MAPKKs, M KK4 
(Guan et al. 1999) and M KK7 (Toumier et al. 1999), which lie upstream o f the JNK 
MAPK. In addition, many studies report that MEK1 and MEK2, which are upstream 
MAPKKs for the ERK1/2 MAPK, are necessary in IL-1 signalling with the use o f 
pharmacological inhibitors and dominant negative constructs (e.g. Laporte et al. 1999; 
Jiang et al. 2004). Details o f how these protein-kinase cascades are activated during 
IL-1 signalling are less well documented. However, roles o f the small guanosine
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triphosphatases (GTPases) have been identified. IL-1 triggers increased GTP binding 
and hydrolysis in membranes and evidence for Rho and Racl GTPase activation has 
been presented. Furthermore, dominant negative mutants for Racl and Cdc42 impair 
activation o f both JNK and p38 M APK in response to IL-1. Additionally, the Ras 
GTPase has been shown to be necessary for p38 MAPK activation and has been 
positioned downstream o f TRAF6 in the IL-1 pathway (see Dunne and O’Neill 2003 
and references therein). A  summary o f the prototypal signalling events leading to the 
activation o f MAPKs and NF-icB by TAK1 are presented in Figure 1.7 below.
IL-1
IL-1 RAcP
kB-kinm* complex M A P -k in ***  fam ily
. P . P . P *P
)< «  NFkB •  •
F ig u r e  1.7 A summary o f the signalling events leading to the activation of 
MAPKs and N F - k B through TAK1 activation by IL-1 (adapted from M artin  and 
Wesche 2002). IL-1 binding to its receptor stimulates the formation o f a receptor 
complex with IL-lRAcP. This results in the recruitment o f MyD88, Tollip and 
IRAK-1 to the active receptor. In parallel, IRAK-4 is also recruited to the receptor 
complex where it initially phosphorylates IRAK-1 and then promotes its auto­
phosphorylation. Hyperphosphorylated IRAK-1 dissociates from the receptor and 
may transiently interact with Pellinos (although not depicted here). The adapter 
protein TAB2 or possibly TAB3, is transported by IR AKI from the membrane to the 
developing signalling complex. IR A K I activates TRAF6 which becomes 
ubiquitinylated (Ub-TRAF6) and may polymerise. TAK1 is recruited to the complex 
with TAB1 and associates with TAB2/3. This leads to auto-phosphorylation o f TAK1 
which subsequently phosphorylates various regulatory kinases leading to the 
activation o f NF-kB- and MAPK-dependent signalling pathways. ‘P’ denotes 
phosphate group.
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1.4.5 O t h e r  s i g n a l l i n g  p a t h w a y s  a c t i v a t e d  b y  IL-1
Apart from the signalling pathways mentioned above, IL-1 is also known to activate a 
number o f other signalling events but the coupling o f these to the IL-1 receptor 
complex is not fu lly understood. One o f these pathways involves 
Phosphatidylinositol-3 kinase (PI3K) and its downstream effector protein kinase B 
(PKB). IL-1 can also induce ceramide production by stimulating neutral and acid 
sphingomyelinases in various cell types. Protein kinase C isoforms have also been 
implicated in IL-1 signalling cascades, mainly with the use o f pharmacological 
inhibitors targeting the various isoforms. PKC isoforms are also downstream 
effectors o f phospholipases, and various phospholipases are reported to be activated 
by IL-1 (see Martin and Wesche 2002 and references therein).
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1.5 IL-6 SIGNALLING PATHWAYS
IL-6 has many diverse functions; it not only regulates immune and inflammatory 
responses, but also plays a role in the regulation o f hematopoiesis, neural 
development and bone metabolism (Stein and Kung Sutherland 1998). The human 
IL-6 protein contains 212 amino acids o f which a 28 amino acid signal peptide is 
cleaved o ff resulting in the generation o f a mature protein o f 184 amino acids that can 
be post-translationally modified (Keller et al. 1996).
1.5.1 IL -6  RECEPTORS
There are two components to the IL-6 receptor complex, the non-signalling a-receptor 
(IL-6Ra) and the signal-transducing receptor component, gpl30. IL-6 first binds to 
the IL-6Ra subunit, and only then can it recruit the gpl30 signalling receptor subunits 
(Heinrich et al. 1998). A schematic representation the IL-6-bound receptor complex 
is shown in Figure 1.8.
m m m
IL-6Ra
Cell membrane
F ig u r e  1.8 A  schematic representation o f the IL-6 receptor complex.
It seems that the function o f the IL-6Ra subunit is to render cells sensitive to IL-6 
because even though gpl30 is ubiquitously expressed, the number o f cell types that 
respond to IL-6 action is more limited. In accordance, the expression o f IL-6Ra is 
restricted, limited to the cell membranes o f leukocytes and hepatocytes in humans 
(Heinrich et al. 1998; Gabay 2006). However, IL-6 action can be potentiated with 
soluble receptors. Like the IL-1 receptors, the IL-6Ra can also exist as a soluble 
form, which lacks transmembrane and cytoplasmic segments. Soluble IL-6Ra can be 
shed from neutrophil membranes by limited proteolysis, for example. In contrast to
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the soluble IL-1 receptors, that function to neutralise IL-1 action, soluble IL-6 
receptors (sIL-6Ra) can act to enhance IL-6 action. The sIL-6Ra can combine with 
IL-6 and bind gpl30 on cell membrane to activate cells by a mechanism termed 
VraAW-signalling’ (Gabay 2006). However, sIL-6Ra action can also be limited by a 
soluble form o f gpl30, which like sIL-6Ra is also detectable in human serum. 
Therefore, the balance between levels o f IL-6 and soluble forms o f IL-6Ra and gpl30 
can dictate the strength and duration o f the IL-6-mediated response (Heinrich et al. 
1998; Heinrich et al. 2003).
The extracellular domains o f both IL-6Ra and gpl30 contain fibronectin type III 
domains and an immunoglobulin-like domain. The fibronectin type III domains 
constitute the ligand-binding module. In each receptor the immunoglobulin-like 
domain is located N-terminally in close proxim ity with the ligand-binding module. In 
contrast w ith the IL-6Ra, gp 130 contains three additional fibronectin type III domains 
and these domains are required for coupling ligand binding and signalling. The 
intracellular domain o f gpl30 contains binding/docking sites for various proteins that 
are necessary for signal transduction. IL-6 principally activates two major signalling 
pathways, the JAK-STAT and the M APK pathways, both o f which are detailed below 
(Heinrich et al. 1998; Heinrich et al. 2003).
1.5.2 IL-6-DEPENDENT ACTIVATION OF THE JAK-STAT PATHWAY
IL-6 activates the Janus family o f tyrosine kinases otherwise known as the JAKs. The 
intracellular, membrane-proximal region o f gpl30 is bound to any o f three JAKs; 
JAK1, JAK2 or Tyk2. The first event in the activation o f the JAK-STAT pathway by 
IL-6 is cytokine-mediated homodimerisation o f gpl30 receptor subunits (Figure 1.8). 
Ligand-induced receptor dimerisation is believed to bring the gpl30-associated JAKs 
into close proxim ity with one another, leading to their activation by phosphorylation. 
Their activation results in the subsequent phosphorylation o f target tyrosine residues 
in the cytoplasmic tail o f gp!30. Phosphorylated tyrosine residues serve as docking 
sites for STATs, to which they are recruited and anchor via their src-homology 2 
(SH2) domains. Subsequently, STATs also become tyrosine-phosphorylated, they 
dimerise (homo- or heterodimerisation) and translocate to the nucleus to their target 
genes. IL-6 action results in the predominant activation o f STAT3 and to as lesser 
extent, STAT1. The phospho-tyrosine residue that is indicative o f STAT1 activation
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is tyrosine701 and for STAT3 it is tyrosine705. Additionally, both these transcription
777factors are also serine-phosphorylated (serine ), in their C-terminal trans-activation 
domains and generally this is believed to be required for maximum transcriptional 
activation. A number o f kinases have been suggested to regulate the serine- 
phosphorylation o f STAT1 and STAT3 (Heinrich et al. 1998; Heinrich et al. 2003). 
In response to IL-6 action, STAT3 serine phosphorylation is reported to be regulated 
by components o f the JNK M APK pathway, specifically MK.K4 and there is also 
evidence for PKC5 involvement (Jain et al. 1999; Schuringa et al. 2000; Schuringa et 
al. 2001). Figure 1.9 shows the sequence o f events resulting in JAK-STAT pathway 
activation as mediated by IL-6.
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F ig u re  1.9 IL -6  signalling via the JAK -S TA T pathw ay (adapted from  H e in rich  
et al. 1998). IL-6 binding leads to the homodimersiation o f gpl30 receptor subunits 
and subsequent JAK activation (1-2). JAKs phosphorylate conserved tyrosine 
residues in the cytoplasmic tail o f gpl30, creating docking sites for the STATs (3). 
STATs are recruited to the receptor complex via their SH2 domains, which they use to 
bind the tyrosine-phosphorylated gpl30 (4). Their binding results in their tyrosine- 
phosphorylation (5), subsequent dimerisation and translocation into the nucleus where 
they regulate gene expression (6). STATs are also substrates for serine kinases and 
both STATI and 3 are known to be phosphorylated at serine727. Abbreviations: 
APRF, acute-phase response factor; APRE, acute-phase response element; Y, 
tyrosine; P, phosphate group.
Negative regulation o f the JAK-STAT pathway is controlled by two groups o f 
inhibitory proteins called suppressors o f cytokine signalling (SOCS) and protein 
inhibitors o f activated STATs (PIAS). In addition, protein phosphatases are also 
involved in the negative regulation o f the JAK-STAT pathway, o f which the action o f 
SHP2 (SH2-domain-containing tyrosine phosphatase) has been reported (see Heinrich 
et a l 2003 and references therein).
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1.5.3 IL-6-DEPENDENT ACTIVATION OF MAPK PATHWAYS
Activation o f the IL-6R-complex also leads to the induction o f the MAPK cascade. 
Studies have indicated a requirement for the tyrosine phosphatase SHP2, which is 
recruited and phosphorylated (by JAK1) at activated gpl30 receptors. SHP2 is also 
an SH2-domain containing protein, harbouring two such domains. Both these 
domains are required for its recruitment to activated receptors and also in the 
regulation o f its phosphatase activity (Heinrich et al. 1998; Heinrich et al. 2003). The 
function o f its phosphatase activity in signalling is not very well known but has been 
shown to be required for M APK activation by EGF. In the present model o f SHP2- 
dependent activation o f MAPKs, SHP2 is believed to ‘ link ’ Grb2-SOS (growth- 
factor-receptor-bound protein/Son o f Sevenless) complex and/or Gabl (Grb2- 
associated binder-1) to gpl30. Recruitment o f SOS (a guanine nucleotide releasing 
protein that activates Ras) to the receptor complex allows Ras activation, resulting in 
subsequent activation o f the Ras-Raf-MAPK pathway (see Heinrich et al. 1998; 
Heinrich et al. 2003 and references therein).
Another route to the activation o f MAPKs by IL-6 is through Gabl. Gabl is a 
scaffolding adapter protein that contains binding sites for Grb2, SHP2 and PI3K. In 
response to IL-6, Gabl is tyrosine phosphorylated and interacts with both PI3K and 
SHP2. IL-6-induced association o f Gabl w ith SHP2 leads to the activation o f ERK2 
MAPK and Gapl deficiency impairs M APK activation by IL-6 in fibroblasts (Itoh et 
al. 2000; Heinrich et al. 2003). IL-6 action also leads to the activation o f both p38 
MAPK and upstream activators o f the JNK M APK module, although the pathways 
leading to their activation are less clear (Heinrich et al. 2003). Figure 1.10 
summarises the signalling pathways associated with IL-6R activation.
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Figure 1.10 A schematic representation o f the known signalling pathways 
activated by IL -6  (taken from Heinrich et al. 2003). IL-6 activates two principal 
pathways, the JAK-STAT pathway (detailed previously) and the MAPK cascade. 
Activation o f JAKs can switch on both pathways, as detailed in the figure. A  number 
o f regulatory proteins are involved in the activation o f the MAPK cascades by IL-6. 
Activation o f this pathway is achieved either directly through SHP2 binding at the 
gpl30 receptors, or by Gabl activation. The precise link between Gabl and the IL- 
6R complex is not clear and is flagged with ?. Gabl activation also activates the PI3K 
(p85 and p i 10) pathway. Abbreviations; TF, transcription factor; Y, tyrosine; P, 
phosphate group.
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1.6 A im s  o f  stu d y
It is evident from the previous discussion that the C/EBPs regulate the expression o f 
many important genes required for the inflammatory response. These include, genes 
encoding multiple cytokines, APR proteins and inflammation-related growth factors 
and their receptors (see section 1.3.1 for details). Furthermore, certain C/EBP family 
members, like C/EBPp but particularly C/EBP6, are themselves induced by cytokine 
action, thus providing the potential for maintenance and amplification o f cytokine- 
mediated inflammatory responses.
O f the C/EBPs discussed previously, C/EBP8 in particular, plays a key role in the 
regulation o f the inflammatory response (Section 1.3.1.2-1.3.1.5). Indeed this is 
further supported by recent evidence presented by Miyoshi and co-workers (2007), 
where C/EBP6 expression was documented to play a significant role in the regulation 
o f inflammatory gene expression (specifically, IL-6, MCP-1 and COX-2) in a model 
o f glomerulonephritis, an inflammatory disease that affects kidney function. 
Moreover, given its key role in the regulation o f inflammatory gene expression, 
C/EBP5 expression was also examined in brain tissue o f Alzheimer’s disease 
sufferers, since this disease also has an associated inflammatory component to it (L i et 
al. 2004). Significantly increased levels o f C/EBP5 were found in brain tissue from 
Alzheimer’s patients, compared to controls. Levels were particularly increased in the 
vicin ity o f amyloid-p deposits which were surrounded by reactive astrocytes.
Despite its significance during the inflammatory reaction, the molecular mechanisms 
by which C/EBP6 is itse lf induced under such conditions are largely unknown. 
Previous studies have pointed to an important role o f the transcription factor STAT3 
in the regulation o f C/EBP5 expression by IL-6 (Yamada et al. 1997; Cantwell et al. 
1998). However, investigations in these studies are restricted to the analysis o f 
C/EBP8 gene promoter activation by this cytokine in transfection based assays and 
have not investigated a role for STAT3 in the regulation o f endogenous C/EBP8 gene 
expression by IL-6. Furthermore, to our knowledge no study has identified the 
transcription factors regulating C/EBP5 expression in response to other key 
inflammatory cytokines like IL-1 for example.
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Given that C/EBP5 expression is like ly to have an impact on inflammatory conditions, 
like the ones mentioned above, and because the mechanisms underlying its expression 
are largely unknown, we decided to investigate its expression and the mechanism(s) 
regulating its expression in response to inflammatory stimuli, such as IL-1 and IL-6.
Numerous studies have reported that a large number o f inflammatory mediators, 
including the cytokines IL-1 and IL-6 strongly induce the expression o f C/EBP6, 
particularly in hepatocytes, the key cells involved in the production o f APPs during 
the APR (Section 1.3.1.2). Therefore because o f their significance in the 
inflammatory response, we decided to use these cells as a model for our studies. Our 
initial investigations were aimed at determining the effects o f various inflammatory 
mediators on C/EBP5 expression in these cells, with focus on IL-1. In conjunction, 
because prelim inary results from our laboratory suggested that the expression o f 
C/EBP6 as induced by IL-1 occurred at the level o f gene transcription (Dr F.T. 
Kockar, personal communication), similar to its regulation by IL-6 (Ramji et al. 
1993a; Yamada et al. 1997; Cantwell et al. 1998), the initial aims o f this project were 
to:
1) Fully delineate the regulatory elements in the human C/EBP5 gene promoter 
responsible for IL-1-induced C/EBPS gene transcription
2) Identify the nuclear factors responsible for the regulation o f this response
In conjunction with these aims, we also carried out investigations to determine 
whether the human C/EBPS gene was subject to auto-regulation, similar to its rat, 
mouse and ovine counterparts, given that this area o f investigation has gone 
unreported and also because this mode o f gene regulation is likely to play a significant 
role in modulating C/EBPS expression during the inflammatory response (Chapter 3).
Further to our initial studies presented in chapter 3, the preliminary aims o f this 
project were revised slightly. More specifically, this was because in contrast to the 
endogenous gene, the human C/EBPS gene promoter was not activated by IL-1, in 
spite o f the fact it was shown to be responsive to IL-6 action consistent with previous 
findings (Yamada et al. 1997; Cantwell et al. 1998). Similar results were also 
obtained on analysis o f the murine C/EBPS gene promoter in response to IL-1 and IL -
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6 action. Therefore, as a result o f this outcome, we decided to change the focus o f the 
project slightly.
Still remaining consistent w ith the overall objective o f the project, we decided to 
utilise an alternative approach into determining the molecular mechanisms by which 
C/EBPS is regulated in response to IL-1 by:
1) Investigating the signal transduction pathways leading to the induction o f 
C/EBPS expression by IL-1 (Chapter 4-6)
2) Characterising the signalling components that are involved in these pathways 
(Chapter 7)
Simultaneously, some investigations were also carried out to determine the identity o f 
transcription factor(s) regulating C/EBPS expression by IL-6 as previous studies 
(Yamada et al. 1997; Cantwell et al. 1998) have not extended their investigations to 
analysing the expression o f the human C/EBPS gene in response to this cytokine 
(Chapters 3 and 6).
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2.1  Suppliers
Table 2.0 details materials used during the course o f this study and the suppliers from 
which they were purchased.
T a b l e  2.0 A  list o f m ateria ls and chemicals used in this study w ith  th e ir  
suppliers.
M a t e r ia l s S u p p l ie r
Apigenin Alexis Biochemicals, Nottinghamshire, UK
Negative/Scrambled control siRNA Ambion, Cambridgeshire, UK
y-32p-a t p
a 32P-dCTP
ECL Western Blotting Detection Reagent 
Megaprime DNA Labelling Kit 
Nick Columns
Rainbow Protein Size Markers 
Random Hexamers (PdN6)
X-ray Film
Amersham, GE Healthcare, Buckinghamshire, 
UK
Acrylamide: Bisacrylamide (29:1) 
Acrylamide: Bisacrylamide (37.5:1)
Anachem, Luton, UK
Agarose
PCR Grade Magnesium Chloride
Taq DNA Polymerase (and lOx Reaction Buffer)
Bioline, London, UK
DTT Boehringer Mannheim, East Sussex, U.K.
Bisindolylmaleimide 
Calphostin C 
Cure urn in 
LY294002
NF-kB Activation Inhibitor
PD98059
SB202190
SB203580
SP600125
Calbiochem, Nottingham, UK
DharmaFECTlM Dharmacon RNA Technologies, USA
LB Agar Capsules 
LB Medium Capsules
DIFCO Laboratories, Surrey, UK
Hep3B Cell Line 
THP-1 Cell Line
European Collection of Animal Cell Cultures 
(ECACC), Salisbury, UK
EDTA
Ethanol
Hydrochloric Acid 
Industrial Methylated Spirits 
Isopropanol 
Methanol 
Sodium Chloride 
Sodium Dodecyl Sulphate 
Sodium Hydroxide 
Tris-Base
Other General Chemicals
Fisher Scientific, Loughborough, UK
Saran Wrap Genetic Research Instrumentation, Essex, UK
Ammonium Persulphate 
DMEM with GlutaMAX™
Gibco BRL, Paisley, UK
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Fetal Calf Serum
2-Mercaptoethanol
Trypsin/EDTA
1ml Cryo-vials 
96 Well Plates
Falcon 15ml and 50ml Polypropylene Tubes
Greiner, Gloucestershire, UK
Cell Scrapers 
Tissue Culture Flasks
Helena Biosciences, Sunderland, UK
High Purity Plasmid Maxi Prep System Marligen Biosciences, High Wycombe, UK
PVDF membrane Millipore Ltd., Gloucestershire, UK
DNA Molecular Weight Markers 
Restriction Endonucleases 
Anti-mouse HRP Conjugate 
Anti-p50/pl05 NF-kB 
Anti-p65 NF-kB 
Anti-rabbit HRP Conjugate 
Anti-SAPK/JNK
Anti-SAPK/JNK pThrl83ATyrl85
Anti-STATl
Anti-STATl pTyr701
Anti-STAT3
Anti-STAT3 pTyr 705
Anti-STAT3 pSer727
SAPK/JNK Kinase Assay Kit (Non Radioactive)
New England Biolabs, Hertfordshire, UK
Phosphate Buffered Saline Tablets Oxoid Ltd., Basingstoke, UK
Micro BCA Protein Assay Kit Pierce, Chester, UK
dNTPs
M M L V  Reverse Transcriptase (and M M L V  5x 
Buffer)
Passive Lysis Buffer (5x)
RNasin
Wizard SV™  Miniprep Kit
Promega, Southampton, UK
SuperFECT™
QIAquick™ Gel Extraction Kit
RNeasy™ Total RNA Isolation Kit (Mini and
Micro)
Qiagen, Crawley, UK
Anti-C/EBPS ( M 17)X  
Anti-CK2 a  and a ’ 
Anti-c-JUN
Santa-Cruz Biotechnology Inc., California, USA
Tissue Culture Filters (0.2pm) Schleicher and Schuell, London, UK
DNA Oligonucleotides Sigma Genosys, Cambridgeshire, UK
Anti-P-Actin
Ampicillin
Aprotonin
Benzamidine
Bovine Serum Albumin
Bromophenol Blue
Ethidium Bromide
DMSO Molecular Biology Grade
Ficoll (Type 400)
Glycerol
Leupeptin
Lipopolysaccharide
Molecular Biology Grade Water
PEI25kDa
Penicillin/Streptomycin
PMA
PMSF
Sodium Fluoride 
Sodium Ortho vanadate 
Sodium Pyrophosphate
Sigma, Poole, UK
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TB E(xlO )
TEM ED
Tissue Culture Grade Water
Tissue Culture Grade DMSO
Triton X-100
Trypan Blue Solution
Tween 20
Zinc Chloride
Human IFN-y Totam Biologicals (Tebu Bio), Cambridgeshire,
Human IL-1 (3 UK
Human IL-6
Human TGF-(3
2.2 P re p a ra t io n  o f  g la s s  and p la s t ic w a re
Glass or plastic-ware for the isolation and manipulation o f DNA, RNA or protein was 
autoclaved for 20min at 121°C, at a pressure o f 975kPa. Solutions were also 
autoclaved under the same conditions.
2.3 Tissue C u lt u r e
A ll reagents used in tissue culture were pre-warmed to 37°C for at least 20min and 
subsequently sterilised with 70% (v/v) ethanol prior to use.
2.3.1 C e l l  l in e s
The cell lines used for experiments detailed in this study were: the human hepatoma 
cell line, Hep3B and the human monocytic cell line, THP-1.
2.3.1.1 M a in t e n a n c e  o f  c e l l  l in e s  in  c u l t u r e
The Hep3B cells were grown in DMEM with GlutaMAX™ (stabilized L-glutamine) 
and the THP-1 cell line was grown in RMPI-1640 with GlutaMAX™ cell culture 
medium. Medium was supplemented with 10% (v/v) heat-inactivated (30min, 56°C) 
fetal ca lf serum (HI-FCS), penicillin (lOOU/ml) and streptomycin (lOOpg/ml) 
(hereafter referred to as complete medium). Supplemental reagents were passed 
through a 0.2pm sterile filter prior to addition to the culture medium. The cells were 
maintained at 37°C in a humidified incubator w ith a 5% (v/v) C 0 2 atmosphere. The 
cell culture medium was replaced twice a week. It is noteworthy, that no cells beyond 
passage 10 o f growth were used in any experiments.
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2.3.1.2 SUBCULTURING OF CELL LINES
Confluent (70%) Hep3B cells were washed once with DMEM with GlutaMAX™. 
The cells were then treated with trypsin/EDTA solution and incubated at 37°C, 5% 
(v/v) CO2 until the cells were visib ly detached from the substratum. Only a minimum 
volume o f trypsin/EDTA adequate to cover the cell monolayer was used for 
trypsinisation. Once detached, the cells were then resuspended in fresh DMEM 
complete medium and centrifuged at 800xg for 5min. The cell pellet were then 
resuspended in an appropriate volume o f fresh DMEM complete medium and seeded 
at a ratio o f 1:6 (i.e. cells from one tissue culture flask were subcultured into six new 
flasks o f the same size).
Confluent THP-1 cells (70%) were split at a ratio o f 1:4, by diluting the cells into 
fresh RPMI-1640 complete medium.
2 .3 .1 .3  P r e s e r v in g  a n d  s t o r in g  o f  c e l l  l in e s
Only cells o f an early passage (between 2-4) were used for long term storage. Cell 
suspensions (prepared as described above) were pelleted by centrifugation at 800xg 
for 5min. Following this, the cell pellets were resuspended in an appropriate volume 
o f HI-FCS containing 10% (v/v) DMSO (Hep3B) or containing 10% (v/v) sterile 
glycerol (THP-1). These cell suspensions were dispensed as 1ml aliquots into sterile 
cryo-vials and insulated with polystyrene. The cells were then frozen at -80°C 
overnight. Following the overnight freeze, the cells were placed into liquid nitrogen 
for long-term storage.
2.3.1.4 T h a w in g  f r o z e n  c e l l s
For thawing cells, cryo-vials were removed from liquid nitrogen storage and 
incubated at 37°C until their contents had thawed completely. The content o f each 
vial was added to 15ml o f HI-FCS and centrifuged at 800x# for 5min. Following 
centrifugation, the HI-FCS was aspirated from the cell pellet, which was then 
resuspended in an appropriate volume o f D M EM  or RMPI-1640 complete medium 
depending on the cell line. The cells were then seeded into tissue culture flasks and 
incubated at 37°C [5% (v/v) CO2].
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2.3.1.5 T r e a t m e n t  o f  c e l l s  w i t h  c y t o k in e s
In the case o f Hep3B cells prior to cytokine treatment, the medium was aspirated from 
the cells and replaced with an appropriate volume o f fresh DMEM complete medium. 
Cytokines were added directly to the culture medium, at various concentrations 
depending on the nature o f the experiment. Routinely, IL-6 was added at lOOOU/ml, 
IL-1 (3 at lOOU/ml and IFN-y at lOOU/ml. Treated cells were incubated at 37°C [5% 
(v/v) CO2 ] and harvested at indicated time points for experimental analysis.
2.3 .1 .6  T r e a t m e n t  o f  c e l l  l in e s  w i t h  p h a r m a c o lo g ic a l  in h ib i to r s
Pharmacological inhibitors were prepared according to the manufacturer’s 
instructions (A lexis Biochemicals, Calbiochem). The majority o f pharmacological 
agents were dissolved in DMSO, unless otherwise stated.
Prior to treatment o f Hep3B cells, the medium was aspirated from the cells and 
replaced w ith an appropriate volume o f fresh DM EM  complete medium and the cells 
returned to the incubator [37°C, 5% (v/v) CO2 ] for 30min. For THP-1 monocytes, 
approximately 24h prior to treatment, confluent cells were diluted with RPMI-1640 
complete medium, seeded into two new flasks and incubated [37°C, 5% (v/v) CO2] 
overnight. On the day o f treatment, the contents o f both flasks was combined and 
centrifuged at 800xg for 5min, the medium aspirated, and the resultant cell pellet 
resuspended in an appropriate volume o f RPMI-1640 complete medium. The cells 
were then plated into new flasks at a ratio o f 1:2 and incubated for a further 4h [37°C, 
5% (v/v) CO2 ], at which point they were ready for inhibitor treatment.
Inhibitors were added directly to the culture medium, at various concentrations 
depending on the nature o f the experiment. As a control, the cells were also treated 
with an appropriate volume o f vehicle that was used to dissolve the inhibitor, typically 
DMSO. In all experiments the cells were incubated [37°C, 5% (v/v) CO2 ] with the 
inhibitors for lh  (to ensure their uptake and action), after which they were treated with 
an appropriate cytokine [or PM A (0.16pM) in the case o f THP-1 cells] and incubated 
further. Following this, the cells were harvested at indicated time points for 
experimental analysis.
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2.3 .1 .7  T r y p a n  b l u e  e x c l u s io n  a s s a y
Trypan blue solution [0.4% (w/v)] was added to the cell culture medium at a ratio o f 
1:100 (v/v) and incubated at 37°C (5-10min). The medium was then aspirated from 
the cells and the cells were washed once with phosphate-buffered saline (PBS). The 
number o f cells taking up the blue stain was estimated by counting those in a 
representative area using phase contrast microscopy. The proportion o f dead cells 
was calculated from this.
2.4 D N A  T r a n s f e c t io n s
2.4.1 PO LYETHYLENIM INE TRANSFECTION (P E I)
Approximately 48h prior to transfection, Hep3B cells were split 1:6 (Section 2.3.1.2) 
and seeded equally into 6-well plates, so that on the day o f transfection the cells were 
between 40-60% confluent. Prior to transfection, the medium was changed to fresh 
complete medium (2ml/well o f plate). Plasmid DNA (2.5-12.5pg) was diluted to a 
volume o f 10pl in 5% (w/v) glucose. Polyethylenimine (PEI) solution (5.625mg/ml, 
pH 7.2) (1.5pl) was added to the DNA, mixed vigorously by pipetting and the 
resulting complex immediately suspended in 1ml o f DMEM complete medium, after 
which it was added dropwise to cells. The cells were then incubated overnight [37°C, 
5% (v/v) CO2 ] after which they were washed twice in DMEM with G lutaMAX™  and 
the medium replaced with fresh DMEM complete medium. A t this stage, i f  necessary 
the mediator in question was added to the cells and incubated further for the requisite 
time period.
2.4.2 P r e p a r a t io n  o f  c e l l  e x t r a c t s  f o r  t h e  d e t e r m in a t io n  o f  r e p o r t e r
GENE A C T IV IT Y
The medium was aspirated from the cells and replaced with PBS. The PBS was then 
aspirated from the cells and 200pl o f lx  passive lysis buffer (Promega) was added 
directly to the cell monolayer and left to incubate for 15min at room temperature. The 
cells were then scraped into the buffer, transferred into a microcentrifuge tube, 
vortexed for 45s and centrifuged at 12,000xg for 2min. The supernatant was 
transferred into a fresh tube and was either stored at -80°C or used immediately for 
the measurements o f luciferase activity.
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2.4.3 M e a s u r e m e n t  o f  l u c if e r a s e  a c t iv it y
The luciferase activity o f samples was determined as described by the manufacturer 
(Promega). Briefly, 20pl o f cell extracts (Section 2.4.2) were mixed, at room 
temperature, with lOOpl o f luciferase assay buffer (Promega) in a luminometer tube. 
The light output for each sample was determined using a luminometer (TD-20/20 
Turner Designs, California, USA). The luminometer was set at a 45% sensitivity 
value, w ith a 2s delay period and a 20s integrate period. A ll measurements were 
taken in duplicate and the background values were subtracted from the sample values. 
Also note that the total protein concentration o f  each sample was determined (Section 
2.7.4). Protein concentrations were then used to analyse the data generated from 
transfection studies. That is, the luciferase counts were normalised to the protein 
concentration (pg/pl) in each sample.
2.4.4 P l a s m id s
During this study, several DNA constructs were used to analyse promoter activity and 
to investigate various signalling pathways. Many o f these constructs were kind gifts 
from various laboratories, the details o f which are discussed briefly below. Where 
applicable, an appropriate reference is also provided. Plasmid maps for all expression 
and reporter vectors can be found in Appendix I.
2.4.4.J pHuC/EBPSfl. 6kbJ-Luc
A 1.6kb region o f the human C/EBPS promoter upstream o f the transcriptional start 
site was cloned into the luciferase reporter vector pLUC (Cleutjens et al. 1993). This 
plasmid was obtained from Dr J Trapman (Erasmus University, Netherlands).
2.4.4.2 pHuC/EBPSf0.2kbJ-Luc
A 0.2kb region o f the human C/EBPS promoter upstream o f the transcriptional start 
site was cloned into the pGL2-Basic luciferase reporter vector. This plasmid was 
created by Dr F.T. Kockar (Balikesir University, Turkey).
2.4.43 pMoC/EBPS[2.2kb/-Luc
A  2.2kb region o f the murine C/EBPS promoter (-2146 to +73) site was cloned into 
the pGL2-Basic luciferase reporter vector (O'Rourke et al. 1999a; Hutt et al. 2000).
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2.4.4.4 p N F kB -L uc
This plasmid was obtained from Dr D. Leake (University o f Reading, U.K) and is 
based on the luciferase reporter vector pTAL-Luc (Clontech) containing an insert o f 
four NF-kB consensus enhancer elements.
2.4.4.5 SAPKa-VPF
This expression plasmid encodes a SAPK/JNK protein, in which the normally 
conserved phosphorylation m o tif o f Thr-Pro-Tyr is altered to Val-Pro-Phe, producing 
an inactive, dominant negative SAPK/JNK protein. This plasmid was a kind g ift from 
E. Nishida (Kyoto University, Japan) (Moriguchi et al. 1995).
2.4.4.6 D /N  C-JUN/TAM67
This expression plasmid encodes a dominant-negative mutant o f c-Jun that dimerises 
with endogenous c-Jun and c-Fos. Thus, this mutant is a potent inhibitor o f AP-1 
mediated trans-activation. The mechanism o f action o f this dominant negative mutant 
has been discussed by Brown et al. (1994).
2.4.4.7 D /N  CK2a-K68A
This expression plasmid encodes a kinase inactive mutant o f the CK2a catalytic 
subunit in which Lys68 has been substituted for Ala in the ATP-binding domain o f 
this subunit. This plasmid was a generous g ift from Drs E.M. Chamburg and C 
Cochet (INSERM, Grenoble, France) (Lebrin et al. 2001).
2.4.4.8 I kB Super-Repressor
This expression plasmid contains a cDNA insert that encodes the human IkB ci protein, 
which acts to inhibit NF-kB signalling when over-expressed. This plasmid was a kind 
gift from Dr D. Krappman (Berlin, Germany) (Krappmann et al. 1996).
2.4.4.9 MSVp
This expression plasmid contains a cDNA insert that encodes the wild-type murine 
C/EBPp protein. This plasmid was a kind g ift from Prof. S.L. McKnight (Carnegie 
Institution o f Washington, Baltimore, U.S.A) (Cao et al. 1991).
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2.4.4.10 MS VS
This expression plasmid contains a cDNA insert that encodes the wild-type murine 
C/EBPS protein. This plasmid was a kind g ift from Prof. S.L. McKnight (Carnegie 
Institution o f Washington, Baltimore, U.S.A) (Cao et al. 1991).
2.4.4.11 pCS2xa
This expression plasmid contains a cDNA insert that encodes the wild-type Xenopus 
laevis C/EBPa protein. This plasmid was created by Dr S. Kousteni (Cardiff 
University, U.K.) (Kockar et al. 2001).
2.5 SMALL INTERFERING R N A  (S lR N A ) TRANSFECTIONS
A ll siRNA transfections were carried out using validated siRNAs against target 
mRNAs obtained from Qiagen and Invitrogen, the details o f which are presented in 
Tables 2.1 and 2.2 respectively. Qiagen retains the right to withhold the sequences o f 
its validated siRNAs and instead provides customers with an ‘ ST reference number 
that identifies every siRNA. As every SI reference number is unique, this can be used 
to identify siRNAs required for publication purposes (Dr K. Brennan, Qiagen, 
personal communication). Therefore in Table 2.1, for siRNAs ordered from Qiagen 
no sequence is provided, in place the SI reference number for each siRNA is 
specified. Invitrogen provides its customers with two validated siRNA duplexes for 
each target mRNA, the sequences o f which are presented in Table 2.2. It is 
noteworthy that in all experiments presented in thesis, involving the use o f these 
siRNAs, the results have been verified with the use o f both the duplexes presented.
siRNA stock solutions were prepared according to the manufacturer’ s instructions 
(Qiagen and Invitrogen) from lyophilised siRNAs.
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T a b l e  2.1 Details o f validated siRNAs used in this study as ordered from 
Qiagen.
T a r g e t
T r a n s c r ip t ( s)
N C B I A c c e s s io n  
N u m b e r ( s ) o f  
T a r g e t ( s)
G e n e  Sy m b o l S I R e f e r e n c e  
N u m b e r /C a t a l o g u e  
N lJMBERf
CK2a’ NM 001896 CSNK2A2 SI00605409
c-JUN NM 002228 JUN SI00300580
JNK1 NM_002750 
NM_139046 
NM_139047 
NM_139049
MAPK8 SI02758637
1022515+
JNK2 NM 002752 
NM_139068 
NM_139069 
NM_139070
MAPK9 SI02222920
1022632+
TAK1 NM 003188 
NMJ45331 
NM_145332 
NM_145333
MAP3K7 SI02758756
p65 NF-kB NM 021975 RELA SI02663094
p50 NF-kB NM 003998 NFK.B1 SI02654932
+ Where SI reference numbers were not available, the unique catalogue number identifying the 
specified siRNA is provided.
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T a b l e  2.2 Details o f validated siRNAs used in this study as ordered from Inv itrogen.
T a r g e t
T r a n s c r ip t (s)
G e n e  Sy m b o l NCBI P r im a r y
A c c e s s io n
N u m b e r
siRNA T a r g e t  
L o c a t io n  B a s e d  O n  
A c c e s s io n  N u m b e r
T a r g e t  S e q u e n c e  
(5’ -► 3’)
CK2a CSNK2A1 NM_001895.3 650
761
Duplex 1 5’-ACCAGACGUUAACAGACUAUGAUAU-3’ 
Duplex 2 5’-UCAUGAUUGAUCAUGAGCACAG AAA-3’
p38 MAPK MAPK 14 NM139012 758
691
Duplex 1 5’-CCAAAUUCUCCGAGGUCUAAAGUAU-3’ 
Duplex 2 5’-GGGCAGAUCUGAACAACAUUGUGAA-3’
STATI STATI NM 007315.2 608
882
Duplex 1 5’-GCAAGCGUAAUCUUCAGGAUAAUUU-3’ 
Duplex 2 5’-GCAGAACAGAGAACACGAGACCAAU-3’
STAT3 STAT3 N M J  39276 453
501
Duplex 1 5’-CCUGCAAGAGUCGAAUGUUCUCUAU-3’ 
Duplex 2 5’-GCAGUUUCUUCAGAGCAGGUAUCUU-3’
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2.5.1 SiRNA TRANSFECTIONS USING D H A R M A F E C T ™
Approximately 48h prior to transfection, Hep3B cells were split 1:6 (Section 2.3.1.2) 
and seeded equally into 24-well or 6-well culture plates depending on the experiment. 
Following an overnight incubation [37°C, 5% (v/v) C 0 2], the medium was changed to 
DMEM complete medium with no antibiotics and the cells were left to incubate 
[37°C, 5% (v/v) C 0 2] for a further 24h. Having reached approximately 40% 
confluence, Hep3B cells were ready to transfect.
The fo llow ing procedure was carried out for the transfection o f cells in one 2cm2 cell 
culture dish. For multiple transfections, the volumes detailed in the protocol below 
were multiplied by the number o f desired transfections. For co-transfections, 
involving the use o f two siRNAs together and for transfections involving different cell 
culture formats the appropriate volumes o f reagents required for transfections are 
shown in Table 2.3.
On the day o f transfection, the medium was aspirated from the cells and replaced with 
lm l o f DM EM  complete medium, containing no antibiotics. Essentially, the 
transfection protocol detailed below is as described by the manufacturer, with minor 
modifications (Dharmacon RNA Technologies). A  2.5pM siRNA solution [siRNA 
was diluted in an appropriate volume o f RNase-free water or siRNA suspension 
buffer (Qiagen)] was prepared. In a sterile tube (Tube 1 in Table 2.3), 2.5pl o f 2.5pM 
siRNA solution was diluted with 47.5pl o f HI-FCS-free and antibiotic-free DMEM 
medium. In a separate tube (Tube 2 in Table 2.3), 0.5pl o f DharmaFECT™ reagent 
(Dharmacon RNA Technologies) was diluted in 49.5pl o f HI-FCS-free and antibiotic- 
free DM EM  medium. The content o f each tube was mixed thoroughly by pipetting, 
before being left to incubate at room temperature for 5min. Subsequently, the content 
o f each tube was combined, mixed and this ‘ transfection-mix’ was incubated for a 
further 20min at room temperature. The resultant transfection-mix was added (lOOpl, 
dropwise) to the cells in the 2cm2 culture dish and the cells were returned to incubate
[37°C, 5% (v/v) CO2 ] for approximately 65h. By observing this protocol, the
2 • • approximate concentration o f siRNA in a 2cm culture dish (containing lm l o f
medium) is 6.25nM. Following the incubation period cells were harvested for RNA
(Section 2.6.2) or protein extraction (Section 2.7.1). Alternatively, where appropriate,
the medium was aspirated from the cells and replaced with DMEM complete medium
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without antibiotics. The cells were then treated with the appropriate mediator, 
incubated further for the requisite time period, before being harvested for RNA 
(Section 2.6.2) or protein extraction (Section 2.7.1).
T a b l e  2.3 Volumes o f reagents required fo r various siRNA transfections in 
different cell culture formats.
R e a g e n t 2 c m 2
CULTURE
DISH
2 c m 2 c u l t u r e
DISH (CO ­
TRANSFECTION)
9 .5 c m 2
CULTURE
DISH
9 .5 c m 2 c u l t u r e  
DISH (CO­
TRANSFECTION)
DMEM 
complete 
medium (minus 
antibiotics) on 
cells (ml)
1 1 2 2
siRNA at 2.5pM 
(pi) TUBE 1
2.5 2.5 (siRNA 1)
+
2.5 (siRNA 2)
5 5 (siRNA 1) 
+
5 (siRNA 2)
HI-FCS- and 
antibiotic-free 
DM EM  medium 
(pi) TUBE 1
47.5 45 45 40
DharmaFECT™ 
(pi) TUBE 2
0.5 0.5 1 1
HI-FCS- and 
antibiotic-free 
DMEM medium 
(pi) TUBE 2
49.5 49.5 49 49
Volume o f 
transfection-mix 
applied to cells 
(Ml)
100 100 100 100
Final siRNA
concentration
(»M)
6.25 12.5 6.25 12.5
siRNA 1 and siRNA 2 denote the different siRNAs used in combination in the co-transfection.
2.6 R N A /D N A  r e l a t e d  t f x h n iq u e s
2.6.1 T o t a l  RNA is o l a t io n  u s in g  R N e a s y ™  m in i  k it  (Q ia g e n )
Total RNA was isolated from cells using the RNeasy™ Total RNA Isolation kit 
(Qiagen) according to the instructions supplied by the manufacturer. Briefly, the 
medium was aspirated from the cells and the cells were then washed once in PBS.
84
C h a p t e r  t w o : M a t e r ia l s  a n d  M e t h o d s
The cells were then scraped into the PBS, transferred to a 15ml polypropylene tube 
and centrifuged at lOOOxg for 5min. The resulting supernatant was discarded and the 
cell pellet was thoroughly resuspended in 350-600pl o f buffer RLT (containing 
lOpl/ml p-mercaptoethanol) supplied in the kit. This lysate was then homogenised by 
passing it through a 0.9mm needle attached to a lm l syringe (5 times). A t this stage, 
the lysate was either stored at -80°C for use at a later date, or immediately used for 
RNA extraction. The integrity o f the RNA was determined by resolving lpg  on a 1% 
(w/v) agarose gel (see Section 2.6.4.1 for details). The purity and concentration o f the 
RNA was assessed by measuring O.D .260 and O.D .280 using a U-1800 Hitachi 
spectrophotometer.
2.6.2 T o t a l  RNA i s o la t io n  u s in g  R N e a s y ™  m ic r o  k i t  (Q ia g e n )
For small scale preparations o f total RNA the RNeasy™ Micro Total RNA Isolation 
K it (Qiagen) was used according to the manufacturer’s instructions. Briefly, Hep3B 
cells were washed once with PBS, which was then aspirated from the growing cells. 
At this stage, 350pl o f Buffer RLT was added directly to the cell monolayer (growing
'y
in a 2cm cell culture dish). The resultant lysate was collected and passed through a 
Qiagen QI shredder column for homogenisation. A t this stage, the total RNA 
isolation procedure was carried out exactly as described by the manufacturer (Qiagen) 
or the lysate was stored at -80°C for use at a later date.
2.6.3 R e v e r s e  t r a n s c r i p t  a s e -p o ly m e ra s e  c h a in  r e a c t io n  (R T -P C R )
RT-PCR can be separated into two steps:
1. Synthesis o f cDNA from RNA using reverse transcriptase (RT).
2. Polymerase chain reaction (PCR), with cDNA from step 1 using gene- 
specific primers to amplify a product o f interest.
2.6.3.1 cDNA SYNTHESIS (RT)
cDNA was synthesised from lpg  o f total cellular RNA (isolated as described in 
Section 2.6.1 and Section 2.6.2). Briefly, to lp g  o f total RNA was added, lp l o f 
(200pmol, PdN6) random hexameric primers and molecular biology grade water to 
achieve final volume o f 13.5pl. Samples were then incubated for 5min at 70°C and 
then quenched on ice. Subsequently, 4pl o f 5x Moloney murine leukaemia virus
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(M M LV) reverse transcriptase buffer (Promega), lp l o f dNTP mix (lOmMeach o f 
dATP, dGTP, dTTP and dCTP), 0.5pl o f 50U/pl recombinant RNase inhibitor 
(RNasin®) and lp l o f M M LV  reverse transcriptase (200U/pl) was added to each 
reaction. Samples were then incubated for lh  at 37°C and the reaction was terminated 
by incubation at 94°C for 2min. The synthesised cDNA was diluted 5-fold by the 
addition o f 80pl nuclease-free H 2O. cDNA prepared in this way was stored at -20°C 
or used for PCR analysis (Section 2.6.3.2).
2.6.3.2 P o l y m e r a s e  c h a in  r e a c t io n  (P C R )
PCR conditions were specific for each primer pair used to amplify various products. 
Table 2.4 documents the PCR primer sequences, the expected PCR product size for 
each primer pair and where applicable, the references from which primer sequences 
were obtained. The reaction conditions required for the amplification o f the various 
PCR products analysed during this study are specified in Table 2.5. It is noteworthy, 
that PCR conditions and cycles o f amplification were optimised for each primer set so 
that products were generated in the exponential phase o f amplification. That is, there 
was a direct correlation between the amount o f product and the amount o f the original 
cDNA template used. Temperature cycling was carried out on either a Techne 
Thermal Cycler or a Peltier Thermal Cycler (PTC-200).
86
C h a p te r  2: M a t e r ia l s  a n d  M e th o d s
T a b l e  2.4 Sequences of forward and reverse primers used to PCR-amplify specified products and their sizes in base pairs (bp).
GENE
(REFERENCE)
FORWARD PRIMER (5’-3’) REVERSE PRIMER (5’-3’) PCR PRODUCT SIZE (BP)
Hu p-actin
(Sabatakos etal. 1998b)
AT GAT AT CGCCGCGCT CG CGCT CGGT GAGGAT CTT CA 580
Hu p-2-microglobulin TTT CT GGCCT GGAGGCT AT C CAT GT CT CGAT CCCACTT AACT 314
Hu C/EBP6 GCGCGAGCGCAACAACATC CCAGGT CCCGCGT GAGCT 143
Hu CK2a T G AGCT ACTTGT AG ACT AT C A CT GAAGAAATCCCTGACATCA 473
Hu CK2a’ G AGCT GGGGT AAT C AAGAT G T AG AATT CT GCC AG ACCCC A 453
Hu GAPDH
(Sabatakos etal. 1998b)
CCCTT CATT GACCT CAACTACAT GG AGT CTT CT GGGT GGCAGT GAT GG 455
Hu JNK1 MAPK ACCTATAGGCTCAGGAG CT CCAT CT GAATCACT 277
Hu JNK2 MAPK (primer set 1) ATAGT GT GCAAGT GGCAG GCAT CCATT AATT CCA 307
Hu JNK2 MAPK (primer set 2) 
(Dadoune et al. 2005)
GAT CAGCCTT CAGAT GCAGCAGT AAGTAG CAAAGT GCT AGAT GGGCAAGT CC AAG 524
Hu LPL
(Irvine etal. 2005)
GAG ATTT CT CT GT AT GGCACC CT GC AAAT GAGACACTTT CT C 276
Hu p38 MAPK GT GCCCG AGCGTT ACCAGAACC CT GT AAGCTT CT GAC ATTT C 313
Hu p50 NF-kB CAACTAT GT GGGACCAGCAA CAT AGAT GGCGT CT GAT ACC 461
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Hu p65 NF-kB (RelA) AT GGCTT CT AT G AGGCT GAG GCAGGT ACT GGAATT CCAT G 579
Hu 28S rRNA 
(Singh and Ramji 2006)
T G AACT AT GCTT GGGCAGGG AGCGCCAT CCATTTT C AGGG 513
Hu STAT1 AAT CCAGAT GT CT AT GAT CAT AACT AT AGT G AACC AGTT CT 505
Hu STAT3 AAG AAT C ACGCCTT CT ACAGA TT GACCAGCAACCT GACTTT A 730
Hu TAK1 
(Klatt et al. 2006)
CCGT GT G AACCAT CCT AAT A GGGCCACCAAT CT CAT C AAA 459
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T a b l e  2.5 Reaction conditions required for the amplification of the various PCR products analysed during this study.
GENE
Forward
primer
(100pM)
Fl
Reverse
primer
(100pM)
dNTPs
(10mM)
Hi
MgCI2
(50mM)
Hi
PCR
buffer
(x10)
H>
DMSO
Hi
cDNA
Hi
Taq 
polymerase 
(5U/pl) pi
Initial
melting
Annealing Extension Melting Final
long
extension
Number
of
cycles
Hu p-actin 0.5 0.5 1 1.5 5 2.5 10 0.5 95°C
5min
57°C
1min
72°C
2min
93°C
0.5min
72°C
10min
16
Hu p-2-
microglobulin
0.5 0.5 1 1 5 • 5 0.25 95°C
5min
60°C
1min
72°C
2min
95°C
0.5min
72°C
8min
19
Hu C/EBP8 0.5* 0.5* 1 1 5 2.5 10 0.5 94°C
2min
60°C
2min
72°C
2min
94°C
2min
72°C
5min
25-29
Hu CK2a 0.5 0.5 1 2 5 2.5 10 0.25 95°C
2min
61°C
1min
72°C
1min
95°C
0.5min
72°C
10min
26
Hu CK2a’ 0.5 0.5 1 1.5 5 2.5 10 0.25 96°C
5min
60.8°C
1min
72°C
1mim
96°C
0.5min
72°C
10min
27
Hu GAPDH 0.5 0.5 0.5 2 5 • 10 0.5 96°C
5min
60°C
1min
72°C
2min
93°C
0.5min
72°C
10min
17
HuJNK1 
MAPK
1 1 1 1 5 2.5 10 0.5 95°C
5min
55°C
1min
72 °C 
1min
95 °C 
0.5min
72 °C 
10min
30
Hu JNK2 
MAPK 
(primer set 1)
1 1 1 1 5 2.5 10 0.5 95°C
2min
51°C
1min
72°C
1min
95°C
0.5min
72°C
5min
30
Hu JNK2 
MAPK 
(primer set 2)
1 1 1 1.5 5 2.5 10 0.5 94°C
2min
71°C
0.5min
72°C
1min
94°C
0.5min
72°C
10min
27
Hu LPL 0.5 0.5 1 2 5 " 10 0.25 96°C
5min
55°C
1min
72°C
2min
93°C
0.5min
72°C
10min
24
Hu p38 MAPK 0.5 0.5 0.5 1.5 5 - 10 0.25 95°C
2min
55°C
1min
72°C
1min
95®C
1min
72°C
5min
22
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Hu p50 NF-kB 0.5 0.5 1 1.5 5 2.5 10 0.25 95°C
2min
62°C
1min
72°C
1min
95<C
0.5min
72°C
10min
25
Hu p65 NF-kB 
(RelA)
0.5 0.5 1 1 5 2.5 10 0.25 95°C
2min
62°C
1min
72°C
1min
95°C
0.5min
72°C
10min
26
Hu 28S rRNA 1 1 1 0.5 5 - 5 0.25 95°C
5min
62°C
1min
72°C
2min
93°C
0.5min
72°C
10min
10
Hu STAT1 0.5 0.5 1 1.5 5 2.5 10 0.5 95°C
2min
58°C
1min
72°C
1min
95°C
0.5min
72°C
10min
28
Hu STAT3 0.5 0.5 1 1.5 5 2.5 10 0.5 95°C
2min
58°C
1min
72°C
1min Ss
s
1*
72°C
10min
25
Hu TAK1 0.5 0.5 1 2 5 2.5 10 0.25 95°C
2min
59°C
1min
72°C
1min
95°C
0.5min
72°C
10min
25
*C/EBP5 PCR primers were prepared at 33.3pM, not lOOpM.
A ll PCRs were prepared in a 50pl reaction volume achieved with the addition o f the appropriate volume o f molecular biology grade water.
Abbreviations: Mo, murine; Hu, human.
90
C h a p t e r  t w o : M a t e r ia l s  a n d  M e t h o d s
2.6.4 A g a r o s e  g e l  e l e c t r o p h o r e s is  o f  RNA/DNA
For the electrophoresis o f DNA and total RNA, a 5x loading dye solution was 
prepared [0.5x TBE, 40% (v/v) glycerol, 0.25% (w/v) bromophenol blue]. The 5x 
loading dye was autoclaved prior to use (Section 2.2). For electrophoresis, a lOx TBE 
[0.89M Tris borate (pH 8.3), 0.02M EDTA (Sigma)] stock buffer was used to prepare 
a lx  TBE buffer, which was made up using ultra-violet (UV) -light treated double­
distilled water (ddH2 0 ).
2.6.4.1 R e s o l v in g  RNA o n  a g a r o s e  g e l s
Routinely, lpg  o f RNA was resolved on 1% (w/v) agarose gels to assess its integrity. 
The gels were made using lxTBE containing ethidium bromide (0.5pg/ml). RNA 
samples were prepared with sterile 5x loading dye and made up to a final volume o f 
20|il w ith RNase free water (Qiagen), before loading. Electrophoresis was carried out 
using a Fisherbrand Horizonal Gel Unit at 100V for 30min, in lxTBE buffer. RNA 
was visualised under UV light using a Syngene Gel Documentation System.
2.6.4.2 R e s o l v in g  DNA o n  a g a r o s e  g e l s
To resolve DNA, gels were prepared between 0.8-2% (w/v) agarose, depending on the 
size o f the DNA requiring size fractionation. Typically, PCR products were resolved 
on 1.5% (w/v) agarose gels and the fragment size determined by comparison to 
standard D NA molecular markers (see Appendix II). Plasmid DNA (approximately 
500ng) was size-fractionated on 0.8% (w/v) agarose gels and again compared against 
standard DNA molecular markers (see Appendix II). The gels were made using 
lxTBE  containing ethidium bromide (0.5pg/ml). DNA samples were prepared using 
5x DNA loading dye, prior to gel loading. DNA electrophoresis was carried out on a 
Fisherbrand Horizontal Gel Unit, at 100V for lh, in lxTBE  buffer. DNA was 
visualised under UV light using a Syngene Gel Documentation System.
2.6.5 E x t r a c t io n  o f  DNA f r o m  a g a r o s e  g e l s
DNA bands were excised from ethidium bromide stained agarose gels and purified 
using the QIAquick™ gel extraction k it (Qiagen), according to the manufacturer’s
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instructions. The efficiency o f purification was assessed by analysing an aliquot o f 
the purified DNA on a 1.5% (w/v) agarose gel by electrophoresis (Section 2.6.4.2).
2.6.6 B a c t e r ia l  s t r a in s  a n d  v e c t o r s
A ll bacterial culture media (LB-agar and LB-liquid media) was prepared according to 
the manufacturer’ s instructions (DIFCO Laboratories). Table 2.6 specifies the 
genotypes o f the Escherichia coli (E. coli) strains used during the course o f this study.
T a b le  2.6 Genotypes of Escherichia coli (E. coli) used
St r a in G e n o t y p e R e f e r e n c e
J M 109 recAl supE44 endAl hsdR17 gyrA96 relA l thi A(Iac- 
proAB) F’ [/raD3<5 proAB lacfi lacZDM15]
(Yanisch-Perron etal. 1985)
DH 5a supE44 AlacUI69 (<p80 lacZAM15) hsdl? recAl endAI 
gyrA 96 thi-1 relA I
(Hanahan 1983)
2.6.6.1 P r e p a r a t io n  o f  c o m p e t e n t  c e l l s
For the preparation o f competent cells, a modified version o f the method described by 
Mandel and Higa (1970) was used. LB-medium (5ml, pre-heated to 37°C) was 
inoculated with a single bacterial colony o f E. coli strain DH5a or JM109 and 
incubated for 12-18h with shaking (300rpm) at 37°C. Subsequently, 0.1ml o f this 
overnight culture was used to inoculate 9.9ml o f fresh LB-medium that was then 
incubated with shaking (300rpm) at 37°C until an O.D.550 o f between 0.5-0.6 was 
observed. The cells were then pelleted by centrifugation at 3000xg for 5min at 4°C, 
resuspended in ha lf their original volume (5ml) o f ice-cold 50mM CaCh, and kept on 
ice for 25min. The cells were then pelleted again by centrifugation as above, and 
resuspended in 1/10 o f their original volume (1ml) o f ice-cold 50mM CaC^. 
Competent cells were kept on ice until required for transformation or mixed with an 
equal volume o f 40% (v/v) sterile glycerol and dispensed into 200pl aliquots in pre­
chilled microcentrifuge tubes and stored at -80°C.
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2.6.6.2 T r a n s f o r m a t io n  o f  c o m p e t e n t  c e l l s
Competent cells were thawed on ice for 30min prior to transformation. Plasmid DNA 
(lOng) was added to 200pl o f competent cells, which were subsequently kept on ice 
for 40-60min. The cells were then heat-shocked at 42°C for 90s and placed back on 
ice for a further 2min. LB-medium (800pl) was added to the cells, which were then 
incubated at 37°C with shaking (300rpm) for lh. For the selection o f ampicillin 
resistant bacterial colonies, the follow ing method was used. The cells (200pl) were 
spread on LB-agar plates containing lOOpg/ml ampicillin. The remaining cells 
(800pl) were pelleted (3000xg, 3min), the supernatant discarded, resuspended gently 
in lOOpl o f fresh LB-medium and plated on agar plates containing 100pg/ml 
ampicillin. Plates were incubated overnight at 37°C, and analysed for ampicillin 
resistant colonies.
2.6.6.3 S m a l l - s c a l e  p r e p a r a t io n  o f  p l a s m id  DNA ( m i n i - p r e p )
LB-medium (10ml) containing ampicillin (lOOpg/ml) was inoculated with a single 
colony o f transformed E. coli and incubated for 16h at 37°C with constant shaking at 
300rpm. Preparation o f plasmid DNA from the bacterial culture was carried out using 
Wizard SV™ Miniprep K it according to the manufacturer’s instructions (Promega).
2.6.6.4 L a r g e - s c a l e  p r e p a r a t io n  o f  p l a s m id  DNA ( m a x i - p r e p )
LB-medium (500ml) containing ampicillin (lOOpg/ml) was inoculated with 1ml o f a 
bacterial culture (from Section 2.6.6.3) derived from a single colony and grown in 
antibiotic selective media for 16h at 37°C with shaking (300rpm). Plasmid DNA was 
subsequently prepared using a High Purity Plasmid Purification Maxiprep kit 
(Marligen Biosciences) according to the manufacturer’s instructions (Marligen 
Biosciences). The plasmid DNA was diluted in sterile molecular biology grade water 
follow ing purification. The concentration and purity o f the DNA was determined by 
measuring O.D.26o and O.D.2go using a U-1800 Hitachi spectrophotometer.
2.6.7 R e s t r ic t io n  e n d o n u c l e a s e  d ig e s t io n  o f  r e c o m b in a n t  p l a s m id  DNA
Typically, restriction endonuclease reactions were performed with 100-500ng o f DNA 
in 20pl reaction volume. Restriction endonuclease digestion reactions were carried
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out in the presence o f a two-fold excess o f the appropriate restriction endonuclease(s). 
Single and double enzyme digestions were typically performed at 37°C (unless 
otherwise stated by the enzyme supplier) for 2h in the recommended buffers [w ith or 
without BSA (lOOpg/ml) depending on the enzyme] provided by the enzyme supplier 
(New England Biolabs). I f  required, restriction endonucleases were heat-inactivated 
at the end o f the digestion to terminate the reaction. Restriction digests were analysed 
using agarose gel electrophoresis (Section 2.6.4.2).
2.6.8 A u t o m a t e d  DNA s e q u e n c in g
DNA was sequenced by LARK using an automated fluorescent dye termination 
method o f sequencing. For further information see http://www.lark.com.
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2.7 P r o t e in  a n a l y s is
Micro-centrifugation steps described in this section were carried out in a Biofuge pico 
micro-centrifuge (Heraeus).
T a b l e  2.7 lists the stock solutions required  fo r protein analysis used during  the 
course o f this study.
So l u t io n C o m p o s it io n
Phosphatase-free whole cell 
extraction buffer
10mM Tris-HCI (pH 7.05), 50mM NaCI, 50mM NaF, 1% (v/v) Triton X- 
100, 30mM Na»P20 7  (sodium pyrophosphate), 5pM ZnCI2, 100pM 
Na3V 0 4 (sodium orthovanadate), ImM DTT, 2.8pg/ml aprotinin, 
2.5pg/ml each of leupeptin and pepstatin, 0.5mM benzamidine, 0.5mM 
PMSF
Nuclei extraction buffer A lOmM HEPES (pH 7.9), l.5mM MgCI2, lOmM KCI, 0.5mM DTT, 
0.5mM PMSF, Ipg/ml pepstatin A, lOpg/ml aprotinin, 10|ig/ml 
leupeptin, lOpg/ml type I-S soybean trypsin inhibitor
Nuclear extraction buffer C 25% (v/v) glycerol, 20mM HEPES (pH 7.9), 420mM NaCI, 1.5mM 
MgCI2, 0.5mM PMSF in isopropanol, lOpg/ml type I-S soybean trypsin 
inhibitor, 0.2mM EDTA, 0.5mM DTT, Ipg/ml pepstatin A, lOpg/ml 
aprotinin, lOpg/ml leupeptin
Laemmli sample buffer 0 .125M Tris-HCI (pH 6.8), 4% (w/v) SDS, 10% (v/v) glycerol, 10% 
(v/v) 0-2-mercaptoethanol
Bromophenol blue solution 0.05% (w/v) bromophenol blue in H20
SDS-PAGE lower gel buffer I.5M Tris-HCI (pH 8.8), 10% (w/v) SDS
SDS-PAGE upper gel buffer 1M Tris-HCI (pH 6.8), 10% (w/v) SDS
SDS-PAGE gel loading buffer 50mM Tris-HCI (pH 6.8), lOOmM DTT, 2% (w/v) SDS, 0.1% (w/v) 
bromophenol blue, 10% (v/v) glycerol
SDS-PAGE running buffer 25mM Tris, 250mM glycine, 0.1% (w/v) SDS
Western blot transfer buffer 25mM Tris, 192mM glycine, 20% (v/v) methanol
lOx Tris-buffered saline (TBS) lOmM Tris-HCI, 20mM NaCI, pH 7.4
2.7.1 P r e p a r a t io n  o f  p r o t e in  e x t r a c t s  u s in g  l a e m m l i  s a m p l e  b u f f e r
Hep3B cells growing in a 9.5cm2 dish were harvested for protein analysis using 
Laemmli sample buffer (Table 2.7). The medium was aspirated and the cells were 
washed with 1ml o f PBS. Once the PBS was removed by aspiration, freshly prepared 
Laemmli sample buffer (75pl) was added directly to the cells and these cells were 
scraped into this buffer. The extracts were then collected and micro-centrifuged 
(12,000rpm, 5min). A t this point, the extracts were either frozen (-80°C) for use on a 
later date or subjected to SDS-PAGE and subsequently, western blotting (Sections
2.7.7 and 2.7.8).
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2.7.2 P r e p a r a t io n  o f  p h o s p h a ta s e - f r e e  w h o le  c e l l  p r o t e in  e x t r a c t s
Phosphatase-free whole cell extracts were prepared as described by Hipskind et al. 
(1994). Hep3B cells were scraped into the medium in which they were growing, 
transferred to a 50ml polypropylene tube (Falcon) and centrifuged at lOOOxg for 
5min. The cell pellet was washed (x2) with ice-cold PBS containing lOmM NaF and 
lOOpM sodium orthovanadate (1ml), and micro-centrifuged (13,000rpm, lm in) 
between washes. The supernatant was discarded and the cell pellet resuspended in 
freshly prepared phosphatase-free whole cell extraction buffer (100-200jil) (see Table 
2.7) by vortexing (45s) and lysed by vigorous pipetting. Following centrifugation 
(10,000xg for lOmin at 4°C), the supernatant, containing the total cellular protein was 
removed and stored at -80°C. The concentration o f total cellular protein was 
determined using the Micro BCA protein assay reagents (Pierce) (Section 2.7.4).
2.7 .3  P r e p a r a t io n  o f  n u c le a r  p r o t e in  e x t r a c t s
Nuclear extracts were prepared according to the protocol described by Ramji et al. 
(1993a) with minor modifications. Hep3B cells were pelleted by centrifugation 
(lOOOxg, 5min) and washed three times by resuspension in ice-cold PBS and micro­
centrifugation (10,000rpm, lm in). After the final washing step, the supernatant was 
discarded and the pellet resuspended in ice-cold buffer A  (50pl) (Table 2.7) and 
incubated on ice (15min). The cells were lysed by drawing 5 times through a 
Hamilton syringe and subjected to micro-centrifugation (10,000rpm, 20s) at 4°C. The 
resulting nuclear pellet was gently resuspended in ice-cold buffer C (60pl) (Table 2.7) 
and incubated on ice (30min). After micro-centrifugation at 4°C (10,000rpm, 5min) 
the supernatant was removed and stored at -80°C. The concentration o f nuclear 
protein extract was determined using the Micro BCA protein assay reagents (Pierce) 
(Section 2.7.4).
2.7 .4  D e t e r m in a t io n  o f  p r o te in  c o n c e n t r a t io n
The concentration o f protein extracts was determined using the Micro BCA Protein 
Assay Reagent K it (Pierce) in accordance w ith the manufacturer’s instruction. A  
standard curve was produced for each assay using bovine serum albumin (BSA) 
solution at concentrations o f 5pg/ml, lOpg/ml, 15pg/ml, 20pg/ml and 25pg/ml in
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lOOpl final volume. Each sample, for which the protein concentration was to be 
determined, was diluted between 1/15-1/200 w ith PBS. For each dilution, samples 
(lOOpl) were aliquoted in duplicate and lOOpl o f protein assay reagent was 
subsequently added. After gentle agitation, the plate was incubated at 37°C for 2h to 
allow colour change to develop. The absorbance o f each sample was read at 595nm 
using a Dynex Technologies M RX microplate reader. The protein concentration o f 
each sample was then calculated from the standard curve.
2.7 .5  SAPK/JNK K in a s e  A c t i v i t y  A ssay
The SAPK/JNK kinase assays were carried out using the SAPK/JNK non-radioactive 
kinase assay kit (Cell Signalling Technology) with minor modifications to the 
protocol provided by the manufacturer essentially as described by Greenow (2004). 
Phosphatase-free whole cell extracts were prepared as described in Section 2.7.2. To 
250pg o f whole cell extract, 20pl o f c-Jun fusion protein beads were added and the 
sample was left to incubate overnight at 4°C, with gentle rocking. Following this 
incubation period, the sample was micro-centrifuged at 13,000rpm for lm in. The 
resultant pellet was washed twice in 300pl o f phosphatase-free whole cell extraction 
buffer minus the Triton-X-100 (Table 2.7), with micro-centrifugation at 13,000rpm 
for lm in  between washes. The pellet was then washed (x2) with lxJN K kinase buffer 
[25mM Tris-HCI (pH 7.5), 5mM (3-glycerophosphate, 2mM DTT, 0.1 mM Na3VC>4 , 
lOmM MgCb] with micro-centrifugation at 13,000rpm for lm in  between washes. 
Following the final wash, the pellet was resuspended in 50pl o f lxJN K kinase buffer 
supplemented with IOOjiM ATP. The kinase mix was incubated at 30°C for 30min. 
The kinase reaction was terminated by the addition o f 25pl o f SDS-PAGE gel loading 
buffer (Table 2.7). The sample was then boiled for 5min and loaded immediately 
onto a 10% (w/v) SDS-PAGE gel. SDS-PAGE and western blotting were carried out 
as described in Sections 2.7.7 and 2.7.8 respectively. An antibody specific to this kit 
(anti-phospho-c-Jun (Ser63)] was used for the immunodetection o f proteins (Section 
2.7.9, see Table 2.9 also).
2.7 .6  C a s e in  K in a s e  2 (C K 2 )  A s s s a y
This method was derived from the protocol used by Sung et al. (2001) and Lodie et 
al. (1997) w ith minor modifications. Phosphatase-free whole cell extracts were
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prepared as described in section 2.7.2 and the anti-CK2a subunit antibody was used to 
immunoprecipitate CK2a from 150pg o f extracts. Immunoprecipitation was carried 
out using Protein A/G agarose beads (Santa Cruz Biotechnology). Whole cell extracts 
were left to incubate overnight at 4°C, with gentle rocking with the anti-CK2a 
antibody (2jig/ml). The resulting protein-antibody complex was then ‘captured’ with 
the addition o f 20pl o f Protein A/G agarose with gentle rocking at 4°C for 2h. The 
immunoprecipitates were recovered by micro-centrifugation (13,000rpm, 2min) and 
the resulting pellet was washed (200pl) twice in phosphatase-free whole cell 
extraction buffer minus the Triton-X-100. The pellet was resuspended in 25pl o f lx  
kinase buffer [lOOmM Tris-HCI (pH 8.0), lOOmM NaCI, 20mM MgCh, 50mM KC1, 
lOOpM Na3 V 0 4 , 5mg/ml p-casein] to which lpC i [y-32P]-ATP was added. The kinase 
reaction was incubated for 15min at 37°C and terminated by the addition o f lOpl o f 
SDS-PAGE reducing gel loading buffer (Table 2.7). Samples were immediately 
subjected to SDS-PAGE (Section 2.7.7) using 15% (w/v) acrylamide gel. Following 
the electrophoresis, the gel was fixed for 20min in a solution containing 40% (v/v) 
methanol and 10% (v/v) acetic acid. A fter the gel had been fixed, it was briefly 
washed with d d ^ O , transferred to Whatmann 3M M  paper and dried under vacuum 
using a Gel Dryer (Model 583, Bio-Rad) at 80°C (lh ). The dried gel was exposed to 
Kodak X-Ray film  in a light proof cassette (GRI) at -80°C for varying exposure 
periods (12-72h). X-ray films were developed using a Gevamatic 60 automatic 
developer (Agfa-Gevaert).
2.7.7 S D S -p o l y a c r y l a m id e  g e l  e l e c t r o p h o r e s is  (SDS-PAGE)
SDS-PAGE was performed under reducing conditions following the method o f 
(Laemmli 1970). Typically, separating gels and stacking gels, containing 10% (w/v) 
and 5% (w/v) acrylamide respectively were used. Gels were prepared from stock 
solutions (see Table 2.7) as shown below in Table 2.8.
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T a b le  2.8 Composition of separating and stacking gels used fo r SDS-PAGE
G e l  COMPONENT 7.5% (W /V) 
Se p a r a t in g  
G e l
10% (w/v) 
S e p a r a t in g  
G e l
12.5% (W /V) 
Se p a r a t in g  
G e l
15% (W /V) 
Se p a r a t in g  
G e l
5% (w/v) 
St a c k in g  
G e l
U p p e r  b u f f e r - - - - 2.5ml
Lo w e r  b u f f e r 2.5ml 2.5ml 2.5ml 2.5ml -
ACRYLAMIDE: BISACRYLAMIDE 
(37 .5 :1 )
1.875ml 2.5ml 3.125ml 3.75ml 1.25ml
d d H 20 5.625ml 5ml 4.26ml 3.75ml 6.25ml
10% (W /V ) APS lOOpl lOOpl lOOpl lOOpl lOOpl
TEMED lOpl lOpl lOpl lOpl lOpl
Electrophoresis was carried out using the Mini-PROTEAN II slab electrophoresis cell 
from Bio-Rad Laboratories with the gel apparatus being assembled as described by 
the manufacturer (Bio-Rad Laboratories).
The separating gel was poured to within 3cm o f the upper edge o f the inner glass 
plate, isopropanol was layered on top o f the gel solution to exclude any air bubbles 
and the gel was allowed to polymerise for 30-40min. Once the gel had set, the 
isopropanol was washed o ff with ddfLO and the upper surface dried with Whatman 
3MM paper. The stacking gel was then poured on top and the well-forming comb 
inserted. Following polymerisation o f the stacking gel, the comb was removed and 
the wells were washed out with ddFLO. The gels were then placed in the 
electrophoresis tank and the upper and lower chambers were filled with lx  running 
buffer containing 0.1% (w/v) SDS (Table 2.7).
Protein samples were prepared for SDS-PAGE with either phosphatase-free whole 
cell extraction buffer or Laemmli sample buffer (Table 2.7). Prior to SDS-PAGE, 
phosphatase-free whole cell extracts (typically between 10-80pg) were mixed with an 
appropriate volume o f SDS-PAGE gel loading buffer (Table 2.7). Where samples 
were prepared with Laemmli sample buffer, extracts were mixed with an appropriate 
volume o f bromophenol blue solution (Table 2.7). A ll samples were then heated to 
100°C for 5min, after which they were quenched on ice. At this stage, samples were 
loaded immediately onto the gel. Rainbow protein size markers (lOpl) (GE 
Healthcare) were loaded into the first lane o f each gel (see Appendix II). The gel was
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then subjected to electrophoresis at a constant voltage o f 200V for 45-50min. The 
gels were then used for western blotting (see below).
2.7.8 W e s t e r n  b l o t t in g
This technique was adapted from Burnette (1981). Electrophoretic transfer o f 
proteins was carried out using a Bio-Rad Trans Blot Electrophoretic transfer cell (Bio- 
Rad Laboratories). The transfer o f protein to PVDF membranes (M illipore) was 
carried out as described by the manufacturer. Briefly, the gel was removed from the 
glass plates and the stacking gel was cut away. The gel was then equilibrated by 
incubation in transfer buffer (see Table 2.7) for 15min at room temperature. 
Whatman 3M M  paper, PVDF membrane (pre-wetted in methanol for 15s), both cut to 
the same size as the gel and the sponge pads o f the transfer apparatus were also pre­
wetted in transfer buffer. The PVDF membrane was then placed on the gel and 
sandwiched between the Whatman 3M M  paper and the sponge pads before being 
placed into the blotting cassette. The cassette was then subjected to electro-blotting in 
a tank containing transfer buffer at 4°C at a constant voltage o f 15V for 12-18h or 
150V for lh.
2.7.9 IMMUNODECTECTION OF PROTEINS
Blotted PVDF membranes were probed immunochemically as described below. The 
membrane was incubated in 20ml o f blocking solution [ lx  TBS containing 5-10% 
(w/v) non-fat m ilk powder and 0.1% (v/v) Tween-20] for lh. Excess blocking 
solution was removed at this point and the membrane washed three times (15min 
washes) in wash solution [ lx  TBS containing 0.1% (v/v) Tween-20]. The membrane 
was then incubated with primary antibody which was diluted in lx  TBS containing 
5% (w/v) skimmed m ilk powder or 5% (w/v) BSA and 0.1% Tween-20 for l-1.5h at 
room temperature or overnight at 4°C (see Table 2.9 for details). The membrane was 
then washed as described above and immersed in the appropriate secondary antibody 
(10-20ml) [horseradish peroxidase-conjugated, anti-rabbit IgG, anti-mouse IgG or 
anti-goat IgG diluted 1:2000-1:10,000 in lx  TBS containing 5-10% (w/v) skimmed 
m ilk  powder and 0.1% (v/v) Tween-20] and incubated for lh  at room temperature. 
Following another set o f washes, detection o f membrane bound protein was carried
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out as described in the instructions supplied with the Enhanced Chemi-Luminescent 
(ECL) detection kit (GE Healthcare).
T a b l e  2 .9  Primary antibodies used fo r the immunodetection o f proteins.
P r im a r y
A n t ib o d y
D i lu t io n  in  
lxTB S  0.1% 
(v /v )  T w e e n  20
%  (w /v )
NON-FAT 
MILK OR
BSA
I n c u b a t io n
PERIOD ( II)
(RT o r  4°C)
S iz e
( k D a )
anti-C/EBP8 1:2000 5
non-fat milk
1.5 (RT) 32
anti-p-actin 1:10,000 5
non-fat milk
1 (R T) 
or
12-18 (4°C)
42
anti-phospho-
SA PK/JN K
(T h r l8 3 /T y r l8 5 )
1:1000 5
BSA
12-18 (4°C) 54/46
anti-SAPK/JNK 1:1000 5
BSA
12-18 (4°C) 54/46
anti-phospho-c-J un 
(Ser63)
1:1000 5
BSA
12-18 (4°C) 35/37
anti-c-Jun 1:1000 5
BSA
12-18 (4°C) 42
anti-CK2a 1:1000 5
non-fat milk
1 (R T) 42
anti-C K 2a’ 1:1000 5
non-fat milk
1 (R T ) 40
anti- N F -kB 
pl05/p50
1:1000 5
BSA
12-18 (4°C) active form 50 
precursor 120
anti-NF-KB p65 1:1000 5
BSA
12-18 (4°C) 75
an ti-T A K l 1:1000 5
BSA
12-18 (4°C) 80-82
anti-STA Tl 1:1000 5
BSA
1 (R T) 84/91
anti-phospho- 
STAT1 (Tyr701)
1:1000 5
BSA
12-18 (4°C) 84/91
anti-STAT3 1:1000 5
non-fat m ilk
12-18 (4°C) 79/86
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anti-phospho- 1:1000 5 12-18 (4°C) 79/86
STAT3 (Tyr705) BSA
anti-phospho- 1:1000 5 12-18 (4°C) 86
STAT3 (Ser727) BSA
RT denotes room temperature.
2.7.10 D e t e c t io n  o f  c h e m il u m in e s c e n t  s ig n a l
Membranes were placed in contact with Kodak X-ray film  in a Genetic Research 
Instrumentation (GRI) Hi-Speed-X light proof cassette, for varying periods o f time 
(lOs-lOmin), depending on the strength o f the signal. The exposed film  was then 
developed in a Gevamatic 60 automatic developer (Agfa-Gevaert).
2.8 E le c t r o p h o r e t ic  M o b i l i t y  S h if t  Assay (EMSA)
This technique was carried out essentially as described by Ramji et al. (1993a) with 
minor modifications.
2.8.1 P r e p a r a t io n  o f  r a d io l a b e l l e d  o l ig o n u c l e o t id e  p r o b e  DNA
The preparation o f radiolabelled oligonucleotide probes was divided into two steps.
1) Annealing o f oligonucleotides
2) Radiolabelling o f double-stranded oligonucleotides with a- P-dCTP
2.8.1.1 A n n e a l in g  o f  o l ig o n u c l e o t id e s
The sequences o f the oligonucleotides used for EMSA analysis are shown in Table 
2.10. Forward and reverse sequences were designed to leave 5’ overhangs containing 
at least one G residue following annealing to allow for complementary binding o f [a- 
32P]-dCTP during radiolabelling.
Forward and reverse oligonucleotides (0.5nmol o f each) were incubated together at 
100°C (lOmin) in the presence o f a medium salt buffer ( lx  NEB Buffer 3) in a final 
volume o f lOOpl. The mixture was then allowed to cool to room temperature. Double 
stranded oligonucleotides prepared in this way were either radiolabelled immediately 
or stored at -20°C.
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T a b l e  2.10 Sequences o f double-stranded oligonucleotides used fo r EMSA 
analysis.
P r o b e A n n e a l e d  O l ig o n u c l e o t id e
NF-kB consensus 5’ GGA GTT GAG GGG ACT TTC CCA GGC 3’
3’ T CAA CTC CCC TGA AAG GGT CCG G 5’
AP-1 consensus 5’ CGC TTG ATG AGT CAG 3’
3' TAC TCA GTC GGC CTT 5’
2.8.1.2 R a d i o l a b e l l i n g  o f  d o u b le - s t r a n d e d  o l ig o n u c le o t id e s
Radiolabelling was carried out using the reagents supplied in the MegaprimerM 
Labelling K it (GE Healthcare) according the manufacturer’s protocol. Annealed 
double-stranded oligonucleotides (60ng) were incubated with lx  Labelling buffer, [a- 
32P]-dCTP (3pl) and Klenow polymerase (2U) in a final volume o f 50pl at 37°C 
(30min). Separation o f the radiolabelled probe from unincorporated nucleotides was 
carried out using a Sephadex G50 nick column. The column was equilibrated with 1 x 
TE [lOmM Tris-HCI (pH 7.5), ImM EDTA] buffer (9ml) and the reaction mix (50pl) 
loaded onto the column and eluted in lx  TE buffer as a 400pl fraction which was then 
discarded. The column was then further eluted with 1 x TE (400pl) and this second 
fraction, collected and stored at -20°C.
2.8.2 D N A - p r o t e in  b in d in g  r e a c t io n s
The following stock solutions were used in this procedure:
lOx Binding Buffer: 340mM KC1, 50mM MgCb, ImM DTT.
Dilution Buffer: 40mM KC1, O.lmM EDTA.
The binding o f the radiolabelled probe to phosphatase-free whole cell or nuclear 
extracts was carried out as described below. For this, 5jig o f phosphatase-free whole 
cell extracts or 5pg o f nuclear extracts were mixed with dilution buffer to a final 
volume o f 26pl. Then, 2-5pl o f lOx binding buffer and 3-6pl o f poly-(dl-dC) (lpg /p l) 
were added to the reaction mixture and this was incubated on ice for lOmin. 
Subsequently, 3pl o f the radiolabelled double-stranded oligonucleotide was added and 
the mixture was left at room temperature for 20min to allow binding to occur.
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Following the addition o f 12pl o f 20% (w/v) Ficoll, the mixture was subjected to 
electrophoresis (Section 2.8.4).
2.8.3 A n t ib o d y  s u p e r s h i f t / i n t e r f e r e n c e  a n d  c o m p e t i t io n  b in d in g  s tu d ie s
For supershift/interference experiments, antibody (0.5pg) was added to the protein 
(whole cell or nuclear) binding reaction and incubated on ice for 20min, prior to the 
addition o f the radiolabelled probe. In competition binding studies, prior to the 
addition o f the radiolabelled probe, the binding reaction mixture was incubated with a 
250 molar excess o f unlabelled competitor oligonucleotides (lOmin on ice).
2.8.4 E l e c t r o p h o r e s i s  o f  D N A - p r o t e in  c o m p le x e s
T a b l e  2.11 Composition of non-denaturing polyacrylamide gels fo r EMSA 
analysis.
C o m p o n e n t 4 %  (w /v )  A c r y l a m id e 6 %  (w /v ) A c r y l a m id e
a c r y l a m id e : B is a c r y l a m id e  
(29:1)
5ml 7.5ml
10XTBE 2.5ml 2.5ml
ddH 20 42.5ml 40ml
10% APS 500pl 500pl
TEMED 50pl 50|il
DNA-protein complexes were resolved by electrophoresis on 4-6% (w/v) non­
denaturing polyacrylamide gels (Table 2.11). Electrophoresis was carried out for 3-4h 
at 150V or 12-18h at 35V (both at 4°C) using vertical gel apparatus (20x20cm, 
Scotlab) with 0.5x TBE as running buffer. Following electrophoresis, the gel was 
transferred to Whatmann 3MM paper and dried under vacuum using a Gel Dryer 
(Model 583, Bio-Rad) at 80°C (lh ). The dried gel was exposed to Kodak X-Ray film  
in a light proof cassette (GRI) at -80°C for varying exposure periods (12-72h). X-ray 
films were developed using a Gevamatic 60 automatic developer (Agfa-Gevaert).
104
C h a p t e r  t w o : M a t e r ia l s  a n d  M e t h o d s
2.9 D e n s ito m e tr ic  a n a ly s is  o f  d a ta
For analysis, the intensity o f bands from agarose gel images, immunoblots and 
EMSAs were analysed using GeneTools™ (Syngene) software as described by 
Harvey et al. (2007). Also see section 3.2.1 for a detailed account on the 
densitometric analysis o f data generated by RT-PCR.
2.10 S t a t is t ic a l  a n a ly s is  o f  d a ta
To assess data for statistical significance a standard student’ s T-test was carried out, 
the details o f which are in Appendix III. Where p<0.05, this was concluded as 
statistically significant.
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3.1 I n t r o d u c t io n
The transcription factor C/EBP5 is an important regulator o f gene expression during 
the inflammatory response. Aberrant inflammation contributes to the 
pathophysiology o f diseases such as asthma (Borger el al. 2002), atherosclerosis 
(Kelkenberg et al. 2002; Hansson 2005) and glomerulonephritis (Miyoshi et al. 2007). 
Studying the cytokine-mediated regulation o f C/EBP5 expression could potentially 
aid advances in the search for therapeutic targets against such diseases.
As discussed in section 1.3.1, the initial phase o f inflammation in the liver is referred 
to as the APR and is characterised by changes in the levels o f several serum APPs, 
synthesised primarily by hepatocytes (Baumann and Gauldie 1994; Cantwell et al. 
1998). The expression o f liver acute phase genes is triggered by several inflammatory 
mediators, including the cytokines IL-6, IL-1 and TNF-a (reviewed in Mackiewicz 
1997; Poli 1998).
Several lines o f evidence indicate C/EBP6 is a key transcription factor for the 
regulation o f liver APR genes. For example, the expression o f C/EBP8 is regulated 
by a number o f inflammatory mediators, including IL-6, IL-1 and IFN-y in 
hepatocytes (Juan et al. 1993; Ramji et al. 1993a; Cantwell et al. 1998; Poli 1998). 
Furthermore, in a number o f experimental animal models o f the APR, C/EBP8 is one 
o f the major transcription factors whose activity/expression is induced in response to 
inflammatory stimuli (Alam et al. 1992; Ray and Ray 1994a; Magalini et al. 1995; 
Dinic et al. 2004). C/EBP5 is also reported to functionally interact with a number o f 
APP gene promoters including, complement C3 (Juan et al. 1993), hemopexin (Poli 
and Cortese 1989), haptoglobin (Oliviero and Cortese 1989; Milosavljevic et al. 
2003), CRP (Majello et al. 1990), rat a2-macroglobulin (Milosavljevic et al. 2002), 
rabbit a -1-acid glycoprotein (Ray and Ray 1994b) and more recently PAI-1 (Dong et 
al. 2005).
3.1.1  E x p e r i m e n t a l  s t r a t e g y
It was decided that the work presented in this thesis would be carried out in 
hepatocytes as these cells are known to be responsive to a range o f inflammatory 
mediators, express C/EBP5 as well as other C/EBP family members and are 
principally involved in the production o f serum APPs during the APR.
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The human hepatoma cell line, Hep3B has been used extensively as a model to study 
the effects o f cytokines on hepatic acute phase gene expression (Oliviero and Cortese 
1989; Juan et al. 1993; Ramji et al. 1993a; Zhang et al. 1995; Cantwell et al. 1998; 
Foka et al. 2003). Hep3B cells are fu lly  adherent hepatocytes first established in 
culture by Aden et al. (1979). These cells share many o f their liver specific 
phenotypes with normal hepatocytes. Specifically, Hep3B cells have been 
characterised with respect to their ability to produce liver specific markers such as 
hepatitis B surface antigen, albumin and a-fetoprotein, as well as a battery o f other 
liver specific genes (Knowles et al. 1980). In addition, these cells have also been 
shown to produce cytokine-mediated responses similar to those observed in humans 
during inflammatory states (Hiron et al. 1992). The use o f such liver cell lines has 
several advantages over the use o f primary hepatocytes and in vivo models for study. 
Firstly, there are obvious limitations concerning the availability o f primary human 
hepatocytes for research. Also, primary cells cannot be used for the long term culture 
in the laboratory and in comparison, cell lines generally provide a more homogeneous 
system for study allowing for the extraction o f greater yields o f RNA and protein. 
Conducting studies in cell lines also avoids having to address the ethical issues that 
surround the use o f animal models in scientific research.
Several studies conducted in our laboratory and by others have successfully used the 
Hep3B cell line in investigations involving the regulation o f C/EBPs during the 
inflammatory response (Ramji et al. 1993a; Ramji et al. 1994; Poli 1998 and 
references therein; Davies et al. 2000; Foka et al. 2001; Ramji and Foka 2002 and 
references therein; Foka et al. 2003). Although some studies into the regulation o f 
C/EBP5 expression by cytokines have been fru itfu l, particularly in relation to IL-6 
action (Yamada et al. 1997; Cantwell et al. 1998), there is limited information 
available regarding its regulation by other cytokines including IL -1 .
Given that there is good evidence for an important role for C/EBP5 during the APR, 
we in itia lly  decided to investigate the effect o f various inflammatory mediators on the 
expression o f this transcription factor. In light o f the findings o f the work presented 
in this chapter, we then pursued a line o f investigation that would help elucidate the 
signalling pathways by which selected cytokines regulate the expression o f C/EBP5 
(Chapters 4-7).
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3.1.1.1 S p e c if ic  a im s
Previously published data shows that C/EBP8 expression is induced by IL-1, IL-6 and 
IFN-y in Hep3B cells (Juan et al. 1993; Ramji et al. 1993a; Cantwell et al. 1998). In 
addition, studies have also demonstrated that in response to other inflammatory 
stimuli including LPS and turpentine oil, C/EBP8 is up-regulated in animal models o f 
the APR (Alam et al. 1992; Ray and Ray 1994a). Therefore, we initia lly wanted to 
investigate the effects o f such mediators on the expression o f C/EBP5 in Hep3B cells 
in an effort to in itia lly  confirm and then expand on the data presented in these 
published reports. From the mediators tested, we decided to focus on the effect o f IL- 
1 action on C/EBP5 expression.
Because initia l studies strongly suggested that this response was regulated at the 
transcriptional level, further studies were aimed to analysing the action o f IL-1 on 
C/EBP5 promoter activation as an initial step towards functional dissection o f the 
promoter. IL-6-mediated activation o f the rat and mouse C/EBP5 promoter has 
previously been reported (Yamada et al. 1997; Cantwell et al. 1998). Therefore we 
also included this cytokine in our experiments for comparative purposes and so that 
we could assess whether the human C/EBP8 gene promoter was regulated in a similar 
manner. In conjunction, experiments were also carried out to determine whether the 
human C/EBP8 gene was subject to auto-regulation. We decided to pursue this line o f 
investigation because previously published reports, including those published by our 
laboratory, have shown that the rat, mouse and ovine C/EBP5 genes are regulated 
through auto-regulatory mechanisms (Yamada et al. 1998; O'Rourke et al. 1999a; 
Davies et al. 2000; Tanabe et al. 2000). Flowever, to our knowledge these findings 
have not yet been extended to the analysis o f the human C/EBP5 gene promoter. In 
addition, these studies have also suggested the existence o f species-specific 
differences in the mechanisms by which the C/EBP8 gene is auto-regulated. For 
example, the 5’ regions o f the mouse and ovine C/EBP5 genes are necessary for auto­
activation (O'Rourke et al. 1999a; Davies et al. 2000), whereas the rat gene is auto­
regulated through sequences present at the 3’ end o f the gene (Yamada et al. 1998). 
Given that these mechanisms o f gene regulation may play a role in controlling the 
expression o f C/EBP8 during the inflammatory response (Ramji and Foka 2002 and 
references therein) and the existence o f species-specific mechanisms o f auto­
regulation it was o f interest to pursue studies into this novel area.
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Figure 3.1 summarises our overall experimental approach that was designed to 
achieve the outlined experimental objectives.
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F ig u r e  3.1 E xperim enta l strategy. The aim o f Phase 1 o f the experimental strategy was to 
establish which inflammatory mediators affect C/EBP8 expression in Hep3B cells. The Phase 
2 experimental strategy was designed to expand on the findings from Phase 1 to the analysis o f 
the C/EBP8 gene promoter and to initiate investigations into auto-activation o f the C/EBP5 
gene.
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3.2 In v e s tig a tio n s  in to  th e  e f f e c t  o f  in f la m m a to ry  m ed ia to rs  
ON C/EBP5 EXPRESSION
3.2.1 E f f e c t  o f  IL-6 o n  t h e  e x p r e s s io n  o f  C/EBP8 in  H ep3B  c e l l s
The effect o f IL-6 on the expression o f C/EBP5 over a 24h time course was analysed 
using semi-quantitative RT-PCR (Section 2.6.3). Hep3B cells were treated with IL-6 
for periods between 0-24h (Section 2.3.1.5), after which cells were harvested for total 
RNA extraction (Section 2.6.1). Total RNA was then quantified and used for RT- 
PCR analysis (Section 2.6.3). The integrity o f total RNA preparations was analysed 
by resolving an aliquot on 1% (w/v) agarose gels (Section 2.6.4.1). Figure 3.2A 
shows ljig  o f total RNA extracted from Hep3B cells, resolved on a 1% (w/v) agarose 
gel. As expected for good quality total RNA, the relative intensity o f the 28S rRNA 
band was approximately twice the intensity o f the 18S rRNA band, for each sample. 
For subsequent work involving RT-PCR, the quality o f the RNA used was o f this 
standard although the data is not shown.
Polymerase chain reactions for the amplification o f C/EBP5 and GAPDH were carried 
out using oligonucleotides and conditions detailed in Tables 2.4 and 2.5. Figure 3.2B 
shows the PCR products for C/EBP8 and GAPDH as fractionated by agarose gel 
electrophoresis (Section 2.6.4.2). The absence o f any PCR product in the ‘no reverse- 
transcriptase’ reaction (-RT) indicates that amplification o f C/EBP8 and GAPDH was 
not derived from contamination o f samples with genomic DNA, but was directly 
related to respective mRNA species in each o f the samples. The correct amplification 
o f C/EBP8 and GAPDH was determined by comparing the PCR product size to 
standard DNA molecular weight markers (Appendix II). In addition, the PCR 
amplification product for C/EBP8 was analysed by DNA sequence analysis (Section 
2.6.8) and its identify confirmed.
The relative intensity o f PCR products for C/EBP8 and GAPDH at each time-point 
were determined using Syngene GeneTools software and used for densitometric 
analysis. The software assigns numerical values to each o f the PCR products under 
analysis, relating directly to the intensity o f the PCR product. Densitometric analysis 
o f the data was determined by relating the intensity o f the C/EBP8 PCR product at 
each time-point to the intensity o f the PCR product for the housekeeping gene,
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GAPDH at the equivalent time-point. The data was normalised to the Oh control and 
expressed as a fold change relative to this (Figure 3.2C). The results indicate that IL- 
6 induces expression o f C/EBP6 (maximally at 3h) and that this high level o f 
expression is maintained up to 24h follow ing stimulation o f cells with IL-6.
Ramji et al. (1993a) and Cantwell et al. (1998) have previously demonstrated that IL- 
6 induces expression o f C/EBP6 mRNA in Hep3B cells for up to 24h following 
treatment by northern blotting. We also report similar results using semi-quantitative 
RT-PCR. Importantly, these results establish that our laboratory has a valid in vitro 
cellular system for examining the effects o f cytokines on C/EBP5 expression and that 
semi-quantitative RT-PCR is a suitable method used to determine expression levels o f 
C/EBPS in Hep3B cells.
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F ig u r e  3.2. Time dependent effect o f IL-6 on C/EBP8 mRNA expression in 
Hep3B cells over a period o f 24h. Hep3B cells were treated with IL-6 and harvested 
for total RNA extraction at each o f the indicated time-points. Oh denotes untreated 
cells harvested at the beginning o f the 24h time-course. Total RNA was extracted, its 
integrity examined (A) and used for RT-PCR analysis (Section 2.6.3). The PCR 
amplification products for C/EBP6 and GAPDH were resolved on 1.5% (w/v) agarose 
gels by electrophoresis (B). The size o f each PCR-amplified product was determined 
by comparing it to standard DNA markers, denoted as ‘ M ’ (New England Biolabs, 
1 OObp DNA ladder. See Appendix II). The sizes o f some o f the markers are shown 
on the left o f the images in Panel B. -R T  denotes the RT-PCR in which no reverse 
transcriptase was included for the preparation o f cDNA (using Oh RNA). Panel C 
displays the ratios o f C/EBP5:GAPDH, normalised to the Oh control as determined by 
densitometric analysis. These data are representative o f two independent 
experimental series.
C/EBP6
GAPDH
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3.2.2 E f f e c t  o f  IL-1, IFN-y, LPS, TGF-p a n d  TNF-a o n  C/EBP8 mRNA
EXPRESSION
Having established the effect o f IL-6 on C/EBP6 mRNA expression in Hep3B cells 
was as expected (Figure 3.2), we next decided to investigate the effects o f other 
inflammatory mediators on the expression o f this gene. IL-1 and IFN-y have 
previously been reported to induce C/EBP8 expression in Hep3B cells (Juan et al. 
1993; Cantwell et al. 1998) and so it was important for us to include these cytokines 
in our investigation. In an animal model o f LPS induced APR, an induction o f 
C/EBP8 expression in the liver has been reported (Alam et al. 1992). Therefore we 
also wanted to investigate the effect o f this mediator on C/EBP5 expression in Hep3B 
cells. In addition, to our knowledge, no study has determined the effect o f TGF-p on 
C/EBP8 expression in the liver, so we also included this cytokine in our investigation. 
Finally, we wanted to investigate the effect o f TNF-a on C/EBP8 mRNA expression 
as previous reports have indicated a role for this cytokine in the regulation o f C/EBPP 
and C/EBP8 in the liver (Diehl et al. 1995; Diehl 1998 and references therein).
Hep3B cells were treated with a range o f inflammatory mediators (with IL-6 
treatment serving as a positive-control) at various concentrations established 
previously in our laboratory (Davies et al. 2000; Granger et al. 2000; Tengku- 
Muhammad et al. 2000; Foka et al. 2001; Foka et al. 2003) and by other researchers 
in the field (Angchaisuksiri et al. 1996; Fransson et al. 1999) and harvested for total 
RNA extraction 6h follow ing the addition o f the inflammatory mediators. The cells 
were harvested at 6h, as previous studies have established this as one o f the optimal 
time-points for maximum induction o f C/EBP mRNA/protein in a range o f cellular 
systems (Ramji et al. 1993a; Cardinaux et al. 2000; Granger et al. 2000). Having 
verified the integrity o f total RNA preparations (data not shown), this RNA was used 
for RT-PCR analysis (Figure 3.3A and B). The data generated from these 
experimental series was analysed as described in Section 3.2.1 [with amplification o f 
a housekeeping gene (e.g. p-actin or p-2-microglobulin) serving as a control], 
normalised to the untreated control (UN) and expressed numerically in Figure 3.3C 
and D.
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F i g i r e  3.3. Effects of various inflammatory mediators on C/EBP8 mRNA expression in Hep3B cells. Hep3B cells were treated with 
inflammatory mediators at various concentrations (IL-1, IL-6, IFN-y and TNF-a were all added to a final concentration o f lOOOU/ml; TGF-P was 
added to a final concentration o f 0.04pg/ml and LPS was added to achieve a final concentration o f lpg/ml). Total RNA was extracted from cells at 
6h following the addition o f the inflammatory mediator and used for RT-PCR analysis (Section 2.6.3). The PCR amplification products for C/EBP8, 
P-actin and p-2-microglobulin were resolved on 1.5% (w/v) agarose gels by electrophoresis. The data is separated into two panels, (A and B) with P- 
actin serving as a control in the experiment displayed in Panel A and p-2-microglobulin serving as a control in the experiment displayed in Panel B. 
The size o f each PCR-amplified product was determined by comparing it to standard DNA markers, denoted as ‘M ’ (New England Biolabs, lOObp 
DNA ladder. See Appendix II). -R T  denotes the RT-PCR in which no reverse transcriptase was included for the preparation o f cDNA (using 
untreated RNA). Panels C and D display the mean ratios o f C/EBP6:p-actin and C/EBP6:p-2-microglobulin respectively, normalised to the untreated 
(UN) control as determined by densitometric analysis. These data are representative o f two independent experimental series.
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Consistent with previously published reports, the data in Figure 3.3 (Panels A and C) 
shows that as well as in response to IL-6, IL-1 and IFN-y induce C/EBP5 mRNA 
expression. However, we did note that the response with IFN-y was less profound 
than that observed with IL-1 and IL-6. We also noted a slight reduction in the 
expression o f C/EBP6 mRNA in response to LPS and TGF-p treatment.
The effect o f TNF-a treatment on the expression o f C/EBP6 was also examined. This 
data is presented in Figure 3.3, Panels B and D. IL-1 treatment served as a positive 
control and LPS treatment served as a negative control for the effect o f these 
mediators on C/EBP5 expression in this experiment. As previously noted (Figure 3.3, 
Panels A  and C), IL-1 treatment o f Hep3B cells caused a dramatic induction o f 
C/EBP5 mRNA compared to untreated cells. Likewise, LPS treatment reduced the 
expression o f C/EBP6 mRNA compared to the control. In addition, we did not note 
any major change in C/EBP8 mRNA levels in Hep3B cells treated with TNF-a.
Given that the data presented above shows that in addition to IL-6, both IL-1 and IFN- 
y induce C/EBP5, it was o f interest to pursue further investigations into the effects o f 
these cytokines on C/EBP5 expression in Hep3B cells.
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3.23 E f f e c t  o f  d if f e r e n t  IL-1 c o n c e n t r a t io n s  o n  C/EBP8 mRNA
EXPRESSION
To confirm the induction o f C/EBP8 mRNA expression by IL-1 and to determine an 
optimal concentration o f this cytokine required to produce the response for future 
experiments, Hep3B cells were treated with three different concentrations o f IL-1. 
The cells were then harvested for semi-quantitative RT-PCR analysis. Figure 3.4 
shows the effect o f various concentrations o f IL-1 on C/EBP5 mRNA expression in 
Hep3B cells. These results indicate that the expression o f C/EBP5 is induced 
maximally at a concentration o f lOOU/ml o f IL-1.
M -RT H2O
IL-1 (U/ml) 10 100 1000 0
10U 100U 1000U ou
IL-1 (U/ml)
F ig u r e  3.4. Concentration-dependent effects o f IL-1 on C/EBP5 mRNA 
expression in Hep3B cells. Hep3B cells were treated with indicated concentrations 
o f IL-1 and harvested for analysis 6h following treatments. Total RNA was subjected 
to RT-PCR, with the amplification o f GAPDH serving as a control and PCR products 
were resolved by agarose gel electrophoresis as described in Figure 3.3. M denotes 
the lOObp DNA ladder used to determine the size o f the PCR products. -R T  denotes 
the RT-PCR in which no reverse transcriptase was included for the preparation o f 
cDNA (using OU RNA). H2O denotes a PCR in which cDNA was replaced with an 
equal volume o f water. Panel B displays the ratios o f C/EBP8:GAPDH, normalised to 
the untreated (0U) control as determined by densitometric analysis.
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3 .2 .4  E f f e c t  o f  IL -1  o n  C/EBP8 m R N A  e x p re s s io n  o v e r  a  24h  t im e  c o u rs e
Having established an appropriate concentration o f IL-1 that produces maximal 
induction o f C/EBP5 expression, it was next necessary to examine the effects o f this 
cytokine on C/EBP6 induction over a period o f 24h. This experiment was important 
because it was necessary to determine an optimal time-point for maximal C/EBP5 
expression (as mediated by IL-1) for future experiments. The results o f the semi- 
quantitative RT-PCR analysis for this experiment are shown in Figures 3.5. Hep3B 
cells were either treated with IL-1 (lOOU/ml) or left untreated and harvested for RT- 
PCR analysis at indicated time-points within a period o f 24h (see figure legend for 
details). A  standard statistical t-test (Appendix III) was carried out for this data and 
the changes in expression were significant to the degree indicated. From these 
datasets, it is apparent that the expression o f C/EBP6 is significantly induced by IL-1, 
maximally at 3h, after which there is a gradual decrease in expression over 24h. It is 
noteworthy that untreated cells harvested at each o f the indicated time-points showed 
minimal variation in constitutive C/EBP5 expression over the 24h period. This 
indicates that the induction o f C/EBP5 expression was mediated solely by IL-1 and 
was not due to a non-specific effect o f harvesting the cells at the various time-points.
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FIGURE 3.5. Time dependent effect o f IL-1 on C/EBP8 mRNA expression in 
Hep3B cells over a 24h time course. Hep3B cells were either treated with IL-1 or 
left untreated and harvested for total RNA extraction at each o f the indicated time- 
points. Total RNA was subjected to RT-PCR analysis and agarose gel electrophoresis 
as described previously. M denotes the lOObp DNA ladder used to determine the size 
o f the PCR products. -R T  denotes the RT-PCR in which no reverse transcriptase was 
included for the preparation o f cDNA (using Oh RNA). H20  denotes a PCR in which 
cDNA was replaced with an equal volume o f water. Panel B displays the ratios o f 
C/EBP8:GAPDH, normalised to the Oh control as determined by densitometric 
analysis. The data shown is the mean ratio + standard deviations (±SD) at each time- 
point from three independent experimental series. *P<0.05, **P<0.01.
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3.2.5 E f f e c t  o f  IFN-y o n  C/EBP5 m RNA e x p re s s io n  o v e r  a  24h t im e  c o u r s e
The effect o f IFN-y on the expression o f C/EBP5 expression over 24h was also 
investigated. The results o f the semi-quantitative RT-PCR analysis for IFN-y time- 
courses are shown in Figure 3.6. These experiments were carried out exactly as 
described in Section 3.2.4, where IFN-y was added to the cells in place o f IL -1 . From 
these datasets, it is apparent that the expression o f C/EBP8 is significantly induced by 
IFN-y, maximally at 3h, after which there was a gradual decrease in expression. As 
before, we noted that there was minimal variation in the expression o f constitutive 
C/EBP5 expression at indicated time points in untreated samples. Therefore, the 
induction o f C/EBP8 was mediated solely by IFN-y and was not due to a non-specific 
effect o f harvesting the cells at the various time-points.
The expression o f C/EBP5 as induced by IFN-y over the 24h time course was not as 
profound as that noted for IL-1. In light o f this and because IL-1 is a major pro- 
inflammatory cytokine, we decided to concentrate on determining the effects o f IL-1 
on C/EBP5 expression. Hence we discontinued our work with the cytokine IFN-y.
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F ig u re  3.6. Time-dependent effect o f IFN-y on C/EBP6 mRNA expression in 
Hep3B cells over a period of 24h. Hep3B cells were either treated with IFN-y or left 
untreated and harvested for total RNA extraction at each o f the indicated time-points. 
Total RNA was subjected to RT-PCR analysis and agarose gel electrophoresis as 
described previously. M denotes the lOObp DNA ladder used to determine the size o f 
the PCR products. -R T  denotes the RT-PCR in which no reverse transcriptase was 
included for the preparation o f cDNA (using Oh RNA). H2O denotes a PCR in which 
cDNA was replaced with an equal volume o f water. Panel B displays the ratios o f 
C/EBPS:GAPDH, normalised to the Oh control as determined by densitometric 
analysis. The data shown is the mean ratio +SD at each time-point from three 
independent experimental series. *P<0.05, **P<0.01.
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3 .2 .6  E f f e c t  o f  IL -1  o n  C/EBP8 p r o t e in  e x p r e s s io n  o v e r  a  2 4 h  t im e - c o u r s e
To confirm the induction o f C/EBP5 mRNA (by IL-1) resulted in the expression o f 
C/EBP8 protein and to establish at which time-point this occurred western blot 
analysis was carried out (Figure 3.7). Hep3B cells were treated with IL-1 (lOOU/ml) 
and harvested at indicated time points over a 24h period. Total cellular protein was 
isolated (Section 2.7.2) and 60pg o f protein extracts were subjected to SDS-PAGE 
(Section 2.7.7) on 10% (w/v) gels, before being transferred to PVDF membranes 
(Section 2.7.8). Membranes were subsequently probed with an anti-C/EBP8 antibody 
(Section 2.7.9, Table 2.9) and then re-probed with an anti-P-actin antibody (Section 
2.7.9, Table 2.9), to ensure equal loading. As shown in Figure 3.7, C/EBP5 was 
undetectable in untreated cells. However, its expression was significantly induced by 
IL-1 at 3h post-treatment and was then expressed at reduced levels over the rest o f the 
24h period. Additionally, C/EBP5 was also undetectable in untreated samples taken 
at the 3 and 6h time-points (data not shown). This indicates that the induction o f 
C/EBP5 expression is solely in response to IL-1. It is noteworthy, that this data 
supports the RT-PCR data presented in Figure 3.5.
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F ig u r e  3.7. Time dependent effect o f IL-1 on C/EBP8 protein expression in 
Hep3B cells over a period of 24h. Hep3B cells were either treated with IL-1 or left 
untreated and harvested for protein extraction at each o f the indicated time-points. 
Western blot analysis was carried out using antibodies specific for C/EBP8 and p- 
actin (A). Panel B displays the ratios o f C/EBP8:p-actin, normalised to the Oh control 
as determined by densitometric analysis. The data shown is the mean ratio + SD from 
three independent experimental series. *P<0.05, **P<0.01
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3 .2 .7  E f f e c t  o f  a c t in o m y c in  D  o n  t h e  IL - 1 - m e d ia t e d  in c r e a s e  o f  C/EBP5 
mRNA l e v e l s  in  H e p 3B  c e l l s
Our data consistently shows that IL-1 induces the expression o f C/EBP8 mRNA (see 
Figures 3.3-3.5) and in addition we also show that this cytokine induces C/EBP8 
protein levels (Figure 3.7) in Hep3B cells. However, to our knowledge no study has 
determined whether the induction o f C/EBP8 mRNA in response to IL-1 is due to 
increased transcription o f the gene or increased stability o f the message, although 
preliminary results from our laboratory suggested the response was regulated at the 
level o f gene transcription (Dr F.T. Kockar, personal communication).
Transcriptional control is one o f the main modes o f regulation governing C/EBP gene 
expression in response to cytokines (Ramji et al. 1993a; see Poli 1998 and references 
therein; N iehof et al. 2001b). As actinomycin D is a chemical inhibitor o f gene 
transcription, we decided to investigate its action on IL-1-mediated induction o f 
C/EBP8 mRNA expression as a rapid method to identify a potential role for 
transcriptional control in the response. Actinomycin D is an antibiotic that inhibits 
the action o f DNA-primed RNA polymerase by complexing with DNA via 
deoxyguanosine residues and therefore blocks transcription (Goldberg et al. 1962). 
Hep3B cells were pre-treated with actinomycin D or with DMSO as a vehicle control. 
They were then cultured in the presence or absence o f IL-1 at each o f the specified 
time-points after which total RNA was extracted and used for RT-PCR analysis as 
described previously. As shown in Figure 3.8, the presence o f actinomycin D 
prevented the increase in C/EBP8 mRNA by IL-1 at each o f the indicated time-points. 
In contrast, the induction o f C/EBP8 in response to IL-1 was evident in cells treated 
with DMSO alone, harvested at the 3h time-point as a control. Together, these results 
suggest that increased transcriptional activation o f the C/EBP8 gene is necessary to 
produce the induction in mRNA levels by IL-1.
To firm ly determine whether transcriptional activation o f the human C/EBP8 gene is 
the main mechanism by which IL-1 mediates its induction, other experiments would 
have to be carried out. Monitoring the decay o f C/EBP8 mRNA over a time, in 
Hep3B cells pre-treated with actinomycin D, would be useful to determine the half- 
life o f the message. Also, nuclear run-on transcription assays conducted with extracts
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from IL-1 treated and untreated Hep3B cells would help definitively establish whether 
the C/EBP6 gene was indeed transcribed in response to IL-1.
0.35
Oh 1h 3h 6h 8h 3h 
Actinomycin D DMSO
F ig u r e  3.8 Effect of actinomycin D on the induction of C/EBP6 mRNA levels by 
IL -1 . Hep3B cells were pretreated with actinomycin D (5pg/ml) or with DMSO as a 
vehicle control for lh  (Cavin et al. 2003). They were then either treated with IL-1 
(lOOU/ml) or left untreated (Control) and harvested for RT-PCR analysis at each o f 
the indicated time-points. The PCR products for C/EBP5 and P-actin were resolved 
by agarose gel electrophoresis as previously described. The graph shows the ratios o f 
C/EBP6:p-actin at each o f the specified time-points as determined by densitometric 
analysis. Results are representative o f two independent experiments.
3.3 I n v e s t ig a t io n s  in t o  t h e  r e g u l a t io n  o f  C/EBP5 p r o m o t e r
A C T IV IT Y
3.3.1 E f f e c t  o f  c y t o k in e s  o n  C /E B P 6  p r o m o t e r  a c t iv a t io n
Our data suggests that IL-1 induces the expression o f C/EBP5 at the level o f gene 
transcription (Figure 3.8). As a result, we decided to initiate investigations into 
studying the effects o f this cytokine on C/EBP5 promoter activation. It was o f 
particular interest for us to pursue this line o f investigation because to our knowledge 
no study has reported the effects o f this cytokine on C/EBP5 promoter activity.
It has also been reported that IL-6-mediated expression o f the C/EBP5 is a 
transcriptional response (see section 1.3.1.3), as demonstrated by several studies
□  Control
□  +IL-1
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(Ramji et al. 1993a; Yamada et al. 1997; Cantwell et al. 1998; Davies et al. 2000). 
These studies (Yamada et al. 1997; Cantwell et al. 1998) show that C/EBP8 gene 
transcription is regulated at least in part, by key proximal promoter regions, 
containing STAT3 and Spl c/s-acting elements. Mutation o f these sites abrogates IL- 
6-mediated C/EBP5 gene promoter activation from mouse (Cantwell et al. 1998) and 
rat (Yamada et al. 1997) gene promoters. However, these studies have not been 
extended to the examination o f the human C/EBP8 gene promoter and its regulation 
by IL-6 in hepatoma cells. Therefore we also wanted to determine the effects o f IL-6 
on human C/EBP8 promoter activity.
For our experiments, we used three C/EBP8 promoter-reporter plasmid constructs 
(Sections 2.4.4.1-2.4.4.3). The pHuC/EBP8[1.6kb]-Luc plasmid contains a 1.6kb 
region upstream o f the transcriptional start site o f the human C/EBP8 gene promoter 
sub-cloned into the pLUC luciferase reporter vector as a 1.75kb fragment (Figure 
3.9). The pHuC/EBP8[0.2kb]-Luc plasmid contains a 0.2kb region upstream o f the 
transcriptional start site o f the human C/EBP8 gene promoter cloned into the pGL2- 
Basic luciferase reporter vector (Appendix I). Both these constructs were considered 
to be suitable models to study the activity o f the human C/EBP8 gene promoter in 
order to provide data directly relevant to the regulation o f gene expression in Hep3B 
cells. Finally, the pMoC/EBP8[2.2kb]-Luc plasmid which contains a 2.2kb (-2146 to 
+73) region o f the murine C/EBP8 gene promoter cloned into the pGL2-Basic 
luciferase reporter vector was also used. This reporter plasmid was used in our 
experiments alongside the human C/EBP8 promoter-reporter constructs described 
above for comparative purposes, since the murine C/EBP8 gene promoter has 
previously been extensively characterised (Cantwell et al. 1998; O'Rourke et al. 
1999a). A ll the plasmids were confirmed by sequencing (Section 2.6.8) or digestion 
with restriction enzymes (Section 2.6.7). Both the pMoC/EBPS[2.2kb]-Luc and 
pHuC/EBP8[0.2kb]-Luc plasmid inserts were sequenced using the GL1 and GL2 
universal primers (Appendix IV). The pHuC/EBP8[1.6kb]-Luc plasmid insert was 
confirmed by restriction endonuclease digestion (Figure 3.9) and by partial DNA 
sequence analysis. Two internal primers (Appendix IV) were designed to confirm the 
sequence o f the proximal region o f this promoter fragment. The entire sequence o f 
this insert has previously been determined by Dr F.T. Kockar (personal 
communication). For the preparation o f plasmid constructs for transfection based
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assays, plasmid DNA was used to transform the bacterial E. coli strain DH5a. 
Plasmid DNA was then extracted from mini cultures grown from a single bacterial 
colony by the Miniprep method (Section 2.6.6.3). The same bacterial colony was 
also used to prepare glycerol stocks and for further extraction o f plasmid DNA by the 
Maxiprep method (Section 2.6.6.4). A ll plasmid constructs that were used are 
described briefly in section 2.4.4.
A.
Xbal
pLUC
Xbal
C /E B P 5 1 .6kb P ro m oter Luciferase
pLUC
BamHI H ind lll
B.
3TM>
3.0kb
2.0kb 
1 5kb1.75kb
5.0kb
FIGURE 3.9. A schematic representation and an analytical digest o f the 
pHuC/EBP8[1.6kb]-Luc plasmid. The 1.6kb human C/EBP5 gene promoter was sub-cloned 
into the pLUC luciferase reporter vector as a 1.75kb BamHI-Hindlll fragment. The promoter 
insert is also flanked by two Xbal sites (A). Panel B shows the results o f the analytical digest 
o f the pHuC/EBP8[1.6kb]-Luc plasmid as digested with the Xbal restriction endonuclease. 
The digested plasmid was size fractionated on a 1% (w/v) agarose gel. The sizes o f the 
digested DNA fragments were determined by comparing them to standard DNA markers, 
denoted as ‘M ’ (New England Biolabs, lkb  DNA ladder. See Appendix II). The size o f some 
o f these DNA markers is indicated on the right. The expected size fragments o f 4.8kb 
(plasmid) and 1.75kb (cloned promoter insert) were obtained as shown on the left o f the 
agarose gel image.
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3.3.1.1 E f f e c t  o f  IL -6  o n  C/EBP8 p r o m o t e r  a c t iv a t io n
Hep3B cells were transfected with either the pHuC/EBP5[1.6kb]-Luc plasmid or the 
pMoC/EBP8[2.2kb]-Luc plasmid (Section 2.4.1). Transfected cells were treated with 
either IL-6 or left untreated for 30h [previously identified as the optimal time-point by 
Dr F.T. Kockar (personal communication)]. The cells were then harvested and 
extracts prepared for luciferase assay and the protein concentration for each sample 
was determined (Sections 2.4.2, 2.4.3 and 2.7.4). Luciferase activity was then 
normalised to the protein concentration o f each sample. We normalised the data to 
protein concentration and not to the activity o f another internal control plasmid (e.g. 
CMV-P-galactosidase or RSV-(3-galactosidase) because in our experience most o f 
these promoters are also responsive to cytokine action (Dr P. Foka and Dr S.A. Irvine, 
personal communications). The results are presented in Figure 3.10. The data shows 
that in response to IL-6 the activity o f both the human and murine C/EBP5 gene 
promoters is significantly induced, indicating that the human C/EBP5 gene promoter 
is regulated in a similar manner to the murine promoter, a novel finding. The degree 
o f induction seen is comparable to that noted in previous studies (Yamada et al. 1997; 
Cantwell et al. 1998).
1.8 * *
□  Conrol
□  -HL-6
Human [1.6kb] Mouse
Promoter construct
F ig u r e  3.10 Analysis o f the effect o f IL-6 treatment on the activity o f the human 
and mouse C/EBP5 promoters in Hep3B cells. Hep3B cells were transfected with 
either the pHuC/EBP5[1.6kb]-Luc (5pg) or the pMoC/EBP5[2.2kb]-Luc (5pg) 
plasmids (Human [1.6kb] and Mouse respectively) as described in section 2.4.1. 
Transfected cells were either treated with IL-6 (lOOOU/ml) or left untreated (Control) 
for 30h. Cell extracts were then prepared for luciferase reporter activity assay. 
Luciferase activity was normalised to the protein concentration o f each sample and is 
presented as a fold change in response to IL-6 relative to the untreated control 
(assigned as 1). Results are presented as mean ±SD from three independent 
experiments, where all treatments were carried out in triplicate in each independent 
experimental series. *P<0.05, **P<0.01.
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3.3.1.2 E f f e c t  o f  IL-1 o n  C/EBP8 p r o m o t e r  a c t i v a t i o n
We next determined the effect o f IL-1 on C/EBP5 promoter activity. As before both 
the human (pHuC/EBP5[1.6kb]-Luc ) and murine (pMoC/EBP8[2.2kb]-Luc) C/EBP5 
promoter-reporter plasmids were used in these experiments. In addition we also 
decided to assess the effect o f IL-1 on promoter activity o f the pHuC/EBP8[0.2kb]- 
Luc plasmid (Section 2.4.4.2), containing the shorter fragment o f the human C/EBP5 
gene promoter. This is because large gene promoter fragments can potentially contain 
silencer elements that could mask the effects o f extracellular mediators on promoter 
activity in transient transfection assays, as previously shown (Cantwell et al. 1998). 
To verify that our transfection system was able to produce a response to IL-1 action at 
the level o f promoter activity, we decided to assess the effect o f IL-1 on NF-kB 
activation. The IL-1-mediated activation o f NF-kB is a well documented 
phenomenon (see O 'Neill 2000; O'Neill 2002 and references therein). For this, we 
used the plasmid pNFkB-Luc (Section 2.4.4.4). This reporter plasmid contains four 
NF-kB consensus enhancer elements fused upstream o f the firefly luciferase gene. 
Hep3B cells were transfected with each o f the plasmids described above exactly as 
detailed in the figure legend o f Figure 3.10, except the cells were treated with IL-1 in 
place o f IL-6. The activity o f the various luciferase reporter-constructs in response to 
IL-1 was subsequently analysed. The results o f these experiments are presented in 
Figure 3.11.
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F ig u r e  3 .11  Analysis o f the effect o f IL -1  treatment on the activity o f the human 
and mouse C/EBP8 promoters in Hep3B cells. Hep3B cells were transfected with 
the p N F k B -L u c  plasmid (5pg) as a control, or each o f the three specified C/EBP8 
gene promoter-reporter plasmid constructs (5pg) as described in Section 2.4.1. 
Transfected cells were either treated with IL-1 (lOOU/ml) or left untreated (Control) 
for 30h. Cell extracts were then prepared for luciferase reporter activity assay. 
Luciferase activity was normalised to the protein concentration o f each sample and is 
presented as a fold change in response to IL-1 relative to the untreated control 
(assigned as 1). Results are presented as mean ±SD from three independent 
experiments, where all treatments were carried out in triplicate in each independent 
experimental series. * * * P<0.001.
As expected, the data presented in Figure 3.11 shows that IL-1 significantly activates 
pNFicB-Luc plasmid in Hep3B cells, with a ~3.2 fold induction in reporter activity 
observed in response to this cytokine. In addition, we did not observe an increase in 
C/EBP8 promoter activity in response to IL-1 in any o f the three promoter-reporter 
constructs used in our experiments. Some potential explanations for these results are 
discussed in detail in the section 3.4 o f this chapter.
3.3.2 In v e s t i g a t io n s  i n t o  C/EBP5 p r o m o t e r  a c t i v a t i o n  t h r o u g h  a u t o -  
r e g u l a t o r y  MECHANISMS
A number o f studies have shown that the expression o f the C/EBP8 gene is regulated 
through auto-regulatory mechanisms in a variety o f species, although species-specific 
differences have been reported (Yamada et al. 1998; O'Rourke et al. 1999a; Davies et 
al. 2000; Tanabe et al. 2000).
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As there is also a potential role for auto-regulation in the regulation o f C/EBP5 gene 
expression during the APR (Yamada et al. 1998; Ramji and Foka 2002 and references 
therein), it was o f interest to us to expand on previously published reports. Although 
these mechanisms have been described for the regulation o f mouse, ovine and rat 
C/EBP8 genes, there is no data on the regulation o f the human C/EBP8 gene by 
similar mechanisms. Therefore, we decided to determine whether the human C/EBP8 
gene was regulated by such mechanisms, in hope that these studies would provide 
novel data with regards to the regulation o f the human C/EBP8 gene.
3.3.2.1 P l a s m id s  u s e d  f o r  a u t o - r e g u l a t io n  s t u d ie s
For our experiments, we used the three promoter-reporter constructs detailed above 
and three expression plasmids present in our laboratory (Section 2.4.4). The MSVp 
and -8  expression plasmids contain fu ll length cDNA encoding wild-type murine 
C/EBPP and -8  respectively. The pCS2xa expression plasmid contains a cDNA 
encoding wild-type Xenopus laevis C/EBPa protein. Given that the C/EBP proteins 
are both highly conserved at the level o f sequence and function (see Ramji and Foka 
2002 and references therein) it was considered acceptable to use expression plasmids 
specifying C/EBP proteins from different species in our experiments as previously 
demonstrated (Foka et al. 2001). A ll plasmids were confirmed by restriction 
endonuclease digestion (carried out by an undergraduate project student Anoushka 
Takooree). Table 3.0 details the restriction enzymes used to confirm the identity o f 
the plasmids and the size o f the cDNA insert excised by digestion. Due to the 
unavailability o f the empty plasmid vectors used in the MSV-P and -8  constructs, 
pcDNA3 was transfected into cells as a control, as previously described (O'Rourke et 
al. 1999a). The empty plasmid vector pCS2x, was used as a control plasmid for 
experiments involving the expression plasmid pCS2xa.
T a b l e  3.0 Restriction endonuclease digestion of expression plasmid constructs.
P l a s m id R e s t r ic t io n
E n d o n u c l e a s e ( s)
cDNA INSERT (k B)
MSVp EcoRl, BamHl 1.5
MSV8 EcoRl, BamHl 1
pCS2xa EcoRl 1.7
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3.3.2.2 E f f e c t  o f  C/EBPa, -p a n d  -8  p r o te in s  o n  t h e  a c t i v i t y  o f  t h e  m u r in e  
AND HUMAN C/EBP8 GENE PROMOTERS
As previous studies have indicated that the murine C/EBP8 gene is subject to auto­
regulation (O'Rourke et al. 1999a), we decided to include the murine C/EBP5 gene 
promoter-reporter construct in our experiments for comparative purposes. Hep3B 
cells were co-transfected with either the pMoC/EBP8[2.2kb]-Luc promoter construct 
or the pHuC/EBP5[1.6kb]-Luc promoter construct and expression plasmids specifying 
either C/EBP6 (MSV5), C/EBPp (MSVp) or C/EBPa (pCS2xa) protein. As a control, 
cells were also co-transfected with either the pMoC/EBP5[2.2kb]-Luc promoter 
construct or the pHuC/EBP8[1.6kb]-Luc promoter construct and the empty expression 
vectors pcDNA3 or pCS2x appropriately. As an additional control, Hep3B cells were 
also co-transfected with the pHuC/EBP8[l .6kb]-Luc promoter construct and either 
MSV6 or MSVp and an alternative empty expression vector, pSG5. Transfections 
were carried out as described previously and results are presented in Figure 3.12.
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F ig u r e  3.12. Effect of C/EBP8, C/EBPp and C/EBPa proteins on the activity of 
the murine (pMoC/EBP8(2.2kb]-Luc) and human (pHuC/EBP5[1.6kb]-Luc) 
C/EBP8 gene promoters in Hep3B cells. Hep3B cells were co-transfected with 
either the pMoC/EBP5[2.2kb]-Luc promoter construct (A) or the pHuC/EBP5[1.6kb]- 
Luc promoter construct (B) and expression plasmids specifying either C/EBP8 
(MSV8), C/EBPp (MSV(3) or C/EBPa (pCS2xa) proteins. As a control, cells were 
also co-transfected with either the pMoC/EBP8[2.2kb]-Luc promoter construct or the 
pHuC/EBP5[1.6kb]-Luc promoter construct and the vectors pcDNA3 or pCS2x 
appropriately. For the experiment displayed in Panel C, Hep3B cells were co­
transfected with pHuC/EBP5[l .6kb]-Luc and MSV5 or MSVp plasmids. As a 
control, pHuC/EBP8[1.6kb]-Luc was also co-transfected with another control 
expression plasmid pSG5. A ll transfections were carried out as specified in Section
2.4.1 using 5pg o f each o f the specified plasmids and cells were harvested 36h post 
transfection for luciferase reporter assays. In all experiments, luciferase activity was 
normalised to the protein concentration o f each sample. In Panels A and B this is 
presented as a fold change relative to the pcDNA3 or pCS2x transfected controls 
appropriately (assigned as 1). Results are presented as mean ±SD from four 
independent experiments, where all treatments were carried out in triplicate in each 
independent experimental series. **P<0.01, ***P<0.001. In Panel C, luciferase 
activity is expressed as the mean ratio o f triplicate samples. Error bars show the +SD 
between triplicate samples.
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F ig u r e  3.13. Effect of increasing amounts of the expression plasmid MSV5, on 
the activity of the human C/EBP8 promoter (pHuC/EBP8[1.6kb]-Luc). Hep3B 
cells were co-transfected with the pHuC/EBP8[1.6kb]-Luc promoter construct (5pg) 
and increasing amounts o f the expression plasmid specifying for C/EBP8 (MSV8). 
As a control, cells were also co-transfected with the pHuC/EBP8[1.6kb]-Luc promoter 
construct (5pg) and the increasing corresponding amounts o f the vector pcDNA3. 
Transfections were carried out as specified in Figure 3.12. Luciferase activity was 
normalised to the protein concentration o f each sample and is expressed as the mean 
ratio o f duplicate samples. This experiment was carried out in conjunction with an 
undergraduate project student, Anoushka Takooree.
Consistent w ith the data in Figure 3.12, the results o f Figure 3.13 show that the human 
C/EBP8 gene is subject to auto-regulation. In addition, we show that this activation 
occurs in a concentration dependent manner. That is, there is an increase in promoter 
activation in response to increasing amounts o f the expression plasmid MSV8, with 
no noted increase in control cells transfected with pcDNA3. We did note a slight 
decrease in promoter activation with 7.5pg o f the expression plasmid, possibly due to 
transcriptional squelching (Ptashne 1988; Natesan et al. 1997).
To begin to isolate the DNA sequence elements that may be responsible for this auto- 
regulatory effect, we wanted to investigate whether the plasmid construct containing 
the minimal human C/EBP8 gene promoter (pHuC/EBP8[0.2kb]-Luc) was also 
responsive to the expression plasmids specifying C/EBP8, -0 and -a . Therefore, 
Hep3B cells were co-transfected exactly as described in Figure 3.12 with the 
pHuC/EBP8[0.2kb]-Luc reporter construct. The results o f these experiments are 
presented in Figure 3.14.
-♦— pcONA3 
* — MSV5
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F i g u r e  3.14. Effect of C/EBP5, C/EBPp and C/EBPa proteins on the activity of 
the human C/EBP8 (pHuC/EBP5[0.2kb]-Luc) minimal promoter in Hep3B cells.
Hep3B cells were co-transfected with 5pg o f the pHuC/EBPS[0.2kb]-Luc promoter 
construct and 5pg o f the expression plasmids specifying either C/EBP8 (MSVS), 
C/EBPp (MSVP) or C/EBPa (pCS2xa) protein. As a control, cells were also co­
transfected with 5pg o f the pHuC/EBP8[0.2kb]-Luc promoter construct and 5pg o f 
the vectors pcDNA3 or pCS2x appropriately. Transfections were carried out exactly 
as specified in Figure 3.12. Results are presented as mean ±SD from three 
independent experiments, where all treatments were carried out in triplicate in each 
independent experimental series. *P<0.05, ***P<0.001.
From the data presented in Figure 3.14, it is apparent that the pHuC/EBP8[0.2kb]-Luc 
promoter construct is also activated in response to expression plasmids specifying for 
C/EBP8, -p and -a . These results indicate that the sequence elements responsible for 
mediating the auto-regulatory effects o f the human C/EBP8 gene are located within 
the proximal promoter region o f the human C/EBP8 gene.
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3.4 D iscussio n
Hepatocytes have an important role in the regulation o f the APR. The transcription 
factor C/EBP6 is an important regulator o f hepatic gene expression during the 
inflammatory response (Section 3.1). Studying the cytokine-mediated regulation o f 
C/EBP8 expression may help develop potential therapeutic targets for treatment o f 
diseases exacerbated by inflammation.
A number o f inflammatory mediators, including the cytokines IL-1, IL-6 and IFN-y 
are known to regulate the expression o f C/EBP8 in hepatocytes (Juan et al. 1993; 
Ramji et al. 1993a; Cantwell et al. 1998). Using semi-quantitative RT-PCR analysis 
we confirmed the induction o f C/EBP8 mRNA expression by IL-6 over 24h (Figure 
3.2). The observation that C/EBP8 expression is maintained over 24h suggests that 
further signalling events are induced to sustain its expression, possibly through auto­
regulation (see Ramji and Foka 2002 and references therein). We also showed the 
induction o f C/EBP8 expression by IL-1 and IFN-y in Hep3B cells (Figure 3.3) 
consistent with data presented in the aforementioned publications. In addition, we 
noted that the induction o f C/EBP8 mRNA in response to IFN-y compared to the 
induction by IL-6 and IL-1 was notably less. These data are consistent with the 
results presented by Cantwell et al. (1998). Data presented in this paper show that 
both IL-6 and IFN-y induce C/EBP8 mRNA expression and that the observed 
induction with IFN-y is less profound that that noted for IL-6 (as determined by 
northern blotting) in Hep3B cells.
Previous studies have reported that hepatic C/EBP8 expression is induced in animal 
models o f the APR, stimulated with LPS (Alam et al. 1992). However, we did not 
note any increase in C/EBP8 expression in hepatocytes stimulated with this mediator 
(Figures 3.3). Data presented by Hetherington et al. (1999) indicates that Hep3B cells 
express the human LPS receptor, CD 14 at very low levels compared to macrophages 
for example. This observation may potentially explain why we did not note an 
increase in C/EBP8 expression in response to LPS in our experiments. It is therefore 
likely that the induction in C/EBP8 expression noted in liver extracts o f LPS-treated 
animals is not triggered by LPS stimulation o f hepatocytes directly but is secondary to 
macrophage activation by this mediator. Intravenous administration o f LPS induces 
an inflammatory response primarily through macrophage activation in treated
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animals. Activated macrophages release a broad spectrum o f cytokines including IL- 
1 and TNF-a. The release o f these cytokines also triggers the production o f other 
cytokines such as IL-6 at the site o f inflammation. These cytokines can act both 
locally and distally and can trigger APP release from the liver (Baumann and Gauldie 
1994). Therefore, it is possible that this wave o f cytokine release is responsible for 
triggering the expression o f hepatic C/EBP8 observed in LPS-stimulated animal 
models o f the APR. Alternatively, the increase in C/EBP8 expression observed in 
liver extracts may be due to an induction o f C/EBP8 expression in Kupffer cells (liver 
macrophages) as C/EBP8 is also induced in LPS-treated macrophages (Tengku- 
Muhammad et al. 2000).
We also did not note any increase in C/EBP8 expression in response to the cytokine 
TNF-a (Figure 3.3). This is consistent with the findings o f Yin et al. (1996). This 
study showed that rather than inducing the expression (determined at the mRNA and 
protein level) o f C/EBPp and -6 , TNF-a promoted rapid nuclear accumulation o f 
C/EBPP and -6 , (between 5-180min after treatment) in conditionally transformed rat 
hepatocytes (cultured at the permissive temperature o f 33°C). Therefore, it is 
plausible that whilst cytokines such as IL-1 and IL-6 induce the expression o f hepatic 
C/EBP8 (Juan et al. 1993; Ramji et al. 1993a), the effect o f TNF-a may be to promote 
nuclear localisation o f the newly synthesised C/EBP8 protein inside the cell, rather 
than induce its expression.
We also determined that the expression o f C/EBP5 mRNA as induced by IL-1 and 
IFN-y was maximal at 3h post treatment and that the levels o f C/EBP8 remained 
induced although at reduced levels over 24h (Figures 3.5 and 3.6). These are novel 
data, as to our knowledge no study has determined the effects o f these cytokines on 
C/EBP8 mRNA expression over an extensive time-course in Hep3B cells. We 
additionally showed that C/EBP8 protein expression was induced at the same time- 
point after IL-1 treatment and that C/EBP8 was undetectable in untreated cells (Figure 
3.7). Data presented by Juan et al. (1993) report similar findings in nuclear extracts 
prepared from Hep3B cells treated with IL-1.
The IL-6-mediated expression o f C/EBP5 is reported to be regulated at the level o f 
gene transcription (Ramji et al. 1993a; Yamada et al. 1997; Cantwell et al. 1998; 
Davies et al. 2000). Studies have reported a ~2 fold increase in C/EBP8 promoter
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activation in response to this cytokine (Yamada et al. 1997; Cantwell et al. 1998; 
Davies et al. 2000) from various species. However, similar investigations into o f the 
effect o f IL-6 on human C/EBP6 gene promoter activity have not been published. 
This prompted us to initiate investigations into this area. We showed that IL-6 did 
significantly induce the activation o f the human C/EBP5 gene promoter (Figure 3.10) 
and confirmed the effect o f this cytokine on the murine gene promoter (Cantwell et al. 
1998). Consistent with our results a recent study reported similar findings (Sanford 
and DeWille 2005). That is, the human C/EBP5 gene promoter is indeed activated in 
response to IL-6 (although in a different cell line, LNCaP) and the degree o f induction 
is comparable to that observed in our transfection system. Previous reports have 
implicated STAT3 and Spl transcription factors in conferring IL-6-mediated 
activation o f the C/EBP5 gene promoters (Yamada et al. 1997; Cantwell et al. 1998) 
and Sanford and DeW ille (2005) confirm that these transcription factors are required 
for the IL-6-mediated activation o f the human C/EBP5 gene promoter.
Despite showing that the IL-1-mediated induction o f C/EBP5 mRNA may be a 
transcriptional response (Figure 3.8) we were unable to note an increase in C/EBP5 
promoter activation in response to this cytokine in any o f the three promoter-reporter 
constructs used (Figure 3.11). We ruled out the possibility that this was a result o f our 
transfection system because we showed the activation o f NF-kB by IL-1 at the 
promoter level. It is possible that we did not observe promoter activation in response 
to IL-1 in our transfection system due to a potential requirement for a specific 
chromatin context that is absent in our transfected plasmids but present in the 
endogenous C/EBP5 gene in situ. Additionally, it may be that the promoter elements 
necessary to confer IL-1-mediated promoter activation are simply absent from the 
promoter reporter constructs we used. Another potential explanation is that the 5’ end 
o f the C/EBP6 gene is not responsible for mediating the IL-1-mediated induction o f 
C/EBP5 gene transcription. Indeed, the rat C/EBP5 gene is auto-regulated through 
sequences present at the 3’ end o f the gene (Yamada et al. 1998). Moreover, despite 
the fact that studies have shown that IL-1 readily induces C/EBP5 mRNA and protein 
levels (Juan et al. 1993; Magalini et al. 1995; Hungness et al. 2002b) in a number o f 
different systems, there are no published reports examining the effect o f IL-1 on 
C/EBP6 promoter activity.
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Studies have reported that the C/EBP8 gene promoter is activated through auto­
regulation (O'Rourke et al. 1999a; Davies et al. 2000). Auto-regulation o f the mouse 
C/EBP8 gene may occur through two C/EBP binding sites identified in the distal 5’ 
promoter region (O'Rourke et al. 1999a). We confirmed that the murine C/EBP8 gene 
is auto-regulated with a ~7 fold increase in promoter activity observed when this 
promoter reporter construct was co-transfected with an expression plasmid specifying 
for C/EBP8, consistent w ith previous findings (Figure 3.12, Panel A). We also 
showed that this promoter is activated in the presence o f an expression plasmid 
specifying for C/EBPp (Figure 3.12, Panel A), again consistent with previous findings 
(O'Rourke et a l  1999a). In addition, we have also demonstrated that the murine 
promoter is activated by C/EBPa (~4 fold, Figure 3.12, Panel A), in contrast to the 
findings o f O’ Rourke et al. (1999a). Whilst this study showed that both C/EBP8 and 
~P activated the murine C/EBP8 gene promoter in HC11 mouse mammary epithelial 
cells. C/EBPa did not. The difference may be attributed to the use o f different cell 
lines between this study and that o f O ’ Rourke et al. (1999a).
We also demonstrate, for the first time, that the 5’ flanking region o f the human 
C/EBP8 gene is likely to mediate auto-regulation o f this gene (Figures 3.12-3.14). 
We have identified the regulatory elements that are responsible for this effect to 
within ~200bp o f the transcriptional start site o f this gene (Figure 3.14). This 
promoter region is also activated by C/EBPa and -p , demonstrating that other C/EBP 
family members can regulate the expression o f the human C/EBP8 gene also (Figure 
3.14). Analysis o f this proximal promoter region o f the C/EBP8 gene for putative 
C/EBP transcription factor binding sites [TESS (Transcription Element Search 
Software) at www.cbil.upenn.edu/cui-bin/tess/tess. See Appendix V for search 
results] did not identify any putative C/EBP binding motifs in this region o f the 
human C/EBP8 gene promoter. The absence o f any consensus C/EBP sites in this 
promoter region suggests that like the ovine C/EBP8 gene (Davies et al. 2000) and the 
human C/EBPa gene (Timchenko et al. 1995), the human C/EBP8 gene may be 
subject to indirect auto-regulation. Our search did however reveal putative binding 
sites for potential transcription factors that could mediate this auto-regulatory effect. 
The human C/EBPa gene is subject to indirect auto-regulation through the binding o f 
Upstream Stimulating Factor protein (USF) to the C/EBPa promoter (Timchenko et 
al. 1995). Similarly the ovine C/EBP8 is subject to indirect auto-regulation as no
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C/EBP binding sites were identified in the promoter region o f this gene. However, in 
common with the human C/EBPa gene promoter, putative USF sites were also 
identified in the promoter region o f the ovine C/EBP5 gene (Davies et al. 2000). 
Additionally, C/EBP8 itself has been reported to bind with high affinity to cAMP 
response elements (CRE) and activate gene transcription through binding at these sites 
(Inoue et al. 1995). Therefore, it is possible that C/EBP8 may auto-regulate its own 
promoter by binding at CRE sites. Putative USF and CRE sites were identified in the 
proximal promoter region o f the human C/EBP5 gene (Figure 3.15).
Putative USF site
-181  c c tg c a H B M g c tg g g g g tc c c c a g g g c c g g g g a g g g g g c c c c g g g g a g g a a
CTGAGAGGGGGCGCGCCCCGGGAAGGCTCGGGGCGGCTCCGGGGCGCCCCCGCG 
Sp1 Putative CRE site
g t g c c g g a g tc g g g g c g g g g c g tg c H M H gccggggcH M B aggcggcgg
Proposed TATAA box
GGCTGGGCCCAGCGAGGTG
t
Transcriptional start site
F ig u r e  3.15. Putative cis-acting elements in the proximal promoter region o f the 
human C/EBP5 gene promoter as sequenced from the pHuC/EBP5|0.2kb]-Luc 
promoter reporter plasmid construct. Transcription factor binding sites were identified 
using TESS (Transcription Element Search Software) at www.cbil.upenn.edu/cgi- 
bin/tess/tess. Putative sites are blocked in colour, the reported TATAA box and 
functional Spl site (Sanford and DeWille 2005) are also shown for reference purposes. 
The transcriptional start site is indicated with the vertical arrow.
Although our proximal promoter sequence o f the human C/EBP5 gene is identical to 
that reported by Cleutjens et al. (1993), we nevertheless decided to compare our 
sequence against those submitted to GenBank (National Center for Biotechnology 
Information at www.ncbi.nlm.nih.gov). With the completion o f the Human Genome 
Project (www.oml.gov/sci/techresources/Human Genome/home/shtml). it was likely 
that this sequence had been updated. We compared our sequence o f the proximal 
promoter region o f the human C/EBP8 gene against the RP11-137L15 clone 
containing the human chromosome 8 sequence (GenBank accession number 
AC023991). The results o f this comparison are presented in Figure 3.16.
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PROHOTER.SEQ 
AC023991. SEQ
PROHOTER.SEQ 
AC023991.SEQ
PROHOTER.SEQ
10 20 30 40 50
i teicaflHaj fcftftaigffipK s raaiisrHffi  m m znr, aaaaasm  m asm  m a m
60 70 80 90 100
si mssm mmm ziw m  mmmme bekes- si n  miwAk m b  asmm
110 120 130 140 150
101 CGCCCCCGCG
50
50
100
100
150
AC023991.SEQ 101 CTCCCAGGGC GCCCCCGCCC CTTCCCCCGC ggccccgggg 150
160 170 180 190 200
PROHOTER.SEQ 151 n g m O T m i
1 1i I 1 Kvswyj/sruz 200
AC023991.SEQ i 5 i  3 5 0 3 3 * 5 5  1 i m um sR 200
210 220 230 240 250
PROHOTER.SEQ 1 S53B............. 250
AC023991.SEQ 2oi w m m  m m  b e .............. 250
FIGURE 3.16. Sequence comparison between the proximal promoter region of the 
human C/EBP8 gene obtained from  the pHuC/EBP8[0.2kb]-Luc and 
pHuC/EBP8[1.6kb]-Luc constructs and that obtained from AC023991. The
alignment was done using DNASIS™. Sequence obtained from the promoter inserts 
in pHuC/EBP8[0.2kb]-Luc and pHuC/EBP8[1.6kb]-Luc is denoted 
PROMOTER.SEQ and that obtained from GenBank is denoted AC023991.SEQ.
Blocked sequence indicates a perfect match between the two sequences and-----------
indicates missing sequence.
It became apparent to us that both our human C/EBP5 promoter constructs 
(pHuC/EBP5[1.6kb]-Luc and pHuC/EBP8[0.2kb]) were lacking a 42bp sequence that 
was present in the AC023991 sequence and therefore may be present in the human 
wild-type C/EBP5 gene promoter. The precise reasons for the noted difference 
between the two sequences remain unclear but could possibly be due to allelic 
variations or cloning artefacts.
The fact that both our human C/EBP8 promoter reporter constructs 
(pHuC/EBP5[1.6kb]-Luc and pHuC/EBP8[0.2kb]-Luc) are lacking this 42bp 
sequence at the proximal end o f the C/EBP5 gene promoter (Figure 3.16), may 
explain why we did not observe promoter activation in response to IL-1. However, 
we believe this is unlikely as the murine C/EBP5 gene promoter is also not responsive 
to IL-1 action (Figure 3.11). Nevertheless, we presently cannot rule out the 
involvement o f this deleted sequence in the regulation o f human C/EBP8 gene 
transcription. Further experiments w ill be required to ascertain the role o f the 
sequence elements present in this deleted sequence in the regulation o f C/EBP8 
expression. However, we can rule out the involvement o f this sequence in mediating
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the auto-regulatory effects observed above (Figures 3.12-3.14) since it is absent in 
both our human C/EBP5 promoter constructs.
In summary, the work presented in this chapter shows that we have successfully 
reproduced and extended the findings published from previous studies with regards to 
the induction o f C/EBP8 expression in Hep3B cells as mediated by the cytokines IL-6, 
IL-1 and IFN-y. Because we established that both IL-1 and IL-6 induced C/EBP8 
much more efficiently than IFN-y, we decided to focus on studying the action o f these 
cytokines in relation to C/EBP5 expression. We have shown that the activity o f the 
human C/EBP6 gene promoter is induced in response to IL-6 in Hep3B cells, a 
previously unreported observation. However, because we did not observe any 
increase in C/EBP5 promoter activity in response to IL-1 we decided not to pursue 
this area o f investigation further. Therefore, we decided to focus on determining the 
signalling pathways by which IL-1 and to a lesser extent IL-6, regulate the expression 
o f C/EBP6, this being the focus o f the remainder o f this thesis. Finally, we have also 
shown for the first time that like the rat, mouse and ovine C/EBP5 genes, the human 
gene is also subject to auto-regulation although through a yet unidentified indirect 
mechanism. We have additionally isolated the putative regulatory elements 
responsible for this effect to w ithin ~200bp o f the transcriptional start site o f this 
gene.
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C h a p t e r  f o u r : A n  i n v e s t i g a t i o n  i n t o  t h e
EFFECTS OF PHARMACOLOGICAL INHIBITORS ON IL- 
1 -MEDIATED EXPRESSION OF C/EBP5
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4.1 I n t r o d u c t io n
As previously described (Section 1.3.1), C/EBP8 plays an important role in regulating 
the inflammatory response and therefore may contribute towards the pathophysiology 
o f inflammatory diseases. Indeed a role for C/EBPs has been described in models o f 
atherosclerosis (Kelkenberg et al. 2002), asthma (Borger et al. 2002) and recently 
C/EBP8 action has been described in a model for glomerulonephritis (Miyoshi et al. 
2007) and in Alzheimer’ s disease (L i et al. 2004). Understanding the signalling 
pathways by which inflammatory cytokines regulate C/EBP8 expression/action may 
help to expand our knowledge on the molecular mechanisms underlying such diseases 
and may also help contribute towards the development o f therapeutic drugs against 
such conditions.
Little work had been published identifying the signalling pathways by which IL-1 
regulates the expression o f C/EBP8. We therefore decided to make this the main 
focus o f our studies. IL-1 has been reported to activate a variety o f signalling 
pathways that are discussed in brief below.
Nuclear Factor-K B (NF-kB)- The activation o f NF-kB by IL-1 is a well documented 
phenomenon (see Martin and Wesche 2002; Dunne and O'Neill 2003 and references 
therein). Many genes involved in the inflammatory response contain NF-kB ex­
acting elements in their promoters, including C/EBP8 (Akira and Kishimoto 1997; 
Yamada et al. 1997; Delhalle et al. 2004). NF-kB, is a dimer composed o f various 
subunits that are members o f the Rel family o f proteins [p i05/50, p i00/52, p65 
(RelA), RelB and c-Rel]. In resting cells, NF-kB proteins reside in the cytoplasm 
where they are sequestered by a fam ily o f inhibitors o f kB (IkB) proteins. Stimulation 
o f cells w ith a variety o f inflammatory agents including cytokines (IL-1 and TNF-a) 
and LPS triggers the phosphorylation o f the IkB and targets it for subsequent 
ubiquitinylation and degradation by the 26S proteasome. Degradation o f IkB allows 
translocation o f activated NF-kB (typically the p50:p65 heterodimers) from the 
cytoplasm to the nucleus where it can induce the transcription o f target genes. 
Phosphorylation o f IkB is dependent on the activity o f IkB kinase (IKK). The IK K  
complex is composed o f three subunits, two o f which are catalytic (IKKa and IKK|3) 
and one regulatory (IKKy/NEM O). IKK(3 regulates the phosphorylation and
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subsequent degradation o f IkB proteins in response to IL-1 and TNF-a. IKKa is 
however responsible for the phosphorylation-mediated processing o f the NF-kB 
precursor p i00 into the mature p52 subunit in certain cell types such as B cells (see 
Ghosh and Karin 2002; Delhalle et al. 2004; Chen et al. 2006b for reviews).
Mitogen-Activated Protein Kinases (MAPK)-  MAPK signalling pathways play an 
important role in regulating eukaryotic gene expression (see Yang et al. 2003) and 
have been shown to regulate a variety o f cellular processes including growth, 
differentiation, inflammation and apoptosis (Woodgett 2003). There are three sub­
groups o f the M APK family o f proteins namely the ERK, JNK and the p38 MAPKs. 
The ERK module is mainly activated by mitogenic stimuli such as growth factors and 
hormones while JNK and p38 modules are activated by cytokines and other stress 
stimuli (Lewis et al. 1998; Kyriakis and Avruch 2001). MAPKs can regulate 
transcription through the phosphorylation o f a range o f transcription factors and co­
regulator proteins or by regulating mRNA stability (Dunne and O'Neill 2003; Yang et 
al. 2003). IL-1 has been shown to activate all three MAPK modules (ERK 1/2, JNK 
and p38) and many o f the upstream kinases involved in MAPK signalling including 
TAK1 (see O'Neill 2000; Dunne and O'Neill 2003 and references therein). A 
previously published study indicates a potential role for the ERK MAPK in the 
regulation o f C/EBP6 by IL-1 in human enterocytes (Hungness et al. 2002b).
Casein kinase 2 (CK2)- CK2 is a ubiquitous, constitutively active serine/threonine 
protein kinase, typically found in tetrameric complexes consisting o f two catalytic (a 
and/or a ’ ) subunits and two regulatory P subunits (Litchfield 2003). However, a third 
a subunit, designated a ”  has also been described (Shi et a l 2001). CK2 has been 
isolated in a variety o f cellular compartments and is known to catalyse the 
phosphorylation o f a broad range o f substrates (Meggio and Pinna 2003). IL-1 
stimulates CK2, which has been reported to phosphorylate directly the p65 subunit o f 
NF-kB (Bird et al. 1997). CK2 has also been reported to directly phosphorylate 
C/EBP6 at least in vitro (Osada et al. 1996).
Phosphatidylinositol-3 kinase (PI3K)- PI3K modulates several physiological 
processes including metabolism, cell growth, proliferation and cell migration 
(Wymann et al. 2003). PI3K consists o f a p i 10 catalytic subunit and a p85 regulatory 
subunit. Following ligand-mediated activation, the SH2 (Src Homology 2) domain o f
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p85 interacts with a tyrosine-phosphorylated m otif in associated receptors. For the 
type 1 IL-1 receptor (IL-1R), tyrosine476 was identified as a putative phosphorylation 
site and mutation o f this residue abrogated PI3K activation (Marmiroli et al. 1998). 
Nuclear translocation o f PI3K has also been reported, stimulated in response to IL-1 
(Bavelloni et al. 1999). Furthermore, the downstream target o f PI3K, Akt/PKB 
(Protein Kinase B) has been implicated in IL-1-mediated activation o f NF-kB (Cenni 
et al. 2003).
Protein Kinase C (PKC)- PKC is a fam ily o f protein kinases consisting o f ~10 
isozymes. These are divided into three subfamilies: conventional (or classical), novel, 
and atypical based on their structure, second messenger and co-factor requirements. 
PKCs regulate a diverse range o f biological responses including cellular growth, 
immune responses, memory and learning (see Newton 1995; Dempsey et al. 2000 for 
reviews). A  plethora o f studies propose an involvement o f PKC isoforms in IL-1 
signalling frequently by employing pharmacological inhibitors (see Schutze et al. 
1994; Martin and Wesche 2002 for reviews). Additionally, in various cell types, NF- 
kB activation involves upstream PKC activation (Ghosh and Karin 2002; Su et al. 
2002; Moscat et al. 2003).
4.1.1 E x p e r im e n t a l  s t r a t e g y
The results presented in the previous chapter have firm ly established that IL-1 
significantly induces the expression o f C/EBP5 at both the mRNA and protein level in 
Hep3B cells. Although our preliminary results also indicate that the increase in 
C/EBP5 expression in response to IL-1 is a transcriptional response we were unable to 
detect any increase in promoter activation in response to this cytokine and potential 
reasons for this are discussed in section 3.4. Consequently, we decided to focus on 
studying the signalling mechanisms by which IL-1 modulates the expression o f 
endogenous C/EBP5 mRNA and protein levels in Hep3B cells.
To initiate our investigations, we decided to make use o f commercially available 
pharmacological inhibitors designed against various components o f known IL-1 
signalling pathways discussed in section 4.1. The inhibitors we selected for use have 
been used extensively in many studies, in a variety o f cellular systems. Table 4.0 lists 
some studies that have made use o f pharmacological inhibitors in their investigations
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into the regulation o f cytokine-mediated gene/protein expression. The table 
particularly focuses on the studies that have used pharmacological inhibitors to 
investigate IL-1-mediated gene/protein expression. It is also worthy o f note, that 
some o f these inhibitors have also been used in vivo and their actions confirmed in 
various animal models (Boehme et al. 1999; Han et al. 2001; van den Blink et al. 
2001; Cheng et al. 2002; Semba et al. 2002; Gaddipati et al. 2003; Wang et al. 2004; 
Yamada et al. 2005). For example, apigenin has been used as an effective CK2 
inhibitor in an animal model o f glomerulonephritis. Inhibition o f CK2 in vivo reduces 
the progression o f this inflammatory disease in rats (Yamada et al. 2005). Aberrant 
inflammation also contributes towards the pathophysiology o f arthritis and the JNK 
M APK inhibitor, SP600125 has been used in vivo to treat this condition (Han et al. 
2001).
Additionally, Table 4.1 describes the mode o f action o f the inhibitors we used in our 
investigation. The concentration o f the inhibitors used in our experiments were based 
on those previously used in our laboratory and in published studies investigating 
hepatocyte gene expression and function (Ohigashi et al. 1999; Cavin et al. 2003; 
G iltiay et al. 2005; Wen-Sheng and Jun-Ming 2005; Cabrales-Romero Mdel et al. 
2006; Lauricella et al. 2006; Wu et al. 2006; Dong et al. 2007; Harvey et al. 2007).
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T a b l e  4.0. L ist of publications utilising pharmacological inhibitors to study signalling pathways regulating cytokine-mediated 
gene/protein expression.
I n h ib it o r  S ig n a l l in g R e f e r e n c e s C y t o k in e  (s) G e n e  o r  p r o t e in
p a t h w a y / c o m p o n e n t A N A L Y S E D
Apigenin CK2 Farah et al. (2003) TNF-a manganese superoxide 
dismutase
Cavin el al. (2003) TGF-0 IkB-c
Mead et al. (2003) IFN-y inducible cAMP early 
repressor
Singh and Ramji (2006) TGF-0 apolipoprotein E
Harvey et al. (2007) IFN-y monocyte chemoattractant 
protein-1
Bisindolylmaleimide PKC Jordan et al. (1996) IL-1 and TNF-a monocyte chemoattractant 
protein-1 and RANTES
Mino et al. (1998) IL-1 and TNF-a IL-11
Cafferata et al. (2000) IL-1 cystic fibrosis
transmembrane conductance 
regulator
Molina-Holgado et al. (2000) IL-1 cyclooxygenase-2 and 
prostaglandin E(2)
Nagy et al. (2001) IL-1 and TNF-a IL-6
Jang et al. (2004) IL-1 beta-defensin 2
Duggan et al. (2007) IL-1 cyclooxygenase-2
Curcumin SAPK/JNK/AP-1 Yokoo and Kitamura (1996) IL-1 matrix metalloproteinase-9
Chaudhary and Avioli (1996) IL-1 IL-8
Xu etal. (1997) IL-1 and TNF-a monocyte chemoattractant 
protein-1
Terry et al. (1998) IL-1 and TNF-a heme oxygenase-1
Li et al. (2002b) IL-1 Na(+)/taurocholate co­
transporting polypeptide
Liacini et al. (2002) IL-1 matrix metalloproteinase-3 
matrix metalloproteinase-13
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Wuyts et al. (2003) IL-1 monocyte chemoattractant 
protein-1
monocyte chemoattractant 
protein-3
Al-Sadi and Kreydiyyeh (2003) IL-1 Na(+)-K(+)ATPase
Lee et al. (2003b) IL-1 and BMP-7 monocyte chemoattractant 
protein-1
Moon et al. (2005) IL-1 prostaglandin E synthase 1
Zimmerman et al. (2006) IL-1 retinoid X receptor alpha
Moon et al. (2006) IL-1 and TNF-a galactose-alphal,4- 
galactose-betal ,4-glucose 
ceramide synthase
Cho et al. (2007) TNF-a IL-1, IL-6, TNF-a and cyclin 
E
LY294002 PI3K Birkenkamp et al. (2000) IL-1 IL-6
Weaver et al. (2001) TNF-a cyclo-oxygenase-2
Varley et al. (2001) IL-1 PKC-e
Kim et al. (2002b) IL-1 mucin 2
Ruhul Amin et al. (2003) IL-1 matrix metalloproteinase-9
Bian et al. (2004) IL-1 monocyte chemoattractant 
protein-1
Jang et al. (2004) IL-1 beta-defensin 2
Yamamoto et al. (2004) IL-1 claudin-2
Gong et al. (2005) IL-1 growth hormone
Huang et al. (2006) IL-1 tissue type plasminogen 
activator
Nam (2006) IL-1 inducible nitric oxide 
synthase
Lin et al. (2007) IL-1 intercellular adhesion 
molecule-1
PD98059 MEK1-ERK1/2 MAPK Kumar et al. (1998) IL-1 and TNF-a low density lipoprotein 
receptor
Lindroos et al. (1998) IL-1 alpha-platelet-derived 
growth factor receptor
Miwa et al. (1999) IL-1 IL-6
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Jiang and Brecher (2000) IL-1 inducible nitric oxide 
synthase
Newton et al. (2000) IL-1 prostaglandin E2
Fan et al. (2001) IL-1 cyclo-oxygenase-2
Suzuki et al. (2001) IL-1 and TNF-a gastrin
Jiang et al. (2001) IL-1 inducible nitric oxide 
synthase
Hungness et al. (2002a; 2002b), IL-1 C/EBPP and -6
Liacini et al. (2002) IL-1 matrix metalloproteinase-3
Yang et al. (2002) IL-1 cyclo-oxygenase-2
Kim et al. (2002b) IL-1 mucin 2
Luo et al. (2003) IL-1 IL-6
Fleenor et al. (2003) IL-1 matrix metalloproteinase-3
Jiang et al. (2004) IL-1 inducible nitric oxide 
cyclo-oxygenase-2
Xie et al. (2004) IL-1 osteopontin
Qian et al. (2004) IL-1 hypoxic-inducible factor-1
Lin et al. (2004) IL-1 cyclo-oxygenase-2
Masuko-Hongo et al. (2004) IL-1 microsomal prostaglandin E 
synthase 1
Lin et al. (2005) IL-1 intercellular adhesion 
molecule-1
Takami et al. (2005) IL-1 and IFN-y hepatocyte growth factor
Ma et al. (2005) IL-1 beta-amyloid precursor 
protein
Giltiay et al. (2005) IL-1 C/EBPp
Nieminen et al. (2005) IL-1 cy c lo-oxygenase-2
Raymond et al. (2006) IL-1 matrix metalloproteinase-1
Liu et al. (2006a) IL-1 renin
SB202190 p38 MAPK Kumar et al. (1998) IL-1 and TNF-a low density lipoprotein 
receptor
Tanaka et al. (2000) IL-1 vascular endothelial cell 
growth factor
Bian et al. (2001) IL-1 and TNF-a IL-8 and monocyte 
chemoattractant protein-1
Degousee et al. (2001) IL-1 group I la phospholipase A(2)
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Degousee et al. (2003) IL-1 cyclo-oxygenase-2
Lin et al. (2004) IL-1 cyclo-oxygenase-2
Wu et al. (2004) IL-1 matrix metalloproteinase-9
Wilczynska et al. (2006) IL-1 tissue inhibitor of 
metal loproteinases-1
Liang et al. (2007) IL-1 matrix metalloproteinase-9
SB203580 p38 MAPK Ridley et al. (1997) IL-1 IL-6, prostaglandin H 
synthase-2, matrix 
metalloproteinase-1, matrix 
metal loproteinase-3
Rovin et al. (1999) IL-1 monocyte chemoattractant 
protein-1
Suzuki et al. (2000) IL-1 and TNF-a IL-6 and IL-8
Waterhouse et al. (2001) IL-1 monocyte chemoattractant 
protein-1
Jung et al. (2001) IL-1 vascular endothelial growth 
factor
Jung et al. (2002) IL-1 IL-8
Parhar et al. (2003) IL-1 IL-8
Lee et al. (2003a) IL-1 matrix metalloproteinase-13
Patil et al. (2004) IL-1 IL-6
Jang et al. (2004) IL-1 beta-defensin 2
Masuko-Hongo et al. (2004) IL-1 prostaglandin E synthase 1
Takami et al. (2005) IL-1 and IFN-y hepatocyte growth factor
Brunius et al. (2005) IL-1 IL-8
Demircan et al. (2005) IL-1 and TNF-a aggrecanase ADAMTS-9
Rossa et al. (2005) IL-1 matrix metalloproteinase-13
Huang et al. (2006) IL-1 tissue type plasminogen 
activator
Chen et al. (2006a) IL-1 cyclo-oxygenase-2
Zhang et al. (2006) IL-1 tissue inhibitor of matrix 
metalloproteinase-1
Rossa et al. (2006) IL-1 and TNF-a receptor-activated NF-kB 
ligand
Inatomi et al. (2007) IL-1 and TNF-a matrix metal loproteinase-3
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SP600125 SAPK/JNK MAPK Oltmanns et al. (2003)
Jang et al. (2004) 
de Haij et al. (2005)
Ma et al. (2005)
Nieminen et al. (2005)
Lee et al. (2006)
Wehkamp et al. (2006) 
Zhang et al. (2006)
Kwakkel et al. (2006) 
Ishikawa and Morris (2006)
Zhang et al. (2007a)
Liang et al. (2007)
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IL-1 granulocyte-macrophage
colony-stimulating factor,
RANTES and IL-8
IL-1 beta-defensin 2
IL-1 IL-6
IL-1 beta-amyloid precursor
IL-1 cyclo-oxygenase-2
IL-1 TGF-pl
IL-1 beta-defensin 2
IL-1 tissue inhibitor of matrix
metalloproteinase-1
IL-1 deiodinase type 1
IL-1 inducible nitric oxide
synthase
IL-1 bradykinin B1 and B2
receptors
IL-1 matrix metalloproteinase-9
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T a b l e  4.1. Action o f pharm acological inhib itors used in this study.
I n h ib it o r C h e m ic a l  N a m e F o r m u l a T a r g e t M e c h a n is m R e f e r e n c e ( s)
Apigenin 4',5,7-Trihydroxyflavone C.sH.oO, CK2 Reversible ATP/GTP-competitive 
inhibitor of CK2
Critchfield et al. 
(1997)
Bisindolylmaleimide I 2-[ 1 -(3-Dimethylaminopropyl)-1 H-indol-3-yl]-3-( 1 H-indol-3-yl)- 
maleimide
c 25h 24n 4o 2 PKC Reversible ATP-competitive 
inhibitor of PKC
Gekeler et al. 
(19% )
Calphostin C Carbonic acid. 2-(12-(2-(benzoyloxy)propyl)-3,10-dihydro-4.9- 
dihydroxy-2,6,7,11 -tetramethoxy-3,10-dioxo-1 -pery lenyl)-1 - 
methylethyl 4-hydroxyphenyl ester
C ^H jjO m PKC Competes with diacylglycerol and 
phorbol esters for binding at PKC 
regulatory domain
K obayashi et al. 
(1989)
Curcumin 1,7-Bis(4-hydroxy-3-methoxypheny 1)-1,6-heptadiene-3,5-dione c 21h 20o 6 JNK
MAPK and 
API
Prevents JNK activation upstream 
of M EK K 1. Inhibits expression of 
c-Jun and prevents API binding
Chen and Tan 
(1998)
Huang et al. 
(1991)
LY294002 2-<4-Morpholinyl)-8-phenyI-4H-1 -benzopyran-4-one c 19h I7n o 3 PI3K Reversible ATP-competitive 
inhibitor of PI3K
Vlahos et al. 
(1994)
NF-kB Activation 
Inhibitor
6-Amino-4-(4-phenoxyphenylethylamino)quinazoline c 22h 20n 4o NF-kB Inhibits NF-kB transcriptional 
activation
Tobe et al. (2003)
PD98059 2'-Amino-3'-methoxyflavone c )6h i3n o 3 MEK1 Selective non-competitive 
inhibitor of the ERK MAPK 
pathway
Dudley et al. 
(1995)
SB202190 4-(4-Fluoropheny l)-2-(4-hydroxyphenyl)-5-(4-pyridy 1) 1H- 
imidazole
c 20h 14f n 3o p38 MAPK Binds inactive p38 and inhibits its 
activation
Frantz et al. 
(1998)
SB203580 4-(4-FluorophenyI)-2-(4-methy lsulfinylpheny l)-5-(4-pyridy I) 1H- 
imidazole
c 2,h 16n 3o s f p38 MAPK ATP-competitive inhibitor of p38 
MAPK
Frantz et al. 
(1998)
SP600125 1,9-Pyrazoloanthrone c )4h 8n 2o JNK/SAPK Reversible ATP-competitive 
inhibitor of JNK 1, -2 and -3
Bennett et al. 
(2001)
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4.1.1.1 S p e c i f ic  a im s
The main aim o f the work presented in this chapter was to use pharmacological 
inhibitors to identify potential signalling pathways that may be involved in regulating 
the expression o f C/EBP8 in response to IL-1. In order to initiate our investigations 
we decided to screen for candidate signalling pathways using semi-quantitative RT- 
PCR. This was because the increase in C/EBP5 mRNA levels in response to IL-1 
were easily detected using this technique, as demonstrated in the previous chapter. In 
addition, this method has repeatedly been used successfully to initiate investigations 
o f a similar nature in our laboratory (Mead et al. 2003; Singh and Ramji 2006; Harvey 
et al. 2007) and by others (Bian et al. 2001; Jang et al. 2004; Wu et al. 2004; Dong et 
al. 2007). Results in the previous chapter additionally show that the induction o f 
C/EBP6 by IL-1 at the mRNA level is also mirrored at the protein level. Therefore, 
any candidate signalling pathway identified through the use o f pharmacological 
inhibitors by RT-PCR would then be confirmed at the protein level using western blot 
analysis.
Figure 4.1 summaries our overall experimental approach that was designed to achieve 
the outlined experimental objectives.
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C /EB P8
HEP3B CELLS
IL-1
T r e a t m e n t  
F o r  3 h
C o n f i r m  f in d in g s
USING WESTERN BLOTS
RT-PCR: A n a ly s e  
C h a n g e s  in  m RNA 
l e v e l s
P r e - t r e a t  w i t h  
P h a r m a c o l o g ic a l  
I n h i b i t o r  f o r  1h
T a r g e t  a n d  B l o c k  
S e l e c t e d  S ig n a l l in g  
P a t h w a y s  w it h  t h e  use  
o f  P h a r m a c o l o g ic a l  
I n h ib it o r s
IDENTIFY  
POTENTIALLY 
NOVEL SIGNALLING 
PATHWAYS 
REGULATING C/EBP6 
EXPRESSION AS 
MEDIATED BY IL-1
F ig u r e  4.1. Experimental strategy. The aim o f the experimental strategy was to 
investigate the involvement o f various signalling pathways in the regulation o f the IL-1- 
mediated induction o f C/EBP5 gene expression. Having identified candidate pathways 
with semi-quantitative RT-PCR, these findings were then extended by western blot 
analysis.
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4.2 R esults
4.2.1 E f f e c t  o f  LY294002, SB203580 a n d  PD98059 o n  t h e  IL - 1 - m e d ia t e d  
INDUCTION OF C/EBPS MRNA LEVELS.
Hep3B cells were pre-treated with LY294002 (5pM and 20pM), SB203580 (5pM), 
PD98059 (50 pM) or DMSO as a vehicle control (Section 2.3.1.6). They were then 
cultured in the presence or absence o f IL-1 for 3h, the time at which C/EBP5 exhibits 
maximal induction (see Figure 3.5). Following treatment, total RNA was extracted 
and RT-PCR analysis carried out as detailed previously. Figure 4.2 shows the PCR 
products for C/EBP6 and P-actin as resolved by agarose gel electrophoresis (Figure 
4.2A) and the band intensities normalised to the P-actin control gene (Figure 4.2B). 
Where experiments were carried out three times or more a student’ s t-test was used to 
assess for statistical significance (Appendix III). It is worthy o f note that the positive 
action o f all three inhibitors has previously been confirmed in other studies conducted 
in our laboratory. In macrophages, the induction o f monocyte chemoattractant 
protein-1 (MCP-1) by IFN-y is inhibited by LY294002 (Harvey et al. 2007) and in 
monocytes the induction o f apolipoprotein E (ApoE) by TGF-p is attenuated by 
SB203580 and SB202190 (Singh and Ramji 2006). Furthermore, the MEK1/ERK 
inhibitor, PD98059 has been shown to inhibit the phorbol 12-myristate 13-acetate 
(PMA)-mediated induction o f lipoprotein lipase (LPL) during the differentiation o f 
monocytes into macrophages (Mead et al. 2003).
As expected, treatment o f Hep3B cells w ith IL-1 stimulated an increase in the levels 
o f C/EBP5 mRNA. When combined with IL-1 treatment, neither LY294002, 
SB203580 nor PD98059 attenuated this response, at least at the specified 
concentrations o f these inhibitors. These data suggested that neither the PI3K, p38 
M APK nor the ERK 1/2 M APK pathways were involved in regulating this response, 
respectively.
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A.
IL-1 (100U/ml)
DMSO LY (5pM) LY (20pM) SB203 PD98059
M ---------------          -RT H2O
— C/EBP6 
— Primer dimer
I— P-actin
B.
1.4 
1.2 - 
J  1
10.8
i3
> 06
& 0.4
0.2 1 
0
1
□  Confol 
Q-HL-1
DMSO LY(5mM) LY (20pM) SB203
Treatment
PD98059
F ig u r e  4.2 Effect o f LY294002, SB203580 and PD98059 on the induction of 
C/EBP8 mRNA expression as mediated by IL-1. Hep3B cells were pre-treated 
with either LY294002; LY  (5pM and 20pM), SB203580; SB203 (5pM), PD98059 
(50pM) or with DMSO as a vehicle control for lh . They were then either treated with 
IL-1 (lOOU/ml) or left untreated (control) for 3h. Total RNA was then extracted and 
used for RT-PCR analysis (Section 2.6.3). The PCR amplification products for 
C/EBP8 and p-actin were resolved on 1.5% (w/v) agarose gels by electrophoresis (A). 
M denotes the lOObp DNA ladder (Appendix II). -R T  denotes the RT-PCR in which 
no reverse transcriptase was included for the preparation o f cDNA (using DMSO - IL -  
1 treated RNA). H20 denotes a PCR in which cDNA was replaced with an equal 
volume o f water. Panel B shows the graphical representation o f the data as 
determined by densitometric analysis. The ratios o f C/EBP6:P-actin were normalised 
to the IL-1 treated DMSO control. The data shown for the LY294002 inhibitor is the 
mean from two independent experiments. The data shown for the SB203580 and 
PD98059 inhibitors is the mean +SD from three independent experiments.
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4.2.2 E f f e c t  o f  SB202190 o n  t h e  IL - 1 - m e d ia t e d  in d u c t io n  o f  C/EBP8 m RNA
LEVELS.
We next investigated the effect o f a second p38 MAPK inhibitor, SB202190 on the 
IL-1-stimulated expression o f C/EBP5 as an additional confirmation o f the result 
presented in Figure 4.2. The experiment was carried out exactly as described in 
section 4.2.1, except the cells were treated with SB202190. PCR amplification o f 
C/EBP8 and GAPDH was carried out as previously described. The data is presented 
graphically in Figure 4.3.
□  Control
□  + IL-1
DMSO SB202190
Treatment
F ig u r e  4.3 Effect o f SB202190 on the induction o f C/EBP5 mRNA expression as 
mediated by IL-1. Hep3B cells were pre-treated with SB202190 (lOpM) or with 
DMSO as a vehicle control for lh. They were then either treated with IL-1 (lOOU/ml) 
or left untreated (control) for 3h. Total RNA was then extracted and used for RT- 
PCR analysis (Section 2.6.3). The PCR amplification products for C/EBP5 and 
GAPDH were resolved by electrophoresis. The histogram displays the ratios o f 
C/EBP5:GAPDH normalised to the IL-1 treated DMSO control as determined by 
densitometric analysis. These data are the mean from two independent experiments.
The results presented in Figure 4.3 shows that SB202190 does not impair the IL-1- 
stimulated increase in C/EBP5 mRNA levels in Hep3B cells (at least at the specified 
concentration). This further suggested that the p38 MAPK pathway was not involved 
in regulating this response, consistent w ith the data presented in Figure 4.2, where 
SB203580 also did not attenuate this response.
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4.2.3 E f f e c t  o f  b is in d o ly lm a le im id e  a n d  c a lp h o s t in  C o n  t h e  IL-1- 
MEDIATED INDUCTION OF C/EBP6 MRNA LEVELS.
To investigate the potential involvement o f PKC in the regulation o f the IL -1 - 
mediated response, the PKC inhibitors bisindolylmaleimide and calphostin C were 
employed. The effect o f these inhibitors on the IL-1-mediated induction o f C/EBP8 
mRNA levels was assessed by RT-PCR analysis as described in the above sections 
and results are presented in Figure 4.4.
The results show that pre-treatment o f Hep3B cells with the specified PKC inhibitors 
does not attenuate the IL-1-mediated increase in C/EBP5 mRNA levels, compared to 
controls. This data suggests that PKCs are not involved in regulating this response. 
Furthermore, as an additional control the positive action o f the bisindolylmaleimide 
inhibitor was also confirmed (section 4.2.4, Figure 4.5) to ensure the inhibitor was 
active in the experiments.
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A. M -RT
DMSO BIS CALC
20nM
CALC
40nM
IL-1 (100U/ml
C/EBP5
Primer dimer
P-ACTIN
B.
12 i
1 -
| 0.8 
a
S 0.6
O)
I  0.4Q>at
0.2 -I
□  Conrol 
n-HL-1
DMSO Bisindoylmaleimide Calphosin C 20nM Calphosin C 40nM
Treatment
F ig u r e  4.4 Effect of bisindolylmaleimide and calphostin C  on the induction of 
C/EBP5 mRNA expression as mediated by IL -1 . Hep3B cells were pre-treated 
with bisindolylmaleimide; BIS (2pM), calphostin C; CAL. C (20nM and 40nM) or 
with DMSO as a vehicle control for lh. As before, following IL-1 treatment, the cells 
were harvested for RT-PCR analysis. The PCR amplification products for C/EBP8 
and P-actin were resolved by electrophoresis (A). M denotes the lOObp DNA ladder 
(Appendix II). -R T  denotes the RT-PCR in which no reverse transcriptase was 
included for the preparation o f cDNA (using DMSO -IL-1 treated RNA). The ratios 
o f C/EBP5:p-actin were determined by densitometric analysis and normalised to the 
IL-1 treated DMSO control, as before (Panel B). The data shown for the 
bisindolylmaleimide inhibitor is the mean from two independent experiments. For 
calphostin C, the data shown is a result o f densitometric analysis o f the above 
experiment.
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4.2.4 A  POSITIVE CONTROL FOR THE ACTION OF BISINDOLYLMALEIMIDE THROUGH 
THE INHIBITION OF PM A -INDUCED LIPOPROTEIN LIPASE EXPRESSION IN THP-1  
CELLS.
The positive action o f bisindolylmaleimide has previously been demonstrated in our 
laboratory (Mead et al. 2003). A  study by Auwerx et al. (1989) showed that 
induction o f LPL gene expression during PMA-mediated differentiation o f THP-1 
monocytes, was blocked by the bisindolylmaleimide-like compound, H-7 also 
reported as a PKC inhibitor (Kawamoto and Hidaka 1984). The inhibition o f this 
response by bisindolylmaleimide has been successfully reproduced in our laboratory, 
using THP-1 monocytes (Mead et al. 2003). Therefore, to confirm the action o f 
bisindolylmaleimide in the above experiments the inhibitor was also used to examine 
its effects on LPL expression in PMA-differentiated THP-1 cells. The results o f this 
experiment are presented in Figure 4.5.
M -RT
DMSO BIS
PMA (0.16pM)
P-ACTIN
F ig u r e  4.5 E ffect o f b is in d o ly lm ale im id e  on the induction o f LPL mRNA  
expression as m ediated by P M A  in THP-1 cells. THP-1 monocytes were pre­
treated with bisindolylmaleimide; BIS (2pM) or with DMSO as a vehicle control for 
lh. They were then either treated w ith PMA (0.16pM) or left untreated for 24h. 
Total RNA was then extracted and used for RT-PCR analysis. The primers and 
conditions used for the PCR amplification o f LPL are specified in Tables 2.4 and 2.5 
respectively. PCR amplification products for LPL and P-actin were resolved by 
electrophoresis as previously described. M denotes the lOObp DNA ladder (Appendix 
II). -R T  denotes the RT-PCR in which no reverse transcriptase was included for the 
preparation o f cDNA (using DMSO -P M A  treated RNA).
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As expected, bisindolylmaleimide attenuated the PMA-induced expression o f LPL in 
THP-1 cells. Therefore, from this experiment we can conclude that the 
bisindolylmaleimide inhibitor used to examine the effects o f PKC inhibition on IL-1- 
mediated induction o f C/EBP5 was active because the same stock o f inhibitor was 
used to determine this effect.
4.2.5 E f f e c t  o f  c u rc u m in  a n d  a p ig e n in  o n  t h e  IL-1-m e d ia te d  in d u c t io n  o f  
C/EBP5 mRNA le v e ls .
We next sought to determine any involvement o f CK2 or JNK MAPK in the 
regulation o f C/EBP5 mRNA expression by IL-1. For this we employed two 
inhibitors, apigenin and curcumin. Apigenin has been described as a CK2 inhibitor 
and work in our laboratory has confirmed this action in macrophages and hepatocytes 
(Mead et al. 2003; Harvey 2006; Singh and Ramji 2006; Harvey et al. 2007). 
Curcumin has been described as a JNK M APK pathway inhibitor and indeed this 
action has been confirmed in our laboratory (Greenow 2004; Singh and Ramji 2006). 
The effect o f curcumin and apigenin on the IL-1-mediated induction o f C/EBP5 
mRNA levels was assessed by RT-PCR analysis as before and results are presented in 
Figure 4.6.
The results suggest a potential involvement o f CK2 and JNK MAPK in the regulation 
o f C/EBP6 expression as induced by IL-1 as both inhibitors significantly attenuated 
this response. The constant expression o f 28S rRNA indicates that these inhibitors 
were not having a global effect on cellular gene expression and therefore the observed 
effects were specific. Furthermore, we excluded the possibility that these effects were 
a result o f the inhibitors compromising the viability o f the cells with a trypan blue 
exclusion assay, using Hep3B cells treated with 20pM apigenin and 30pM curcumin 
(Section 2.3.1.7).
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F ig u r e  4.6 Effect of curcumin and apigenin on the induction of C/EBP5 mRNA  
expression as mediated by IL -1 . Hep3B cells were pre-treated with curcumin; CUR 
(30pM), apigenin; API (20pM) or w ith DMSO as a vehicle control for lh  or left 
untreated (UN). Following stimulation w ith IL-1, the cells were harvested for RT- 
PCR analysis as before. The PCR amplification products for C/EBP8 and 28S rRNA 
were resolved by electrophoresis (A). M denotes the lOObp DNA ladder (Appendix 
II). -R T  denotes the RT-PCR in which no reverse transcriptase was included for the 
preparation o f cDNA (using untreated RNA). H20 denotes a PCR in which cDNA 
was replaced with an equal volume o f water. Panel B displays the ratios o f 
C/EBP5:28S rRNA normalised to the IL-1 treated DMSO control as determined by 
densitometric analysis. The data shown is the mean +SD from three independent 
experiments. *P<0.05, **P<0.01.
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We also noticed that apigenin caused a significant reduction in the basal expression o f 
C/EBP8. However, given the low constitutive expression o f C/EBP8 in unstimulated 
cells, it was d ifficu lt to accurately assess this effect by densitometric analysis and 
therefore may require additional confirmation.
4.2 .6  E f f e c t  o f  c u r c u m in  a n d  a p ig e n in  o n  t h e  IL - 1 - m e d ia t e d  in d u c t io n  o f  
C/EBP8 mRNA l e v e l s  is c o n c e n t r a t io n  d e p e n d e n t
In order to confirm the inhibitory effects o f apigenin and curcumin on the IL-1- 
mediated increase in C/EBP8 mRNA levels it was necessary to assess whether the 
effects o f these compounds occurred in a concentration dependent manner. Therefore, 
Hep3B cells were pre-treated with various concentrations o f either inhibitor or DMSO 
as a vehicle control. Following IL-1 treatment, the expression o f C/EBP8 and a 
constitutive control (p-2-microglobulin) was determined by RT-PCR for each o f the 
samples. The results o f the RT-PCR analysis are presented in Figures 4.7.
Both inhibitors, curcumin and apigenin attenuated the IL-1-mediated induction o f 
C/EBP5 expression in a concentration-dependent manner. In addition, the expression 
o f another constitutive control, P-2-microglobulin was unaffected in the presence o f 
either o f the inhibitors. This indicates that the inhibitory effect o f these agents on the 
IL-1-mediated induction o f C/EBP5 was specific to this and not a result o f the 
inhibitors affecting global gene expression in treated cells. Together, these results add 
further support to our hypothesis, indicating a potential requirement for JNK MAPK 
and CK2 in the regulation o f this response.
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F ig u r e  4.7. Effect o f various concentrations o f curcumin (A) and apigenin (B) 
on the IL-l-m ediated induction o f C/EBP5 mRNA expression. Hep3B cells were 
pre-treated with curcumin; CUR (30pM, 40pM and 50pM), apigenin; API (lOpM, 
20pM and 40pM) or with DMSO as a vehicle control for lh. Following IL-1 
treatment, the cells were harvested for RT-PCR analysis as before. The PCR 
amplification products for C/EBP5 and p-2-microglobulin were resolved by 
electrophoresis. M denotes the lOObp DNA ladder (Appendix II). -R T  denotes the 
RT-PCR in which no reverse transcriptase was included for the preparation o f cDNA 
(using DMSO -IL-1 treated RNA). H20 denotes a PCR in which cDNA was replaced 
with an equal volume o f water.
167
C h a p t e r  f o u r : A n  in v e s t ig a t io n  in t o  t h e  e f fe c ts  o f  p h a r m a c o l o g ic a l  in h ib it o r s  o n  IL -1 -m e d ia t e d  e x p r e s s io n  o f
C /E B P 8
4.2.7 E f f e c t  o f  c u rc u m in  a n d  a p ig e n in  o n  t h e  IL -1 -m e d ia te d  in d u c t io n  o f  
C /E B P 8  PROTEIN LEVELS.
Given that our previous data established that the JNK inhibitor curcumin and the CK2 
inhibitor apigenin significantly attenuated the IL-1-mediated induction o f C/EBP5 
mRNA levels, it was next necessary to establish whether the effects o f these inhibitors 
were extended to the C/EBP8 protein level. For this, Hep3B cells were pre-treated for 
lh , with either curcumin or apigenin. They were then cultured in the presence or 
absence o f IL-1 for 3h (previously shown to be the time-point at which C/EBP8 
protein is induced maximally in response to IL-1. See Figure 3.7) before being 
harvested for protein extraction (Section 2.7.2). Samples were then used for western 
blot analysis for subsequent immunoblotting using antisera for the detection o f 
C/EBP8 and p-actin. Densitometric analysis o f the data was carried out and the 
results are presented in Figure 4.8. The results demonstrate that both curcumin and 
apigenin significantly reduced the IL-1-mediated increase in C/EBP5 protein levels 
and that this affect was specific to C/EBP8 as no similar inhibition was observed in P- 
actin protein levels. These data are consistent with our RT-PCR data detailed 
previously.
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F ig u r e  4.8. Effect o f curcumin (A) and apigenin (B) on the IL-1-mediated induction of C/EBPS protein expression. Hep3B cells were pre-treated
with either curcumin (30pM), apigenin (20pM and 40pM) or DMSO as a vehicle control for Ih. They were then either treated with IL-1 (lOOU/ml) or
left untreated (control) for 3h at which point they were harvested for protein extraction (Section 2.7.2). Protein extracts were used for western blot
analysis with 60pg o f each sample subjected to 10% (w/v) SDS PAGE. Blots were probed with an anti-C/EBP5 antibody and visualised using ECL
detection reagent. The same blot was then re-probed with an anti-f-actin antibody to ensure equal loading. Graphs display the ratios o f C/EBP8: p-actin,
normalised to the IL-1 treated DMSO control as determined by densitometric analysis. Data shown for the inhibitor curcumin is the mean + SD from
three independent experiments and for the inhibitor apigenin, data shown is the mean + SD from four independent experiments. i
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4.2.8 E f f e c t  o f  SP600125 o n  t h e  IL - 1 - m e d ia t e d  in d u c t io n  o f  C/EBP6 \iR N A
AND PROTEIN LEVELS
Oiven that the JNK MAPK inhibitor curcumin significantly attenuated the expression 
of C’/HBP8 by IL-1 at both the mRNA and protein level, we next wanted to confirm 
these data with the use o f another JNK M APK inhibitor. Therefore, we employed the 
pharmacological inhibitor SP600125, which has been described as a specific inhibitor 
of JNlK MAPK (Bennett et al. 2001).
Hep3B cells were pre-treated with SP600125 (50pM and IOOjiM) or with DMSO as a 
vehicle control. Following IL-1 treatment, samples were harvested for subsequent 
RT-pCR and western blot analysis, as described in the previous sections. The results 
are presented in Figure 4.9. Pre-treatment w ith SP600125 was found to significantly 
decrease, in a concentration-dependent manner, the induction o f C/EBP5 by IL-1 at 
both tiie mRNA and protein level. Owing to the constant expression o f p-actin. we 
also concluded that these results were specific to C/EBP5 and the SP600125 inhibitor 
was riot having a global effect on cellular gene expression. Together, these results 
support a role for the JNK M APK pathway in the regulation o f the IL-1-mediated 
induction o f C/EBP6 expression in Hep3B cells, consistent with our previous 
findings.
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F ig u r e  4.9 Effect o f SP600125 on the induction o f C/EBP5 mRNA (A) and protein (B) expression as mediated by IL-1. Hep3B cells were pre-treated 
with SP600125 (50pM and lOOpM) or with DMSO as a vehicle control for lh. They were then either treated with IL-1 (lOOU/ml) or left untreated (control) 
for 3h at which point samples were harvested for RT-PCR and western blot analysis as described previously. The PCR amplification products for C/EBP5 
and p-actin were resolved by electrophoresis (A). M denotes the lOObp DNA ladder (Appendix II). -R T  denotes the RT-PCR in which no reverse 
transcriptase was included for the preparation o f cDNA (using DMSO -IL-1 treated RNA). Ratios o f C/EBP5:P-actin were normalised to the IL-1 treated 
DMSO control as determined by densitometric analysis. The RT-PCR data shown is the mean +SD from three independent experiments. Protein extracts 
were used for western blot analysis exactly as described in the legend o f Figure 4.8 (B). Ratios o f C/EBP5: P-actin were normalised to the IL-1 treated DMSO 
control as determined by densitometric analysis. The western blot data shown is the mean + SD from three independent experiments. *P<0.05, **  P<0.01, 
***P<0.001.
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We next investigated the effect o f a lower concentration o f SP600125 (25pM) on this 
response. Western blot analysis was carried out exactly as described in previous 
sections and results are presented in Figure 4.10 below. We did not note any marked 
decrease in the expression o f C/EBP5 expression as induced by IL-1 in cells pre­
treated with 25pM SP600125 compared to controls. Consistent with our previous 
results, we noted a decrease in the expression o f C/EBP8 as induced by IL-1 at the 
higher concentration o f the inhibitor (50pM), compared to controls.
DMSO SP600125 25pM SP600125 50pM
IL-1 (100U/ml) + - + +
C/EBP6 
p-ACTIN
F ig u r e  4.10. Effect o f SP600125 (25pM) on the IL-l-m ediated induction of 
C/EBP8 protein expression. Hep3B cells were pre-treated with SP600125 (25pM 
and 50|iM) or DMSO as a vehicle control for lh. Post IL-1 treatment, samples were 
harvested for protein extraction as described previously. Western blot analysis for the 
detection o f C/EBP8 and p-actin was carried out exactly as described in the legend o f 
Figure 4.8. Results are representative o f two independent experiments.
4.2.9 E f f e c t  o f  NF-kB A c t i v a t i o n  I n h i b i t o r  o n  t h e  IL - 1 - m e d ia t e d  
INDUCTION OF C/EBP8 PROTEIN LEVELS
Our previous data presented above, indicates a potential requirement for CK2 and 
JNK in the regulation o f C/EBP5 expression as mediated by IL-1. Given that both the 
CK2 and JNK MAPK are known to modulate N F -kB activation (see section 4.3 for 
details) and because N F -kB is a major transcription factor regulated by IL-1 action 
(Martin and Wesche 2002; Dunne and O'Neill 2003), we wanted to determine whether 
N F-kB was involved in the regulation o f C/EBP8 expression by IL-1. For this we 
used a recently described N F -kB activation inhibitor (see Table 4.1 Tobe et a l 2003).
Western blot analysis was carried out as specified previously, using antibodies against 
C/EBP8 and p-actin. Figure 4.11 shows the result o f this western blot.
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F ig u r e  4.11. Effect o f NF-kB Activation Inh ib ito r on the IL-l-mediated 
induction o f C/EBP5 protein expression. Hep3B cells were pre-treated with the 
NF-kB Activation Inhibitor; NF-kB ACT. INHIB. ( lp M  and lOpM) or DMSO as a 
vehicle control for lh. They were then either treated with IL-1 (lOOU/ml) or left 
untreated for 3h at which point they were harvested for protein extraction and 
subsequently analysed by western blotting. The same blot was then re-probed with an 
anti-P-actin antibody.
The results presented above suggest that NF-kB is potentially involved in regulating 
the IL-l-mediated expression o f C/EBP8. The NF-kB activation inhibitor attenuates 
the IL-1-induced expression o f C/EBP5 protein compared to the control at both 
specified concentrations and the inhibition appears to occur in a concentration- 
dependent manner. In addition, the inhibitor does not appear to affect the expression 
o f the P-actin control, suggesting that the results are specific to C/EBP5 expression.
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4.3 D iscussion
The transcription factor C/EBP8 regulates the expression o f numerous inflammatory 
genes in various cell types including macrophages (Godambe et al. 1994a; Godambe 
et al. 1994b; Plevy et al. 1997; Hu et al. 1998; Liu et al. 2006b), epithelial cells 
(Hungness et al. 2002a; Hungness et al. 2002b; Svotelis et al. 2005), mesangial cells 
(Granger et al. 2000; Miyoshi et al. 2007) and hepatocytes (Poli 1998). However, 
there are limited studies devoted to determining the signalling pathways by which the 
expression/activity o f this transcription factor is regulated by inflammatory stimuli.
Thus the primary aim o f this project was to identify signalling pathways by which the 
pro-inflammatory cytokine, IL-1 may regulate C/EBP5 expression in hepatocytes. 
We hoped that these investigations would provide further insight into the molecular 
mechanisms by which C/EBP8 expression is regulated. The data presented in the 
previous chapter firm ly establishes that IL-1 induces the expression o f C/EBP8 at both 
the mRNA and protein levels in Hep3B cells. These results therefore provided a good 
basis for further study. Therefore, to initiate our investigations, we analysed the 
action o f pharmacological inhibitors targeting key signalling pathways on the IL - l-  
mediated induction o f C/EBP5 expression. Table 4.2 summarises the findings from 
these investigations.
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Table 4.2. Summary of experimental findings from investigations into the effect 
of pharmacological inhibitors on the IL-l-m ediated induction of C/EBP5 
expression.
I n h ib it o r C o n c e n t r a t io n E f f e c t  o n  IL -1-
M EDIATED INDUCTION OF
C/EBP8 m RNA a n d  
P r o t e in
F ig u r e ( s)
Apigenin 10-40pM Inhibits mRNA and protein 
levels at 20 and 40pM
Figure 4.6 
Figure 4.7(B) 
Figure 4.8
Bisindolylmaleimide 2pM No effect on mRNA levels Figure 4.4
Calphostin C 20 and 40nM No effect on mRNA levels Figure 4.4
Curcumin 30-50pM Inhibits mRNA and protein 
levels between 30-50pM
Figure 4.6 
Figure 4.7(A) 
Figure 4.8
LY294002 5 and 20pM No effect on mRNA levels Figure 4.2
NF-kB activation 
inhibitor
1 and lOpM Inhibits at protein level at both 
concentrations
Figure 4.11
PD98059 50pM No effect on mRNA levels Figure 4.2
SB202190 IOjiM No effect on mRNA levels Figure 4.3
SB203580 5pM No effect on mRNA levels Figure 4.2
SP600125 25-100pM Inhibits mRNA and protein at 
50 and lOOpM
Figure 4.9 
Figure 4.10
The inhibitors against the JNK MAPK, CK2 and NF-kB signalling pathways 
successfully attenuated the IL-l-mediated induction o f C/EBP5 expression at the 
mRNA and/or protein level in Hep3B cells, all novel findings. Therefore, further 
investigations were undertaken to analyse in more detail the role o f these pathways in 
the regulation o f this response, this being the focus o f the next three chapters.
The JNK MAPK pathway is known to be activated by a diverse group o f extracellular 
signals, for example, UV light, inflammatory cytokines (including IL-1) and a variety 
o f other cellular stresses (see section 5.1). The transcription factor c-Jun is a 
downstream target o f the JNK M APK pathway. A role for c-Jun in the regulation o f 
C/EBP5 expression has recently been described (Huang et al. 2007). Peptidoglycan 
induces the expression o f C/EBP5 in murine macrophages and this increase is
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mediated at least in part, by the transcription factor c-Jun. In addition, another study 
has also suggested a role for the JNK M APK pathway in the regulation o f C/EBP6 
expression as mediated by IL-1 in the HepG2 cell line (Dong et al. 2007). The 
experimental findings o f the Dong et al. (2007) study are discussed in detail in chapter 
8 o f this thesis. With the use o f the inhibitor SP600125, the authors demonstrate that 
the IL-l-mediated increase in C/EBP5 expression is reduced in cells pre-treated with 
this inhibitor. We also report similar findings in relation to the expression o f C/EBP5 
by IL-1 in the Hep3B cell line. In addition, we provide further evidence for a role o f 
the JNK M APK pathway in the regulation o f this response with the use o f another 
JNK M APK inhibitor, curcumin.
The role o f CK2 in the regulation o f C/EBP5 expression by IL-1 was investigated 
with the inhibitor apigenin. Apigenin inhibited, in a concentration-dependent manner, 
the IL-l-mediated induction o f C/EBP5 expression at both the mRNA and protein 
level [Figures 4.6, 4.7(B) and 4.8]. These results are potentially novel because to our 
knowledge, no study has analysed a role for CK2 in the regulation o f C/EBP8 
expression during the inflammatory response. We did note however that apigenin 
also significantly inhibited the constitutive expression o f C/EBP8 mRNA (see Figure 
4.6). Unfortunately, the low basal level o f C/EBP5 mRNA and protein expression in 
unstimulated cells made it d ifficu lt to accurately assess this effect by semi- 
quantitative RT-PCR and western blotting. Nevertheless, this observation potentially 
suggests that CK2 may also function to regulate the constitutive expression o f 
C/EBP8. A role for CK2 in constitutive gene expression is plausible given the known 
properties o f this enzyme. CK2 is ubiquitously expressed and is constitutively active 
(although its activity is also reported to be inducible. See section 5.1). It is therefore 
possible, that CK2 may have dual roles in the regulation o f both the constitutive and 
IL-1-induced expression o f C/EBP5. Indeed CK2 has been reported to modulate 
transcription o f mRNA produced by RNA polymerse II by regulating the activity o f 
the basal transcription machinery (Cabrejos et al. 2004; Lewis et al. 2005b) and CK2 
has also been implicated in the regulation o f inducible gene/protein expression 
through the regulation o f other transcription factors such as Egr-1, STAT1, AP-1 and 
ICER (Zdunek et al. 2001; Mead et al. 2003; Singh and Ramji 2006; Harvey et al. 
2007). Further studies would be required to determine the role ( i f  any) o f CK2 in the 
constitutive expression o f C/EBP5. A  potential role for CK2 in the regulation o f
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C/EBP8 activity has previously been suggested (Osada et al. 1996). Given this, the 
fact that CK2 action has previously been implicated during the inflammatory response 
(L i et al. 2005; Yamada et al. 2005) and that IL-1 has been reported to stimulate CK2 
(Bird et al. 1997), we decided that determining the role o f CK2 in IL-l-mediated 
induction o f C/EBP8 warranted further investigation (Chapters 5 and 6).
Our results also suggest a potential role for NF-kB in the regulation o f C/EBP5 
expression by IL-1 (Figure 4.11). Numerous studies have demonstrated a key role for 
NF-kB activation during IL-1 signalling (see Martin and Wesche 2002; Dunne and 
O'Neill 2003 and references therein). However, a role for NF-kB in the regulation o f 
C/EBP5 expression as mediated by IL-1 is yet to be reported. Recently, NF-kB has 
been implicated in the regulation o f C/EBP5 expression as mediated by LPS and 
peptidoglycan in murine macrophages (Liu et al. 2006b; Huang et al. 2007). The role 
o f NF-kB in the regulation o f C/EBP8 expression by IL-1 was investigated further and 
the results o f these investigations are presented in chapter 7 o f this thesis.
Although the JNK MAPK, CK2 and NF-kB pathways have been discussed separately 
with regards to their potential role in regulating IL-l-mediated expression o f C/EBP5, 
one cannot rule out the possible relevance o f cross-talk between the pathways in 
relation to the regulation o f this response. Cross-talk between CK2 and the JNK 
M APK pathways has previously been described (Fleming et al. 2000; Singh and 
Ramji 2006). Fleming et al. (2000) showed that CK2 catalysed the phosphorylation 
o f JNK2a2 at serine407 and threonine404, at least in vitro. Although the role o f 
serine407 and threonine404 phosphorylation was not determined in this study, it was 
suggested that phosphorylation o f these two residues could play a role in regulating 
stability o f JNK2a2, or mediating its interactions with other proteins. In a separate 
study conducted in our laboratory, a role for CK2 in JNK MAPK signalling was also 
suggested (Singh and Ramji 2006). TGF-P induces the expression o f ApoE in human 
monocytes and this induction is regulated by three principle pathways involving JNK, 
p38 M APK and CK2. In relation to this response, the action o f CK2 and the JNK 
M APK pathway converged on c-Jun/AP-1 (Singh and Ramji 2006). However, no 
experiments were carried out to determine the role for CK2 in the regulation o f TGF- 
P-mediated activation o f JNK MAPK. These studies are particularly interesting in 
relation to this study, because they suggest a possible link between these two
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pathways and therefore provided us with a basis for future experiments (Chapters 5 
and 6).
In addition, cross-talk between the JNK M APK and the NF-kB pathways has also 
been described (Schulze-Osthoff et al. 1997; Nakano et al. 2006; Wullaert et al. 2006; 
Liu et al. 2006c; Tirumurugaan et al. 2007). Furthermore, a number o f studies have 
also presented evidence for CK2 in the regulation o f NF-kB activity (McElhinny et al. 
1996; Landesman-Bollag et al. 2001; Romieu-Mourez et al. 2001; Romieu-Mourez et 
al. 2002; Cavin et al. 2003; Yu et al. 2006). Given that our data suggests a potential 
requirement for JNK MAPK, CK2 and NF-kB in the regulation o f IL-l-mediated 
induction o f C/EBP8 expression, the possibility that cross-talk or convergence 
between the pathways may occur was not ruled out and therefore was investigated 
further (Chapters 5-8).
The other results presented in this chapter suggest that neither the ERK1/2 MAPK nor 
the p38 M APK are involved in regulating the IL-l-mediated induction o f C/EBP5 
expression, at least as assessed by RT-PCR (see Figures 4.2 and 4.3). This response 
was not attenuated by PD98059, SB203580 or SB202190. Since the positive action 
o f these inhibitors has previously been confirmed in our laboratory (see section 4.2.1) 
these data were unlikely to be a result o f the inhibitors themselves being inactive. 
Based on these results, we did not pursue detailed investigations into the role o f these 
MAPKs in the regulation o f this response. Roles for the p38 and ERK1/2 MAPK 
pathway in the IL-l-mediated regulation o f C/EBP8 have been suggested in two 
separate studies. IL-l-mediated activation o f C/EBP5 is reported to be regulated by 
p38 MAPK, but not the ERK1/2 M APK in IEC-6 intestinal epithelial cells (Svotelis et 
al. 2005). The other study indicates a role for the ERK1/2 MAPK in modulating the 
activity/expression o f C/EBP6 by IL-1 in the Caco-2 intestinal epithelial cell line 
(Hungness et al. 2002b). Because both groups having utilised intestinal epithelial 
cells for their studies, a cell line type-specific mechanism o f C/EBP8 regulation by IL- 
1 is suggested.
Our results also suggest that the PI3K pathway is also not required in the regulation o f 
this response, given that the specific inhibitor LY294002 did not attenuate the 
expression o f C/EBP8 mRNA as determined by RT-PCR (see Figure 4.2). Again, as 
the positive action o f this inhibitor has previously been confirmed in our laboratory
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(section 4.2.1) these data are unlikely to be a result o f the inhibitor itself being 
inactive. However, a role for the PI3K pathway has been suggested in the regulation 
o f C/EBP6 as induced by EGF. The induction o f C/EBP8 expression by EGF was 
found to be mediated via a PI3K/p38 MAPK/CREB dependent pathway in human 
epidermoid carcinoma A431 cells (Wang et al. 2005).
Finally, our data also suggests that the PKCs are not required for the regulation o f 
C/EBP8 by IL-1 (Figure 4.4). To add further support to this result, we also confirmed 
the action o f the generic PKC inhibitor, bisindolylmaleimide in our experiments 
(Figure 4.5). The PMA-mediated induction o f LPL expression was successfully 
blocked by bisindolylmaleimide in THP-1 cells, as previously described (Mead et al. 
2003). This ruled-out the possibility the inhibitor we used in our experiments was 
inactive.
In conclusion, the results in this chapter have successfully identified three signal 
transduction pathways (JNK MAPK, CK2 and NF-kB) that may be involved in 
regulating the IL-l-mediated induction o f C/EBP5 expression. These data are novel 
and provide a basis for the further investigation o f these pathways in the regulation o f 
this response, which is the focus o f the remainder o f this thesis. The following 
chapters w ill examine the potential role o f each o f these pathways in more detail.
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5.1 I n t r o d u c t io n
The results presented in the previous chapter suggest a potential role for the JNK 
MAPK and CK2 signalling pathways in the regulation o f IL-l-mediated induction o f 
C/EBP5 expression. As the JNK M APK module and CK2 have not been described in 
detail previously in this thesis, a description o f  these signalling components is given 
below.
JN K M APK- As mentioned earlier in sections 1.4.4 and 4.1, JNK is one o f three 
major M APK modules found in mammalian systems and all MAPK pathways are 
organised into a central three-tiered ‘core signalling system’ . A  summary o f the 
events resulting in M APK activation is presented in Figure 5.1.
STIMULUS 
ACTIVATOR PROTEIN
MAPK
(ACTIVE)
MAPKKK
(INACTIVE)
MAPKK
(ACTIVE)
MAPKK
(INACTIVE)
MAPKKK
(ACTIVE)
MAPK
(INACTIVE)
M/
CELLULAR RESPONSE
F ig u r e  5.1. A schematic representation o f the core MAP kinase signalling 
module (adapted from  K yriak is  and Avruch  2001). A  variety o f extracellular 
signals feed into the core module, activating the pathway. Activated MAPKKKs 
catalyse the serine/threonine phosphorylation o f downstream effectors, the MAPKK. 
The phosphorylation o f M APKK concomitantly activates their kinase activity and 
results in the phosphorylation o f the M APK substrates. The threonine and tyrosine 
phosphorylation o f the M APK activates these enzymes, which in turn phosphorylate 
their target proteins. The downstream targets o f this cascade then coordinate the 
appropriate cellular response.
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The stress-activated protein kinases (SAPKs) or JNK MAPKs are strongly induced in 
cells that have been exposed to a variety o f ‘ stress-inducing’ treatments. These 
include heat shock, ionising radiation, oxidant stress, DNA damaging chemicals 
(topisomerase inhibitors and alkylating agents) and protein synthesis inhibitors such 
as cycloheximide and anisomycin (H ibi et al. 1993; Derijard et al. 1994; Kyriakis et 
al. 1994; Kyriakis and Avruch 1996; Pombo et al. 1996). JNKs are also strongly 
activated in response to inflammatory cytokines such as IL-1 and TNF-a (see Davis 
1999; Kyriakis and Avruch 2001 and references therein; Li et al. 2001a). A t least 
twelve separate JNK isoforms have been identified as the products o f three genes 
(JNK 1-3) (Kallunki et al. 1994; Kyriakis et al. 1994; Gupta et al. 1996; Dreskin et al. 
2001; Kyriakis and Avruch 2001). Differential mRNA splicing leads to the 
generation o f two predominant forms o f JNK, p54 and p46 (Kyriakis and Avruch 
2001). Dual phosphorylation [at threonine and tyrosine residues in a conserved tr i­
peptide m otif (Thr-X-Tyr)] and therefore activation o f the JNKs is mediated by two 
MAPKKs, MKK4/SEK1 and MKK7/SEK2 (Toumier et al. 1999). Moreover, several 
recent studies have demonstrated that JNKs are activated synergistically by M KK4 
and M KK7 (Fleming et al. 2000; Matsuoka et al. 2004; Nishina et al. 2004). Several 
M APKKKs have been reported to activate the JNK pathway in response to various 
stimuli. These are members o f the M E K K  family (MEKK1-4), including, the 
apoptosis signal-regulating kinase group (ASK1 and ASK2), TAK1 and Tpl-2 (the 
product o f the col proto-oncogene). Additionally, the mixed-lineage protein kinase 
family (MLK2-3 and Dual Leucine zipper Kinase-DLK) are also a group o f 
M APKKKs reported to be potent inducers o f the JNK MAPKs (see Kyriakis and 
Avruch 2001 and references therein).
JNK protein kinases were originally described as activators o f the transcription factor 
c-Jun. JNKs phosphorylate the NFL-terminal activation domain o f this transcription 
factor at serine63 and serine73 resulting in increased c-Jun transcriptional activity 
(Pulverer et al. 1991; Smeal et al. 1991; Adler et al. 1992; Franklin et al. 1992; Hibi 
et al. 1993). c-Jun is a major component o f the AP-1 transcription factor complex and 
the JNKs regulate its recruitment/activation in response to extracellular stimuli. AP-1 
is a heterodimer comprised o f bZIP transcription factors, typically c-Jun, JunD, 
members o f the fos  (usually c-Fos) and activating transcription factor (ATF-2)
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families (Kyriakis and Avruch 2001). A  summary o f the major components in JNK 
M APK signalling is presented in Figure 5.2.
MAPKKK
MAPKK
MAPK
TRANSCRIPTION 
FACTORS
CYTOKINES 
CELLULAR STRESS
1 
J
MEKKS, MLKS, ASKS 
TAK1.TPL- 2
JNK 
(p54and p46)
c-JUN, Elk -1, ATF-2
CELLULAR RESPONSE
Figure 5.2. A schematic representation of the JNK signalling cascade.
Abbreviations: SEK, SAPK/ERK kinase; Elk-1, Ets-domain transcription factor.
CK2-As mentioned briefly in section 4.1, CK2 is a highly conserved, pleiotropic 
protein serine/threonine kinase. This enzyme is ubiquitously expressed, constitutively 
active and regulates a variety o f cellular processes. These include, cell cycle 
regulation, circadian rhythms, apoptosis, transformation, tumorigenesis, inflammation 
and recently a role for CK2 in the regulation o f cell morphology has emerged (Pinna
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1997; Pinna 2002; Litchfield 2003; L i et al. 2005; Yamada et al. 2005; Canton and 
Litchfield 2006). Typically, the enzyme exists as a tetrameric holoenzyme consisting 
o f two catalytic subunits (in any combination o f a, a ’ or a” ) and two regulatory P 
subunits. However, catalytic isoforms are active in isolation and as part o f the 
holoenzyme. Although the catalytic subunits are structurally similar, a and a ’ are 
reported to exhibit some differential functions (Litchfield 2003). A  body o f work 
indicates that the p subunit regulates the assembly o f tetrameric CK.2 complexes, 
enhances the catalytic activity and stability o f the kinase and is involved in regulating 
substrate selectivity o f CK2 (see Litchfield 2003 and references therein). CK2p is 
also proposed to have functions independent o f the CK2 tetramer because firstly, this 
subunit does not exclusively co-localise w ith the catalytic subunits o f the kinase 
inside cells. Also, CK2p interacts with and regulates the activity o f a number o f other 
serine/threonine kinases in the absence o f CK2 catalytic subunits (Bibby and 
Litchfield 2005). In terms o f cellular localisation, CK2 has been found in the nucleus, 
the cytoplasm and in association with the plasma membrane, golgi and endoplasmic 
reticulum (Faust et al. 2001; Faust et al. 2002; Filhol et al. 2003).
The mechanisms by which CK2 is regulated are poorly understood. Despite being 
constitutively active, the kinase is subject to inducible regulation by a variety o f 
stimuli, including IFN-y (Mead et al. 2003), EGF (Pepperkok et al. 1991), TNF-a 
(Sayed et al. 2000), TGF-p (Zdunek et al. 2001; Singh and Ramji 2006), UV-B light 
(Brenneisen et al. 2002) and LPS (Lodie et al. 1997). Other mechanisms that have 
also been proposed to contribute towards the regulation o f CK2 include; regulated 
expression and assembly o f the enzyme, control by covalent modification and 
modulation through interactions with other proteins and/or non-protein molecules (see 
Litchfield 2003 and references therein).
There is an ever growing list o f CK2 substrates with over 300 documented in 2003 
(Meggio and Pinna 2003). They include signalling molecules, transcription factors, 
proteins affecting DNA/RNA functions and protein synthesis, viral proteins, 
cytoskeleton-structural proteins and metabolic enzymes (Meggio and Pinna 2003). 
Given the diversity o f its substrates and its role in a number o f global cellular 
processes, CK2 is likely to regulate a variety o f signal transduction pathways.
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5.1.1 E x p e r i m e n t a l  s t r a t e g y
Work in this chapter was carried out w ith the aim o f determining in more detail, the 
role o f JNK MAPK and CK2 in the regulation o f C/EBP8 gene expression by IL-1 . In 
relation to JNK MAPK signalling, this was firstly to be achieved by analysing the 
changes in the phosphorylation o f JNK in response to IL-1 treatment. In conjunction, 
the activity o f this kinase in response to cytokine treatment was also analysed. The 
effect o f pharmacological inhibitors on IL-l-mediated JNK activation was also 
assessed to determine potential mechanism(s) by which IL-1 stimulates JNK 
activation. Dominant negative (DN) mutants against selected components o f the JNK 
pathway were then used to determine their effect on IL-l-mediated induction o f 
C/EBP8 mRNA levels. Using a similar approach, we also examined the effect o f IL-1 
on the activation o f CK2 and used a DN CK2 mutant to elucidate a role for this kinase 
in regulating C/EBP8 expression by IL -1 .
Figure 5.3 summaries our overall experimental approach that was designed to achieve 
the outlined experimental objectives.
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CK2JN K
M A P K
K in a s e  A c t iv it y  
A ssay
K in a s e  A c t iv it y  
A s s a y
T r a n s f e c t io n  o f  
D o m in a n t  N e g a t iv e  
M u t a n t
T r a n s f e c t io n  o f  
D o m in a n t  N e g a t iv e  
M u t a n t s
D e t e r m in e  e f f e c t  
o f
PHARMACOLOGICAL 
INHIBITORS ON
ACTIVATION
A n a l y s e
P h o s p h o r y l a t io n
STATUS IN RESPONSE 
TO IL-1 BY WESTERN 
BLOT
A n a ly s e  r o le s  o f  JNK an d  
CK2 IN TH E REGULATION OF 
C/EBP8 EXPRESSION BY IL-1
F ig u r e  5 .3. E x p e rim e n ta l strategy. Potential roles o f JNK and CK2 during IL-1 signalling 
in relation to C/EBP8 expression were investigated by determining the effect o f cytokine 
treatment on the activation o f these kinases. Possible mechanisms o f regulation were 
determined with the on going use o f pharmacological inhibitors and with the use o f DN 
mutants.
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5.2 R e s u l t s
5.2.1 E f f e c t  o f  IL-1 o n  JNK p h o s p h o r y l a t i o n  in  H e p 3 B  c e l l s
The effect o f IL-1 on JNK phosphorylation was analysed by studying the dual 
phosphorylation o f JNKs at threonine183 and tyrosine185 characteristic o f JNK 
activation (Kyriakis and Avruch 2001), by western blotting. For this, a 
PhosphoPlus® SAPK/JNK (T h rl83 /T yrl85 ) antibody kit was commercially available 
(see Table 2.0). This k it contains two highly selective antibodies, one o f which 
specifically recognises only the dually phosphorylated form (Thrl83/Tyrl85) o f JNK 
and the other detects total JNK (phosphorylation-state independent) levels. 
Antibodies such as these have been used extensively to investigate the role o f JNK 
signalling in different cell types including Hep3Bs (Dreskin et al. 2001; Kim et al. 
2004; Yeh and Yen 2005).
Hep3B cells were either treated w ith IL-1 or left untreated and harvested for 
phosphatase-free whole cell protein extraction at various intervals up to 3h following 
stimulation by IL-1 (Section 2.7.2). Extracts were used for western blot analysis 
using the anti-phospho-SAPK/JNK antibody or the anti-total-SAPK/JNK antibody 
(Section 2.7.7-2.7.10 and Table 2.9). The results are presented in Figure 5.4.1.
Differential splicing o f the JNK genes leads to the generation o f two predominant 
forms o f this enzyme, p54 (54kDa) and p46 (46kDa) (Dreskin et al. 2001; Kyriakis 
and Avruch 2001). Western blot analysis o f protein extracts from human cells, using 
antibodies specific for JNK detection, reveal that the p46 JNK isoforms often appear 
as more than one band (often a doublet) and the p54 JNK isoforms as a single band 
when these proteins are size fractionated by SDS-PAGE (Dreskin et al. 2001). Our 
results show that IL-1 induces rapid phosphorylation o f mainly p54 JNK, after only 5 
minutes o f treatment. IL-1-mediated phosphorylation o f p54 JNK peaks with 3.5-fold 
induction at 15min. The phosphorylated p54 isoform can be clearly detected up to 45 
minutes following IL-1 treatment, w ith levels returning to basal at 180 minutes 
(Figure 5.4.1, Panel A). Total-JNK levels do not vary between each o f the samples 
examined (Figure 5.4.1, Panel C), indicating that the changes observed in Panel A  are 
due to phosphorylation alone and not increased expression o f the JNK proteins.
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F i g u r e  5.4.1. Time dependent effect of IL-1 on phospho- and total-JNK MAPK 
levels in Hep3B cells over a period of 3h. Hep3B cells were either treated with IL-1 
or left untreated (Omin) and harvested for phosphatase-free protein extraction (Section 
2.7.2) at each o f the indicated time-points. Western blot analysis was carried out by 
SDS-PAGE using 10% (w/v) gels as previously described with 80pg o f each sample 
and blots were probed using an anti-phospho-JNK antibody (A) or an anti-total-JNK 
antibody (C). The phosphorylated p54 protein level for each time-point was 
determined by densitometric analysis, normalised to the Omin control and plotted as a 
histogram (B). The data shown in Panel B is the mean + SD from three independent 
experimental series (*P<0.05). Sim ilarly, the total p54 protein level for each time- 
point was also determined by densitometric analysis, normalised to the Omin control 
and plotted as a histogram (Panel D). The data in Panel D shown is the mean from 
two independent experimental series.
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We next sought to show that the observed phosphorylation o f p54 JNK as 
demonstrated in Figure 5.4.1 was solely due to the stimulation o f Hep3B cells with 
IL-1 and not a result o f the time-point at which the cells were harvested. For this, we 
decided to repeat the time-course detailed in Figure 5.4.1 and in addition, harvested 
untreated cells at the 5min and 30min time-points, for phosphatase-free whole cell 
protein extraction and subsequent western blot analysis as detailed previously. These 
time-points were specifically chosen to harvest untreated cells because as shown in 
Figure 5.4.1, p54 JNK phosphorylation is induced at both 5 and 30min following 
stimulation o f Hep3B cells with IL-1. The results are shown in Figure 5.4.2.
IL-1 (100U/ml ) - + + .  + + + +
Omin 5min 5min 15min 30min 30min 45min 60min 180min
Phospho-JNK
-p54
-p46
Total-JNK
.p54
.p46
F ig u r e  5.4.2. Time dependent effect of IL -1  on phospho- and total-JNK M A P K  
levels in Hep3B cells over a period of 3h. Hep3B cells were either treated with IL-1 
or left untreated (Omin, 5min -IL -1  and 30min -IL -1 ) and harvested for phosphatase- 
free whole cell protein extraction at each o f the indicated time-points. Extracts were 
then used for western blot analysis as described in Figure 5.4.1.
The results clearly show that the noted increase in phosphorylation o f JNK is due to 
the stimulation o f Hep3B cells w ith IL-1 and not a result o f the time-points at which 
the cells were harvested. The levels o f phosphorylated JNK in untreated samples at 
5min (5min -IL -1 ) and 30min (30min -IL -1 ) are comparable to the Omin control. 
Together with the data presented in Figure 5.4.1, these results demonstrate that upon 
stimulation with IL-1, the JNK pathway is activated in Hep3B cells, a novel finding. 
Total-JNK levels were also examined from the same set o f samples and as before, 
there was minimal variation between the samples. These data together with our data 
presented in the previous chapter supports our hypothesis for a role o f the JNK 
M APK pathway in the regulation o f C/EBP8 expression by IL-1.
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5.2.2 E f f e c t  o f  c u r c u m in , a p ig e n in  a n d  SP600125 on  IL - 1 - m e d ia t e d  JNK
PHOSPHORYLATION
The results from chapter 4 show that the JNK inhibitors, SP600125 and curcumin 
significantly attenuate the IL-1-mediated induction o f C/EBP8 mRNA and protein 
expression. Therefore, we wanted to confirm the activity o f both curcumin and 
SP600125 as JNK inhibitors in Hep3B cells. A  study by Chen and Tan (1998) 
suggested that curcumin acts as an upstream inhibitor o f the JNK pathway. This 
compound is believed to act at the M A P K K K  level, probably through the inhibition o f 
MEKK1 (Chen and Tan 1998) and therefore may block JNK phosphorylation. In 
other studies curcumin is shown to act as a c-Jun/AP-1 activation inhibitor (Huang et 
a l 1991; Takeshita et a l 1995; Bierhaus et a l  1997). SP600125 targets the catalytic 
activity o f JNK by competing w ith ATP for the active site o f the kinase and 
subsequently prevents phosphorylation o f  c-Jun (Bennett et a l 2001). However, 
recent studies have shown that SP600125 also prevents the phosphorylation o f JNK 
itse lf (Wang et a l 2002; Tokuda et a l 2003; Nakahara et a l 2004; Cho et a l 2005; 
Tamagno et a l 2005).
The CK2 inhibitor apigenin also inhibits the expression o f C/EBP8 by IL-1 (See 
chapter 4). Given that CK2 has previously been suggested to function as an upstream 
component o f the JNK pathway (Fleming et a l  2000; M in et a l 2003) we wanted to 
investigate whether apigenin inhibited JNK phosphorylation.
A ll the above mentioned inhibitors were used to examine their effect on IL-1 - 
mediated induction o f JNK phosphorylation. Hep3B cells were pre-treated with 
curcumin (30pM), apigenin (40pM) or SP600125 (50pM and lOOpM) in addition to 
DMSO (vehicle-control), for lh  prior to the addition o f IL-1. The cells were then 
harvested at 15min, follow ing cytokine treatment for phosphatase-free whole cell 
protein extraction as before. The cells were harvested at 15min because it is at this 
time-point that maximum JNK phosphorylation was observed in response to IL-1 
(Figures 5.4.1 and 5.4.2). Western blot analysis was carried out on protein extracts as 
specified above, immunoblotting w ith the specific antibodies raised against phospho- 
JNK and total-JNK. Results are presented in Figure 5.5.
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Figure 5.5. The effect of inhibitors on IL-l-mediated JNK phosphorylation in 
Hep3B cells. Hep3B cells were treated with the indicated inhibitor at the specified 
concentrations in addition to DMSO (vehicle-control), for lh  prior to the addition o f 
IL-1 (lOOU/ml). Phosphatase-free protein extracts were prepared from cells harvested 
at 15min following the addition o f IL-1 and used for western blot analysis as 
described in Figure 5.4.1. The images are shown in Panels A  and C. The 
phosphorylated and total p54 protein level for each sample was determined by 
densitometric analysis. Panels B and D show the ratios o f phosphorylated p54 
JNK:total p54 JNK for each sample, normalised to the IL-1 treated DMSO control 
that has been assigned as 1. The data shown in Panel B is the mean +SD from three 
independent experimental series. The data shown in Panel D is representative o f two 
independent experiments.
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Because our data consistently shows that the total-JNK levels remain relatively 
unaffected by the treatment o f Hep3B cells with IL-1 (and therefore, the increase in 
JNK phosphorylation observed in response to IL-1 is not due to an increase in de novo 
synthesis o f the JNK proteins), the data presented in Figure 5.5 is displayed as ratios 
o f phosphorylated JNK:total JNK. As expected, IL-1 induced the phosphorylation o f 
JNK (Panel A  and C). This effect was marginally prevented by curcumin, although 
this inhibition in phosphorylation was not statistically significant. Apigenin did not 
inhibit IL-1-mediated phosphorylation o f  JNK. Consistent with the aforementioned 
publications, SP600125 reduced the IL-1-mediated JNK phosphorylation in a 
concentration-dependent manner. Total JNK levels remained unchanged by these 
inhibitors, suggesting that the observed effects on phosphorylation were specific to 
this.
5.2.3 E f f e c t  o f  IL -1  o n  JNK k in a s e  a c t i v i t y  in  H ep3B c e l l s
Although detecting Thrl83 /Tyrl85  phosphorylation is a good marker o f JNK 
activation, it is also useful to monitor JNK kinase activity directly from cell extracts. 
JNK activation can be routinely measured by protein kinase activity towards the 
transcription factor c-Jun. We decided to monitor JNK activation in this manner in 
light o f the findings presented in Figure 5.5 and additionally to confirm our previous 
results. Several studies have demonstrated the effect o f curcumin as an inhibitor o f 
the JNK pathway by monitoring the activity o f this kinase in vitro , rather than 
assessing the effect o f this inhibitor on JNK phosphorylation (Parra et al. 2000; 
Comalada et al. 2003; Singh and Ramji 2006). In the Singh and Ramji (2006) study, 
the effect o f both curcumin and SP600125 on the TGF-p-mediated phosphorylation o f 
JNK was analysed by western blot analysis. Neither inhibitor affected this 
phosphorylation but both significantly attenuated the TGF-p-stimulated increase in 
JNK kinase activity (Singh 2003; Singh and Ramji 2006). In this study, a non­
radioactive method o f measuring JNK activity was employed based on a JNK activity 
assay kit from New England Biolabs (see Table 2.0 and Section 2.7.5).
Therefore, as an initial experiment we wanted to determine whether the previously 
observed increase in JNK phosphorylation in response to IL-1 correlated with an 
increase in the kinase activity o f JNK. Hep3B cells were either treated with IL-1 or
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left untreated and harvested at 15min and 30min post treatment for phosphatase-free 
whole cell protein extraction (Section 2.7.2). Kinase assays were performed as 
described in section 2.7.5, whereby c-Jun fusion proteins linked to agarose beads were 
used to ‘pull-down’ the active JNKs present in the protein extracts. Addition o f ATP, 
results in the phosphorylation o f the c-Jun substrate by active JNKs present in the 
sample. Phosphorylated c-Jun was subsequently detected by western blot analysis. 
The primary antibody used for phospho-c-Jun detection specifically recognises 
phospho-serine63, the residue that is characteristically phosphorylated by activated 
JNKs (H ibi et al. 1993). The detection o f p-actin by western blotting was used as a 
control for equal loading o f samples, as described previously. The results are shown 
in Figure 5.6.
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Figure 5.6. The effect o f IL-1 on JN K  activ ity in Hep3B cells. Hep3B cells were 
either treated with IL-1 (lOOU/ml) or left untreated (Omin -IL-1, 15min -IL -1 ) and 
harvested for phosphatase-free protein extraction at each o f the indicated time-points. 
JNK kinase assays were carried out using 250pg o f the protein extracts as described in 
Section 2.7.5 and blotted membranes were probed with the phospho-c-Jun (serine63) 
antibody as shown in Panel A  and B. For p-actin western blots, lOpg o f each protein 
extract was subjected to western analysis as described previously (A and B). The 
phospho-c-Jun and P-actin protein level for each sample was determined by 
densitometric analysis. Panel C displays the ratios o f Phospho-c-Jun:P-actin 
normalised to the Omin control. The data shown in Panel C is the mean +SD from 
three independent experimental series. *P<0.05.
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IL-1 induces JNK kinase activity in Hep3B cells harvested at 15 and 30 minutes 
following treatment. In addition we also demonstrate that this induction is absent 
from untreated samples taken at the 15min time-point indicating that the observed 
induction was only due to stimulation o f Hep3B cells with IL-1 (Figure 5.6 Panel B). 
These results are in keeping with the previous data presented in this chapter, whereby 
IL-1 induces JNK phosphorylation at the same time-points, indicating that increased 
phosphorylation o f JNK correlates w ith an increase in kinase activity.
5.2.4 E f f e c t  o f  c u r c u m in , SP600125 a n d  a p ig e n in  on  IL - 1 - m e d ia t e d  JNK
KINASE ACTIVITY
We next examined the effect o f curcumin, SP600125 and apigenin on IL-1-mediated 
JNK kinase activity. Hep3B cells were treated with either curcumin (30pM), 
SP600125 (50pM) or apigenin (20 and 40pM) in addition to DMSO (vehicle-control), 
for lh  prior to the addition o f IL -1 . The cells were then harvested at 15min, following 
the addition o f IL-1 for phosphatase-free total cell protein extraction as described 
previously. JNK kinase assays were carried out as specified above in section 5.2.3. 
The results o f these assays are presented in Figure 5.7.
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Figure 5.7. The effect of inhibitors on IL-l-mediated JNK kinase activity in 
Hep3B cells. Hep3B cells were treated with each o f the specified inhibitors in 
addition to DMSO (vehicle-control) as indicated, for lh  prior to the addition o f IL-1. 
Phosphatase-free protein extracts were prepared from cells harvested at 15min 
following the addition o f IL-1. The JNK kinase assays and p-actin westerns were 
carried out as specified in Figure 5.6 and are shown in Panels A  and C. Panels B and 
D show the ratios o f Phospho-c-Jun:P-actin for each sample, normalised to the IL-1 
treated DMSO control that has been assigned as 1. The data shown in Panel B is the 
mean +SD from three independent experimental series, ***P<0.001. The data shown 
in Panel D is the mean o f two independent experiments.
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The data presented above, clearly shows that both curcumin and SP600125 
significantly inhibit the IL-1-mediated JNK kinase activity in Hep3B cells. Therefore, 
judging from these data we can conclude that both curcumin and SP600125 are 
effective JNK inhibitors in Hep3B cells. Importantly, these data also support our 
previous results from chapter 4 in which both these inhibitors significantly impair IL- 
1-mediated C/EBP8 expression, further implicating a role for the JNK pathway in the 
regulation o f this response. In addition, in support o f the data presented in Figure 5.5 
where apigenin did not affect JNK phosphorylation as induced by IL-1, this inhibitor 
also did not impair the IL-1-mediated increase in JNK kinase activation at both the 
specified concentrations. However, we did note that at the higher concentration o f 
40pM, apigenin inhibited basal JNK activity, although we also observed that the basal 
JNK activity in the image presented in Panel C was higher than that o f the basal 
activity presented in Panel A. Also o f note, P-actin protein levels did not vary in the 
presence o f these inhibitors strongly indicating that the observed effects on JNK 
activity were specific to this.
5.2.5 E f f e c t  o f  IL -1  o n  CK2 k in a s e  a c t i v i t y  a n d  p r o t e in  e x p r e s s io n  in  
H e p 3B  c e l l s
Apigenin does not prevent IL-1-mediated activation o f JNK suggesting that CK2 may 
not regulate this enzyme during IL-1 signalling in Hep3B cells (Figures 5.5 and 5.7). 
Therefore this also suggests that CK2 may act independently o f the JNK pathway in 
the regulation o f C/EBP8 expression by IL-1. In light o f these findings, we next 
wanted to explore whether IL-1 stimulated CK2 activation. For this, an in vitro assay 
for CK2 activity was carried out as previously described (Mead et a l 2003). Hep3B 
cells were either treated with IL-1 or left untreated for various time-points over 3h and 
harvested for phosphatase-free whole cell protein extraction. For initial experiments, 
the 30min, 60min and 180min time-points were chosen based on previous studies in 
our laboratory analysing inducible CK2 activation (Greenow 2004) and because the 
maximum induction o f C/EBP8 by IL-1 occurs at 3h post treatment (see Chapter 3). 
CK2 was immunoprecipitated from extracts using an antibody against the a catalytic 
subunit and immunoprecipitates were then used in an assay where the ability o f 
CK2/CK2a to phosphorylate a representative substrate, p-casein was determined. 
This assay utilised y-32-P-labelled ATP, as a phosphate donor in a substrate mix
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containing P-casein. Following the incubation o f samples with the substrate mix, the 
content o f each was size-fractionated by SDS-PAGE. Phosphorylated-p-casein was 
then detected by autoradiography (See section 2.7.6 for details). As an additional 
measure, the expression o f the CK2a subunit was also determined in extracts by 
immunoblotting, to assess for any action o f IL-1 on de novo synthesis o f the protein. 
The results are shown in Figure 5.8.
P-P-CASEIN
(24kDa)
CK2a
P-p-CASEIN
(24kDa)
Figure 5.8. Effect o f IL-1 on CK2 activ ity  and protein expression in Hep3B cells.
Hep3B cells were either treated w ith IL-1 or left untreated at each o f the indicated 
time-points and harvested for protein extraction. The CK2 kinase assays (A and C) 
were carried out using 150pg o f phosphatase-free whole cell extracts as detailed in 
section 2.7.6. Also shown is a positive control for the kinase assay in Panel C using 
purified CK2 enzyme (1U; Promega) which was incubated separately with the P- 
casein substrate mix during the kinase assay. Protein extracts were also used to detect 
CK2a by immunoblotting (B). Western blot analysis was carried out by SDS-PAGE 
using 10% (w/v) gels as described previously with 35pg o f each sample and blots 
were probed using an anti-CK2a antibody. Experiments were carried out at least 
three times.
+VE
+IL-1 (100U/ml)
Omin 30min 60min 180min
Omin 30min 60min 180min
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Results from initial experiments were encouraging (Figure 5.8A), indicating that IL-1 
may indeed induce CK2 activation, however in all subsequent experiments IL-1 
produced a variable and inconsistent effect on CK2 activation (compare Figure 5.8A 
and C, as an example). Nevertheless, as can be seen from Panel C in Figure 5.8, the 
positive control sample, containing purified CK2, produced a dramatic 
phosphorylation o f p-casein, indicating that the assay itself was reliable. Therefore, 
based on these data alone we could not make any firm  conclusions on the effect o f IL- 
1 on CK2 activation. In addition, we consistently did not note any change in the 
levels o f CK2a expression in response to IL-1 at the indicated time-points (Panel B).
5.2.6 E f f e c t  o f  DN m u t a n t s  o f  CK2, JNK a n d  c -J u n  o n  t h e  in d u c t io n  o f  
C/EBP8 mRNA e x p r e s s io n  by IL-1
We decided that it was crucial to next assess the action o f DN mutants o f both CK2 
and key components o f the JNK pathway on the IL-1-mediated increase in C/EBP6 
mRNA expression in order to directly assess the involvement o f these signalling 
components in the regulation o f this response.
Plasmids encoding DN forms o f CK2, JNK and c-Jun are detailed in section 2.4.4. It 
was decided that Hep3B cells were to be transfected by the PEI method (Section
2.4.1). This method has proven to be very effective for transfecting these cells with a 
high level o f efficiency as demonstrated in a previous study conducted in our 
laboratory (Harvey 2006). In this study, the use o f this method o f transfection to 
deliver a plasmid specifying for the DN mutant o f CK2 into Hep3B cells, helped to 
successfully identify a potential role for CK2 in the regulation o f endogenous MCP-1 
expression by IFN-y in these cells (Harvey 2006; Harvey et al. 2007). It is also 
worthy o f note that all these plasmids have been used in previous studies to identify 
potential roles o f CK2 and JNK in a variety o f responses (see section 2.4.4, Singh and 
Ramji 2006; Greenow 2004; Harvey et al. 2007).
Hep3B cells were transfected with each o f the plasmids specifying for DN forms o f 
CK2, JNK, c-Jun and with the empty plasmid expression vector pcDNA3 (Section
2.4.1). The cells were then either stimulated with IL-1 for 3h or left untreated, at 
which point samples were prepared for RT-PCR analysis as previously described. 
RT-PCR was carried out using primers specific for C/EBP5 and p-actin. PCR
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products were resolved by agarose gel electrophoresis and the results are presented in 
Figure 5.9.
M -RT
pcDNA3 DN-CK2 DN-JNK
—  C/EBP5
Primer dimer
P-actin
B.
M -RT H20
pcDNA3 DN-c-JUN
IL-1 + - +
:/EBP6
■Primer dimer
F ig u r e  5.9. Effect o f DN inh ib ito rs o f CK2, JN K  and c-Jun on the induction of 
C/EBP8 mRNA expression by IL -1 . Hep3B cells were transfected with plasmids 
specifying for DN mutant forms o f CK2, JNK and c-Jun. As a control, cells were also 
transfected with pcDNA3. A ll plasmids were transfected using 10pg o f plasmid DNA 
by the PEI method (Section 2.4.1). Hep3B cells were then either treated with IL-1 
(lOOU/ml) or left untreated for 3h and harvested for RT-PCR analysis. Primers 
against C/EBP8 and P-actin were used to PCR-amplify the respective products as 
described previously. PCR products were then size-fractionated by electrophoresis as 
before. The size o f each PCR-amplified product was determined by comparing it to 
standard DNA markers, denoted as ‘M ’ (New England Biolabs, lOObp DNA ladder. 
See Appendix II). -R T  denotes the RT-PCR in which no reverse transcriptase was 
included for the preparation o f cDNA (using pcDNA3 transfected -IL-1 RNA). H2O 
denotes a PCR in which cDNA was replaced with an equal volume o f water. Results 
in Panel A  are representative o f two independent experiments.
As expected, IL-1 produced an increase in the levels o f C/EBP8 mRNA. However, 
none o f the plasmids specifying for DN forms o f CK2, JNK or c-Jun inhibited the 
induction o f C/EBP8 expression by IL-1 compared to the pcDNA3 transfected 
controls. The results o f these experiments, together with the other findings presented 
in this chapter are discussed in detail below.
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5.3 D iscussio n
The potentially novel roles o f JNK and CK2 in the regulation o f C/EBP5 expression 
by IL-1 were investigated in this chapter. Our results show, for the first time, that IL- 
1 transiently activates JNK M APK in Hep3B cells with rapid kinetics (Figures 5.4.1, 
5.4.2 and 5.6). This novel data, and together with data presented in the previous 
chapter supported a role for this pathway in the regulation o f C/EBP5 expression by 
IL-1. Because JNK inhibitors, SP600125 and curcumin significantly inhibited the 
induction o f C/EBP5 expression by IL-1 (Chapter 4), we wanted to confirm their 
action as JNK inhibitors in our cellular system. We found that curcumin did not 
significantly inhibit IL-1-mediated JNK phosphorylation in Hep3B cells (Figure 
5.5A). We like others, (Cho et al. 2005) only noted a partial inhibition in JNK 
phosphorylation by curcumin. Consistent w ith previous studies (Parra et a l 2000; 
Comalada et al. 2003; Greenow 2004; Singh and Ramji 2006) we confirmed the 
action o f curcumin as an effective inhibitor o f JNK activity (Figure 5.7A). Similarly 
we confirmed the role o f  SP600125 as an inhibitor o f JNK phosphorylation (Figure 
5.5C) and activity (Figure 5.7A) (Bennett et al. 2001; Tokuda et al. 2003; Nakahara et 
al. 2004; Cho et al. 2005; Tamagno et al. 2005). The effect o f apigenin on IL-1- 
mediated JNK phosphorylation was also examined in an effort to elucidate a possible 
role for CK2 in the regulation o f the JNK M APK during IL-1 signalling, given that 
JNK is a known substrate o f CK2 (Fleming et al. 2000; Meggio and Pinna 2003). 
Apigenin did not attenuate IL-1-mediated JNK phosphorylation or activity (Figures 
5.5A and 5.7C respectively). Notably however, apigenin (40pM) reduced basal JNK 
activity (Figure 5.7C). The precise reasons for this observation are presently unclear 
but since CK2 is a constitutively active enzyme (Pinna 2002) it may contribute 
slightly to the constitutive activity o f JNK either directly or indirectly through kinases 
that phosphorylate JNK or other factors that modulate JNK activity. This however is 
distinct from IL-1-mediated regulation o f JNK as this is not affected by apigenin at 
this concentration.
Because apigenin did not attenuate IL-1-mediated JNK activation we hypothesised 
that CK2 may act independently o f the JNK pathway in relation to its regulation o f 
C/EBP5 expression by IL-1. Therefore we next investigated the action o f IL-1 on 
CK2 activation. IL -1 produced a variable and inconsistent effect on CK2 activation in
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Hep3B cells (Figure 5.8). Therefore based on these data it is tempting to speculate 
that IL-1 does not regulate CK2 activation in these cells. However, no definitive 
conclusions can be made based on these data alone. Further experiments would have 
to be conducted to firm ly establish whether IL-1 does modulate CK2 activity in these 
cells. Our in vitro kinase assay was lim ited to the isolation o f CK2 from cell extracts 
by immmunoprecipitation using an anti-CK2a antibody only. Considering that this is 
not the only catalytic subunit identified for this enzyme (Litchfield 2003), it would be 
interesting to determine whether immunoprecipitation with anti-CK2a’ and anti- 
CK2a”  antibodies produced similar results in the kinase assay in relation to IL-1 
action on CK2. This would be particularly intriguing since differential functions for 
the catalytic subunits have been described and because individual catalytic subunits 
have been identified both in isolation and as part o f the holoenzyme in cells (see 
Litchfield 2003 and references therein). Moreover, the CK2a”  has been found to be 
differentially expressed in the liver and not other tissues, indicating a cell-type 
specific role for this isoform in hepatocytes (Shi et al. 2001; Hilgard et al. 2004). In 
order to decipher whether IL-1 differentially regulates the activity o f individual CK2 
catalytic subunits, our in vitro  kinase assay could be modified slightly. There are 
CK2 substrates, a prototype being calmodulin, that are preferentially phosphorylated 
by individual CK2 catalytic subunits but not by tetrameric CK2 (Marin et al. 1999; 
Arrigoni et al. 2004). Therefore substituting calmodulin for p-casein in the kinase 
assay may determine whether IL-1 preferentially influences the action o f individual 
catalytic subunits over the tetrameric enzyme.
Another potential explanation for our data is that IL-1 may not regulate activation o f 
CK2 directly but instead influence its association with other signalling proteins. This 
theory is supported by the findings o f Bird et al. (1997). These authors investigated 
the activation o f NF-kB by IL-1 in the HepG2 cell line (a closely related cell line to 
Hep3B), and report that this activation is accompanied by CK2-mediated 
phosphorylation o f the p65 NF-kB subunit. Similar to our findings, these authors 
report little apparent stimulation o f CK2 activity by IL-1 in treated cells, although an 
increased association o f CK2 w ith NF-kB was noted in response to cytokine 
treatment. Given that a potential role for NF-kB has been suggested in the regulation 
o f C/EBP8 expression by IL-1 by our previous data (Chapter 4) and because our 
pharmacological inhibitor data also suggests an involvement for CK2, the results
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presented by B ird  et a l  (1997) may bare particular significance in relation to this 
project and provide a basis for future work (See chapter 8).
In order to further determine a role o f the JNK pathway and CK2 in IL-1-mediated 
C/EBP6 expression, DN inhibitors o f components o f the JNK pathway and CK2 were 
used. The induction o f C/EBP8 expression by IL-1 was not impaired by transfecting 
Hep3B cells w ith  plasmids specifying for DN-CK2, DN-JNK or DN-c-Jun (Figure 
5.9). These results could suggest that some functional redundancy may exist between 
the pathways that regulate C/EBP8 expression by IL-1 in Hep3B cells. Similar results 
have been reported by Mestre et al. (2001). The transcriptional up-regulation o f 
cyclooxygenase-2 (COX-2) gene expression by LPS was examined in RAW 264.7 
and THP-1 macrophages. Whilst, ERK2, p38, JNK MAPKs and PKC-£ were all 
shown to regulate this response, transfection o f DN mutant forms o f any one o f these 
signalling components failed to abrogate the LPS-mediated increase in human COX-2 
promoter activity. In addition, three functional promoter elements consisting o f an 
NF-kB, C/EBP and CRE sites were all shown to regulate the LPS-mediated induction 
o f COX-2 promoter activity. However, mutation o f any one o f these cis-acting 
elements at the promoter was not enough to abrogate the response. The response was 
only impaired when all three sites were mutated together or two o f the three sites were 
mutated simultaneously. Furthermore, expression plasmids encoding wild-type 
proteins for each o f the MAPKs and PKC-£ had a synergistic effect with LPS to 
induce luciferase activity driven by COX-2 promoter-reporter constructs containing a 
single wild-type sequence o f NF-kB, C/EBP or CRE. However, expression plasmids 
encoding DN mutant plasmids for MAPKs and PKC-£ did not diminish LPS-mediated 
COX-2 promoter activation from the same promoter-reporter constructs. Therefore, 
this suggests that COX-2 gene transcription through each promoter element (i.e. NF- 
kB-, C/EBP-, or CRE-driven transcription) is supported by at least two different 
signalling pathways (Mestre et al. 2001). Given this apparent redundancy, 
transcriptional repression o f COX-2 could not be achieved by targeting a single 
pathway or transcription factor. Functional redundancy has also been described 
during Notch signalling (Krebs et al. 2000), between the Src family o f tyrosine 
kinases (Lowell et a l 1994), between transcription factors such as the STATs 
(Ramana et al. 2005), AP-1 family members (Mechta-Grigoriou et a l 2001) and 
Nur77 steroid nuclear receptors (Cheng et a l 1997).
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Another plausible explanation for our results in Figure 5.9 is the possibility that the 
DN plasmids were delivered into the cells with low efficiency. However, we consider 
this unlikely because our chosen method o f transfection has previously been 
demonstrated to transfect Hep3B cells w ith a high level o f efficiency. For example, 
transfecting the plasmid specifying for the DN-CK2 mutant protein into Hep3B cells 
using the same method, is sufficient to attenuate the IFN-y-induced MCP-1 expression 
in these cells (Harvey 2006). Alternatively, it may be such that neither CK2, JNK or 
c-Jun are necessary to regulate IL-1-mediated regulation o f C/EBP5 in isolation. 
Therefore, to address these issues and to investigate the potential existence o f 
redundancy between the pathways, we decided to extend our investigations with the 
use o f siRNA technology, this being the focus o f the next chapter.
To summarise, the results in this chapter have firm ly established that IL-1 activates 
JNK M APK and that both curcumin and SP600125 are effective inhibitors o f this 
kinase in Hep3B cells. Furthermore, our results also suggest CK2 may not be an 
upstream regulator o f this pathway during IL-1 signalling. In addition, we suggest 
that the role o f CK2 in IL-1 signalling may not be regulated at the level o f activity, 
although further experiments are required in this area o f investigation. Finally, our 
data also suggests the possibility that some functional redundancy may exist between 
the pathways that regulate C/EBP5 expression by IL-1 and this possibility w ill be 
explored in the following chapter.
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6.1 I n t r o d u c t io n
The introduction o f double-stranded RNA (dsRNA) into a cell activates the RNA 
interference (RNAi) pathway which triggers the degradation o f mRNAs that show 
sequence complementarity to the exogenous dsRNA. This phenomenon whereby 
gene expression is silenced by homologous sequences was first described in 
transgenic plants and was termed post-transcriptional gene silencing. Attempts to 
deepen the violet colour o f Petunias, by introducing multiple copies o f a transgene 
encoding chalcone synthase into these plants (an enzyme responsible for the 
production o f the violet pigment), unexpectedly resulted in the production o f white 
flowers (Napoli et al. 1990). The introduction o f extra copies o f the chalcone 
synthase gene caused an unexplained decrease in the expression o f its mRNA, rather 
than the anticipated increase. Then in 1998, Fire and colleagues made a breakthrough 
finding. Using Caenorhabditis elegans as a model, the group discovered that 
injecting dsRNA into the nematode worm was more effective at inducing gene 
silencing, than injecting either sense or antisense RNA alone, against a target gene. 
Similar gene silencing phenomena have since been described in multiple organisms 
(see Dykxhoom et al. 2003; Stevenson 2003 and references therein).
In eukaryotic cells, RNAi represents an evolutionarily conserved cellular defence 
mechanism regulating the expression o f ‘ foreign genes’ . When viruses infect 
eukaryotic cells or when transposons and transgenes are randomly integrated into the 
host genome, dsRNA is frequently produced from the foreign genes. The RNAi 
pathway acts as a surveillance system that responds to the presence o f dsRNA by 
activating the cellular processes that inhibit gene expression (post-transcriptionally) to 
silence the expression o f invading genes (Tuschl and Borkhardt 2002).
The discovery that dsRNA produced RNAi, prompted a series o f investigations into 
elucidating the mechanism by which this occurs (see Tuschl and Borkhardt 2002; 
Dykxhoom et al. 2003; Stevenson 2003 and references therein). The process occurs 
in the cell cytoplasm (Zeng and Cullen 2002) and is ATP dependent (Nykanen et al. 
2001). When dsRNA is introduced into a cell, it is processed into -22 nucleotide 
segments by an RNAse-III-like dsRNA-specific ribonuclease termed Dicer (Zamore 
et al. 2000; Bernstein et al. 2001). These short fragments o f cleaved RNA are then
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incorporated into a multiprotein RNA-induced silencing complex, RISC (Hammond 
et al. 2000). As a prerequisite for incorporation by RISC, dsRNA must be 5’ 
phosphorylated and short dsRNAs that lack a 5’ phosphate are rapidly phosphorylated 
by an endogenous kinase (Schwarz et al. 2002). The dsRNA is then unwound, 
leaving the antisense strand to ‘ guide’ RISC to the homologous target mRNA for 
endonucleolytic cleavage. The target mRNA is cleaved at a single site in the centre o f 
the duplex region between the guide RNA and the target RNA and the resulting RNA 
fragments are subsequently degraded (Elbashir et al. 2001a).
Initial attempts to recreate RNAi in mammalian cells were unsuccessful. This is 
because in mammalian cells, the introduction o f dsRNA greater than 30 nucleotides in 
length, induces an interferon response (Elbashir et al. 2001b). Interferon mediates the 
degradation o f mRNA by inducing 2’ -5’ oligoadenylate synthase which subsequently 
activates RNAse L. Furthermore, interferon also activates protein kinase R (PKR), 
which ultimately leads to global inhibition o f mRNA translation (Stark et al. 1998). 
However, further studies showed that the introduction o f chemically synthesised 
dsRNAs between 21-22 nucleotides in length; containing 3’ overhangs (and therefore 
mimicking the structure o f the Dicer cleavage products) were effective at causing 
RNAi in mammalian cells without activating the interferon response. These short 
strands o f dsRNA were collectively termed small interfering RNAs or siRNAs 
(Elbashir et al. 2001b). The known cellular events leading to RNAi with the use o f 
siRNAs are summarised in Figure 6.1.
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siRNA
Cytoplasm
Cellular Kinase
Assembly of RISC
siRNA unwindingNucleus ADP+Pi
siRNA-mediated target 
recognition
Transcription
Target mRNA cleavageTarget mRNA
Target gene
Sequence specific 
gene silencing
FIGURE 6.1. Gene silencing by RNA interference using siRNA (adapted from  Lewis 
2005a). A rtific ia l siRNAs introduced into the cell are phosphorylated on their 5’ ends by a 
cellular kinase. These siRNAs are then incorporated into the RNA-inducing silencing 
complex (RISC) which contains both helicase and ribonuclease activity. Although the uptake 
o f siRNAs by RISC is an ATP independent process, the unwinding o f the siRNA duplex 
requires ATP. RISC is directed by the antisense strand o f the unwound siRNA to the target 
mRNA through sequence complementarity and the target mRNA is subsequently cleaved and 
degraded.
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With the use o f siRNAs, the natural RNAi process has now been manipulated as a 
research tool in a wide range o f molecular biology applications including gene 
mapping, signalling pathway dissection and functional gene analysis. Chemically 
synthesised siRNAs are now commercially available for studying the effects o f gene 
silencing in a number o f scientific applications, including those mentioned above. 
Importantly, there is also scope for the use o f RNAi as a therapeutic strategy in a 
number o f clinically challenging conditions including cancer and HIV infection 
(Tuschl and Borkhardt 2002; Dykxhoom et al. 2003; Stevenson 2003).
Prior to the application o f siRNA technology, gene knock-down in mammalian 
systems was primarily restricted to the generation o f knock-out mouse models. 
Production o f knock-out mice for study is both expensive and labour intensive. 
Additionally, researchers often encountered unforeseen problems with the generation 
o f knock-out mice such as embryonic lethality, for example. This is particularly 
apparent with attempts to produce multiple gene knock-out mice. Also, data 
generated from murine studies are not always relevant to human physiology. Certain 
differences between mouse and human cell biology have been documented (Ginis et 
al. 2004; Mestas and Hughes 2004) and such disparities should be taken into account 
i f  relating data generated from murine studies to human physiology.
With the advent o f RNAi as a research tool, the problems associated with creating 
multigene knock-out or knock-down models for scientific research can be 
circumvented. For instance, this has been well demonstrated in a study by Huang et 
al. (2004). This study aimed at better understanding the clathrin-mediated 
endocytosis o f the EGF receptor. To assess the contribution o f the Rab5 family o f 
endosomal proteins in this process, the group used siRNAs directed against the 
various family members. Individually, none o f the three Rab5 isoforms (Rab5a, b and 
c) were found to contribute to this form o f receptor internalisation. However, when 
the expression o f all three genes was simultaneously depleted by RNAi, the 
contribution o f this family was clarified. These results represent just one example that 
illustrates the strength o f RNAi-induced gene silencing as a tool in pathway 
dissection. Furthermore, as also demonstrated by the Huang et al. (2004) study, the 
use o f this technology also permits the researcher to overcome barriers associated 
with genetic redundancy.
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6.1.1 E x p e r i m e n t a l  s t r a t e g y
Already the use o f siRNA technology has advanced our understanding o f signal 
transduction pathways that regulate cellular growth, proliferation and function (Tuschl 
and Borkhardt 2002; Brummelkamp and Bernards 2003; Moffat and Sabatini 2006).
Certainly, siRNAs that target the message o f JNK MAPK or components o f this 
pathway, have been used successfully in studies to implicate this pathway in the 
regulation o f various responses (Gururajan et al. 2005; Hocevar et al. 2005; Kuntzen 
et al. 2005; Gao et al. 2006). Sim ilarly, siRNAs directed against the catalytic 
subunits o f CK2 (mainly CK2a) have also been used successfully to elucidate a role 
for this kinase in various cellular activities (D i Maira et al. 2005; Yanagawa et al. 
2005; Di Maira et al. 2007).
Therefore, in light o f recent advances in the field we decided to make use o f this 
technology and examine the effects o f silencing the message o f components o f the 
JNK M APK pathway and CK2 on IL-1-mediated induction o f C/EBP5 expression. In 
theory, silencing the expression o f such genes should interrupt these signalling 
pathways and therefore impair any responses that are primarily regulated by the JNK 
M APK and CK2 in transfected cells. Indeed, this has been shown to be the case in the 
studies listed above. In addition, w ith the use o f RNAi we were also able to assess i f  
potential redundancy between JNK and CK2 exists in mediating the induction o f 
C/EBP5 expression by IL-1. This was particularly important in light o f the findings 
presented in the previous chapter.
Additionally, in conjunction with this study, a similar study was also initiated in our 
laboratory in relation to IL-6 signalling. Dr S.A. Rogers (personal communication) 
examined the effect o f a panel o f pharmacological inhibitors on the IL-6-mediated 
induction o f C/EBP5 expression in an effort to initiate more detailed investigations 
into the signalling pathway(s) by which IL-6 up-regulates C/EBP5 expression in 
Hep3B cells. As determined from Dr Rogers’ data, the principle pathways identified 
in regulating this response also involved JNK and CK2. These data were particularly 
relevant to this study and suggested the possibility that common signalling pathways 
may regulate pro-inflammatory cytokine-mediated induction o f C/EBP8 expression.
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As mentioned in chapter 3 and section 1.3.1.3, IL-6 is reported to increase the 
transcriptional expression o f the C/EBP6 gene and the principle transcription factor 
reported to regulate this response is STAT3. However, the majority o f studies that 
indicate this are primarily restricted to promoter analysis and in vitro DNA binding 
assays (Yamada et al. 1997; Cantwell et al. 1998; Sanford and DeWille 2005). We 
also showed that the human C/EBP5 gene promoter is responsive to IL-6 (Chapter 3). 
However, to our knowledge no study has o f yet determined whether the STAT3 
transcription factor regulates the expression o f endogenous C/EBP6 levels as 
mediated by IL-6. With the use o f RNAi, we also sought to determine a role for this 
transcription factor in the regulation o f endogenous C/EBP5 levels (mRNA and 
protein) as induced by IL-6.
Because a study by Ramana et al. (2005) suggested that some redundancy exists 
between STAT1 and STAT3 transcription factors and because redundancy has been 
suggested to exist between other components o f the gpl30/JAK/STAT signalling 
pathway (Carbia-Nagashima and Arzt 2004), we designed our experiments to take this 
into consideration. Using siRNA directed against STAT1 and STAT3, we co­
transfected Hep3B cells w ith both siRNAs and subsequently assessed the relative 
contribution o f these transcription factors in producing the IL-6-mediated increase in 
C/EBP8 mRNA and protein levels. In conjunction, because Dr Rogers’ data 
suggested a requirement for JNK M APK and CK2 in the regulation o f this response, 
we also assessed the role o f these signalling mediators in regulating STAT1 and 
STAT3 activation by IL-6 w ith the use o f pharmacological agents, in an attempt to 
determine a possible mechanism o f regulation. Work in these areas could lead to the 
generation o f potentially novel data in relation to IL-6-mediated regulation o f C/EBP5 
expression. Therefore, studies presented in this chapter are split into two lines o f 
investigation. In the first part o f this chapter we present our RNAi data in relation to 
determining a role for JNK M APK and CK2 in the regulation o f the IL-1-mediated 
induction o f C/EBP5 expression. And in the second part o f this chapter we present 
data relevant to the IL-6-mediated regulation o f C/EBP5 expression. Figure 6.2 
summarises our overall experimental approach that was designed to achieve the 
outlined experimental objectives.
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F ig u r e  6.2 E xp erim en ta l strategy. Potential roles o f various signalling mediators in the 
regulation o f IL-1- and IL-6-mediated increase o f C/EBP5 expression were assessed by RNAi. 
siRNA directed against CK2 and components o f the JNK MAPK was used to determine the 
requirement o f these signalling pathways in the regulation o f C/EBP8 expression by IL-1 and to 
assess any functional redundancy between the pathways in the regulation o f the response. A 
potential requirement o f the STAT transcription factors in the regulation o f C/EBP5 expression 
by IL-6 was also assessed using RNAi. In association with this, activation o f STAT1 and 
STAT3 by IL-6 was examined by western blot analysis. Because previous data from our 
laboratory suggested a role o f JNK MAPK and CK2 in the regulation o f C/EBP5 expression by 
IL-6, the effects o f pharmacological agents against these signalling mediators on STAT 
activation were also monitored by western blot analysis. 215
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6.2 I n v e s t ig a t io n s  in t o  t h e  e f f e c t  o f  s ile n c in g  c o m po n en ts  of 
THE JNK MAPK PATHWAY AND CK2 ON IL-1-INDUCED C/EBP6 
EXPRESSION
6.2.1 E f f e c t  o f  s il e n c in g  JNK1 a n d  JNK2 o n  t h e  I L - 1 - in d u c e d  e x p r e s s io n  
o f  C/EBP8 mRNA l e v e l s
As mentioned briefly in section 5.1, JNKs are the products o f three different genes, 
JNK1, 2 and 3 respectively. Messenger RNA for JNK1 and JNK2 is ubiquitously 
expressed, whereas JNK3 expression is reported to be predominant in the brain and 
testis (Kumagae et al. 1999). Therefore we restricted our experiments to the use o f 
siRNA against JNK1 and JNK2 genes.
Commercially available validated siRNAs specifically targeting the mRNA o f human 
JNK1 and JNK2 genes were purchased from Qiagen (Table 2.1). Additionally, for the 
purpose o f controlling for the siRNA transfection, a ‘negative’ or ‘ scrambled-control’ 
siRNA was purchased from Ambion®. The negative control siRNA is comprised o f a 
19bp non-targeting sequence w ith 3’ dT overhangs. The sequence has no significant 
similarity to any known gene sequences from mouse, rat or human origins. Therefore, 
this siRNA should not silence any known genes in human cells into which it is 
transfected. Transfecting negative siRNA into cells, alongside the siRNA targeting 
the gene o f interest, ensures that the results obtained from experiments are solely due 
to the silencing o f the gene o f interest and not as a result o f the transfection itself.
For preliminary analysis, Hep3B cells were transiently transfected with negative 
siRNA and siRNA targeting JNK2 (Section 2.5.1). The cells were then either treated 
with IL-1 or left untreated for 3h. Total RNA was extracted (Section 2.6.2) and used 
for semi-quantitative RT-PCR analysis as described previously. Polymerase chain 
reactions for the amplification o f C/EBP5, JNK2 and P-actin were carried out with 
primers and conditions detailed in Tables 2.4 and 2.5. Figure 6.3 shows the PCR 
products for C/EBP5, JNK2 and P-actin respectively, as size fractionated by agarose 
gel electrophoresis.
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F ig u r e  6.3. Effect o f silencing JNK2 on IL-l-induced C/EBP5 mRNA 
expression in Hep3B cells. Hep3B cells were either transiently transfected with 
negative siRNA (6.25nM) or siRNA designed against JNK2 (6.25nM) using 
DharmaFECT reagent as described in Section 2.5.1, with each transfection carried out 
in duplicate. Post transfection, the media was changed on the cells to DMEM 
complete-medium minus antibiotics and the cells were either treated with IL-1 
(lOOU/ml) or left untreated for 3h. Total RNA was extracted from cells and used for 
semi-quantitative RT-PCR analysis. The PCR amplification products for C/EBP5, 
JNK2 (amplified using primer set 2 in Table 2.4) and P-actin were resolved on 1.5% 
(w/v) agarose gels by electrophoresis. The size o f each PCR-amplified product was 
determined by comparing it to standard DNA markers denoted as ‘M ’ (New England 
Biolabs, lOObp DNA ladder. See Appendix II). -R T  denotes the RT-PCR in which 
no reverse transcriptase was included for the preparation o f cDNA (using JNK2 
siRNA transfected, -IL-1 RNA).
As shown in Figure 6.3, siRNA directed against JNK2 specifically silenced this gene, 
as only a very small amount o f JNK2 PCR product was detected in samples 
transfected with the corresponding siRNA, in contrast to cells transfected with 
negative siRNA. These results suggest that levels o f JNK2 mRNA in cells transfected 
with the corresponding siRNA are dramatically depleted compared to control cells. In 
addition, the constant expression o f p-actin in all the samples suggests that neither 
siRNA was having a global effect on gene expression in cells, further indicating that 
the results are indeed specific. Additionally, as previously observed, IL-1 induces the 
expression o f C/EBP6 in Hep3B cells, and this is also the case for those cells 
transfected with negative siRNA, suggesting that the presence o f this siRNA did not 
affect this previously observed induction. Furthermore, the induction o f C/EBP5 
expression by IL-1 in cells transfected with JNK2 siRNA is comparable with the 
induction observed in cells transfected with negative siRNA. These results indicate
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that depletion o f JNK2 mRNA levels alone in Hep3B cells is not sufficient to impair 
the induction o f C/EBP6 expression by IL -1 .
We next extended the above experiment to include siRNA against JNK1, either alone 
or in combination with siRNA against JNK2. Therefore, Hep3B cells were either 
transfected with negative siRNA, siRNA against JNK1, siRNA against JNK.2 or co­
transfected with siRNA against JNK1 and JNK2, as above. Following IL-1 treatment, 
samples were harvested for RT-PCR analysis. Polymerase chain reactions for the 
various gene products were carried out as described above, with the addition o f PCR- 
amplification o f JNK1 (see Tables 2.4 and 2.5 for primers and conditions). The 
results are presented in Figure 6.4.
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F ig u r e  6 .4. Effect of silencing JNK1 and JNK2 on IL-l-induced C/EBP8 mRNA 
expression in Hep3B cells. Hep3B cells were either transiently transfected with 
negative siRNA (12.5nM) or siRNA designed against JNK1 (12.5nM), JNK2 
(12.5nM) or co-transfected with siRNA against both JNK1 and JNK2 (6.25nM o f 
each siRNA) as described before, with each transfection carried out in duplicate. Post 
transfection, the cells were either treated with IL-1 (lOOU/ml) or left untreated for 3h 
as described previously. Total RNA was then extracted and used for semi- 
quantitative RT-PCR analysis. The PCR amplification products for C/EBP8, JNK1, 
JNK2 (amplified using primer set 2 in Table 2.4) and p-actin were resolved by 
electrophoresis as before. The size o f each PCR-amplified product was determined by 
comparing it to standard DNA markers denoted as ‘M ’ (New England Biolabs, lOObp 
DNA ladder. See Appendix II). -R T  denotes the RT-PCR in which no reverse 
transcriptase was included for the preparation o f cDNA (using negative siRNA 
transfected, -IL-1 RNA), Panel A. Although images for each PCR product in Panel A 
are separated by a gap, it should be noted that PCR products for each gene were 
resolved on the same agarose gel. Panel B displays the ratios o f C/EBP8: P-actin, 
averaged for duplicate samples, normalised to the IL-1-treated negative siRNA 
transfected control, assigned as 1, as determined by densitometric analysis. Similarly, 
in Panel C, the average ratios o f JNK1 :p-actin and JNK2:p-actin, were determined for 
the specified samples and the percentage (%) reduction in expression for both JNK1 
and JNK2 was calculated by normalising their expression in negative siRNA 
transfected samples to 100%. The results shown in both Panels B and C are the mean 
ratio +SD from three independent experimental series. **P<0.01, ***P<0.001.
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The results show siRNAs directed against JNK1 and JNK2 specifically silence the 
expression o f these genes in transfected Hep3B cells, compared to controls. 
Moreover, the results also show that siRNA directed against JNK1 did not inhibit the 
expression o f JNK2 and vice versa, producing further evidence for the specificity o f 
the siRNA used in our experiments. Co-transfecting JNK1 and JNK2 together also 
produced similar effects, resulting in knock-down o f JNK1 and JNK2 expressions 
comparable to that observed when either siRNA was transfected alone (Panel A). On 
average, the knock-down in expression o f JNK.1 was between 80-90% and that o f 
JNK2 was between 70-80% in three experiments (Panel C). In addition, depletion o f 
JNK1 and JNK2 expression did not result in a decrease in C/EBP5 expression as 
induced by IL-1 (Panels A and B). In fact, co-transfecting siRNAs against JNK1 and 
JNK2 produced a slight increase in C/EBP8 expression (Panel B). To eliminate the 
possibility this effect was due to negative control siRNA in use, the experiment was 
repeated with an alternative control siRNA.
siRNA directed against GAPDH has previously been used as a control for 
experiments involving RNAi (Larigauderie et al. 2004; Yang and Sharrocks 2004; 
Chen et al. 2005a). Therefore, we tested this siRNA as a control in our transfection 
system. siRNA directed against the human GAPDH gene was purchased from 
Ambion®. The action o f this siRNA has previously been validated in our laboratory 
in both Hep3B and THP-1 cell lines (Dr S.A. Rogers and Dr P. Foka, personal 
communications). Hep3B cells were transfected with siRNA directed against 
GAPDH or co-transfected w ith siRNA against JNK1 and JNK2. The cells were then 
either treated with IL-1 or left untreated exactly as described before and samples were 
harvested for RT-PCR analysis. PCRs for the various gene products were carried out 
as described previously and the results o f this experiment are presented in Figure 6.5.
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GAPDH JNK1+JNK2
h-C/EBP5  
“JNK1 
— JNK2
—p-2-microglobulin
F ig u r e  6.5. Effect o f simultaneously silencing JNK1 and JNK2 on IL-l-induced  
C/EBP8 m RNA expression in Hep3B cells. Hep3B cells were either transiently 
transfected with GAPDH siRNA (12.5nM) or co-transfected with siRNA against 
JNK1 and JNIC2 (6.25nM o f  each), as before. The cells were then either treated with 
IL-1 (lOOU/ml) or left untreated for 3h. Total RNA was extracted from cells and used 
for semi-quantitative RT-PCR analysis. The PCR amplification products for the 
indicated genes were then size fractioned by electrophoresis. The size o f each PCR- 
amplified product was determined by comparing it to standard DNA markers denoted 
as ‘ M ’ (New England Biolabs, lOObp DNA ladder. See Appendix II). -R T  denotes 
the RT-PCR in which no reverse transcriptase was included for the preparation o f 
cDNA (using GAPDH siRNA transfected, -IL-1 RNA). Inverted images are shown 
for clarity.
The induction o f  C/EBP5 in response to IL-1 Was apparent in cells transfected with 
GAPDH siRNA, at a level comparable to that observed in cells transfected with 
negative siRNA from previous experiments. This induction was also comparable to 
that observed from cells co-transfected with JNK1 and JNK2 in this experiment. In 
addition, as previously observed, the messages for both JNK1 and JNK2 genes were 
depleted in cells that were co-transfected with the corresponding siRNAs.
Together, data presented in this section indicates that knock-down o f JNK MAPK 
alone is not sufficient to impair the expression o f C/EBP5 by IL-1, at least at the 
mRNA level.
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6.2.2 E f f e c t  o f  s i le n c in g  J N K 1  a n d  J N K 2  on  t h e  IL -1 - in d u c e d  e xp ress io n  
OF C/EBP8 PROTEIN LEVELS
To further validate the use o f GAPDH siRNA as a control, and to determine the 
effects o f silencing JNK1 and JNK2 on C/EBP8 expression by IL-1 on the protein 
level, western blot analysis was carried out.
Hep3B cells were either transfected with siRNA directed against GAPDH, co­
transfected with siRNA against JNK1 and JNK2 or alternatively left untransfected 
(included for comparative purposes). Post IL-1 treatment, samples were harvested for 
protein extraction (Section 2.7.1) and used for western blot analysis (Sections 2.7.7 
and 2.7.8). Immunodetection o f C/EBP8, total JNK and P-actin was carried out as 
described previously. The results o f these experiments are displayed in Figure 6.6.
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F ig u r e  6.6. Effect of simultaneously silencing JNK1 and JNK2 on IL-l-induced 
C/EBP8 protein expression in Hep3B cells. Hep3B cells were either transiently 
transfected with GAPDH siRNA (12.5nM), co-transfected with siRNA against both 
JNK1 and JNK2 (6.25nM o f each siRNA) or left untransfected as described before. 
Post transfection, the cells were either treated with IL-1 (lOOU/ml) or left untreated 
for 3h exactly as before. Protein extracts were then prepared (Section 2.7.1) and 
samples were used for western blot analysis, using antibodies against C/EBP8, total 
JNK and p-actin for immunodetection. For p-actin detection, the western blot used to 
detect C/EBP5 was re-probed with the anti-p-actin antibody, Panel A. Panel B 
displays the ratios o f C/EBP8:p-actin, normalised to the IL-1-treated GAPDH siRNA 
transfected control, assigned as 1, as determined by densitometric analysis. Similarly, 
in Panel C, the ratios o f total JNK:P-actin, were determined for the specified samples 
and the % reduction in expression o f total JNK was calculated by normalising its 
expression in GAPDH siRNA transfected samples to 100%. The results shown in 
both Panels B and C are the mean ratio +SD from three independent experimental 
series. **P<0.01, ***P<0.001.
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As expected, siRNA directed against both JNK1 and JNK2 produced a significant 
decrease in the expression o f total JNK protein, compared to GAPDH siRNA 
transfected controls (Panels A  and C). Importantly, the expressions o f total JNK and 
C/EBP8 (as induced by IL-1) were comparable in both untransfected samples and 
those transfected with GAPDH siRNA, further validating the use o f this siRNA as a 
control for future experiments. However we also noted that depletion o f total JNK 
produced a significant increase in the expression o f C/EBP5 as induced by IL-1, 
compared to controls. These data support the RT-PCR data presented in Figure 6.4, in 
which we observed a similar effect.
6.2.3 E f f e c t  o f  s il e n c in g  c -J u n  o n  t h e  IL - 1 - in d u c e d  e x p r e s s io n  o f  C/EBP8
PROTEIN LEVELS
As discussed previously (Chapter 5), the transcription factor c-Jun is an important 
target for activation by JNK MAPK. We decided to determine i f  there was a potential 
role for this transcription factor in the regulation o f C/EBP5 expression by IL-1 using 
RNAi. Validated siRNA specifically targeting c-Jun was ordered from Qiagen (Table 
2.1).
Hep3B cells were either transfected with siRNA directed against GAPDH, c-Jun or 
left untransfected. The cells were then either treated with IL-1 or left untreated as 
before. Samples were then harvested for western blot analysis o f C/EBP5 and P-actin 
as above, or for c-Jun. Details for immunodetection o f total c-Jun are shown in Table
2.9. The results o f these experiments are displayed in Figure 6.7.
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F ig u r e  6 .7. Effect of silencing c-Jun on IL-l-induced C/EBP8 protein 
expression in Hep3B cells. Hep3B cells were either transiently transfected with 
siRNA directed against GAPDH (6.25nM), c-Jun (6.25nM) or left untransfected as 
described above. The cells were either treated with IL-1 or left untreated for 3h 
exactly as before. Protein extracts were then prepared (Section 2.7.1) and samples 
were used for western blot analysis, using antibodies against C/EBP8, total c-Jun and 
P-actin for immunodetection. Western blot analysis was carried out by SDS-PAGE 
using 12.5% (w/v) gels, for subsequent immunoblotting using the anti-c-Jun antibody 
and western blot analysis o f C/EBP5 was carried out as described previously. For P- 
actin detection, the western blot used to detect C/EBP5 was re-probed with the anti-P- 
actin antibody. Panel B displays the ratios o f C/EBP5:P-actin, normalised to the IL-1- 
treated GAPDH siRNA transfected control, assigned as 1, as determined by 
densitometric analysis. Similarly, in Panel C, the ratios o f total c-Jun:P-actin, were 
determined for the specified samples and the % reduction in expression o f total c-Jun 
was calculated by normalising its expression in GAPDH siRNA transfected samples 
to 100%. Results are representative o f two independent experiments.
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siRNA targeting the transcription factor c-Jun caused a 70-80% decrease in its 
expression, as anticipated compared to controls (Panel A  and C). As noted 
previously, the expression o f total c-Jun and C/EBP8 (as induced by IL-1) were 
comparable in both untransfected samples and those transfected with GAPDH siRNA. 
Depletion o f total c-Jun also produced an increase in the expression o f C/EBP5 as 
induced by IL-1, compared to controls, sim ilar to the findings presented in Figure 6.6, 
whereby knock-down o f total JNK produced a comparable effect. As an unrelated 
observation, we also noted that IL-1 produced an increase in the expression o f the c- 
Jun protein in treated samples (Panel A). Together, these results suggest that as noted 
for JNK, siRNA-mediated depletion o f  c-Jun is not sufficient to impair the IL-1 - 
mediated induction o f C/EBP5 expression in transfected cells.
6.2.4 E f f e c t  o f  s il e n c in g  CK2 o n  t h e  I L - 1 - in d u c e d  e x p r e s s io n  o f  C/EBP8 
m R N A  a n d  p r o t e in  l e v e l s
To elucidate a role for CK2 in the regulation o f C/EBP5 expression by IL-1, we used 
siRNA against this kinase. Validated siRNA targeting mRNA for the catalytic 
subunits o f CK2, CK2a and CK2a’ were purchased from Invitrogen and Qiagen 
respectively (see Tables 2.1 and 2.2).
Because Invitrogen provides two siRNA duplexes for every target gene, in 
preliminary experiments we used both duplexes for analysis. Hep3B cells were either 
transfected with negative siRNA or siRNA targeting CK2a (both siRNA duplexes) as 
before. Following IL-1 treatment, cells were harvested for RT-PCR analysis. PCRs 
for the amplification o f C/EBP6 and p-actin were carried out as before and PCR- 
amplification o f CK2a was carried out using primers and conditions specified in 
Tables 2.4 and 2.5. The results are presented in Figure 6.8.
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F ig u r e  6 .8 . Effect o f silencing CK2a on IL -l- induced  C/EBP5 mRNA expression in Hep3B 
cells. Hep3B cells were either transiently transfected with negative siRNA (6.25nM) or with two 
siRNA duplexes (duplex #1 and duplex #2) designed against CK2a (6.25nM) as described before, 
with each transfection carried out in duplicate. The cells were either treated with IL-1 (lOOU/ml) 
or left untreated for 3h as before. Total RNA was extracted from cells and used for semi- 
quantitative RT-PCR analysis. The PCR amplification products for C/EBP5, P-actin and CK2a 
were resolved by electrophoresis. The size o f each PCR-amplified product was determined by 
comparing it to standard DNA markers denoted as ‘M ’ (New England Biolabs, lOObp DNA 
ladder. See Appendix II). -R T  denotes the RT-PCR in which no reverse transcriptase was 
included for the preparation o f cDNA (using negative siRNA transfected, -IL-1 RNA). Results 
are representative o f two independent experiments.
Both siRNA duplexes targeting CK2a, appeared to be equally efficient at producing a 
decrease in the expression o f the CK2a transcript in transfected cells, compared to 
controls. Neither siRNA duplex appeared to affect the expression o f the p-actin 
control, supporting the specificity o f siRNA action. Furthermore, the IL-l-induced 
expression o f C/EBP8 did not appear to be affected in the near absence o f the CK2a 
transcript in cells transfected with corresponding siRNA, compared to controls. 
Therefore, we next examined the effect o f knocking-down the expression o f both 
CK2a and CK2a’ simultaneously, on the IL-1-mediated induction o f C/EBP8 mRNA 
expression. For this, Hep3B cells were either transfected with siRNA targeting 
GAPDH or co-transfected with siRNA against CK2a and CK2a’ using the same 
procedure as described before. Following IL-1 treatment, the cells were harvested for 
RT-PCR analysis for the expression o f C/EBP5, CK2<x, CK2<x’ and p-2- 
microglobulin. Primers and conditions for the PCR-amplification o f CK2a’ are 
presented in Tables 2.4 and 2.5 respectively. Results are presented in Figure 6.9.
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F ig u r e  6.9. Effect of simultaneously silencing CK2a and CK2a’ on IL -l- 
induced C/EBP8 mRNA expression in Hep3B cells. Hep3B cells were either 
transiently transfected with GAPDH siRNA (12.5nM) or co-transfected with siRNA 
against both CK2a and CK2a’ (6.25nM o f each siRNA), as described above. The 
cells were either treated with IL-1 (lOOU/ml) or left untreated for 3h as described 
before. Total RNA was then extracted and used for semi-quantitative RT-PCR 
analysis. PCR amplification products for C/EBP8, CK2a (CK2A1), CK2a’ (CK2A2) 
and p-2-microglobulin were resolved by electrophoresis. The size o f each PCR- 
amplified product was determined by comparing it to standard DNA markers denoted 
as ‘ M ’ (New England Biolabs, lOObp D NA ladder. See Appendix II). -R T  denotes 
the RT-PCR in which no reverse transcriptase was included for the preparation o f 
cDNA (using GAPDH siRNA transfected, -IL-1 RNA), Panel A. Panel B displays the 
ratios o f C/EBP8:p-2-microglobulin, averaged for duplicate samples, normalised to 
the IL-1-treated GAPDH siRNA transfected control, assigned as 1, as determined by 
densitometric analysis. Similarly, in Panel C, the average ratios o f CK2a:|3-2- 
microglobulin and CK2a’ :P-2-microglobulin, were determined for the specified 
samples and the % reduction in expression for both CK2a and CK2a’ was calculated 
by normalising their expression in GAPDH siRNA transfected samples to 100%. The 
results shown in both Panels B and C are the mean ratio +SD from three independent 
experimental series. *P<0.05, **P<0.01, ***P<0.001.
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Co-transfecting siRNA directed against both catalytic subunits o f CK2 (CK2a and 
CK2a’) in Hep3B cells, resulted in a subsequent decrease in respective mRNA pools 
as determined by RT-PCR (Panel A). On average, a 60% reduction in the expression 
o f CK2a and a 90% decrease in the expression o f CK2a’ was noted from three 
experiments (Panel C). Knock-down in the expression o f CK2 correlated with a 
minor but significant decrease in the expression o f C/EBP6 as induced by IL-1, 
compared to controls (Panel B). In order to assess whether this decrease was apparent 
at the level o f protein expression, the same experiment was carried out as above but 
samples were harvested for protein extraction and subsequent western blot analysis. 
The results are shown in Figure 6.10.
siRNA
IL-1(100U/ml)
GAPDH CK2a + CK2a’
C/EBP5
CK2a
CK2a’
P-actin
F ig u r e  6.10. Effect o f simultaneously silencing CK2a and C K2a’ on IL - l -  
induced C/EBP8 protein expression in Hep3B cells. The cells were either 
transiently transfected with GAPDH siRNA (12.5nM) or co-transfected with siRNA 
against both CK2a and CK2a’ (6.25nM o f each siRNA), as described in Figure 6.9. 
Post transfection, the cells were either treated with IL-1 (lOOU/ml) or left untreated 
for 3h exactly as before. Protein extracts were then prepared (Section 2.7.1) and 
samples were used for western blot analysis, using 10% (w/v) SDS-PAGE gels and 
antibodies against C/EBP5, CK2a, CK2a’ and p-actin for immunodetection (see Table 
2.9). For P-actin detection, the western blot used to detect C/EBP5 was re-probed 
with the anti-P-actin antibody.
As expected, siRNAs directed against CK2a and CK2a’ caused a decrease in the 
expression o f respective proteins in transfected cells, correlating with the decrease in 
mRNA levels as noted above (Figure 6.9). However, we did not note any visible
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decrease in the expression o f C/EBP5 by IL-1 in this experiment, compared to the 
control.
6.2.5 E f f e c t  o f  s il e n c in g  JN K  M A P K  a n d  CK2 s im u l t a n e o u s l y  o n  t h e  IL -1-
INDUCED EXPRESSION OF C/EBP8 PROTEIN LEVELS
In light o f the findings presented in the previous chapter and so far in this chapter, we 
wanted to determine i f  there could be some functional redundancy between JNK 
MAPK and CK2 in relation to the regulation o f the IL-1-mediated induction o f 
C/EBP8 expression. Therefore, we targeted both these signalling mediators in our 
next RNAi experiment. Three genes were selected for knock-down by siRNA, JNK1, 
JNK2 and CK2a. We decided to target CK2a over CK2a’ because from our previous 
experiments it was apparent that the expression o f CK2a was more abundant in 
comparison to the expression o f CK2a’ in Hep3B cells (see Figures 6.9 and 6.10). 
We chose not to target both catalytic subunits o f CK2 because we wanted to avoid 
saturating the cellular RNAi machinery and thus avoid any potential ‘off-target’ 
effects produced in response to high siRNA concentrations (Cullen 2006).
Hep3B cells were therefore either transfected with siRNA targeting GAPDH or co­
transfected with siRNA against JNK1, JNK2 and CK2a. Following treatment with 
IL-1, samples were prepared for analysis by western blotting as before. The results 
are presented in Figure 6.11.
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F ig u r e  6.11. Effect of simultaneously silencing JNK1, JNK2 and CK2a on IL-1- 
induced C/EBP8 protein expression in Hep3B cells. Hep3B cells were either 
transiently transfected with GAPDH siRNA (18.75nM), co-transfected with siRNA 
against JNK1, JNK2 and CK2a (CK2A1) (6.25nM o f each siRNA) as described 
above. Post transfection, the cells were either treated with IL-1 (lOOU/ml) or left 
untreated for 3h exactly as before. Samples were used for western blot analysis as 
described previously, using antibodies against C/EBP5, total JNK, CK2a and P-actin. 
For P-actin detection, the western blot used to detect C/EBP8 was re-probed with the 
anti-p-actin antibody, Panel A. Panel B displays the ratios o f C/EBP5:p-actin, 
normalised to the IL-1-treated GAPDH siRNA transfected control, assigned as 1, as 
determined by densitometric analysis. Similarly, in Panel C, the ratios o f total JNK:p- 
actin and CK2a:P~actin, were determined for the specified samples and the % 
reduction in expression o f total JNK and CK2a was calculated by normalising their 
expression in GAPDH siRNA transfected samples to 100%. The results shown are 
representative o f two independent experiments.
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Consistent w ith our previous results, siRNA against JNK M APK and CK2a depleted 
the expressions o f respective proteins relative to controls. The constant expression o f 
p-actin suggests that none o f the siRNAs in use were affecting cellular gene 
expression on a global level at the concentration used. In addition, we observed an 
increase in the expression o f C/EBP8 as induced by IL-1 compared to the control. 
These results indicate that reducing the expressions o f total JNK and CK2a proteins in 
Hep3B cells is not sufficient to attenuate the IL-1-mediated induction o f C/EBP8 
expression.
6.2.6 E f f e c t  o f  s il e n c in g  p38  M A P K  o n  t h e  IL - 1 - in d u c e d  e x p r e s s io n  o f  
C/EBP5 mRNA l e v e l s
Because a recent paper was published indicating a requirement for the p38 MAPK in 
the regulation o f C/EBP8 by IL-1 in rat intestinal epithelial cells (Svotelis et al. 2005), 
we decided to investigate the effect o f depleting p38 M APK expression with siRNA 
in Hep3B cells on IL-1-mediated induction o f C/EBP5 expression. Furthermore, 
because our previous data did not suggest a requirement o f the p38 MAPK pathway in 
the regulation o f this response in Hep3B cells (Chapter 4), we wanted to ascertain 
whether similar results were obtained w ith the use o f RNAi.
Validated siRNA targeting p38 M APK was purchased from Invitrogen (Table 2.2). 
Hep3B cells were transfected w ith siRNA against GAPDH or p38 M APK in the 
normal way and treated with IL-1 appropriately. Samples were then harvested for 
RT-PCR analysis. PCR-amplification o f C/EBP5 and p-actin was carried out as 
described above. The primers and conditions for amplifying p38 M APK are 
presented in Tables 2.4 and 2.5 respectively. Results o f these experiments are 
presented in Figure 6.12.
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F ig u r e  6.12. Effect of silencing p38 MAPK on IL-l-induced C/EBP6 mRNA 
expression in Hep3B cells. Hep3B cells were either transiently transfected with 
GAPDH siRNA (6.25nM) or siRNA directed against p38 M APK (6.25nM), as before. 
The cells were then either treated with IL-1 (lOOU/ml) or left untreated for 3h as 
described above. Total RNA was then extracted and used for semi-quantitative RT- 
PCR analysis. PCR amplification products for C/EBP5, p38 MAPK and p-actin were 
resolved by electrophoresis. The size o f  each PCR-amplified product was determined 
by comparing it to standard D NA markers denoted as ‘M ’ (New England Biolabs, 
lOObp DNA ladder. See Appendix II). -R T  denotes the RT-PCR in which no reverse 
transcriptase was included for the preparation o f cDNA (using GAPDH siRNA 
transfected, -IL-1 RNA), Panel A. Panel B displays the ratios o f C/EBP5.p-actin, 
averaged for duplicate samples, normalised to the IL-1-treated GAPDH siRNA 
transfected control, assigned as 1, as determined by densitometric analysis. Similarly, 
in Panel C, the average ratio o f p38 MAPK:P-actin was determined for the specified 
samples and the % reduction in p38 M APK expression was calculated by normalising 
its expression in GAPDH siRNA transfected samples to 100%. Results are 
representative o f two independent experiments.
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Consistent with our previous data from chapter 4, the results presented in Figure 6.12, 
also suggest that the p38 M APK may not be involved in regulating the IL-1-mediated 
induction o f C/EBP6 expression in Hep3B cells. Despite siRNA-mediated knock­
down o f p38 MAPK (Panels A  and C), the induction o f C/EBP5 by IL-1 was 
comparable between GAPDH siRNA transfected cells and those transfected with 
siRNA for p38 MAPK.
63 I n v e s t ig a t io n s  i n t o  d e t e r m in in g  a  r o l e  o f  ST ATI a n d  
STAT3 TRANSCRIPTION FACTORS IN  TH E REGULATIO N OF I IM ­
MEDIATE D INDUCTION OF C/EBP5 EXPRESSION USING RNAl
As previously mentioned, the transcription factor STAT3 has been suggested to 
regulate the expression o f C/EBP5 by IL-6, in a number o f different models. 
However, to our knowledge no study has provided evidence linking this transcription 
factor to the regulation o f endogenous C/EBP5 levels (as induced by IL-6). Given 
that we had established a working transfection system to successfully deliver siRNA 
into Hep3B cells, we wanted to investigate the role o f STAT3 and in conjunction 
STAT1, in the regulation o f IL-6-mediated increase in C/EBP5 expression using 
RNAi. Previously published reports suggest that some redundancy exists between 
ST ATI and STAT3 in relation to regulation o f gene expression in fibroblasts 
(Ramana et al. 2005). In addition, activation o f  both ST A T I and STAT3 is reported 
upon IL-6 stimulation o f various cell types (Chung et al. 1997; L iu et al. 1998; 
Heinrich et al. 2003). Taking this evidence into consideration, we decided to co­
transfect Hep3B cells with siRNA targeting both STAT1 and STAT3 transcription 
factors for our RNAi experiments. In association, we also decided to investigate the 
effect o f depleting ST A T I and STAT3 by R N A i, on the IL-l-mediated induction o f 
C/EBP8 expression for comparative purposes.
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6.3.1 E f f e c t  o f  s il e n c in g  ST A TI a n d  STAT3 o n  t h e  IL-6- a n d  I L - 1 - m e d ia t e d  
EXPRESSION OF C/EBP6 MRNA LEVELS
Validated siRNA targeting both STAT1 and STAT3 was purchased from Invitrogen 
(Table 2.2). Hep3B cells were transfected with GAPDH siRNA or co-transfected 
with siRNA against STAT1 and STAT3 in the normal way. The cells were then 
treated with IL-1 or IL-6 appropriately and harvested for RT-PCR analysis. PCR- 
amplification o f C/EBP8 and p-2-microglobulin was carried out as outlined 
previously and details for the PCR-amplification o f STAT1 and STAT3 are presented 
in Tables 2.4 and 2.5. The results o f these experiments are presented in Figure 6.13.
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F ig ure  6.13. Effect of simultaneously silencing STATI and STAT3 on IL-6- and 
lL-1-ioduced C/EBP8 mRNA expression in Hep3B cells. Hep3B cells were either 
transiently transfected with GAPDH siRNA (12.5nM) or co-transfected with siRNA 
against both STATI and STAT3 (6.25nM o f each siRNA) as described previously, 
with each transfection carried out in duplicate. Post transfection, the cells were either 
treated with IL-6 (lOOOU/ml), IL-1 (lOOU/ml) or left untreated for 3h as described 
before. Total RNA was then extracted and used for semi-quantitative RT-PCR 
analysis. The PCR amplification products for C/EBP8, P-2-microglobulin, STAT1 
and STAT3 were resolved by electrophoresis as before. The size o f each PCR- 
amplified product was determined by comparing it to standard DNA markers denoted 
as ‘M’ (New England Biolabs, lOObp DNA ladder. See Appendix II). -R T  denotes 
the RT-PCR in which no reverse transcriptase was included for the preparation o f 
cDNA (using GAPDH siRNA transfected, untreated RNA), Panel A. Panel B 
displays the ratios o f C/EBP5:p-actin, averaged for duplicate samples, normalised to 
the untreated GAPDH siRNA transfected control, assigned as 1, as determined by 
densitometric analysis. Similarly, in Panel C, the average ratios o f STATLP-2- 
microglobulin and STAT3:p-2-microglobulin, were determined for the specified 
samples and the % reduction in expression for both STAT1 and STAT3 was 
calculated by normalising their expression in GAPDH siRNA transfected samples to 
100%. The results shown in both Panels B and C are the mean ratio +SD from four 
independent experimental series. *P<0.05, ***P<0.001.
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Co-transfection o f siRNAs targeting STAT1 and STAT3 depleted levels o f respective 
mRNA pools dramatically, with a 60-90% reduction in expression observed on 
average in four independent experiments, compared to controls. We confirmed the 
induction o f C/EBP8 expression by IL-6 in GAPDH siRNA transfected samples 
(Chapter 3). However, we also found that depletion o f STAT1 and STAT3 caused a 
significant decrease in the expression o f C/EBP8 as mediated by IL-6, compared to 
the controls, GAPDH siRNA transfected samples (Panel A  and B). We did not note 
any significant changes in the levels o f  C/EBP5 expression as induced by IL-1, 
compared to controls (Panel A  and B). The constant expression o f P-2-microglobulin 
in all samples suggests that none o f the siRNAs used in these transfections were 
affecting gene expression at a global level, further indicating the aforementioned 
results were specific. These results were confirmed with the use o f both siRNA 
duplexes provided by Invitrogen targeting STAT1 and STAT3 (Table 2.2).
6.3.2 E f f e c t  o f  s il e n c in g  ST ATI a n d  STAT3 o n  t h e  IL-6- a n d  I L - 1 - m e d i a t e d
EXPRESSION OF C/EBP5 PROTEIN LEVELS
We next wanted to determine i f  the results presented in Figure 6.13, were mirrored at 
the level o f C/EBP8 protein expression. For this, the experiment above was repeated 
but samples were harvested for protein extraction as described before and used for 
subsequent western blot analysis. Antibodies for the detection o f C/EBP8 and P-actin 
were used as described previously for the detection o f the respective proteins. The 
details for immunodetection o f total STAT1 and STAT3 proteins are detailed in Table
2.9. The results are presented in Figure 6.14.
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F ig u r e  6.14. Effect of simultaneously silencing STATI and STAT3 on IL-6-and 
IL-l-induced C/EBP8 protein expression in Hep3B cells. Hep3B cells were either 
transiently transfected with siRNA directed against GAPDH (12.5nM) or co­
transfected with siRNA directed against STAT1 and STAT3 (6.25nM o f each siRNA) 
as described in Figure 6.13. The cells were either treated with IL-6, IL-1 or left 
untreated for 3h exactly as described above. Protein extracts were then prepared 
(Section 2.7.1) and samples were used for western blot analysis, using antibodies 
against C/EBP5, total STAT1, total STAT3 and P-actin for immunodetection. 
Western blot analysis was carried out by SDS-PAGE using 7.5% (w/v) gels, for 
subsequent immunoblotting using antibodies specific for STAT1 and STAT3, and for 
C/EBP8, as described previously. For p-actin detection, the western blot used to 
detect C/EBP6 was re-probed with the anti-P-actin antibody. Panel B displays the 
ratios o f C/EBP8:P-actin, normalised to the untreated GAPDH siRNA transfected 
control, assigned as 1, as determined by densitometric analysis. Similarly, in Panel C, 
the ratios o f total ST A T I : p-actin and total STAT3: P-actin, were determined for the 
specified samples and the % reduction in their expression was calculated by 
normalising their expression in GAPDH siRNA transfected samples to 100%. Results 
in Panel B are displayed as the mean ratio +SD from three independent experiments 
(*P<0.05). From two o f these three independent experiments, the same samples were 
also used for the immunodetection o f ST A T I and STAT3. Therefore, data in Panel C 
are shown as the mean ratios o f two independent experiments.
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The data presented in Figure 6.14 are consistent w ith the RT-PCR results presented in 
Figure 6.13. In essence, siRNA-mediated depletion o f STAT1 and STAT3 proteins in 
Hep3B cells significantly attenuates the IL-6-induced expression o f C/EBP5 protein 
compared to controls. As before, the IL-1 response was unaffected by STAT1 and 
STAT3 depletion. Our results strongly suggest that the IL-6-mediated expression o f 
C/EBP8 is regulated by the STAT transcription factors in Hep3B cells.
Previous data (see Figure 6.15) from our laboratory, suggested a role o f CK2 and JNK 
MAPK in the regulation o f IL-6-mediated induction o f C/EBP8, as the 
pharmacological inhibitors apigenin, curcumin and SP600125 significantly impaired 
this response. Therefore, in light o f the findings presented in Figures 6.13 and 6.14, 
we hypothesised that CK2 and JNK M A P K  may be regulating STAT activation in 
response to IL-6. A  series o f experiments were conducted to test our hypothesis.
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FIGURE 6.15. Effect of pharmacological inhibitors on the induction of C/EBP8 
expression as mediated by IL-6. Data and figure courtesy of Dr S. A. Rogers.
Hep3B cells were pre-treated w ith pharmacological inhibitors [AG490 (lOOpM), 
Apigenin (50pM), Curcumin (30pM), LY294002 (20 pM), PD98059 (50 pM) and 
SP600125 (50 pM)] or w ith DMSO as a vehicle control for lh. They were then either 
treated with IL-6 (lOOOU/ml) or left untreated for 3h. Total RNA was extracted and 
used for RT-PCR analysis (A). A lternatively, cells were harvested for protein 
extraction and samples were used for western blot analysis (B). Experiments were 
carried out at least three times. *P<0.05, **P<0.005.
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633 E f f e c t  o f  IL-6 o n  STATI a n d  STAT3 p h o s p h o r y l a t io n  in  H e p 3 B  c e l l s
As discussed in detail in section 1.5.2, activation o f the STATs requires their tyrosine 
phosphorylation at a single residue (T yr701 in STAT1 and Tyr705 in STAT3). This 
leads to the formation o f active STAT dimers that can translocate into the nucleus and 
subsequently regulate gene expression accordingly. In addition to tyrosine
727phosphorylation, serine phosphorylation o f  STAT1 and STAT3 has been described 
and this post-translational modification is suggested to maximise the /ra/«-activation 
potential o f these transcription factors (Wen and Darnell 1997; Heinrich et al. 2003). 
STAT1 and 3 exist as two predominate isoforms, a and (3 in cells, with ratios o f a:P 
expression varying according to cell type (see Biethahn et al. 1999 and references 
therein).
Antibodies specific for the detection o f  the various phosphorylated forms o f STAT1 
and STAT3 are commercially available (Table 2.0) and have been used extensively in 
a number o f studies (Bromberg et al. 1999; McBride et al. 2000; M itsui et al. 2003) 
and in the Hep3B cell line (Sehgal et al. 2003). Therefore, initial experiments were 
conducted to determine whether IL -6  stimulation o f  Hep3B cells resulted in the 
phosphorylation and therefore activation, o f  the STAT1 and STAT3 over a time- 
course. Hep3B cells were stimulated w ith  IL-6  over a time-course o f 3h and 
harvested at various time-points for phosphatase-free whole cell protein extraction 
(Section 2.7.2) for use in western b lo t analysis and membranes were probed with 
indicated antibodies. Results are shown in Figures 6.16 and 6.17.
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FIGURE 6.16. Time dependent effect of IL-6 on levels of phospho-(Tyr701)- and 
total-STATl levels in Hep3B cells over a period of 3h. Hep3B cells were either 
treated with IL-6 (lOOOU/ml) or left untreated (Omin) and harvested for phosphatase- 
free protein extraction at each o f the indicated time-points. Western blot analysis was 
carried out by SDS-PAGE using 7.5% (w/v) gels as previously described. For 
detection o f phospho-STATl, 40pg o f each sample was used and membranes were 
probed with an anti-phospho-(Tyr701)-STATl antibody. For detection o f total- 
STATl, lOpg o f each sample was used and membranes were probed using an anti- 
total-STATl antibody (Panel A). The tyrosine phosphorylated STAT1 protein level 
for each time-point was determined by densitometric analysis, normalised to the Omin 
control and plotted as a histogram (Panel B). Similarly, the total STAT1 protein level 
for each time-point was also determined by densitometric analysis, normalised to the 
Omin control and plotted as a histogram in Panel C. The results are representative o f 
two independent experimental series.
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F ig u r e  6.17. Time dependent effect of IL-6 on levels of phospho-(Tyr705)-, 
phospho-(Ser727)- and total-STAT3 levels in Hep3B cells over a period of 3h.
Hep3B cells were either treated w ith IL-6 (lOOOU/ml) or left untreated (Omin) and 
harvested for phosphatase-free protein extraction at each o f the indicated time-points. 
Western blot analysis was carried out by SDS-PAGE using 7.5% (w/v) gels as 
previously described. For detection o f phospho-STAT3, 40pg o f each sample was 
used and membranes were probed using an anti-phospho-(Tyr705)-STAT3 or an anti- 
phospho-(Ser727)-STAT3 antibody. For detection o f total-STAT3, lOpg o f each 
sample was used and membranes were probed using an anti-total-STAT3 antibody 
(Panel A). The tyrosine and serine phosphorylated forms o f STAT3 protein level, for 
each time-point were determined by densitometric analysis, normalised to the Omin 
control and plotted as histograms (Panel B and C). Similarly, the total STAT3 protein 
level for each time-point was also determined by densitometric analysis, normalised 
to the Omin control and plotted as a histogram in Panel D. Results in Panels B and D 
are shown as the mean + SD from three independent experimental series (*P<0.05, 
**P<0.01, ***P<0.001). Data in Panel C is the mean value from two independent 
experimental series.
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Results from Figure 6.16 reveal that IL -6  induces the tyrosine phosphorylation o f 
STAT1 (both a and p isoforms, predominately a), w ith phosphorylated levels o f 
STAT1 detected after just 5min fo llow ing stimulation (Panel A). Maximum 
phosphorylation was detected at the 15 and 30min time-points, with levels gradually 
returning to basal at subsequent time-points. Levels o f total-STATl were unchanged 
by IL-6 treatment, indicating that the observed phosphorylation was not due to de 
novo protein synthesis.
Similarly, data in Figure 6.17 reveals that IL-6 also induces the tyrosine 
phsophorylation o f STAT3 (predominately the a isoform), with tyrosine 
phosphorylated levels o f STAT3 detected after just 5min follow ing stimulation (Panel 
A and B). Again, maximum tyrosine phosphorylation was detected at the 15 and 
30min time-points, w ith levels gradually declining at subsequent time-points. Levels 
of total-STAT3 were unchanged by IL -6  treatment, indicating that the observed 
phosphorylation was not due to de novo protein synthesis (Panel D).
Since STAT3 is the major transcription factor implicated in the regulation o f C/EBP6 
expression by IL-6, we also decided to determine the effect o f IL-6 on STAT3 
serine727 phosphorylation. IL-6 also induced STAT3 serine phosphorylation, although 
more modestly than compared to tyrosine phosphorylation (Figure 6.17 Panel A, B 
and C). Levels o f phosphorylated serine727 were induced after 5min follow ing IL-6 
treatment. Similar levels were maintained between 15-45min, following treatment 
and levels gradually reduced at subsequent time-points. Together results in Figure 
6.16 and 6.17 strongly suggest that IL -6  activates both STAT1 and STAT3 in Hep3B 
cells.
63.4 E f f e c t  o f  a p i g e n i n , c u r c u m i n  a n d  SP600125 o n  I L - 6 - m e d ia t e d  
TYROSINE PHOSPHORYLATION OF STAT1 AND STAT3 IN H E P 3B  CELLS
The results presented above provided us w ith a basis to study the effects o f 
pharmacological inhibitors against CK2 and JNK M APK on the activation o f both 
STAT1 and STAT3. The effect o f  curcumin, SP600125 and apigenin on IL-6- 
mediated activation o f both STAT1 and STAT3 was therefore analysed by western 
blot analysis.
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Hep3B cells were pre-treated w ith inhibitors at various concentrations or vehicle for 
lh  at which point they were treated with IL-6 appropriately and harvested for 
phosphatase-free protein extraction 15min following stimulation. The cells were 
harvested at this time-point because it is one o f the time-points at which IL-6- 
mediated phosphorylation o f STAT1 and STAT3 is maximal. Samples were used for 
western blot analysis as described in the above sections, using antibodies to detect 
tyrosine phosphorylated forms o f STAT1 and STAT3 and total levels o f these 
proteins. Results are presented in Figures 6.18 and 6.19.
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F ig u r e  6.18. The effect of inhibitors on IL-6-mediated phosphorylation of 
STAT1 (Tyr701) in Hep3B cells. Hep3B cells were treated with the indicated 
inhibitor at the specified concentration in addition to DMSO (vehicle-control), for lh  
prior to the addition o f IL-6 (lOOOU/ml). Phosphatase-free protein extracts were 
prepared from cells harvested at 15min fo llow ing the addition o f IL-6 and used for 
western blot analysis as described in Figure 6.16 (Panels A  and C). The tyrosine- 
phosphorylated STAT1 and tota l-STATl protein level for each sample was 
determined by densitometric analysis. Panel B shows the ratios o f phosphorylated- 
STATktota l-STATl, for each sample, normalised to the IL-6-treated DMSO control, 
which has been assigned as 1. The data shown in Panel B is the mean +SD from three 
independent experimental series (**P<0.01, ***P<0.001). Images in Panel C show 
the effect o f various concentrations o f each inhibitor on Tyr701 phosphorylation o f 
STAT1, from one experiment.
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F ig u r e  6.19. The effect of inhibitors on IL-6-mediated phosphorylation of 
STAT3 (Tyr705) in Hep3B cells. Hep3B cells were treated with the indicated 
inhibitor at the specified concentration in addition to DMSO (vehicle-control), for lh  
prior to the addition o f IL-6 (1 OOOU/ml). Phosphatase-free protein extracts were 
prepared from cells harvested at 15min fo llow ing the addition o f IL-6 and used for 
western blot analysis essentially as described in Figure 6.17, with 20pg o f each 
sample used for western blot analysis and subsequent immunoblotting using anti- 
phospho-(Tyr705)-STAT3. The tyrosine-phosphorylated STAT3 and total-STAT3 
protein level for each sample was determined by densitometric analysis. Panel B 
shows the ratios o f phosphorylated-STAT3:total-STAT3, for each sample, normalised 
to the IL-6-treated DMSO control, which has been assigned as 1. The data shown in 
Panel B is the mean +SD from three independent experimental series (*P<0.05). 
Images in Panel C show the effect o f  various concentrations o f each inhibitor on 
Tyr705 phosphorylation o f STAT3, from one experiment. Numbers displayed at the 
bottom o f each image represent ratios o f  phospho-(Tyr705)-STAT3:total-STAT3 as 
determined by densitometric analysis.
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All three inhibitors significantly inhibited the IL-6-mediated Tyr701 phosphorylation 
of STAT1, w ith levels o f phosphorylated STAT1 reduced by more than 50%, 
compared to the control (Figure 6.18, Panels A  and B). The inhibitors did not affect 
the expression o f total-STATl levels, indicating that the observed inhibition o f 
Tyr701 phosphorylation was not caused by the inhibitors having a general effect on 
STAT1 expression in the cells. Images in Panel C o f Figure 6.18, suggest that the 
inhibition o f Tyr701 phosphorylation o f  STAT1 by these pharmacological agents 
occurs in a concentration dependent manner. Results presented here potentially 
suggest a role for CK2 and JNK M APK in the regulation o f Tyr701 phosphorylation 
of STAT1 (by IL-6) in Hep3B cells.
The effect o f apigenin, curcumin and SP600125 on IL-6-mediated Tyr705 
phosphorylation o f STAT3 was next examined (Figure 6.19). Curcumin caused a 
minor but significant decrease in IL-6-induced Tyr705 phosphorylation o f STAT3, 
compared to the control. However, the effect o f SP600125 on this phosphorylation 
was not statistically significant. Because the effect o f curcumin on STAT3-Tyr705 
phosphorylation (as mediated by IL-6) was minor, and also because SP600125 did not 
significantly attenuate this phosphorylation (at 50pM), it is unlikely that JNK MAPK 
plays a major role in regulating STAT3-Tyr705 phosphorylation as induced by IL-6, 
although this requires further investigation. Apigenin also caused a minor and 
significant decrease in Tyr705 phosphorylation o f  STAT3 (by IL-6). Images in Panel 
C o f Figure 6.19, show effect o f  various concentrations o f these inhibitors on IL-6- 
mediated STAT3 phosphorylation. Although these data suggest a concentration 
dependent decrease in IL-6-mediated Tyr705 phosphorylation by the inhibitors 
curcumin and SP600125, the concentration-dependent effect o f apigenin was less 
apparent, therefore all these results require confirmation. Levels o f total-STAT3 were 
unaffected in the presence o f all three inhibitors.
6.3.5 E f f e c t  o f  a p i g e n i n , c u r c u m i n  a n d  SP600125 ON I L - 6 - m e d ia t e d  
SERINE727 PHOSPHORYLATION OF STAT3 IN  H E P 3B  CELLS
The mechanisms and/or kinases involved in regulating the serine phosphorylation 
of STATs are less well understood than those regulating tyrosine phosphorylation. 
Evidence for the involvement o f PKC6, p38 MAPK, MEKK1, ERK MAPK, JNK 
MAPK, Ca2+/calmodulin dependent kinase II (see Heinrich et a l 2003 and references
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therein) and CK2 (Timofeeva et a l  2006) have been reported. IL-6-mediated STAT3
• 727 i •serine phosphorylation and trans-activation is dependent on the sequential 
activation o f Rac-1, MKK4/SEK1 and PKC8 in HepG2 cells (Schuringa et a l 2001).
Because some studies have suggested that serine727 phosphorylation o f STAT3 may 
positively regulate its /rans-activation potential (Wen and Darnell 1997; Schuringa et 
a l 2001) and because a number o f different kinases, including JNK MAPK (Lim  and 
Cao 1999) and CK2 (Timofeeva et a l  2006) have been suggested to regulate serine727 
phosphorylation o f STAT3 and STAT1 respectively, we sought to determine a 
potential role for these kinases in the regulation o f serine727 phosphorylation o f 
STAT3 in Hep3B cells. We have already shown that IL-6 induces the
• •  797phosphorylation o f STAT3 at serine (Figure 6.17) in these cells. Therefore, protein 
extracts used for experiments presented in Figure 6.19, were also used to assess the 
effect o f apigenin, curcumin and SP600125 on this phosphorylation. Results are 
presented in Figure 6.20 below.
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Fig ure  6.20. The effect of inhibitors on IL-6-mediated phosphorylation of STAT3 (Ser727) in 
Hep3B cells. Phosphatase-free protein extracts used for experiments presented in Figure 6.19, were 
used for western blot analysis and subsequent immunoblotting using the anti-phospho-(Ser727)-STAT3 
antibody. Total-STAT3 levels from experiments presented in Figure 6.19 (Panel A) were used as 
controls. The serine-phosphorylated STAT3 and total-STAT3 protein level for each sample was 
determined by densitometric analysis. Panel B shows the ratios of serine-phosphorylated-STAT3:total- 
STAT3, for each sample, normalised to the IL-6-treated DMSO control, which has been assigned as 1. 
Results are representative o f two independent experiments. 262
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• •  •  797A modest induction o f  serine phosphorylation as mediated by IL-6 was observed, 
consistent w ith previously presented data (Figure 6.17). This induction was, at least 
in part, inhibited by all the pharmacological agents examined, although the inhibition 
was less apparent w ith the inhibitor SP600125. Nevertheless, densitometric analysis 
o f the two datasets, suggested that all three inhibitors may inhibit this 
phosphorylation. These preliminary data suggest that CK2 and JNK MAPK may
77 7
contribute, to some extent, to the serine phosphorylation o f STAT3, although these 
results require further confirmation. These results together with all the data presented 
in this chapter are discussed in detail in section 6.4.
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6.4 D isc u ssio n
RNAi mediated knock-down o f gene expression has been successfully applied as a 
tool for pathway dissection in an ever growing list o f studies and as mentioned in 
section 6.1 has allowed researchers to overcome barriers associated with genetic 
redundancy. In some cases its application has also helped resolve controversial issues 
in a particular area o f research. For example, insulin signalling is reported to be 
principally regulated through activation o f the PI3K and subsequent activation o f its 
downstream effector, Akt/PKB (see Jiang et al. 2003 and references therein). 
However, the role o f A kt in insulin signalling is debatable. Mice lacking the A k tl 
isoform have normal reactions to insulin (Cho et al. 2001a) and skeletal muscle from 
mice deficient in Akt2 (the predominate isoform expressed in muscle and fat), is only 
marginally less sensitive to low levels o f the hormone, compared to controls. 
Furthermore, insulin sensitivity is restored in these cells exposed to higher dose o f the 
hormone (Cho et al. 2001b). Genetic knock-out o f both A k tl and Akt2 genes in mice 
is lethal. However, RNAi-mediated knock-down o f A k tl and/or Akt2 gene 
expression in cultured adipocytes helped elucidate a role for both Akt isoforms during 
insulin signalling. In addition, the same investigation revealed that some functional 
redundancy existed between the two genes, results that were only revealed with the 
simultaneous siRNA-mediated knock-down o f A k tl and Akt2 gene expression (Jiang 
et al. 2003). The results from this study also provided evidence to potentially explain 
previously reported contradictory data.
Given the success o f this application in scientific research we decided to use RNAi as 
a technique to investigate potential pathways by which the cytokines IL-1 and IL-6 
regulate C/EBP5 expression.
6.4.1 CK2 a n d  JNK MAPK p a t h w a y  in  t h e  r e g u l a t io n  o f  C/EBP8 
EXPRESSION BY IL-1
Results presented in the previous chapter suggest a role for the JNK MAPK during 
IL-1 signalling in Hep3B cells, owing to the activation o f this kinase in response to 
this cytokine. In relation to the expression o f C/EBP5 by IL-1, dominant-negative 
mutants o f  JNK and c-Jun (a downstream effector o f this pathway), transfected into 
Hep3B cells did not impair this response. Similarly, transfecting Hep3B cells with a
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dominant negative mutant o f CK2 also did not abrogate the response. We 
hypothesised that these results may suggest the existence o f some functional 
redundancy between JNK and CK2 in the regulation o f this response. With the use o f 
siRNA we tested this hypothesis.
Initial experiments were carried out w ith the aim o f investigating a role for either JNK 
MAPK or CK2 in the regulation o f  C/EBP5 expression by IL-1. siRNA targeting 
JNK was used to deplete levels o f this kinase in Hep3B cells. In all our experiments 
(Figures 6.3-6.6), siRNA against JNK caused a dramatic decrease in the expression o f 
this kinase. However, depleting levels o f JNK did not result in a concomitant 
decrease o f C/EBP5 expression as induced by IL-1 at the mRNA or protein level. In 
fact, results in Figures 6.4 and 6.6 suggest that depleting JNK actually enhanced the 
response, compared to controls. We next decided to target a more downstream 
component o f the JNK pathway using siRNA. The expression o f the transcription 
factor c-Jun was depleted using siRNA and the effect on the IL-1-induced expression 
o f C/EBP6 was examined by western blot analysis (Figure 6.7). siRNA against c-Jun 
caused a dramatic decrease in its expression as expected. Despite the knock-down in 
its expression, levels o f C/EBP5 induced by IL-1 were not decreased. As observed 
previously, with siRNA-mediated knock-down o f JNK, the response was in fact 
enhanced slightly. These results could suggest that by interrupting the JNK MAPK 
pathway in Hep3B cells, other signalling pathway(s) are engaged to compensate for 
its loss and in turn these pathway(s) are able to restore the expression o f C/EBP5 by 
IL-1. Indeed, a similar concept has been described by Mestre et al. (2001), as 
described in section 5.3.
We next decided to analyse the effect o f siRNA-mediated depletion o f CK2 
expression on the IL -1-mediated induction o f C/EBP6 expression. Targeting CK2a 
alone did not attenuate this response as determined by RT-PCR analysis (Figure 6.8). 
However, our data suggested that siRNA-mediated depletion o f both CK2a and 
CK2a’ caused a minor but significant decrease (-15% ) in the IL-1-mediated induction 
o f C/EBP8 expression compared to controls, at the mRNA level (Figure 6.9). To 
further investigate this result, we decided to determine the effect o f siRNA-mediated 
depletion o f CK2a and CK2a’ on IL -1-mediated induction o f C/EBP5 protein levels. 
We did not note any change in the levels o f C/EBP5 protein as induced by IL-1,
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compared to the control in this experiment (Figure 6.10). Therefore, further 
experiments would have to be carried out to fu lly  investigate these findings. 
Importantly, this is necessary so as results from at least three independent experiments 
can be assessed for convincing statistical significance and therefore results from RT- 
PCR experiments can be compared to data from western blotting experiments.
To address the issue o f functional redundancy, we next decided to target both JNK 
MAPK and CK2a using siRNA and investigate the effect o f this on IL-1-mediated 
induction o f C/EBP6 at the protein level. However, knocking-down the expression o f 
both CK2a and JNK caused no apparent decrease in the expression o f C/EBP5 as 
induced by IL-1 compared to the control (Figure 6.11). Ideally, knocking-down both 
CK2a and CK2a’ in conjunction w ith JNK M APK would be more appropriate to 
determine the existence o f any functional redundancy between the two pathways. 
However, in our current transfection system this was not feasible, given the high 
concentration o f siRNA required for the transfection and the risk o f potential off- 
target effects caused by this (Cullen 2006). Also, given that the expression o f three 
CK2a (CK2a, CK2a’ and CK2a” ) subunits has been described in the human 
hepatoma cell line, HuH-7 (Shi et al. 2001), the existence o f a third CK2a isoform in 
the human hepatoma cell line, Hep3B cannot be ruled out. It is therefore tempting to 
speculate that by depleting the expression o f CK2a and/or CK2a’ (with RNAi), CK2 
activity could be compensated by the third catalytic isoform CK2a” . Further 
investigations would have to be initiated in order to determine the expression levels o f 
CK2a”  in Hep3B cells. Therefore, although our current data does not suggest that 
any functional redundancy exists between CK2 and JNK MAPK, in relation to the 
regulation o f C/EBP5 expression by IL-1, further experiments would have to be 
carried out in order to fu lly  examine this.
Another potential explanation for our results discussed in this section was suggested 
by Professor D.R. Alessi (University o f  Dundee), a leading expert in protein kinases. 
In a seminar presented at our university, Prof. Alessi mentioned that siRNA-mediated 
knock-down o f kinases used for the purposes o f pathway dissection did not always 
lead to interruption o f the signalling pathway under examination. Because siRNA- 
mediated depletion o f a target protein only leads to a knock-down o f its expression, 
any remaining protein, escaping the silencing process (especially in the case o f
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kinases), can still function to compensate for its reduced expression, and in the case o f 
cellular signalling, still activate the pathway.
A similar concept is described for recessive traits acquired by a Mendelian mode o f 
inheritance. As an example, the genetic inheritance o f Duchenne Muscular Dystrophy 
(DMD) is described. D M D  is a debilitating genetic disease characterised by 
progressive muscle weakness caused by the inability o f muscle fibres to produce the 
protein dystrophin. The dystrophin gene is located on the X chromosome making 
DMD an X-linked recessive disorder, usually affecting only males (Hoffman et al. 
1987; Koenig et al. 1987). Because females have two copies o f the X  chromosome, a 
woman who has one correct copy o f the dystrophin gene and one mutated copy o f the 
same gene (heterozygote or carrier), can nearly always produce enough dystrophin to 
have normal muscle function. This is despite the fact she can only produce 50% of 
the wild-type protein compared to a non carrier. In essence, due to random X- 
chromosome inactivation, 50% o f her muscle fibres are able to produce the wild-type 
dystrophin protein, whereas the other 50% are not (they produce the mutated protein). 
The presence o f only ha lf the amount o f  wild-type protein produced by a carrier 
compared to a non carrier can compensate for the missing 50% o f the protein 
(information regarding genetic inheritance o f D M D  retrieved from OMIM(TM), 
Online Mendelian Inheritance in Man at http://vvww.ncbi.nlm .nih. gov/omim and the 
Centre o f Genetics Education at http://www.genetics.com.au).
Furthermore, some studies have shown that although in homozygous gene knock-out 
mouse models, disruption/deletion o f  a target gene results in the manifestation o f an 
abnormal phenotype, the heterozygous gene knock-out counterparts have a normal 
phenotype. For example, this is the case for the mouse knock-out model for the 
insulin receptor gene (IR). IR-/- mice display major metabolic defects, such as severe 
diabetes and hepatic steatosis resulting from abnormally high levels o f triglycerides 
and free-fatty acids. These mice die w ith in  one week o f birth as a result o f these 
metabolic defects. However, the IR+/- mice do not show any major metabolic 
abnormalities and have normal glucose tolerance compared to control mice 
(Kadowaki 2000). Sim ilarly, whereas knocking out the regulatory p subunit o f CK2 
in mice leads to early embryonic lethality, heterozygous CK2p (CK2p+/~) knockout 
mice do not show an obvious phenotype. Interestingly, CK2P embryonic stem cells
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(ES) express a considerably lower level o f  CK2p than wild-type ES, whereas the level 
of CK2p in organs from heterozygous adult mice does not significantly differ from 
those o f wild-type mice (Buchou et al. 2003; Blond et al. 2005). The results o f such 
studies suggests that although heterozygous mice can technically only produce 50% o f 
the wild-type protein, compared to controls, this amount is enough to compensate for 
the missing 50% o f the protein.
Another possible explanation for our results is that the pharmacological agents used to 
identify CK2 and JNK M APK as players in the regulation C/EBP8 expression by IL-1 
(Chapter 4) could be inhibiting more than just CK2 and JNK MAPK in Hep3B cells. 
Indeed, both curcumin and apigenin have been described to inhibit NF-kB, albeit in 
some cases inhibition o f NF-kB is secondary to inhibition o f JNK M APK and CK2 
respectively, by these agents (Singh and Aggarwal 1995; Xu et al. 1997; Liang et al. 
1999; Romieu-Mourez et al. 2001; Shukla and Gupta 2004a; Shukla and Gupta 
2004b; Cho et al. 2007; Shakibaei et al. 2007). Preliminary data presented in chapter 
4 suggests a role for NF-kB in the regulation o f C/EBP8 expression by IL-1. 
Therefore the role o f NF-kB in the regulation o f  this response is explored in detail in 
the following chapter.
6.4.2 R o l e  o f  STAT1 a n d  STAT3 in  t h e  r e g u l a t i o n  o f  C/EBP8 e x p re s s io n  
b y IL - 6
Several studies have suggested a role for STAT3 in the regulation o f C/EBP5 
expression as mediated by IL-6 (Yamada et al. 1997; Cantwell et al. 1998; Sanford 
and DeWille 2005). We expanded on the findings o f these studies and with the use o f 
RNAi, report a role for the STATs in the regulation o f endogenous C/EBP5 
expression by IL-6, a novel finding. Our R N A i experiments (Figures 6.13 and 6.14) 
consistently show that simultaneous siRNA-mediated depletion o f ST A T I and 
STAT3 abrogates the expression o f C/EBP5 by IL-6, whereas the IL-1 response is 
unaffected. Further RNAi experiments carried out by Dr S.A. Rogers’ (personal 
communication), suggest a predominant role o f STAT3 over STAT1 in the regulation 
IL-6-mediated expression o f C/EBP5, consistent w ith previous findings (Cantwell et 
al. 1998). In support o f our findings, we also show that IL-6 activates both STAT1 
and STAT3 in stimulated Hep3B cells (Figures 6.16 and 6.17 respectively). Also 
consistent w ith previous reports (Heinrich et al. 2003; Sehgal et al. 2003) we show
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that IL-6 activates STAT3 more efficiently than STAT1 and with slightly different 
kinetics.
As a potential role for JNK M APK and CK2 had previously been suggested in the 
regulation o f C/EBP8 expression by IL-6 (Figure 6.15), we carried out experiments to 
assess a role for these kinases in the activation o f STATI and STAT3 as mediated by 
IL-6, with the use o f pharmacological agents, in an effort to determine a mechanism 
o f regulation. As shown in Figure 6.18, the CK2 inhibitor apigenin, and the two JNK 
MAPK inhibitors SP600125 and curcumin all significantly attenuated the Tyr701 
phosphorylation and therefore activation o f  STAT1, as mediated by IL-6, without 
affecting the total levels o f this transcription factor. Thus, these results potentially 
suggest a role for CK2 and JNK M APK in the regulation o f this response.
Similarly, in a separate study presently being carried out in our laboratory, SP600125 
has been shown to inhibit the IFN-y-mediated Tyr701 phosphorylation o f STAT1, 
without affecting total-STATl levels in THP-1 macrophages (Na Li, personal 
communication). Although the effect o f  curcumin on this response has presently not 
been examined, these results could suggest a potential role for JNK M APK in the 
regulation o f both IL-6 and IFN-y-mediated activation o f STATI, although further 
experiments would have to be carried out to determine this. In accordance with our 
results, curcumin is also reported to inhib it the oncostatin M  (OSM)-mediated Tyr701 
phosphorylation o f STAT1 in both bovine and human chondrocytes (L i et al. 2001b). 
Oncostatin M is a member o f the IL-6 superfamily o f cytokines, and in chondrocytes 
activates the JAK/STAT signalling pathway by phosphorylation o f JAK1, JAK2, 
JAK3 and STAT1. In addition, this cytokine also induces the activation o f all three 
MAPKs, ERK1/2, p38 and JNK in these cells. Curcumin suppresses OSM-stimulated 
Tyr701 phosphorylation o f STAT1, DNA-binding activity o f ST A T I and in 
accordance with its role as a JNK M APK inhibitor, OSM-mediated JNK MAPK 
phosphorylation. The specificity o f this compound towards the inhibition o f these two 
responses was confirmed as curcumin failed to inhibit OSM-mediated 
phosphorylation o f JAK1, JAK2, JAK3, ERK1/2 and p38 (L i et al. 2001b). The 
mechanism by which curcumin specifically inhibited OSM-mediated Tyr701 
phosphorylation o f ST A T I was not reported in this study and unfortunately the effect 
o f SP600125 on this phosphorylation was not examined. As curcumin also inhibited
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the activation o f JNK M APK as mediated by OSM, the potential involvement o f JNK 
in the regulation o f OSM-mediated Tyr701 phosphorylation o f STAT1 is entirely 
plausible.
Our data also suggests a possible role for CK2 in the regulation o f Tyr701 
phsophorylation o f STAT1 as mediated by IL-6 (Figure 6.18). Judging from the 
present literature, there may be an emerging role for CK2 in the regulation o f STAT1 
activation (Harvey 2006; Timofeeva et al. 2006; Harvey et al. 2007). The IFN-y- 
mediated phosphorylation o f STAT1 (Ser727) is inhibited by the CK2 inhibitor 
apigenin, in J774.2 murine macrophages (Harvey 2006). However, no effect o f this 
inhibitor on IFN-y-stimulated phosphorylation o f Tyr701 o f STAT1 was noted in the 
same cells. In the Timofeeva et al. (2006) study, constitutively phosphorylated 
STAT1-Ser727 was inhibited by apigenin and another CK2 inhibitor, TBB (4, 5, 6, 7- 
tetrabromobenzotriazole), in cells derived from patients w ith W ilms’ tumours and the 
human kidney cell line, HEK293T. The effect o f these inhibitors on Tyr701 
phosphorylation o f STAT1 was not examined. The effect o f apigenin on IFN-y- 
mediated Tyr701 phosphorylation o f  STAT1 has also been examined in fibroblasts. 
However, apigenin did not attenuate this response, indicating CK2 may not be 
required in the regulation o f  this phosphorylation in this cell type (Higashi et al. 
2003).
We also examined the effect o f curcumin, SP600125 and apigenin on IL-6-mediated 
phosphorylation o f STAT3 (Tyr705 and Ser727). Tyrosine phosphorylation o f 
STAT3 (as induced by IL-6) was not significantly inhibited by SP600125 and only 
marginally inhibited by curcumin, indicating that JNK may not regulate this response 
in Hep3B cells (Figure 6.19). Apigenin caused a marginal but significant decrease in 
the phosphorylation o f STAT3 (Tyr705) by IL-6, without affecting total levels o f 
STAT3. However, the concentration-dependent effect o f apigenin on this response 
requires confirmation. I f  the action o f apigenin on this response is confirmed to act in 
concentration-dependent manner, the results could potentially indicate that CK2 may 
be required, at least in part, to regulate the response. In support o f this possibility, the 
CK2 inhibitors K27 and TBB have been reported to inhibit both the Tyr and Ser 
phosphorylation o f STAT3 as mediated by IL-6, in OPM2 cells, a multiple myeloma 
cell line. In addition, Tyr phosphorylation o f STAT3 as mediated by IL-6, is also
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inhibited in primary CD 138+ cells extracted from multiple myeloma patients (Piazza 
et al. 2006). The possibility that these inhibitors were acting by inhibiting the activity 
of JAK tyrosine kinases was excluded by these authors because neither inhibitor is 
reported to affect the activation o f a panel o f  tyrosine kinases tested (see Piazza et al. 
2006 and references therein). Together, these findings support a novel role for CK2 
in the regulation o f STAT activation.
Because the activation o f the STATs is best characterised by their tyrosine 
phosphorylation as mediated by the JAKs (JAK1-3 and Tyk2) during IFN-y and IL-6 
signalling (Leonard and O'Shea 1998; Heinrich et al. 2003), the role o f other kinases, 
like JNK and CK2, in the regulation o f this process is less well documented. Despite 
this, judging from the aforementioned publications, a role o f JNK and CK2 in STAT 
activation is emerging and clearly warrants further investigation. In further support o f 
this, a role for JNK in the regulation o f  EGF-stimulated Tyr705 phosphorylation o f 
STAT3 has been reported (L im  and Cao 1999).
Given that STAT3 was the major transcription factor implicated in the regulation o f 
C/EBP6 expression as induced by IL-6, we also decided to assess whether the 
pharmacological inhibitors apigenin, curcumin and SP600125 attenuated the IL-6- 
mediated Ser727 phosphorylation o f  STAT3. IL-6 induces the phosphorylation o f 
this residue and this is believed to maximise the /rarcs-activation potential o f STAT3 
in stimulated HepG2 cells (Schuringa et al. 2000; Schuringa et al. 2001). 
Components o f the JNK M APK pathway have been implicated in the regulation o f 
STAT3 Ser727 phosphorylation (L im  and Cao 1999; Schuringa et al. 2000; Schuringa 
et al. 2001). Also, results from the Piazza et al. (2006) study suggest a role for CK2 
in the regulation o f IL-6-induced Ser727 phosphorylation o f STAT3 in myeloma 
cells.
IL-6 induces the Ser727 phosphorylation o f STAT3, in stimulated Hep3B cells 
(Figure 6.17). Our preliminary data suggests that there could be a potential role for 
CK2 in the regulation o f Ser727 phosphorylation by IL-6, because apigenin attenuated 
this phosphorylation compared to controls (Figure 6.20). The effects o f SP600125 
and curcumin on this phosphorylation are more d ifficu lt to interpret and require 
further investigation.
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The results presented in the aforementioned studies, including our own, are mainly 
generated with the use o f pharmacological inhibitors. And although data generated 
with the use o f pharmacological agents provides a good basis for study, further 
experiments are always required to back-up preliminary findings. Our results suggest 
that activation o f STAT1 and in part, activation o f STAT3 by IL-6 may be regulated 
by CK2 and JNK M APK in Hep3B cells. These results warrant further investigation 
with alternative experimental approaches. Results generated from such studies could 
identify a potentially novel role for CK2 and JNK in STAT signalling, in relation to 
the IL-6-mediated induction o f  C/EBP8 expression.
In summary, RNAi data presented in this chapter suggests that CK2 and components 
o f the JNK MAPK pathway may not be principle regulators modulating IL-1-induced 
expression o f C/EBP5 in Hep3B cells. As the pharmacological agents apigenin and 
curcumin have also been demonstrated to act as inhibitors o f NF-kB, and because 
preliminary data presented in chapter 4 suggests a role for NF-kB in the regulation o f 
IL-1-mediated induction o f C/EBP5 expression, we investigated this in more detail in 
the following chapter. In conjunction, we also investigated a role for JNK and CK2 in 
the regulation o f NF-kB activation.
Additionally, with the use o f R NAi we have shown, for the first time that STATs 
regulate endogenous expression o f C/EBP5 as induced by IL-6 in Hep3B cells. 
Consistent with their role in IL-6 signalling, we also show both STAT1 and STAT3 
are activated by this cytokine in Hep3B cells. Our data also suggests that STAT 
activation by IL-6 may be at least in part, regulated by CK2 and JNK MAPK, 
although these results require further investigation.
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7.1 I n t r o d u c t io n
As previously mentioned in chapters 1 and 4 the activation o f NF-kB by IL-1 is a well 
documented phenomenon. The signalling events resulting in the activation o f NF-kB 
by IL-1 are discussed in detail in section 1.4 o f this thesis. A brief summary o f these 
processes is given below.
IL-1-mediated signalling is initiated when IL-1 binds to the receptor complex, 
consisting o f IL-1RI and IL -lR A cP  and the subsequent recruitment o f MyD88. 
MyD88 is an adapter protein and functions to recruit the kinases IR A K I and IRAK4 
to the activated receptor. A t the receptor complex, IR AK I auto- and/or cross- 
phosphorylates itself, a process like ly to be triggered by IRAK4 activation. 
Hyperphosphorylated IR A K I then associates with the ubiquitin protein ligase, 
TRAF6 (Martin and Wesche 2002).
The M APKKK, transforming growth factor-p-activated kinase-1 or TAK-1 and its 
associated adapter proteins TAB 1-3 have also been implicated in IL-1 signalling (see 
Yao et al. 2007 and references therein). IR A K I mediates the activation o f TAK1 by 
introducing TRAF6 to the TAK1-TAB1-TAB2-TAB3 complex. Protein 
ubiquitinylation is thought to be essential for TRAF6-mediated TAK1 activation. 
TRAF6 itself is a target for ubiquitinylation and by an unknown mechanism 
polyubiquitinylated TRAF6 facilitates the complete activation o f TAK1, which 
activates itself through auto-phosphorylation (Kishimoto et al. 2000). TAK-1 can 
then activate two kinase cascades, one which involves the MAPKs and the other leads 
to the activation o f the IK K  (Wang et al. 2001). IK K  subsequently phosphorylates 
IkB and causes it to release NF-kB (typically p50:p65) which translocates into the 
nucleus to regulate gene transcription (see Figure 1.7 for details).
7.1.1 E x p e r i m e n t a l  s t r a t e g y
Preliminary data from pharmacological inhibitor studies presented in chapter 4 
indicates a potential requirement for N F-kB in the regulation o f C/EBP5 expression 
by IL-1 and additionally a role for JNK M APK and CK2 was also suggested. Despite 
this, experiments involving DN mutants (Chapter 5) and RNAi experiments presented 
in the previous chapter (Section 6.2) could not confirm the potential role o f CK2 and 
JNK MAPK in the regulation o f this response. However, both JNK MAPK and CK2
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can act as regulators o f NF-kB (McElhinny et al. 1996; Schulze-Osthoff et al. 1997 
also see section 4.3). Furthermore, because several studies have shown that the 
activity o f NF-kB can be inhibited by treatment o f cells with apigenin or curcumin 
(Gerritsen et al. 1995; Singh and Aggarwal 1995; Xu et al. 1997; Jobin et al. 1999; 
Choi et al. 2004; Schulze-Tanzil et al. 2004; Shukla and Gupta 2004a; Shukla and 
Gupta 2004b; Cao et al. 2005; Moon et al. 2005; Moon et al. 2006; Cho et al. 2007), 
we investigated a role for NF-kB in the regulation o f C/EBP5 expression by IL-1 in 
more detail. This was in itia lly achieved w ith the use o f siRNA technology, by 
targeting NF-kB. The effect o f siRNA-mediated knock-down o f NF-kB on the IL -1 - 
mediated induction o f C/EBP6 expression was examined. The same approach was 
also used to determine the effect o f siRNA-mediated knock-down o f TAK1 on the 
response, given that TAK1 is a key component implicated in IL-1 signalling.
We have previously demonstrated that IL-1 stimulates /ra«s-activation by NF-kB in 
Hep3B cells, using a luciferase-reporter construct driven by four NF-kB enhancer 
elements in a transfection based assay (Chapter 3). Using the same system we also 
determined the effect o f apigenin and curcumin on this activation. Additionally, a 
role for CK2 and JNK M APK in the regulation o f this response was also investigated 
with the use o f DN mutants. The effect o f IL-1 on NF-kB DNA binding was also 
investigated by EMSAs and in conjunction, the effect o f apigenin and curcumin on 
IL-1-mediated NF-kB DNA binding was also examined.
Figure 7.1 summarises our overall experimental approach that was designed to 
achieve the outlined experimental objectives.
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Fig u r e  7.1 Experimental strategy. Potential roles o f NF-kB and TAK1 in the regulation o f 
C/EBP5 expression by IL-1 were assessed w ith the use o f siRNA technology. 7><ms-activation 
by NF-kB as mediated by IL-1 was investigated in a transient transfection assay. The effect o f 
apigenin and curcumin on this /ram-activation was also examined. In conjunction, the effect o f 
DN CK2 and JNK mutants on /nms-activation was investigated in an effort to determine a 
possible mechanism o f activation. Finally, the effect o f IL-1 on NF-kB DNA binding was 
examined by EMSA analysis and in association the effect o f apigenin and curcumin on DNA 
binding was also determined.
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7.2 R e s u lts
7.2.1 E f f e c t  o f  s i le n c in g  p50 a n d  p65 N F -k B  o n  t h e  IL -1 - in d u c e d
EXPRESSION OF C/EBP8 MRNA AND PROTEIN
The most abundant form o f NF-kB in cells is the p50:p65 heterodimer (Ghosh and 
Karin 2002) and therefore we decided to target this for siRNA-mediated knock-down 
in our RNAi experiments. Commercially available validated siRNAs specifically 
targeting the mRNA o f human p50 and p65/RelA genes were purchased from Qiagen 
(Table 2.1). Hep3B cells were transiently transfected with GAPDH siRNA or co­
transfected with siRNA targeting p50 and p65 NF-kB as described previously 
(Section 2.5.1 and Chapter 6). The cells were then either treated with IL-1 or left 
untreated and used for semi-quantitative RT-PCR analysis as before. PCRs for the 
amplification o f C/EBP5, p50, p65/RelA and p-actin were carried out with primers 
and conditions detailed in Tables 2.4 and 2.5. Figure 7.2 displays the results o f these 
experiments.
RNAi-mediated knock-down o f p50 and p65 NF-kB caused a dramatic depletion in 
the expression o f respective mRNA pools compared to GAPDH siRNA transfected 
controls as determined by RT-PCR analysis (Panel A  and C). Levels o f p50 and p65 
were reduced by ~80% compared to their expression in GAPDH siRNA transfected 
controls. The expression o f p-actin was unaffected by these siRNAs, indicating that 
the observed knock-down in p50 and p65 expression was specific. In addition, we 
observed a significant decrease in the expression o f C/EBP8 as mediated by IL-1 
(~40% + 10.6%) in samples transfected w ith p50 and p65/RelA siRNA compared to 
the GAPDH siRNA transfected controls. We next sought to determine whether this 
reduction in C/EBP6 expression was also apparent at the protein level by western blot 
analysis.
For this, the transfection outlined in Figure 7.2 was repeated, samples harvested for 
protein extraction (Section 7.2.1) and used for western blot analysis as described 
previously (Sections 2.7.7 and 2.7.8). Immunodetection o f C/EBP8 and p-actin was 
carried out as described before (Section 2.7.9) and details for the detection o f p50 and 
p65 NF-kB are presented in Table 2.9. The results o f these experiments are displayed 
in Figure 7.3.
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F ig u r e  7.2. Effect of silencing p50 and p65/RelA NF-kB on IL-l-induced 
C/EBP8 mRNA expression in Hep3B cells. Hep3B cells were either transiently 
transfected with GAPDH siRNA (12.5nM) or co-transfected with siRNA against both 
p50 and p65/RelA (6.25nM o f each siRNA) as described in section 2.5.1, with each 
transfection carried out in duplicate. Post transfection, the cells were either treated 
with IL-1 (lOOU/ml) or left untreated for 3h. Total RNA was then extracted and used 
for semi-quantitative RT-PCR analysis. The PCR amplification products for C/EBP8, 
p50, p65/RelA and P-actin were resolved by electrophoresis as before. The size o f 
each PCR-amplified product was determined by comparing it to standard DNA 
markers denoted as ‘M ’ (New England Biolabs, lOObp DNA ladder. See Appendix 
II). -R T  denotes the RT-PCR in which no reverse transcriptase was included for the 
preparation o f cDNA (using GAPDH siRNA transfected -IL-1 RNA), Panel A. Panel 
B displays the ratios o f C/EBP5: p-actin, averaged for duplicate samples, normalised 
to the IL-1-treated GAPDH siRNA transfected control, assigned as 1, as determined 
by densitometric analysis. Similarly, in Panel C, the average ratios o f p50:P-actin and 
p65:P-actin, were determined for the specified samples and the % reduction in 
expression for both p50 and p65 was calculated by normalising their expression in 
GAPDH siRNA transfected samples to 100%. The results shown in both Panels B 
and C are the mean ratio +SD from three independent experimental series. **P<0.01, 
***P<0.001.
278
C ha pter  s e v e n : A n  in v e s t ig a t io n  in t o  t h e  r o le  o f  N F -kB  in  t h e  r e g u l a t io n  o f  C/EBP8 expr ess io n  b y  IL-1
A.
siRNA
IL-1 (100U/ml)
B.
1.2
1
co
5  0.8
«  0.4 o>Q£
0.2
0
M -RT
GAPDH p50 + p65/RelA NF-kB
C/E BPS
p65/RelA
Relative C/EBP6 Expression
GAPDH siRNA p50 + p65/RelA siRNA
Treatment
Relative p50 and p65 NF-kB Expression
□  confrol
□  +IL-1
120.00%
100.00%
c  80.00% 
o
|  60.00% Q.
,2
3(5 40.00% 
20.00%  
0 .00%
Treatment
siRNA
* * *  * * *  
di!i
Control
GAPDH
Control 
p50 + p65/RelA
+IL-1
GAPDH
* **  ***
L t
□  p50
□  p65/RelA
-HL-1 
p50 + p65/RelA
C hapter seven A n  in v e s t ig a t io n  in to  th e  r o l e  o f  N F -k B in th e  r e g u la t io n  o f C/FBP5 exp ress ion  by IL-1
FIGURE 7.3. Effect of simultaneously silencing p50 and p65 NF-kB on IL-1- 
induced C/EBP5 protein expression in Hep3B cells. Hep3B cells were transiently 
transfected with the indicated siRNAs and treated with IL-1 exactly as described in 
Figure 7.2. Protein extracts were then prepared (Section 2.7.1) and samples were used 
for western blot analysis, using antibodies against C/EBP5, p50, p65 and P-actin for 
immunodetection, Panel A. Western blot analysis o f p50 and p65 NF-kB was carried 
out by SDS-PAGE using 7.5% (w/v) gels and for the detection o f C/EBP5 and p- 
actin, as described previously. Panel B displays the ratios o f C/EBP8:P-actin, 
normalised to the IL-1-treated GAPDH siRNA transfected control, assigned as 1, as 
determined by densitometric analysis. Sim ilarly, in Panel C, the ratios o f p50:P-actin 
and p65:P-actin were determined for the specified samples and the % reduction in 
expression o f respective proteins was calculated by normalising their expression in 
GAPDH siRNA transfected samples to 100%. The results shown in both Panels B 
and C are the mean ratio +SD from three independent experimental series. 
♦♦♦P<0.001.
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As expected, siRNA directed against both p50 and p65 NF-kB produced a significant 
decrease in the expression o f respective proteins, compared to GAPDH siRNA 
transfected controls without affecting P-actin expression (Figure 7.3, Panels A  and C). 
Immunodetection o f p50 NF-kB also produced a second immunoreactive band on the 
western blot corresponding to the precursor o f this protein, p i05 (Ghosh and Karin
2002) as shown in Panel A. A dramatic decrease in the expression o f C/EBP8 as 
induced by IL-1 was noted in samples co-transfected with siRNA directed against p50 
and p65 NF-kB compared to controls. These data support the RT-PCR data presented 
in Figure 7.2, in which we observed a similar effect. Together, our RNAi data 
strongly suggests a role for NF-kB in the regulation o f C/EBP8 expression as induced 
by IL-1 in Hep3B cells, a novel finding.
7.2.2 E f f e c t  o f  s il e n c in g  TA K 1 o n  t h e  IL - 1 - in d ij c e d  e x p r e s s io n  o f  C/EBP8 
mRNA a n d  p r o t e in
TAK1 has been shown to regulate multiple signalling pathways in vivo including 
those involving IL-1 action (Shim et al. 2005). IL-1-mediated activation o f TAK1 
results in the subsequent activation o f N F - kB (Takaesu et al. 2003) and MAPK 
signalling cascades (Martin and Wesche 2002; Dunne and O'Neill 2003). Given that 
our previous data indicates an involvement o f N F -kB and a potential requirement for 
JNK MAPK in the regulation o f C/EBP8 expression by IL-1 (Chapter 4) and because 
these pathways bifurcate at the level o f TAK1 (Martin and Wesche 2002; Dunne and 
O'Neill 2003), we decided to target TAK1 for siRNA-mediated knock-down. We 
examined the effect o f TAK1 knock-down by RNAi on the IL-1-mediated induction 
of C/EBP8 in Hep3B cells.
Commercially available validated siRNA specifically targeting the mRNA o f human 
TAK1 was purchased from Qiagen (Table 2.1). Hep3B cells were transfected with 
this siRNA and treated with IL-1 exactly as described in section 7.2.1 and cells were 
harvested for RT-PCR or western blot analysis, as above. Primers and conditions for 
the PCR-ampIification o f TAK1 are displayed in Tables 2.4 and 2.5 respectively and 
details for the immunoblotting o f TAK1 protein are shown in Table 2.9. The results 
of these experiments are displayed in Figures 7.4. and 7.5 respectively.
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FIGURE 7.4. Effect of silencing TAK1 on IL-l-induced C/EBP8 mRNA 
expression in Hep3B cells. Hep3B cells were either transiently transfected with 
GAPDH siRNA (6.25nM) or w ith TAK1 siRNA (6.25nM) and treated with IL-1 as 
above with each transfection carried out in duplicate. Total RNA was then extracted 
and used for semi-quantitative RT-PCR analysis. The PCR amplification products for 
C/EBP5, TAK1 and p-actin were resolved by electrophoresis as before. The size o f 
each PCR-amplified product was determined by comparing it to standard DNA 
markers denoted as ‘ M ’ (New England Biolabs, lOObp DNA ladder. See Appendix 
II). -R T  denotes the RT-PCR in which no reverse transcriptase was included for the 
preparation o f cDNA (using GAPDH siRNA transfected -IL -1  RNA), Panel A. Panel 
B displays the ratios o f C/EBP5:P-actin, averaged for duplicate samples, normalised 
to the IL-1-treated GAPDH siRNA transfected control, assigned as 1, as determined 
by densitometric analysis. Sim ilarly, in Panel C, the average ratio o f T A K 1 :P-actin 
was determined for the specified samples and the % reduction in expression for TAK1 
was calculated by normalising its expression in GAPDH siRNA transfected samples 
to 100%. Results are representative o f  two independent experiments.
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F ig u r e  7.5. Effect of silencing TA K 1 on IL-l-induced C/EBP5 protein 
expression in Hep3B cells. Hep3B cells were transiently transfected with the 
indicated siRNAs and treated with IL-1 exactly as described in Figure 7.4. Protein 
extracts were then prepared (Section 2.7.1) and samples were used for western blot 
analysis, using antibodies against C/EBP8, TAK1 and P-actin for immunodetection, 
Panel A. Western blot analysis o f TAK1 was carried out by SDS-PAGE using 7.5% 
(w/v) gels and for the detection o f C/EBP5 and p-actin, as described before. Panel B 
displays the ratios o f C/EBP5:p-actin, normalised to the IL-1-treated GAPDH siRNA 
transfected control, assigned as 1, as determined by densitometric analysis. Similarly, 
in Panel C, the ratio o f TAK1 :P-actin determined for the specified samples and the % 
reduction in expression o f TAK1 protein was calculated by normalising its expression 
in GAPDH siRNA transfected samples to 100%. Results are representative o f two 
independent experiments.
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Results from Figures 7.4 and 7.5 show that transfection o f siRNA directed at TAK1 
into Hep3B cells caused a dramatic decrease in the expression o f this M APKKK, 
without affecting the expression o f the constitutive control, P-actin. However, we did 
not note any marked change in the expression o f C/EBP8 by IL-1, compared to 
controls, between the mRNA and protein levels.
7.2.3 E f f e c t  o f  a p i g e n i n  a n d  c u r c u m i n  o n  t /m /v s - a c t i v a t i o n  b y  NF-kB a s  
M E D IA T E D  BY I L - 1
Thus far, our RNAi data suggest that N F -kB is required for the induction o f C/EBP5 
expression by IL-1 (Figures 7.2 and 7.3) and that TAK1 may not be involved in 
regulating this response. Our pharmacological inhibitor data also supports a role for 
NF-kB in the regulation o f C/EBP8 expression by IL-1 (Chapter 4). Because apigenin 
and curcumin have also been described as inhibitors o f N F -kB activation (see section 
7.1.1 for references) in addition to direct inhibitors o f CK2 and JNK respectively, we 
wanted to examine their effect on N F - kB /raws-activation potential in Hep3B cells. 
As mentioned in section 2.4.4.4 the plasmid p N F kB -L uc, contains four N F -kB 
consensus enhancer elements fused upstream o f a luciferase reporter gene in the 
pTAL-Luc vector (Appendix I). We have previously shown that IL-1 stimulates the 
activation o f this luciferase-reporter system in transfected Hep3B cells (Section
3.3.1.2). Therefore, we used the same transfection assay to determine the effect o f 
apigenin and curcumin on N F - kB activation by IL -1 .
For this, Hep3B cells were transiently transfected (Section 2.4.1) with the p N F kB -L uc 
plasmid. Following transfection, the cells were pre-treated with DMSO (vehicle- 
control) or various concentrations o f apigenin and curcumin and then stimulated with 
IL-1. They were then harvested for the determination o f luciferase reporter activity 
(Sections 2.4.2 and 2.4.3) and protein concentration (Section 2.7.4). Results are 
shown in Figure 7.6.
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Figure 7.6. Effect of apigenin and curcumin on the trans-activation potential of 
NF-kB stimulated by IL-1 in Hep3B cells. The cells were transiently transfected 
with 2.5(ig o f pN FkB-Luc plasmid by the PEI method (Section 2.4.1). Post­
transfection, the cells were washed w ith DM EM  complete medium, and pre-treated 
with DMSO or the specified inhibitors at the indicated concentrations for lh. The 
cells were then either stimulated w ith IL-1 (lOOU/ml) or left untreated for 3h, before 
being harvested for luciferase reporter activity and protein concentration 
determination. Luciferase activity was normalised to the protein concentration o f 
each sample and is presented as a fold change in response to IL-1 relative to the 
untreated control for each treatment (assigned as 1). Results are presented as mean 
±SD o f three independent experiments, where all treatments were carried out in 
triplicate in each independent experimental series. *P<0.05, **P<0.01, ***P<0.001.
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IL-1 stimulated the activ ity o f the luciferase-reporter construct, pNFicB-Luc consistent 
with results presented in chapter 3. In addition, it should be noted that as a control for 
this response, Hep3B cells were also transfected with the parent vector for this 
plasmid, pTAL-Luc. No such response was noted in Hep3B cells transfected with this 
plasmid in the presence o f IL-1 in three separate experiments (data not shown). This 
indicates that the increase in reporter activity noted in cells transfected with pNFicB- 
Luc in response to IL-1 was only due to the presence o f the NF-kB enhancer elements 
driving the expression o f the luciferase gene in this plasmid. Therefore it can be 
concluded that IL-1 stimulates NF-kB activation in Hep3B cells. In addition, both 
apigenin and curcumin caused a statistically significant decrease in the reporter 
activity o f p N F kB -L uc as induced by IL-1 in cells transfected with this plasmid. The 
significant action o f  apigenin was seen at 40pM, whereas curcumin inhibited at all 
three concentrations.
7.2.4 E f f e c t  o f  DN m u t a n t s  o f  JN K  a n d  C K2 o n  t /m m s - a c t iv a t io n  b y  NF-kB 
AS MEDIATED BY IL-1
In order to determine whether the inhibition o f NF-icB-mediated fra/w-activation by 
IL-1, caused by apigenin and curcumin was due to the action o f these inhibitors on 
CK2 and JNK M APK or whether this effect was independent o f their ability to inhibit 
these kinases, we investigated the effect o f  DN mutants o f CK2 and JNK on N F -kB 
trans-activation potential as induced by IL-1. Expression plasmids specifying for 
these DN mutant proteins have previously been described in chapters 2 and 5. We 
additionally decided to examine the effect o f an expression plasmid specifying for 
hcBa (IkB SR, section 2.4.4.8) on N F -kB activation. In resting cells, N F -kB is 
sequestered in the cytoplasm through its interaction with IkB ci. Phosphorylation and 
subsequent ubiquitin-mediated degradation o f IkBoi permits N F -kB to translocate into 
the nucleus where it activates gene expression (Ghosh and Karin 2002). Over­
expression o f IkB ci would therefore have an inhibitory effect on N F -kB activation. 
We therefore hypothesised that over expression o f IkB ci would inhibit the trans- 
activation potential o f N F - kB as induced by IL-1 in our transfection based assay. We 
decided to include the expression plasmid IkB SR in our experiment, alongside the 
plasmids specifying for DN CK2 and DN JNK, as a positive control. That is, to 
ensure that the experimental conditions were appropriate for the expression o f these 
plasmids. cDNAs specifying for IkB ci and the DN mutant form o f JNK are cloned in
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to the expression plasmid pcDNA3 and cDNA specifying for the DN form o f CK2 is 
cloned in the pSG5 plasmid vector (Appendix I). Therefore we used both the empty 
expression plasmids pcDNA3 and pSG5 as controls in our experiments. Hep3B cells 
were co-translected with the pNFicB-Luc plasmid and plasmids specifying for DN 
CK2, DN JNK, or IkB SR as described in section 7.2.3. For control purposes, cells 
were also co-transfected with the p N F kB -L uc and the empty expression plasmids 
pcDNA3 or pSG5. Following IL-1 treatment, the cells were harvested for luciferase- 
reporter activity and for the determination o f protein concentration, as before. The 
results o f these experiments are shown in Figure 7.7 below.
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F ig u r e  7.7. Effect o f I k B over-expression and DN mutants o f CK2 and JN K  
M APK on the /ra/is-activation potential o f N F -k B stimulated by IL-1 in Hep3B 
cells. The cells were transiently co-transfected w ith 2pg o f pNFxB-Luc plasmid and 
4pg o f the specified expression plasmids, as described in Figure 7.6. The cells were 
then either stimulated with IL-1 (lOOU/ml) or left untreated for 3h, before being 
harvested for luciferase reporter activity and protein concentration determination as 
before. Luciferase activity was normalised to the protein concentration o f each 
sample and is presented as a fold change in response to IL-1 relative to the untreated 
control for each treatment (assigned as 1). Results are presented as mean ±SD o f 
three independent experiments, where all treatments were carried out in triplicate in 
each independent experimental series. ***P<0.001, comparing the pcDNA3 IL-1- 
treated control to the IkB SR IL-1-treated data. #P<0.05, comparing the pSG5 IL-1- 
treated control to the DN CK2 IL-1-treated data.
As expected IL-1 treatment caused an increase in the reporter activity o f the p N F kB- 
Luc plasmid, compared to controls. In addition, analysis o f these data showed that the 
expression o f IkBci, significantly inhibited the activation o f N F-kB by IL-1, compared 
to the pcDNA3 transfected control, as we hypothesised, indicating that our 
experimental conditions were appropriate lor the production ot proteins specified by
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the various expression plasmids used in our transfection system. However, expression 
o f the DN mutant o f JNK did not attenuate the activation o f NF-kB as induced by IL- 
1, compared to the pcDNA3 transfected control. Furthermore, we also noted that the 
expression o f DN CK2 caused a minor but significant decrease in the activation o f 
NF-kB by IL-1, compared to the pSG5 transfected control. These results suggest that 
JNK may not be a regulator o f N F -kB activation by IL-1 in Hep3B cells and that CK2 
contributes marginally towards the regulation o f this response.
7.2.5 E f f e c t  o f  IL -1  o n  p r o t e in  b i n d in g  t o  a n  NF-kB c o n s e n s u s  DNA
SEQUENCE
Next we decided to determine the effect o f IL-1 on N F-kB DNA binding. Binding o f 
NF-kB to a consensus kB site was determined by EMSA, using a radiolabelled DNA 
probe. Nuclear (Section 2.7.3) and phosphatase-free whole cell extracts (Section
2.7.2) were prepared from Hep3B cells stimulated with IL-1 for 15min or left 
untreated. We decided to harvest the cells at this time-point for preliminary 
experiments because results from a previous study indicate that IL-1 induces NF-kB 
DNA binding in Hep3B cells at this time-point (Voleti and Agrawal 2005). The 
EMSA probe (Table 2.10, NF-kB consensus) was radiolabelled and incubated in a 
protein binding reaction with nuclear and phosphatase-free whole cell extracts as 
described in sections 2.8.1 and 2.8.2 respectively. The resulting DNA-protein 
complexes were resolved on a non-denaturing polyacrylamide gel and visualised by 
exposure to X-ray film  (Section 2.8.4). The results o f this experiment are shown in 
Figure 7.8. IL-1 treatment o f Hep3B cells resulted in the formation o f five distinct 
DNA-protein complexes (a-e) in both whole cell and nuclear extracts. Four o f these 
complexes (a, c, d and e) were also present in untreated samples (although signals for 
c and d were faint), but induced by varying degrees with IL-1 treatment. Complex b 
was entirely induced by IL-1 treatment. These results indicate that IL-1 rapidly 
induces NF-kB DNA binding in stimulated Hep3B cells.
The specificity o f the DNA-binding reaction was next examined by competition- and 
antibody-supershifit/interference-EMSA analysis (Section 2.8.3). The phosphatase- 
free whole cell extract sample prepared from IL-1 treated cells used in the experiment 
in Figure 7.8 was employed for further analysis. For competition-EMSA analysis, the 
extract (5pg) was pre-incubated w ith a 250 molar excess o f unlabelled kB or AP-1
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consensus probe (Table 2.10). Antibody supershift/interference-EMSA analysis was 
carried out using NF-kB specific antibodies (0.5pg o f each) used previously (Figure 
7.5, Section 2.8.3). Pre-incubation w ith non-immune serum (NIS) served as a control. 
Subsequent EMSA analysis was then carried out exactly as described previously. The 
results o f these experiments are shown in Figure 7.9.
WCE NE
IL-1 (1 OOU/ml) + - +
a 
b 
c 
d
e
FIGURE 7.8. Effect o f IL-1 on N F - k B DNA b ind ing to a consensus kB site. A 
comparison o f DNA-protein complexes obtained from  whole cell extracts (W CE) 
and nuclear extracts (NE). Hep3B cells were either stimulated with IL-1 for 15min 
or left untreated before being harvested for the preparation o f phosphatase-free whole 
cell and nuclear extracts. EMSA analysis was carried out for extracts (5pg) using a 
radiolabelled NF-kB consensus probe. DNA-protein complexes were resolved on 6% 
(w/v) non-denaturing polyacrylamide gels and visualised by autoradiography.
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F ig u r e  7.9. Competition- and antibody supershift/interference-EM SA analysis 
o f the NF-kB DNA-protein complexes produced in response to IL -1 . The WCE
sample prepared from IL-1 treated cells used in the experiment in Figure 7.8 was 
employed for further analysis. For competition-EMSA analysis, the extract (5pg) was 
pre-incubated with a 250 molar excess o f unlabelled kB or AP-1 consensus probe. 
Antibody supershift/interference-EMSA analysis was carried out using NF-kB 
specific antibodies used previously. Pre-incubation with NIS served as a control. 
EMSA analysis was then carried out using the radiolabelled kB consensus probe as 
above. Antibody supershift/interference studies are representative o f two independent 
experiments. ? denotes that the identity o f the protein involved in the DNA-protein 
interaction is unknown (see text for details), ss denotes supershift.
Protein binding was competed by an excess o f the unlabelled kB  probe, but not by a 
consensus sequence for AP-1 (Table 2.10, AP-1 consensus). Pre-incubation with the 
anti-p50 N F -kB  antibody resulted in the formation o f slower migrating antibody 
DNA-protein supershift complex (denoted ss p50 in Figure 7.9). Formation o f 
complex b was completely inhibited in the presence o f the anti-p50 N F -kB  antibody 
but not with the anti-p65 N F -kB  antibody, indicating this complex was formed by a 
p50:p50 homodimer. Formation of complex a was also partially inhibited, indicating 
that p50 was also necessary for the formation o f this complex. Pre-incubation with 
anti-p65 N F-kB  interfered with the formation o f complexes a and d. Therefore, 
complex a could potentially be formed by a p50:p65 heterodimer, as it is also partially 
inhibited by pre-incubation with anti-p50 N F -kB . p65 N F-kB  may also be a 
component o f complex d. Complexes c, e and a component o f complex d (flagged 
with ?) may potentially be formed by other N F -kB  family members such as c-Rel,
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RelB and p52, although further antibody supershift/interference experiments would 
have to be carried out to determine this. Together results presented in Figure 7.9 
confirm that NF-kB, in extracts from IL-1-treated Hep3B cells, does specifically bind 
to the consensus kB probe used in our experiments.
We next examined the effect o f IL-1 on N F -kB binding over a time-course, in order to 
confirm this binding and to ensure that harvesting Hep3B cells 15min post- IL-1 
treatment was an optimal time-point to assess N F -kB binding for future experiments. 
Also, this experiment was important to determine i f  there were any other time- 
dependent changes in DNA-protein interactions as mediated by N F -kB. A s our 
previous experiments (Figure 7.8) show that the N F -kB DNA-protein complexes 
formed in response to IL-1, are similar from both whole cell and nuclear extracts, 
cells were harvested for phosphatase-free whole cell protein extraction (Section 2.7.2) 
for subsequent experiments. Hep3B cells were treated with IL-1 and harvested for 
protein extraction over a time-course o f 3h. Extracts were then used for EMSA 
analysis as before with the consensus kB radiolabelled probe. Results are presented in 
Figure 7.10.
As expected, IL-1 induced the formation o f NF-kB DNA-protein complexes 
compared to the untreated control (Omin), as determined by EMSA analysis. 
Complex a and b were most visibly induced. The induction was transient and 
apparent 5min post IL-1 treatment and decreased at 180min.
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+IL-1 (1 OOU/ml)
Omin 5min 15min 30min 45min 60min 180min
FIGURE 7.10. Effect of IL-1 on N F -k B DNA-protein complex formation over a 3h 
time-course. Hep3B cells were treated w ith IL-1 and harvested for phosphatase-free 
whole cell protein extraction at each o f  the indicated time-points over a 180min time- 
course. Protein extracts (5pg) were then used for EMSA analysis using the 
radiolabelled kB probe exactly as described in Figure 7.8. Results are representative 
of two independent experiments.
7.2.6 E f f e c t  o f  a p ig e n in  a n d  c u r c u \ i i n  o n  IL - 1 - in d u c e d  N F -k B DNA- 
p r o t e in  BINDING
Our previous data suggests that the pharmacological inhibitors apigenin and curcumin 
prevent NF-icB-mediated trans-activation, as induced by IL-1 (Figure 7.6). Therefore, 
we next sought to determine i f  the action o f these inhibitors prevented IL-1-induced 
NF-kB DNA binding in Hep3B cells. Phosphatase-free whole cell protein extracts 
were prepared from Hep3B cells pre-treated with these inhibitors or DMSO (vehicle) 
and stimulated with IL-1 for 15min. Extracts were then used for EMSA analysis 
using the radiolabelled consensus kB  probe, as before. The results are presented in 
Figure 7.11.
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DMSO DMSO CURCUMIN APIGENIN
IL-1 (100U/mi) - + + +
DMSO DMSO CURCUMIN APIGENIN
+ IL-1
F ig u re  7.11. Effect o f apigenin and curcum in on IL -l-m ed ia ted  DNA binding o f 
NF-kB. Hep3B cells were pre-treated w ith the inhibitors apigenin (40pM), curcumin 
(50pM) or DMSO (vehicle-control) for lh . They were then either stimulated with IL- 
1 for 15min or left untreated, before being harvested for phosphatase-tree whole cell 
protein extraction, as before. Extracts (5pg) were then used tor EMSA analysis using 
the radiolabelled consensus k B  probe, exactly as before (Panel A). Densitometric 
analysis (determined by measuring the intensity o f each complex, in each sample and 
then calculating the sum value) o f these data is presented in Panel B, normalised to 
the IL-1-treated DMSO control. The results shown in Panel B are the mean ratio +SD 
from three independent experimental series. #P<0.05, compared to the DMSO-treated 
control. *P<0.05 and **P<0.01 compared to the IL-1-treated DMSO control.
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As expected IL-1 significantly induced the binding o f NF-kB to the consensus kB 
radiolabelled oligonucleotide. This binding was significantly attenuated when Hep3B 
cells were pre-treated with the pharmacological inhibitors apigenin and curcumin. 
These results indicate that these agents may act as inhibitors o f NF-kB activation in 
Hep3B cells by interfering with DNA binding o f NF-kB.
We next extended the findings presented in Figure 7.11, by assessing the effect o f 
various concentrations o f apigenin and curcumin on IL-1-induced NF-kB DNA 
binding. The results o f these experiments are presented in Figure 7.12. Hep3B cells 
were pre-treated with apigenin and curcumin exactly as described previously at the 
indicated concentrations. Following IL-1 treatment, cells were harvested for protein 
extraction and subsequent EMSA analysis using the consensus k B  radiolabelled 
oligonucleotide as a probe, exactly as before.
This preliminary data from a single experiment suggests that curcumin inhibits the 
binding o f NF-kB as mediated by IL-1, at all three concentrations o f the inhibitor, in 
what appears to be a concentration-dependent manner, although more experiments are 
required to confirm this observation (Figure 7.12, Panel A). Similarly, apigenin also 
inhibited binding, at all three concentrations used. However, to determine whether 
this effect occurs in a concentration-dependent manner (Figure 7.12, Panel B) requires 
further experiments to be carried out, as it is not entirely clear from the present data.
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a .
DMSO CURCUMIN
30pM 40pM 50(jM 
IL-1 - + + + +
0.63 1.00 0.67 0.48 0.47
B.
DMSO APIGENIN
10pM 20pM 40(jM 
IL-1 + + + +
0.75 1.00 0.66 0.70 0.63
FIGURE 7.12. Effect o f various concentrations o f curcum in and apigenin on IL -1- 
mediated DNA binding o f NF-kB. Hep3B cells were pre-treated with the inhibitors 
curcumin (A) and apigenin (B), at the indicated concentrations or DMSO (vehicle- 
control) for lh. They were then either stimulated with IL-1 for 15min or left 
untreated, before being harvested for phosphatase-free whole cell protein extraction, 
as before. Extracts (5pg) were then used for EMSA analysis using the radiolabelled 
consensus k B  probe, exactly as described previously. Densitometric analysis o f these 
data was carried out as described in Figure 7.11 and is presented as ratio of the IL-1- 
treated DMSO control.
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7.3 D is c u s s io n
Due to the importance o f C/EBP8 in the regulation o f the inflammatory response and 
the potential to uncover the signalling pathways by which its expression is regulated 
by the major pro-inflammatory cytokine, IL-1, further investigations were undertaken 
to examine a role for NF-kB in the regulation o f this response.
A role for NF-kB in the regulation o f C/EBPS expression by IL-1 was indeed 
suggested by the results presented in this chapter and to our knowledge; this is the 
first study to show this. RNAi-mediated knock-down o f p50 and p65/RelA NF-kB 
significantly attenuated the expression o f C/EBPS as mediated by IL-1 at both mRNA 
and protein level, compared to controls (Figures 7.2 and 7.3). However, we noticed 
that this impaired response was more evident at the protein level (Figure 7.3) than at 
the mRNA level (Figure 7.2). This difference could potentially be due to the different 
techniques used to detect expression o f C/EBP8, RT-PCR and western blot analysis. 
Nevertheless, with the use o f both techniques, a significant reduction in the expression 
o f C/EBP8 by IL-1 was noted in Hep3B cells transfected with siRNA targeting NF- 
kB, compared to the controls. A  role for NF-kB in the regulation o f C/EBP8 
expression by IL-1 was also suggested by preliminary data presented in chapter 4. 
Additionally, our previous data (Chapter 3), suggests that the regulation o f C/EBP8 by 
IL-1 is a transcriptional response and in keeping with this we have suggested a role 
for NF-kB in the regulation o f this response.
As mentioned briefly in section 4.3 the expression o f C/EBP8 as regulated by LPS 
and peptidoglycan is regulated at least in part, by NF-kB (Liu et al. 2006b; Huang et 
al. 2007). A  role for NF-kB in the regulation o f  C/EBPS expression as mediated by 
LPS has also been demonstrated in mouse embryonic fibroblasts (MEFs). MEFs 
deficient in p65 NF-kB or IKK|3 fail to induce the expression o f C/EBP8 as mediated 
by LPS, compared to their wild-type counterparts (Kravchenko et al. 2003). 
Furthermore, also with the use o f mutant MEFs deficient in IKKa, IKK(3 or IKKy, a 
role for NF-kB in the regulation o f TNF-a-induced C/EBP8 expression has also been 
suggested, as determined by DNA microarray analysis (L i et al. 2002c). Although to 
our knowledge, no study has suggested a role for NF-kB in the regulation o f C/EBP8 
expression by IL-1, a requirement o f this transcription factor in the regulation o f this 
response is entirely plausible. As mentioned previously, NF-kB is a known regulator
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o f IL-1 dependent signalling events and NF-kB m-acting elements have been 
identified in the promoter region o f  the rat, mouse (Yamada et al. 1997; Huang et al. 
2007) and human C/EBP5 gene promoters (see Figure 7.13 below). Moreover, the 
fact that the aforementioned studies have suggested a role for NF-kB in the regulation 
LPS-mediated induction o f C/EBP5, is particularly intriguing. Receptors for IL-1 and 
LPS are members o f the Toll/interleukin-1 receptor (TIR) family and therefore not 
surprisingly, utilise very sim ilar intracellular signalling mechanisms to activate 
downstream targets, including NF-kB (Martin and Wesche 2002; Dunne and O'Neill
2003). Given this, it is possible that the signalling events governing the expression o f 
C/EBP5 by IL-1 and LPS are similar.
-1 8 3 0
ACTCTAAAGAAATATGTTTGTTCTTTAGGAAACCTATTAAATATCCCATAGTGCAACGTTAGAAATGAC
CTCTGGAACTGACTGCAGAAACTGCACAGCAGTTAGTAGAGCTTGGTGTTCCGACGCAGATCTGGTGAG
AGGCCTGCGCAGGAAGAGACTCGACATGGAGCAGGTGTGACTAGCGATAGTGATTTAATGGATTTGGGC
CCGACATGGTGGCTCACGCCTGTAATCCCAGCACTTTGGGAGGCTGAGGCCGGCGAATCTCTTAAGCCC
AGGAGTTTGAAACCAGCCTGGACAATATTGTGAGATCCCATCTCAATTTTTTTTTTGAGATGGAGTCTC
GCTCTGTCGCCCAGGCTGGAGTGCAATGGAACGATCTCGGCTCACTGCAACCTCCGCCTCCCGGGTTCA
a g c g a t t c t c c t g c c t c a g c c t c c c g a g t a g c Jt g g g a t t a c a g g c g c a c g c c a c t a c g c t t g g c t a a t t
TTTGTATTTTTAGTAGAAATGGGGTTTCACCATGTTGACCAGGCTGGTTTCAAACTCCTGACCTCAAGT
GATCCGCCCACCTCAGCCTCCCAAAATGCjf’GGGATTACGGGCATGAGCCACTGTGCTCGGCTGAAAAAA
ACCATATTTTTAATTTAAAATAATAAATGGGTCTGACCAGAAATGCCTGCCTCAAATTGCAGGACACAT
GACAAAGCCCATTCTTACTTAAGACATTTTCAGTGTGCGATGGGTCTACCGGGATGTAACCCCATCGTG
AGTCGAGGCCCATCTGCACCCTGCTATAGCTACTGGTAGATCTTACCTGTTTCCCAAAAAGGACCCAAC
TACTTTAGGTTCAAGGCACTTTTTTGGAATATTTAACAGGGAAAGAGCCTGGAACTAAAAACAGGTCTA
ACGCAAGATGCCGCCACACGATGGCACTGCTTCCGTAGACCTGGAAGAAACGCGGGCGCGGGAGCTGGC
GGCGGACGCCCGGGTCTGCGGGGTCGGGGAGTAGCGTCCGGCCGGAGAGCCCGCACCTCGAGGAGCCGG
CGGAGGACGCGGTGTCGTGACCGCGTCTCCCCCATCTGCTCTGCTTTTGGCGACAGCGTCCCGTCGGCC
TTTCGGCCAGGACGCAGCAGCCGCGTCTCTGGGCCTCGACCCCCAGGGCCGGCCGGACCCGGGACCTCC
GAGGAGAGCAGCGAGAACCGGCCCGGATTCCCCGAGGCGCCCGAGTGCGGTGCGGGCAGCCCTCCCCGC
CTGCCAGGCCGCCGCTGTCCCCACGTCTGGTCCCCCACGCCTCTTCCCGCATCTGGTCCCACGGTGGAG
GCGCGGGGCGAGGGCCTCACGCGCGTGCCCACGGTCGGGGGGCGTCCTTGGACGCGCGGGTCCTCTCCC
ACGGGTCTCCACCCCCCGCCCTCCGGCGACAGGAGCCGGCCTGGGACGCGCGCGCTGCGGCCAAGTCCT
g g t t t t g a t t t c a c t c c c a a c c c c g a g g a g B H M B H B a g c c c a c a a a c a g g a a g a a g a g a a g g
CCCTGGAGTGCTGGCAGAGGGAGTGTCATTCCCAGCAGCGCAGCGCAGGCCGGCCCGGGCCGGGGAGGG 
AGCAGCAGCGCGGGCACCCTCCTGCAACGTGGGCTGGGGGTCCCCAGGGCCGGGGAGGGGGCCCCGGGG 
AGGAACTGAGAGGGGGCGCGCCCCGGGAAGGCTCGGGGCGGCTCCGGGGGGCTCCCAGGGCGCCCCCGC 
CCCTTCCCCCGCGGCCCCGGGGCGCCCCCGCGGTGCCGGAGTCGGGGCGGGGCGTGCACGTCAGCCGGG 
GCTAGAAAAGGCGGCGGGGCTGGGCCCAGCGAGGTG +1
FIGURE 7.13. Putative NF-kB m -acting elements in the promoter region of the human 
C/EBP5 gene promoter. The promoter sequence was obtained from GenBank, nucleotide 
sequence o f AC023991 (Homo sapiens chromosome 8, clone RP11-137L15, complete 
sequence). A putative p50 NF-kB binding site was identified and is blocked in yellow and the 
putative p65 NF-kB binding site is blocked in turquoise. Putative binding sites for c-Rel were 
also identified and are blocked in green. These are included because it has been reported that 
c-Rel can heterodimerise with either p50 or p65 NF-kB to activate target genes (Wietek and 
O'Neill 2007). The proposed T A T A  A  box is highlighted in red for reference purposes. 
Binding sites for NF-kB transcription factors were identified using Matlnspector transcription 
factor binding site search tool at http://www.iJenomatix.de/ and also TFSEARCH: Searching 
Transcription Factor Binding Sites (version 1.3) at
http://www.cbrc.jp/research/db/TFSEARCH.html (see Appendix V for search results).
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In an effort to initiate investigations into delineating the signalling pathway by which 
IL-1 induces the expression o f C/EBP5 through NF-kB, we targeted the M APKKK, 
TAK1 for RNAi-mediated knock-down. As mentioned in section 1.4 and 7.1, TAK1 
is an upstream regulator o f both MAPKs and NF-kB during IL-1-dependent 
signalling. RNAi-mediated knock-down o f TAK1 expression resulted in a marginal 
decrease in the expression C/EBP5 as mediated by IL-1, at the mRNA level (Figure 
7.4). However, the same observation was not noted by analysing the effect o f siRNA- 
mediated TAK1 knock-down on the IL-1-mediated induction o f C/EBP5 protein 
levels (Figure 7.5). Given that gene function is carried out by the protein that it 
encodes for, data generated relating to protein expression, is probably more 
conclusive than mRNA expression data and therefore taking this into consideration, 
we decided not to carry out any further experiments in relation to the role o f TAK1 in 
the regulation o f C/EBP8 expression by IL -1 .
Interestingly, a recent study has demonstrated the existence o f two independent 
pathways leading to the activation o f N F -kB , as mediated by IL-1. One pathway is 
TAK1-dependent and the other MEKK3-dependent and both these pathways bifurcate 
at the level o f IR AKI (Yao et al. 2007). The possibility o f an additional N F -kB  
activating mechanism, independent o f TAK1 was first suggested through the study o f 
TAK1 deficient cells (Sato et al. 2005; Shim et al. 2005). Although both studies 
reported that TAK1 deficiency results in defects in IL-1 signalling, IL-1-mediated 
N F-kB  activation was only partially impaired in TAK1 deficient cells. As an 
extension o f these studies, Yao and colleagues (2007) successfully identified two 
independent IL-1-regulated pathways leading to the activation o f N F -kB . The first is 
TAK1 -dependent and causes IKKa/p phosphorylation and IKKp activation, leading to 
classical N F -kB  activation through IkBoi phosphorylation and degradation. The 
second pathway is TAK1-independent, MEKK3-dependent and induces IKKy 
phosphorylation and IKKa activation, resulting in N F -kB  activation through IkBci 
phosphorylation and its subsequent dissociation from N F -kB  but without causing 
IkBoi degradation. Furthermore, this novel MEKK3-dependent pathway o f IL-1- 
mediated N F-kB  activation was found to be conserved in primary intestinal epithelial 
cells, suggesting that the existence o f this pathway is not just restricted to the mouse 
embryonic fibroblasts in which it was first identified.
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Therefore, it is plausible that the regulation o f IL-1-mediated C/EBP8 expression by 
NF-kB, in Hep3B cells, is not completely dependent on TAK1 activation (as 
suggested by our RNAi data) and could potentially be modulated through the 
activation o f MEKK3, although further experiments would have to be carried out to 
elucidate this.
Results presented in chapter 4 show that both pharmacological inhibitors apigenin and 
curcumin significantly inhibit the IL-1-induced expression o f C/EBP8. Several 
studies have reported that these agents, apigenin and curcumin can also act as 
inhibitors o f NF-kB (Gerritsen et al. 1995; Singh and Aggarwal 1995; Xu et al. 1997; 
Jobin et al. 1999; Liang et al. 1999; Plummer et al. 1999; Choi et al. 2004; Schulze- 
Tanzil et al. 2004; Shukla and Gupta 2004a; Shukla and Gupta 2004b; Cao et al. 
2005; Moon et al. 2005; Moon et al. 2006; Cho et al. 2007; Shakibaei et al. 2007). In 
particular, with relation to the action o f apigenin, inhibition o f CK2 by this agent 
impairs NF-kB activation as CK2 is a known regulator o f NF-kB (Romieu-Mourez et 
al. 2001; Romieu-Mourez et al. 2002; Cavin et al. 2003; Yu et al. 2006).
To determine whether apigenin and curcumin inhibited N F -kB  activation as mediated 
by IL-1 in Hep3B cells, we carried out a transient transfection assay. The pN F kB -Luc  
plasmid contains four N F-kB  enhancer sequence elements fused upstream o f a 
luciferase-reporter gene. Transfection o f this plasmid into Hep3B cells, coupled with 
IL-1 treatment, induces a dramatic increase in luciferase-reporter activity. However, 
pre-treatment with apigenin or curcumin significantly inhibits the increase in reporter 
activity as induced by IL-1, although with varying degrees o f inhibition with each 
agent (Figure 7.6). Therefore, our results suggested that these agents can act to impair 
N F-kB  activation in Hep3B cells. In related transfection based assays, several studies 
have reported similar findings (Gerritsen et al. 1995; Liang et al. 1999; Plummer et al. 
1999; Cavin et al. 2003; Yu et al. 2006). It is also important to mention that, given 
that our pharmacological inhibitor data from chapter 4 also shows that the IN K  
MAPK specific-inhibitor, SP600125 significantly inhibits the IL-1-mediated increase 
in C/EBP8 expression, it is also necessary to establish the effects o f this inhibitor on 
NF-kB activation. Unfortunately, due to time constraints, we were unable to carry out 
these experiments and therefore this is an area that requires future investigation.
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In an attempt to determine a possible mechanism by which IL-1 action leads to an 
increase in the tram -activation potential o f NF-kB, we investigated a role for CK2 
and JNK MAPK in the regulation o f this response. As previously mentioned (see 
Table 4.0); numerous studies have implicated apigenin and curcumin as inhibitors o f 
CK2 and JNK MAPK respectively. Indeed, our results from chapter 5 (Figure 5.7) 
also suggest that curcumin is an effective inhibitor o f JNK activity in Hep3B cells, 
consistent with previous studies (see chapter 5). Therefore, we wanted to determine i f  
the inhibitory action o f apigenin and curcumin on IL-1-mediated /nms-activation by 
NF-kB was mediated through the action o f these inhibitors on CK2 and JNK, (as 
mentioned in section 7.1.1, several studies have reported a role o f JNK and CK2 in 
the regulation o f NF-kB activation), or whether the effect was independent o f their 
action on these kinases. For this, we used plasmids specifying for DN mutant forms 
o f CK2 and JNK. We assessed the effect o f these expression plasmids on NF-kB 
activation by IL-1 in co-transfection assays (Figure 7.7). Our results suggest that JNK 
may not contribute to the activation o f NF-kB by IL-1, given that expression o f a DN 
mutant o f this kinase did not significantly attenuate this response, compared to the 
appropriate control. In contrast, we noted a minor but significant decrease in the IL- 
1-induced reporter activity, in cells co-transfected with a DN mutant form o f CK2, 
compared to the control. Although, the decrease was minor, this result does suggest 
that CK2 may contribute to the activation o f NF-kB by IL-1, in Hep3B cells to some 
extent. This is consistent with a role for CK2 as a regulator o f NF-kB 
phosphorylation, as mediated by IL-1 in hepatocytes, suggested by Bird et al. (1997). 
In addition, a role for CK2 in the regulation o f NF-kB is suggested in several other 
reports. For example, inhibition o f CK2 blocks Her-2/neu (second member o f the 
epidermal growth factor receptor family o f tyrosine kinases) -mediated activation o f 
NF-kB, in breast cancer cells (Romieu-Mourez et al. 2002). CK2 is also reported to 
regulate the phosphorylation o f IKKp and thus modulate activation o f NF-kB in 
squamous carcinoma cells (Yu et al. 2006). In hepatocytes, TGF-pl-mediated 
inhibition o f CK2 activity promotes IkBci stabilisation and therefore inhibits NF-kB 
activation (Cavin et al. 2003). CK2 is also known to regulate the /nms-activation
529 *potential o f the p65 NF-kB subunit by phosphorylation at serine in response to 
TNF-a treatment (Wang et al. 2000). Interestingly, p65 NF-kB is also reported to be 
a phosphorylation target for CK2 in IL-1-treated HepG2 cells, and one o f the putative
303
C h a p te r  seven: A n in v e s t ig a t io n  in to  th e  r o le  o f  N F -k B in t h e  r e g u la t io n  o f  C/EBP8 e xpress ion  by IL - i
sites for phosphorylation was suggested to be a serine residue potentially located in 
the C-terminal /ra/«-activation domain o f this NF-kB subunit (Bird et al. 1997).
Although the results in Figure 7.7 do suggest a minimal requirement for CK2 in the 
regulation o f NF-kB activation by IL-1, we at present, cannot rule out the possibility 
o f potential functional redundancy between CK2 and JNK MAPK, as we have not 
analysed the effect o f simultaneously inhibiting CK2 and JNK MAPK using DN 
mutants on NF-kB activation by IL-1 in our transient transfection assay. Thus, this 
suggested experiment may be necessary for future studies.
So, although our results from Figure 7.6 show that both apigenin and curcumin inhibit 
NF-kB activation by IL-1, it is unlikely that these agents mediate this effect through 
their action on CK2 or JNK M APK exclusively, as suggested by our results in Figure 
7.7. It is plausible that these agents may act to inhibit various components o f the NF- 
kB activation pathway, independently o f their ability to inhibit CK2 and JNK MAPK 
respectively. In support o f this, several studies have suggested that curcumin acts as 
an inhibitor o f NF-kB activation by blocking IkB  phosphorylation and its subsequent 
ubiquitin-triggered degradation, in addition to its ability to inhibit the JNK-API 
pathway (Singh and Aggarwal 1995; Xu et al. 1997; Jobin et al. 1999; Moon et al. 
2005; Moon et al. 2006). In other studies, curcumin is suggested to prevent the 
nuclear translocation and DNA binding o f NF-kB (Schulze-Tanzil et al. 2004; Cao et 
al. 2005; Shakibaei et al. 2007). The inhibitory action o f apigenin on NF-kB 
activation is reported to act at multiple levels. Apigenin is reported to inhibit 
constitutive expression o f both p50 and p65 NF-kB subunits in human prostate cancer 
cells, DU 145 (Shukla and Gupta 2004b). Also, apigenin is reported to prevent NF-kB 
nuclear translocation, DNA binding (Choi et al. 2004), IkB degradation and IK K  
activity (Liang et al. 1999). However, it should also be noted is that a role for CK2 in 
the regulation o f NF-kB activation was not investigated in any o f the aforementioned 
studies. Therefore, it still remains to be determined whether the inhibitory effect o f 
apigenin on NF-kB activation as documented in these studies, is through its inhibition 
o f CK2 or whether its effect is independent o f this.
We next examined the effect o f IL-1 on NF-kB DNA binding. Using a radiolabelled 
oligonucleotide containing a consensus kB sequence, we show that IL-1 induces the 
DNA binding o f NF-kB (Figures 7.8-7.10), consistent with our previous data
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presented in this chapter supporting a role for this transcription factor in the regulation 
of C/EBPS expression by IL -1 . In an effort to initiate investigations into resolving the 
mechanism by which both curcumin and apigenin attenuate the activation o f NF-kB 
by IL-1, we examined the effect o f these inhibitors on NF-kB binding. Both these 
inhibitors significantly attenuated the DNA-binding o f NF-kB as mediated by IL-1 
(Figure 7.11). Preliminary data (Figure 7.12, Panel A) indicates that the DNA- 
binding o f NF-kB, induced by IL-1 is inhibited by curcumin in a concentration- 
dependent manner. Although apigenin also does attenuate the DNA-binding o f NF- 
kB (Figure 7.12, Panel B), consistent w ith our previous data, whether this effect is 
concentration-dependent is d ifficu lt to assess from the current data. Therefore, further 
experiments would have to be carried out in order to confirm these findings. 
Together, our data suggests that both apigenin and curcumin inhibit NF-kB activation 
as induced by IL-1 by preventing DNA-binding. Similar results have been reported 
by other researchers. For example, curcumin has been shown to concentration- 
dependently inhibit the DNA-binding o f NF-kB as induced by TNF-a, in human colon 
epithelial cells (Plummer et al. 1999). Similar results are reported by Jobin et al. 
(1999), where curcumin also inhibited the NF-kB DNA-binding as mediated by IL-1 
in the human HT-29 colonic epithelial cell line. Furthermore, results presented by 
Singh and Aggarwal (1995) show that curcumin inhibits NF-kB DNA binding in the 
human myelomonoblastic leukemia cell line, M L-la . Apigenin is also reported to 
prevent NF-kB DNA-binding (Liang et al. 1999; Romieu-Mourez et al. 2001; Cavin 
et al. 2003). However, to our knowledge this is the first study to show that these 
pharmacological agents may act as inhibitors o f NF-kB in the Hep3B cell line.
Our EMSA data strongly indicates that NF-kB DNA-binding to a consensus kB 
oligonucleotide, is induced in response to IL-1 action in Hep3B cells. However, in 
order to extend these investigations to potentially provide further experimental 
evidence for a role o f NF-kB in the regulation o f C/EBP5 expression by IL-1, it is also 
necessary to determine whether NF-kB-DNA binding is induced by IL-1, to putative 
NF-kB binding sites as identified in the human C/EBP5 gene promoter, presented in 
Figure 7.13. Ideally this should be done in an in vivo setting with normal chromatin 
context, achieved by ChIP analysis, given that our results in chapter 3 suggest that the 
C/EBP5 gene promoter is not responsive to IL-1 action in an in vitro transfection 
assay. Identification o f NF-kB subunits by ChIP analysis would entail Hep3B cells
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being treated with IL-1 (or left untreated) for a requisite time period, and then 
incubated with formaldehyde to cross-link the NF-kB subunits to DNA in vivo. 
Nuclear fractions o f the cells would then be prepared and follow ing lysis, the 
chromatin would be fragmented by sonication and subjected to immunoprecipitation 
using antibodies specific to the NF-kB subunit(s) o f interest. Immunoprecipitates 
would then be used to purify genomic DNA fragments which would then be subjected 
to PCR analysis. Specifically, PCR analysis would be carried out using primers that 
would amplify the region containing the putative p50 and p65 NF-kB binding sites o f 
the human C/EBP8 gene proximal promoter (Figure 7.13). After resolving the PCR 
products by agarose gel electrophoresis, densitometric analysis o f the PCR products 
from untreated verses IL-1-treated samples would then reveal i f  NF-kB binding was 
indeed induced at the C/EBP8 gene promoter in response to IL-1 action. I f  indeed, 
the results from these experiments were positive then this would provide very strong 
evidence for a role for NF-kB in the regulation o f C/EBP8 expression by IL-1, 
together with our other results presented in this chapter. In addition, these 
investigations could also be extended to the analysis o f pharmacological inhibitor 
action on NF-KB-DNA-binding in this context, to confirm the inhibitory action o f 
apigenin and curcumin on NF-kB DNA-binding.
Furthermore, to establish whether the inhibitory action o f apigenin and curcumin on 
NF-kB DNA-binding occurs by the direct action o f these inhibitors on NF-kB, EMSA 
could be carried out using in vitro  generated p50 and p65, for example. Similarly, 
cell-free in vitro transcription assays, using extracts depleted o f CK2 or JNK MAPK, 
could be useful to determine whether CK2 or JNK MAPK were involved in the 
regulation o f NF-KB-mediated gene transcription, thus helping to definitively 
establish whether there is a requirement for these signalling mediators in the 
regulation o f NF-kB activity.
In summary, the results presented in this chapter suggest a role for NF-kB in the 
regulation o f C/EBP8 expression by IL-1, a novel finding. We show that IL-1 
activates NF-kB in stimulated Hep3B cells and that this is inhibited by the 
pharmacological agents apigenin and curcumin, through the interference o f DNA- 
binding. In further support for a role o f NF-kB in the regulation o f C/EBP8 
expression by IL-1, both these inhibitors were shown to inhibit the IL-1-mediated 
increase in C/EBPS expression at both the mRNA and protein level in chapter 4. In
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addition, preliminary data also presented in chapter 4 shows that an independent NF- 
kB inhibitor (NF-kB Activation Inhibitor) also attenuates the IL-1-mediated induction 
of C/EBP5 expression at the protein level.
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8.1 O v e r v ie w  o f  r esu lts  p r es e n te d  in  t h is  th esis
C/EBPS is an important transcription factor involved in the regulation o f the 
inflammatory response, where its expression/activity is controlled by many 
inflammatory mediators including the cytokines IL-1 and IL-6. It is therefore o f 
interest to examine the mechanisms governing its expression during this process. 
Unfortunately, only a lim ited number o f studies have focused on discerning the 
signalling events leading to its expression and activation in response to inflammatory 
mediators.
Evidence also strongly suggests that C/EBPS is a major regulator o f cellular growth 
and proliferation (O'Rourke et al. 1999b; Sivko et al. 2004). Its expression in LNCaP 
prostrate cancer cells is modulated by IL-6 action and its induction by this cytokine, 
induces growth arrest in these cells (Sanford and DeWille 2005). Therefore, studying 
the regulation o f C/EBPS expression by cytokines such as IL-6 should not only have 
an impact on understanding mechanisms o f inflammation but may also have a broader 
impact on our knowledge o f other processes that it regulates, such as cell growth and 
proliferation.
The work detailed in this study has used several different approaches in order to 
elucidate mechanisms into the regulation o f C/EBPS expression by IL-1 and to a 
lesser extent, IL-6. The work was carried out in hepatocytes as these cells play a key 
role in the regulation o f the inflammatory response and are known targets for the 
action o f IL-1 and IL-6.
Our initial studies were designed to analyse the effects o f various inflammatory 
mediators on the expression o f C/EBPS. O f the mediators examined, we found that 
IL-1, IL-6 and IFN-y caused a significant increase in its expression, consistent with 
previous observations (Juan et al. 1993; Ramji et al. 1993a, Cantwell et al. 1998) and 
we extended our investigations to include a time-course analysis o f C/EBPS 
expression by IL-1 and IFN-y. Additionally, we confirmed that the effect o f IL-1 
action on C/EBPS expression occurred in a concentration-dependent manner. 
Because we, like others (Cantwell et al. 1998), noted that IFN-y was less efficient at 
inducing C/EBPS expression, than other cytokines like IL-1 and IL-6, we did not 
continue our investigations w ith this cytokine. However, this is an area that may be
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the focus o f future studies in our laboratory, given that IFN-y is a major inflammatory 
cytokine.
In line with the original aims o f this study, whereby we intended to fu lly  delineate the 
regulatory elements present in the human C/EBP8 gene promoter that were 
responsible for mediating its induction in response to IL-1, we also initiated 
investigations into the regulation o f C/EBP5 promoter activity. Using a transient 
transfection system that we had established, we examined the effects o f both IL-1 and 
IL-6 on the promoter activity o f both human and murine C/EBP8 genes. Whilst IL-6 
action caused a significant increase in promoter activity from both species, we did not 
observe a similar response with IL -1 . Consequently, we verified that our transfection 
system was able to produce a response to IL-1 action at the level o f promoter activity 
with a positive control in our experiments. Therefore, although we clearly 
demonstrated that the C/EBP8 gene promoters were active in transfected cells, in 
contrast to the observed increase in mRNA and protein levels o f C/EBP8 by IL-1, the 
promoters were not responsive to this cytokine. There are several possible reasons for 
this, but in our view, one o f the most like ly explanations for this is that for maximum 
activation o f the C/EBP8 gene in vivo, there may be a requirement for a specific 
chromatin context, that is absent from transfected plasmid DNA. Indeed, recent 
studies have shown that C/EBP8 gene activation is highly dependent on the 
methylation status o f its promoter in vivo (Tang et al. 2006; Agrawal et al. 2007).
Additionally, our other transfection data strongly indicates that the human C/EBP8 
gene is auto-regulated, a novel finding. We further demonstrated that the proximal 
promoter region o f the gene is sufficient to mediate this effect and have suggested 
candidate cA-acting elements that may be responsible for auto-regulation. However, 
in order to more firm ly pin-point the c/s-acting elements that are responsible for 
mediating auto-activation o f the gene, further deletion/mutation constructs o f the gene 
promoter would have to be generated and analysed (see section 8.3).
In light o f the findings presented in chapter 3, it was therefore decided, in line with 
our original aims, to focus on investigating the signalling pathways by which IL-1 
regulates the expression o f C/EBP8. Experiments based on the use o f 
pharmacological inhibitors o f potential mediators o f IL-1 signalling, identified a 
selective and novel role for CK2, JNK M APK and NF-kB in the regulation o f this
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response. A  role for JNK M APK was subsequently supported through the use o f 
western blot analysis and associated kinase assays. We showed that IL-1 transiently 
activated the JNK M APK in stimulated hepatocytes and confirmed that 
pharmacological inhibitors o f JNK M A P K  acted specifically to block the activation o f 
this kinase by IL-1. Using the same approach, we also showed that CK2 was not 
involved in regulating the activation o f JNK M APK by IL-1, suggesting the existence 
of an independent IL-1-regulated signalling pathway. Therefore, our work was also 
extended to the examination o f CK2 activation by IL-1. Consistent with the findings 
of Bird et al. (1997) and a very recent study by Parhar et al. (2007), the only studies to 
our knowledge, to have examined the effect o f IL-1 action on CK2 activation, we did 
not note any consistently marked increase in overall CK2 activity in response to IL-1 
action, from CK2a immunoprecipitates. However, we could not rule out a role for 
CK2 in the regulation o f C/EBP8 expression by IL-1, based on these results alone 
given that our kinase assay was lim ited to the immunoprecipitation o f CK2a and to 
the use o f a single substrate, p-casein. Furthermore, the Bird et al. (1997) study had 
implicated CK2 as a regulator o f p65 NF-kB phosphorylation, in IL-1 treated HepG2 
hepatocytes, a closely related cell line to our model hepatocyte cell line, Hep3B. This 
observation was consistent w ith our pharmacological inhibitor data that suggested a 
role for both CK2 and NF-kB in the regulation o f C/EBP8 expression by IL-1.
We also noted that expression o f DN mutants o f CK2, JNK and c-Jun did not 
attenuate the IL-1-mediated induction o f C/EBP5 expression, potentially suggesting 
the existence o f some functional redundancy between the two signalling pathways. 
Extensive cross-talk and overlap amongst signalling pathways has previously been 
documented and the existence o f functionally redundant signalling pathways is 
therefore plausible and indeed has been reported (Fambrough et al. 1999; Mestre et al. 
2001).
Therefore, in an attempt to more definitively establish the role o f CK2 and JNK 
MAPK in the expression o f C/EBP5 by IL-1, we adopted an alternative strategy. One 
of the most effective ways o f elucidating the functional properties o f a component o f a 
signalling pathway is to suppress its expression with for example, the use o f siRNA. 
As discussed in chapter 6, the use o f RNAi as a method for pathway dissection has 
been tremendously successful. To illustrate this, a recent literature search has 
identified over 12,000 studies in which the authors have made use o f RNAi as a
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research tool (see chapter 6 for examples). RNAi is particularly useful because it is 
highly specific and also allows the researcher to overcome barriers associated with 
functional redundancy. More specifically, w ith the use o f multiple siRNAs, one can 
examine the effects o f simultaneous gene knock-down on a response o f interest. We 
therefore examined the effect o f siRNA-mediated knock-down o f CK2 and 
components o f the JNK M APK pathway on the IL-1-mediated induction o f C/EBP8 
expression. We set up an effective transfection system to successfully deliver siRNA 
into Hep3B cells, where in most cases the knock-down o f gene expression, as 
assessed at the mRNA and/or protein level, was more than 50%. However, siRNA- 
mediated knock-down o f either CK2 (CK2a and CK2a’) or JNK (JNK1 and JNK2) 
and also c-Jun, could not confirm a role for these signalling mediators in the 
regulation o f C/EBP8 expression by IL-1. We therefore addressed the issue o f 
functional redundancy by investigating the effect o f simultaneous knock-down o f 
CK2a and JNK (JNK1 and JNK2) w ith siRNA. Concomitant knock-down o f CK2a 
and JNK (JNK1 and JNK2) also did not attenuate the IL-1-mediated increase in 
C/EBP5 expression. Based on these data alone however, we cannot completely rule- 
out the existence o f functional redundancy between the JNK and CK2 pathways, as 
we were unable to examine the effect o f depleting levels o f both catalytic subunits o f 
CK2 and JNK simultaneously, given the high concentration o f siRNA required for 
this particular experiment. Therefore, the issue o f functional redundancy may have to 
be readdressed in future investigations. O f further note, as discussed in chapter 6, 
siRNA-mediated suppression o f gene expression only results in a knock-down o f 
expression, not a complete knock-out, therefore there is always the possibility that any 
remaining protein, escaping the silencing process, is sufficient for function, thus also 
potentially explaining our results.
In addition to analysing putative signalling pathways by which IL-1 action resulted in 
an increase in C/EBP5 expression using siRNA, we also carried out investigations, 
using the same approach, to determine which signalling mediators led to the induction 
of C/EBP5 expression by IL-6. Previous studies have pointed to a role o f STAT3 in 
the regulation o f this response, primarily with data generated from promoter-reporter 
assays (Yamada et al. 1997; Cantwell et al. 1998) and therefore we took this into 
consideration with the design o f our experiments. Simultaneous siRNA-mediated 
knock-down o f both ST A T I and STAT3 significantly attenuated the endogenous
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expression o f C/EBP6 by IL-6, and to our knowledge we are the first to report this. 
Furthermore, we additionally showed that IL-6 stimulation o f Hep3B cells led to the 
transient activation o f both these transcription factors, albeit with different kinetics. 
However, further investigations are required to ascertain the exact signalling events 
resulting in their activation.
Using the same siRNA-based approach, we have also identified NF-kB as a regulator 
of C/EBP6 expression by IL-1, consistent w ith our inhibitor data that suggested a 
requirement for this transcription factor in the regulation o f this response. These are 
novel data, as to our knowledge we are the first to report such a finding. We further 
report that this response is not completely dependent on a previously identified 
upstream regulator o f IL-1-mediated NF-kB activation, the MAPKKK, TAK1. 
Consistent with our data, we show that NF-kB is activated by IL-1 using a 
transfection-based assay and by EMSA. Our data also suggests that the 
pharmacological inhibitors apigenin and curcumin inhibit NF-kB activation by IL-1, 
possibly by preventing its binding to D NA in Hep3B cells, also a novel finding. The 
role o f JNK M APK and CK2 in the regulation o f NF-kB activation was also 
investigated given that both these signalling mediators have been reported to modulate 
NF-kB and because the pharmacological inhibitors o f these kinases (curcumin and 
apigenin, respectively) attenuated NF-kB activation by IL-1 (see chapter 7 for details). 
The role o f CK2 in the regulation o f  this response was o f particular interest, given that 
the Bird et al. (1997) study had suggested a direct involvement o f CK2 in the 
regulation o f NF-kB phosphorylation by IL-1, in HepG2 hepatocytes. Our data 
suggest that CK2 is, at least in part, responsible for the regulation o f NF-kB by IL-1 in 
Hep3B cells, as a DN mutant o f this kinase significantly prevented tram -activation o f 
NF-kB by IL-1, in a transient transfection assay.
Therefore, in summary, the work presented in this thesis has uncovered several key 
findings in relation to the expression o f C/EBP5 during the inflammatory response. 
These being:
• Induction o f C/EBP6 expression by the inflammatory cytokines IL-1, IL-6 and 
IFN-y
• Auto-regulation o f the human C/EBP8 gene
• Identification o f STAT1 and STAT3 as mediators o f C/EBP8 expression by 
IL-6
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• Identification o f NF-kB as a regulator o f C/EBP8 expression by IL -1
Furthermore, these data can be approached with a good degree o f confidence given 
that we have carried out all our experiments with appropriate controls, accurately 
reproduced previous findings, and verified novel findings with the use o f a number o f 
experimental approaches.
During the final stages o f completion o f this Ph.D. project, a study was published by 
Dong et al. (2007), in which the role o f  C/EBP8 in the regulation o f PAI-1 expression 
by IL-1 and IL-6 was examined in HepG2 hepatocytes. Consistent with our data, the 
authors showed that both IL-1 and IL-6  induced the expression o f C/EBP8 in human 
hepatocytes and additionally in primary murine hepatocytes. In conjunction, their 
data also indicated that C/EBP8 was the major transcription factor involved in 
inducing PAI-1 expression in response to both IL-1 and IL-6, consistent with its key 
role in the APR.
Similar to our initial investigations, in an effort to identify the key signal transduction 
pathways by which C/EBP8, and in association PAI-1, were induced by both 
cytokines, a panel o f pharmacological inhibitors were employed for analysis. Indeed, 
some o f the inhibitors used in this study were also used in the Dong et al. (2007) 
study. These included the JNK M APK inhibitor, SP600125; the p38 MAPK inhibitor, 
SB203580 and the PI3K inhibitor LY294002. In addition, the ERK MAPK inhibitor, 
U0126; the JAK inhibitor, JAK inhibitor 1; the NF-kB inhibitor, SN50 and the 
PKB/Akt inhibitor, API-2 were also used in their study. By contrast, we used in this 
study, a second JNK M APK inhibitor, curcumin; a second p38 MAPK inhibitor 
SB202190; the ERK M APK/M EK1 inhibitor, PD98059; the NF-kB inhibitor, NF-kB 
Activation Inhibitor and the CK2 inhibitor, apigenin.
Again, using a similar approach to ours, Dong and colleagues (2007) examined the 
effect o f blocking the aforementioned signalling pathways on C/EBP8 expression 
(mRNA and protein) as induced by IL-1 and IL-6. The JNK MAPK inhibitor, 
SP600125 was shown to significantly impair the induction o f C/EBP8 expression by 
IL-1, in HepG2 hepatocytes. Consistent with these findings, we report similar 
findings in Hep3B hepatocytes and we additionally confirmed these results with a 
second JNK M APK inhibitor, curcumin. However, Dong and colleagues (2007) also
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report that the IL-1-mediated induction o f C/EBP8 expression was attenuated by the 
p38 MAPK inhibitor, SB203580 and the ERK M APK inhibitor U0126, at both the 
mRNA and protein level. In contrast, we did not note similar results by examining the 
effects o f the two p38 M APK inhibitors (SB202190 and SB203580) and the ERK 
MAPK/MEK1 inhibitor, PD98059 on the IL-1-mediated induction o f C/EBP8 mRNA 
expression as determined by semi-quantitative RT-PCR (see chapter 4). Therefore, in 
light o f these recent results we decided to determine the effects o f the p38 MAPK 
inhibitor, SB203580 and the ERK M APK/M EK1 inhibitor, PD98059 on the induction 
of C/EBP8 protein as mediated by IL-1, by western blotting given that we have not 
previously carried out this experiment. In addition, we also decided to examine the 
effect o f the PI3K inhibitor, LY294002 on this response given that we have also not 
previously determined its effect on C/EBP8 protein expression as mediated by IL-1. 
Furthermore, as a positive control, we also included the inhibitors apigenin and 
curcumin in our experiments as we have previously demonstrated that both inhibitors 
significantly attenuate the IL-1-mediated induction o f C/EBP8 expression at both the 
mRNA and protein level (Chapter 4).
Therefore, Hep3B cells were pre-treated w ith the aforementioned inhibitors or DMSO 
(vehicle-control) for lh. They were then either treated with IL-1 or left untreated for 
3h before being harvested for protein extraction (Section 2.7.2) and subsequent 
western blotting (Sections 2.7.7 and 2.7.8). Immunodectection o f C/EBP8 and P-actin 
was carried out as described in section 2.7.9 using C/EBP8 and p-actin specific 
antibodies. The results o f  these experiments are shown in Figure 8.1.
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F ig u r e  8.1. Effect of pharmacological inhibitors on the IL-l-m ediated induction 
of C/EBP5 protein expression. Hep3B cells were pre-treated with pharmacological 
inhibitors apigenin; API (20pM), curcumin; CUR (30pM), SB203580; SB203 (5pM), 
PD98059; PD98 (50pM) and LY294002; LY29 (5pM) or DMSO as a vehicle control 
for lh. They were then either treated w ith IL-1 (lOOU/ml) or left untreated for 3h and 
harvested for protein extraction (Section 2.7.2). Total cell protein extracts were used 
for western blot analysis w ith 60pg o f each sample subjected to 10% (w/v) SDS 
PAGE and subsequent western blotting. Immunodetection o f C/EBP8 was carried out 
using the anti-C/EBP8 antibody as described in section 2.7.9. The same blot was then 
re-probed with the anti-P-actin antibody (A). Panel B displays the ratios ot 
C/EBP5:P-actin, normalised to the IL-1 treated DMSO control as determined by 
densitometric analysis. The data shown is the mean from two independent 
experiments.
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Consistent with our previous findings, IL-1 dramatically induced the expression o f 
C/EBP5 in Hep3B cells and pre-treatment o f cells with the pharmacological inhibitors 
apigenin and curcumin decreased this induction. Additionally, the PI3K inhibitor, 
LY294002 did not attenuate the IL-1-mediated induction o f C/EBP8 protein 
expression, consistent w ith our previous RT-PCR data presented in chapter 4 and also 
consistent with the findings o f Dong and co-workers (2007), who also report similar 
results with this inhibitor, in relation to the IL-1 response. Also, we noted that both 
the p38 M APK and the ERK M APK/M EK1 inhibitors, SB203580 and PD98059 
respectively, caused a decrease in C/EBP8 protein expression by IL-1. Given that we 
had not previously noted a sim ilar effect at the level o f mRNA, as assessed by semi- 
quantitative RT-PCR (Chapter 4), we also decided to re-examine the effects o f these 
two inhibitors on the expression o f C/EBP8 mRNA as induced by IL-1.
For this, Hep3B cells were pre-treated w ith the inhibitors SB203580, PD98059 and as 
a positive control, apigenin or vehicle-control (DMSO) and then cultured in the 
presence or absence o f IL-1 exactly as described in Figure 8.1. Samples were 
subsequently prepared for RT-PCR analysis (Section 2.6.3). PCR-amplification 
products for C/EBP8 and P-actin were then resolved by electrophoresis (Section 
2.6.4). The results o f this experiment are shown in Figure 8.2 below.
M +IL-1 -RT
DMSO DMSO PD98 SB203 SB203 API 
5pM 10^M
C/EBP5 
P-actin
FIGURE 8.2. Effect o f PD98059, SB203580 and apigenin on the I L - 1 -mediated 
induction o f C/EBP5 m R N A expression. Hep3B cells were pre-treated with 
pharmacological inhibitors PD98059; PD98 (50pM), SB203580; SB203 (5pM and 
lOpM), apigenin; API (20pM) or DMSO as a vehicle control for lh. They were then 
either treated with IL-1 (lOOU/ml) or left untreated for 3h. Total RNA was then 
extracted and used for RT-PCR analysis. The PCR amplification products for 
C/EBP8 and P-actin were resolved on 1.5% (w/v) agarose gels by electrophoresis. M 
denotes the lOObp D N A ladder (Appendix II). -R T  denotes the RT-PCR in which no 
reverse transcriptase was included for the preparation o f cDNA (using DMSO —IL-1 
treated RNA).
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Consistent with our previous findings, the IL-1-mediated induction o f C/EBP8 was 
inhibited by apigenin and not affected by pre-treatment o f cells with SB203580 at a 
concentration o f 5pM (Chapter 4). However, we noted that at the higher 
concentration o f lOpM, SB203580 did attenuate the response. Given that we have not 
previously carried out this experiment using this higher concentration o f SB203580, 
this result requires confirmation. Therefore, although we, like Dong and co-workers 
(2007), have previously only used SB203580 at the concentration o f 5pM, at this 
concentration o f the inhibitor the IL-1-mediated induction o f C/EBP8 expression is 
not attenuated, at least at the mRNA level in Hep3B cells. In contrast, the same 
concentration o f the inhibitor caused a significant decrease in the IL-1-mediated 
induction o f C/EBP8 expression at the mRNA level as assessed by quantitative RT- 
PCR in HepG2 cells, data presented by Dong and colleagues (2007). However, one 
should note that the experimental conditions vary between this study and that o f Dong 
et al. (2007). Whilst in our study, all our experiments were carried out in Hep3B cells 
cultured in medium containing 10% (v/v) serum (FCS), in the Dong et al. (2007) 
study, HepG2 cells were cultured in medium without serum for 24h prior to 
experimentation. Furthermore, HepG2 cells were then cultured in the presence o f 
pharmacological agents for lh  and subsequently exposed to IL-1 or IL-6 for a further 
4h, again in the absence o f serum. Given that no cell viability assay was carried out in 
this study and the expression o f a control, housekeeping gene was not examined in 
experiments involving pharmacological inhibitors used in western blot analysis, it is 
difficult to ascertain the effect o f combined inhibitor and cytokine treatment on 
HepG2 cell viability from the Dong et al. (2007) study. This point is particularly 
relevant, as serum deprivation is reported to induce oxidative stress and in extreme 
cases cell death, in the HepG2 cell line (Bai and Cederbaum 2006).
In addition, to the above mentioned observations, we also noted (Figure 8.2) that 
unexpectedly, the inhibitor ERK M APK/MEK1 inhibitor, PD98059 also caused a 
decrease in the IL-1-mediated induction o f C/EBP8 expression at the mRNA level. 
Given that we have not observed this decrease in our previous experiments (Chapter 
4), this result requires further investigation. It is also worthy o f note that owing to the 
constant expression o f p-actin, that none o f the inhibitors used in our experiments 
were having a global affect on cellular gene expression, and therefore the results 
presented in Figure 8.1 and 8.2 were specific to C/EBP8 expression. Therefore, i f  the
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results presented in Figures 8.1 and 8.2 are confirmed, in relation to the inhibitory 
action o f both SB203580 and PD98059, on the IL-l-mediated induction o f C/EBP8 
expression, further experiments w ill be required to ascertain the roles o f the p38 and 
ERK 1/2 MAPK pathways in the regulation o f  this response.
The other result presented by Dong et al. (2007) that merits discussion is that these 
authors did not observe a decrease in the expression o f C/EBP8 as induced by IL-1, in 
response to the inhibition o f NF-kB by a pharmacological agent, SN50. This is in 
contrast to our data, in which we show that, not only does a pharmacological inhibitor 
of NF-kB attenuate this response (Chapter 4) but also confirm this by using siRNA 
targeting NF-kB (Chapter 7). In addition, we have also carried out a series o f 
investigations confirming that NF-kB is indeed activated by IL-1 in Hep3B cells, 
consistent with previous reports (see chapter 7 for details). Although the role o f NF- 
kB in the regulation o f C/EBP8 expression by IL-1 was investigated by Dong et al. 
(2007), their data is restricted to the use o f the pharmacological inhibitor SN50, and 
additionally these authors present no evidence to suggest that this inhibitor does 
indeed inhibit NF-kB in HepG2 cells at the concentration they have used. In addition, 
no experiments were carried out to determine the effect o f different concentrations o f 
this inhibitor on the expression o f C/EBP8 as mediated by IL-1. Another potential 
explanation for these contrasting results may be in the use o f the different cell lines 
between this study (Hep3B) and that o f Dong and co-workers (HepG2). Although 
both these cell lines are closely related, differences in signalling, in response to 
cytokine action have been reported. For example, in Hep3B cells, IL-6 leads to the 
activation o f the PI3K/Akt pathway (Chen et al. 1999), whereas no significant Akt 
activation is observed in IL-6-treated HepG2 cells (Kortylewski et al. 2003). Thus, 
cell-type specific signalling events may also potentially explain the differences in the 
results.
In relation to the expression o f C/EBP8 by IL-6, the Dong et al. (2007) study reports a 
major role for the JAKs in the regulation o f this response, because a generic JAK 
inhibitor attenuates this response. However, this result is in contrast to Dr S.A. 
Rogers’ (personal communication) data (Figure 6.15, Chapter 6), who showed that the 
JAK2 inhibitor, AG490 did not attenuate this response in Hep3B cells. Therefore, 
although a role for JAK2 in the regulation o f this response is unlikely, given that Dr 
S.A. Rogers’ pharmacological inhibitor data does not support this, the role o f other
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JAKs, like JAK1 and Tyk2 should be investigated further. This is also important 
given that our siRNA data fu lly  supports a role for the STATs in the regulation o f 
C/EBP8 expression by IL-6. Additionally, it is worthy o f note that the Dong et al. 
(2007) study did not investigate a role for the JNK. MAPK or CK2 in the regulation o f 
the IL-6-mediated induction o f C/EBP8 expression, or investigate a role for CK2 in 
the regulation o f the IL-1 response.
One should also take into consideration that in the Dong et al. (2007) study, the 
identification o f the signalling pathways by which IL-1 and IL-6 mediate the 
induction o f C/EBP8 expression, is purely based on results obtained with the use o f 
pharmacological agents and no other follow-up experiments (for example, with the 
use o f siRNA) were carried out to investigate these initial findings. This point is 
particularly significant in the light o f the findings o f this study and stresses the 
importance o f carrying out additional experiments to back-up preliminary findings. In 
further support o f this, it should also be noted that preliminary RNAi data presented in 
chapter 6 (Figure 6.12), does not suggest an immediate role for the p38 MAPK in the 
regulation o f C/EBP8 expression by IL-1 in Hep3B cells. siRNA mediated knock­
down o f p38 M APK did not attenuate the induction o f C/EBP8 expression by IL-1 at 
the mRNA level, compared to controls.
The following section w ill aim to discuss the findings o f this thesis in relation to 
recently published reports relevant to the various aspects o f our studies and 
summarises the significance o f our findings in the context o f regulation o f the APR by 
C/EBPS.
8.2 Per spectives
Studies presented in this thesis have provided evidence for a role o f NF-kB, as a 
mediator o f IL-1 signalling in Hep3B cells and have also implicated this factor as a 
regulator o f C/EBP8 expression by IL-1. In addition our investigations also indicate 
that the protein kinase, CK2 may also be involved, at least in part, in regulating NF- 
kB activation by IL -1 . A  requirement for CK2 in the regulation o f IL-l-mediated NF- 
kB activation has also been demonstrated in the recently reported study by Parhar and 
colleagues (2007). W hilst these authors showed that overall CK2 activity was 
unaffected by IL-1 treatment o f HCT116 cells (human colon cancer cell line, 
intestinal epithelial cells), consistent w ith our data, they report kinase activation by
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IL-1, in pools o f CK2 bound to either p65 N F -k B or IKKy/NEMO. Protein extracts 
from HCT116 cells treated with IL-1, immumnoprecipitated with antibodies for p65 
or IKKy, were subjected to a CK2 kinase assay using GTP as a phosphate donor and 
casein as a substrate. In both sets o f  immunoprecipitates, a modest increase in CK2 
kinase activity, in response to IL-1 was observed. These findings are also consistent 
with those reported by the Bird et al. (1997) study that reported a marked increase in 
CK2 kinase activity as mediated by IL-1, in protein extracts immunoprecipitated with 
NF-icB-specific antibodies, but not in extracts immunoprecipitated using CK2-specific 
antibodies. Also consistent w ith our data, Parhar et al. (2007) report that the CK2 
inhibitor apigenin, prevented the IL-1-induced activation o f N F -kB in a transient 
transfection assay that mirrored the transfection-based assay we used in this study 
(Chapter 7, Figure 7.6). These researchers further report that DN mutants o f CK2 also 
attenuated the activation o f N F -k B as mediated by IL-1, consistent with our data. 
Moreover, another very significant result reported by these authors is that in response 
to IL-1, CK2 increases the /nms-activation potential o f the p65 N F -kB subunit by its 
phosphorylation o f its C-terminal rraws-activation domain at serine529. In contrast to 
our results however, which show that pre-treatment o f Hep3B cells with apigenin 
prevents IL-1-induced N F -k B D N A binding, these researchers report that neither o f 
the CK2 inhibitors, apigenin or DRB (5, 6-dichloro-l-beta-D- 
ribofuranosylbenzimidazole) affect the N F -kB DNA binding as mediated by IL-1 in 
Caco2 cells, although it should be noted that these experiments were only carried out 
with a single concentration o f each inhibitor (Parhar et al. 2007). In light o f these 
recent findings, a role for CK2 in the regulation o f N F -kB activity by IL-1 in Hep3B 
cells may require further investigation as discussed in section 8.3.
As already discussed in chapter 1, NF-kB is a key mediator o f IL-1 signalling. In 
addition, IL-1 is also known to activate all three branches o f MAPK signalling, JNK, 
p38 and the ERK 1/2 MAPKs. Indeed, we have shown that this cytokine activates 
both NF-kB and the JNK M APK in Hep3B cells. A  flow o f recent studies have 
indicated that activation o f the MAPKs, in some cases all three modules, and NF-kB 
is necessary for the induction o f certain genes, in response to IL-1 action. This is o f 
particular interest in light o f the results presented in Figures 8.1. and 8.2. For 
example, induction o f the matrix metalloproteinase-9 (MMP-9) gene by IL-1 is 
dependent on the activation o f all three MAPKs and NF-kB for its expression in
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human tracheal smooth muscle cells (Liang et al. 2007). Interestingly, activation o f 
NF-kB is independent o f M APK activation, thus the MAPKs are likely to activate 
other transcription factors important for MMP-9 expression (Liang et al. 2007). In 
contrast, other studies suggest that a degree o f cross-talk does exist between N F -kB 
and the MAPKs and that such cross-talk is important for IL-l-mediated gene 
expression. For example, IL-1 induces IL-8 production in lung epithelial cells, 
derived from cystic Fibrosis patients, and its production is dependent on p38, ERK 
MAPK and N F -k B activation. However, the roles o f these signalling mediators in the 
regulation o f this response only became apparent with combined inhibition o f either 
p38 or ERK MAPKs with N F -k B, determined w ith the use o f pharmacological agents. 
Used individually, none o f the pharmacological inhibitors o f p38, ERK MAPK or NF- 
kB markedly impaired the production o f IL-8 by IL-1 (Muselet-Charlier et al. 2007). 
As well as indicating that a degree o f cross-talk exits between the p38, ERK MAPK 
and N F -kB dependent signalling pathways, this study also suggests the existence o f 
some functional redundancy between the pathways.
Regulation o f C/EBP5 expression by IL-1 may also be a complex process. Recent 
evidence suggests that its expression in response to certain inflammatory stimuli is 
also likely to be dependent on the activation o f both NF-kB and the MAPKs. 
Although, there are no published studies examining in detail the signalling pathways 
by which IL-1 regulates C/EBP5 expression, NF-kB and MAPK activation by 
peptidoglycan and LPS is required for its expression in murine macrophages (Liu et 
al. 2006b; Huang et al. 2007). For maximal C/EBP8 expression as mediated by 
peptidoglycan, three transcription factors are required; Spl, c-Rel and c-Jun. 
Combined inhibition o f all three M A P K  pathways, with the use o f pharmacological 
inhibitors, impairs the increase o f c-Jun noted in nuclear fractions o f cells as mediated 
by peptidoglycan, but does not affect c-Rel. Conversely, nuclear levels o f c-Rel are 
reduced by an NF-kB inhibitor, but c-Jun levels are not. Therefore, in response to 
peptidoglycan, C/EBP8 expression is likely to be regulated by two independent 
signalling pathways, one dependent on NF-kB, c-Rel activation and the other 
dependent on M APK activation o f c-Jun (Huang et al. 2007).
Additionally, as mentioned in section 7.3, receptors for IL-1 and LPS are members o f 
the Toll/interleukin-1 receptor fam ily and therefore are able to regulate gene 
expression by activating many o f the same signalling pathways. It is therefore
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intriguing that both the MAPKs and NF-kB are involved in regulating C/EBP8 
expression by LPS, in murine macrophages. Combined inhibition o f all three MAPKs 
or NF-kB with the use o f pharmacological agents attenuates its expression and DNA 
binding activity as mediated by LPS (L iu  et al. 2006b). Moreover, the existence o f 
potential cross-talk between these pathways in relation to their regulation o f C/EBP8 
expression by LPS cannot be ruled out as in this study, no experiments were carried 
out to determine the effects o f different inhibitor combinations on C/EBP5 expression 
by LPS. Therefore it appears, by evaluating the current literature that the mechanisms 
governing gene expression as modulated by IL -1 can be complex. It is emerging that 
genes like C/EBPS can be regulated by a combination o f signalling pathways 
involving the MAPKs and NF-kB in response to inflammatory mediators like IL-1 
and LPS and that the activation o f all these signalling pathways contributes to gene 
expression in response to the single stimulus. Such pathways can either function 
independently o f one another or can act together via cross-talk. Where there is a 
necessity for the activation o f multiple signalling pathways required for the expression 
of a certain gene, then the existence o f some functional redundancy between these 
pathways is always plausible and indeed this notion is supported by previous work 
(Mestre et al. 2001).
Finally in relation to the APR, it should be noted that the collective results o f this 
study provide experimental evidence to support a model for C/EBP8 action in APP 
gene regulation similar to that described by Valeria Poli (1998) (See section 1.3.1.4 
and Figure 1.5). In our scheme o f events, IL-1 and IL-6 transiently activate the 
transcription factors NF-kB and STAT3 respectively and these transcription factors in 
turn induce the expression o f C/EBP8 and other APP genes in ‘early’ stage o f the 
APR. However, unlike NF-kB and STAT3 whose activation is short-lived, C/EBP8 
expression is maintained over many hours following its initial induction. This 
sustained expression is probably due to auto-activation o f the gene and its expression 
is likely to support APP gene transcription in the ‘ late’ phase o f the APR. A 
schematic representation o f the events like ly to regulate C/EBP8 expression during 
the inflammatory response is shown in Figure 8.3.
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F ig u r e  8.3. Regulation o f C/EBPS gene expression during the inflam m atory 
response in human hepatocytes. Binding o f IL-1 and IL-6 to their cognate receptors 
activates various signalling pathways leading to the activation ot N F -k B  and STAT3, 
respectively. Both N F -k B  and STAT3 induce C/EBPS gene transcription (EARLY). 
Because the activation o f N F -k B  and STAT3 is transient, it is unlikely that these 
nuclear factors drive the transcription o f the C/EBPS gene during the later stages o f 
the response. C/EBPS either as a homodimer or as a heterodimer (with other C/EBPs 
like C/EBPP), is like ly to drive its own expression by auto-activation (although the 
precise nature o f this process, whether it occurs by a direct or indirect mechanism, is 
presently unclear) during the latent phase (LATE). Filled orange circles represent 
phosphate groups.
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8.3 F u t u r e  s t u d i e s
As a result o f the work presented in this thesis, several avenues for future 
investigations have become apparent. For future studies in relation to the auto­
regulation o f the C/EBP5 gene, creation o f further DNA constructs o f the proximal 
promoter region o f the human C/EBP8 gene, containing deleted or mutated putative 
c/s-acting elements, hypothesised to be potentially responsible for the response (e.g. 
CRE and/or USF sites), may be useful. These constructs could then be used in a 
similar transfection-based assay, as described in chapter 3 to help determine the exact 
promoter elements necessary for mediating the auto-regulation response. Following 
the identification o f the sequence elements necessary for the response, it may be 
worthwhile confirming the results o f transfection-based assays by EMSA. 
Furthermore, EMSA antibody interference/supershift experiments may help to 
identify the nuclear factors that bind to the required sequence elements responsible for 
mediating the auto-regulation response. Thus, such experiments may help to elucidate 
a mechanism for auto-regulation.
Additionally, given that our D NA sequencing data in chapter 3 (Figure 3.16) suggests 
that the human C/EBP5 gene promoter may potentially contain a 42bp sequence that 
is absent from our promoter-reporter constructs, it would be o f interest to investigate 
this. PCR primers could be designed, flanking the deleted sequence in the promoter 
and used to PCR-amplify human genomic DNA. Further DNA sequence analysis 
would help ascertain whether this sequence is indeed present. Depending on the 
outcome o f these experiments, it may be necessary to create further promoter- 
constructs for experimental analysis.
In relation to the role o f CK2 in IL-1 signalling, it would be very interesting to 
determine whether specific pools o f cellular CK2 were activated by IL-1 as suggested 
by Parhar et al. (2007). Evidence in this study suggests that the activity o f CK2 
associated with p65 NF-kB and IK K y is increased in response to IL-1. Given that a 
role for NF-kB and a potential role for CK2 had been suggested in this study, in the 
regulation o f C/EBP5 expression by IL-1, studies in this area may be particularly 
fruitful. Therefore, it may first be o f interest to determine whether IL-1 action 
induces an association between CK.2 and p65 NF-kB in human hepatocytes, as 
suggested by Bird et al. (1997). For this, co-immunoprecipitation assays could be
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earned out. This would entail using an anti-p65 NF-kB antibody to 
immunopreciptiate p65 NF-kB from protein extracts derived from Hep3B cells 
harvested either in the presence or absence o f IL -1 . These immunoprecipitates would 
then be subjected to western blotting and subsequent immunodetection using anti­
c s  antibodies. Results from these experiments would reveal whether IL-1 action 
caused a physical interaction between CK2 and p65 NF-kB. For kinase assays, the 
CK2 activity assay used in this study could be modified slightly (Chapter 5). For this, 
rather than producing immunoprecipitates using anti-CK2 antibodies for the assay, an 
anti-p65 antibody could be used instead, for example. These immunoprecipitates 
could then be subjected to the kinase assay, in much the same way as described in 
section 2.7.6. It could then be determined i f  IL-1 does indeed induce CK2 activation 
in NF-KB-associated CK2 pools in treated Hep3B cells. Additionally, it may also be 
worthwhile determining whether the Hep3B cell line expresses a third catalytic 
isoform o f CK2, CK2a” , given that its expression has been reported in hepatocytes 
(Shi et al. 2001). This could be done by RT-PCR and western blot analysis. 
Depending on the outcome o f these experiments, further studies, for example with the 
use o f siRNA, may be undertaken to further investigate a role for CK2 in the 
regulation o f C/EBP8 expression by IL -1 .
Although our data has shown that N F -k B is necessary for the induction o f C/EBPS 
expression by IL-1 in Hep3B cells, further investigations into the identification o f the 
upstream mediators regulating this response are required. Our data suggests that the 
MAPKKK, TAK1 is not required for this response but the role o f another MAPKKK, 
MEKK3, which has also been implicated as regulator o f N F -kB activation by IL-1 
(Yao et al. 2007), requires investigation. Studies utilising siRNA or DN mutants o f 
this kinase may help determine its role ( i f  any), in the regulation o f C/EBPS 
expression by IL-1. Future investigations should also aim to determine the precise 
nature o f the inhibitory action o f apigenin and curcumin on N F -kB activation by IL-1, 
with suggested experiments discussed in section 7.3. In conjunction, the effect o f 
SP600125 on N F -k B activation by IL-1 should also be examined using a similar 
experimental approach as described in chapter 7, given that this pharmacological 
agent has also been shown to significantly inhibit the expression o f C/EBPS as 
induced by IL-1 (Chapter 4). Studies should also be carried out to determine i f  there 
is any functional redundancy between CK2 and JNK in the regulation o f N F -kB
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activation by IL-1, as suggested in section 7.3, given that we were unable to address 
this issue due to time constraints. Finally, as we have identified putative NF-kB 
binding sites in the promoter region o f the human C/EBP5 gene promoter it would be 
o f interest to determine whether these sites were indeed target binding sites for NF-kB 
in vivo, in IL-1 stimulated Hep3B cells. ChIP assays carried out as described in 
section 7.3 and EMSA analysis would help determine this.
In relation to the IL-6-mediated induction o f C/EBP8 expression, future studies should 
aim to determine the upstream activators o f  STAT3 [given that Dr S.A. Rogers’ 
(personal communication) data points to a predominant role o f STAT3 over STAT1 in 
the regulation o f this response] and should first focus on discerning a role o f the JAK1 
or Tyk2 in this process. Given that Dr S.A. Rogers’ data suggests a potential 
requirement for CK2 and JNK in the regulation o f C/EBP5 expression by IL-6, a role 
for these kinases in the regulation o f  this response should be investigated with the use 
o f siRNA and DN mutants o f these kinases.
Future studies should also concentrate on extending the results presented in this thesis 
to primary hepatocyte cell cultures in order for these findings to be fu lly relevant to 
the inflammatory response. Such experiments should be carried out to ensure that the 
responses we have characterised in Hep3B cells are not just specific to this cell line 
but are also significance in other hepatocyte cell cultures. This is o f particular 
importance because there have been reported instances where differences in certain 
cellular responses between primary cell cultures and cell lines have been noted (Rao 
2001).
I f  the results presented in Figures 8.1 and 8.2 are confirmed, in relation to the 
inhibitory action o f the p38 M APK inhibitor, SB203580 and the ERK MAPK 
inhibitor, PD98059, on the IL-l-m ediated induction o f C/EBP8 expression, then 
future studies should also investigate these signalling pathways. Studies should first 
aim to determine whether these kinases act as upstream regulators o f NF-kB, as 
previous reports have suggested this (Chen et al. 2004; Larsen et al. 2005). This 
could be achieved with the use o f pharmacological inhibitors o f these kinases, used in 
a transfection-based assay; similar to the assay described in section 7.2.3, used to 
assess their effect on trans-activation o f NF-kB by IL-1. Additionally, the effect o f 
inhibiting these kinases on NF-kB D N A binding as induced by IL-1 could be assessed
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by EMSA. Further experiments should aim to determine a role for these kinases in 
the regulation o f C/EBP8 expression by IL-1 with the use o f DN mutant constructs 
and siRNA. Additionally, use o f phospho-specific antibodies o f p38 and ERK MAPK 
in western blot analysis and associated kinase activity assays, would help determine 
whether these pathways are indeed activated in Hep3B cells, in response to IL-1.
Additional investigations could also be carried out to confirm the role o f NF-kB and 
STAT3 in the IL-1- and IL-6-mediated increase o f C/EBPS expression, respectively. 
For example, the expression o f C/EBP5 as mediated by IL-1 could be examined in 
NF-kB deficient cells. Indeed, Kravchenko et al. (2003) showed that the LPS- 
mediated induction o f C/EBPS was impaired in mouse embryonic fibroblasts deficient 
in p65 NF-kB compared to controls, and therefore studies o f a similar nature could be 
extended to the analysis o f the IL-1 response. Unfortunately, the analysis o f C/EBPS 
expression by IL-1 in p65 knock-out mice is not a feasible option, as these animals are 
embryonic lethal (Beg et al. 1995), although a p50 knock-out mouse model is viable 
(Sha et al. 1995). Therefore, the creation o f a conditional knock-out mouse model for 
p65 NF-kB may be required for future studies. A  similar approach may also be used 
to verify the role o f STAT3 in the regulation o f C/EBPS expression by IL-6, although 
it should be noted that A lonzi et al. (2001) report that C/EBPS expression as induced 
by IL-6 was only m inimally impaired in STAT3 deficient mouse cells, indicating that 
STAT3 independent mechanisms o f regulating C/EBPS expression by IL-6 may also 
exist in murine cells. Potentially, the absence o f STAT3 in these cells could be 
compensated for by STAT1, as functional redundancy between these two STATs has 
previously been reported. STAT3 activity can, at least in part, replace STAT1 activity 
in STAT1 deficient cells (Ramana et al. 2005).
To evaluate more ‘globally’ the role o f NF-kB, STAT3 and C/EBPS in the regulation 
of the inflammatory response gene expression, ChlP-on-chip assays could be carried 
out using hepatocytes stimulated with and without IL-1 or IL-6. Essentially, ChlP-on- 
chip assays combine chromatin immunoprecipitation assays with DNA microarray 
technology. Similar to convential ChIP analysis, ChlP-on-chip is used to investigate 
interactions between D NA and proteins in vivo. However, in contrast to conventional 
ChIP analysis, where one is required to have an idea about which DNA sequence that 
the protein o f interest may bind prior to experimentation, ChlP-on-chip requires no 
prior knowledge about potential D N A binding sites. Therefore this technique allows,
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by a non biased approach, the identification o f DNA binding sites o f the protein o f 
interest, on a large, genome-wide scale. In brief, the protein o f interest is 
immunoprecipitated from chromatin, in much the same way as conventional ChIP 
analysis. Following the reversal o f cross-linking and DNA purification, the DNA is 
subjected to an amplification and denaturation step. A t this point, the DNA is 
fluorescently labelled and hybridised to a DNA microarray which is spotted with 
short, single-stranded sequences that cover the genomic portion o f interest. 
Subsequently, the DNA microarray data can be anlaysed to identify DNA sequences 
to which the protein o f interest was bound to. Further computational analysis o f the 
DNA sequences, would help determine the genes associated with the identified DNA 
sequences. In theory, ChlP-on-chip assays could be used to calculate the proportion 
o f genes and potentially help identify novel genes, which may require NF-kB, STAT3 
or C/EBP8 for their regulation in response to IL-1 or IL-6 in hepatocytes.
8.4 C o n c l u d i n g  r e m a r k s
The work presented here demonstrates that the expression o f the transcription factor 
C/EBP8 is subject to transcriptional regulation by a number o f mechanisms during the 
inflammatory response. As this transcription factor is key to the regulation o f 
inflammatory gene expression, it is hoped that studies o f this nature w ill in the long 
term lead to the eventual development o f therapeutic strategies to combat 
inflammatory disease.
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t-Test
Mean 1 = x\ Standard deviation 1 = a  i
Mean 2 = r 2 Standard deviation 2 = 0 2  
Variance = acf
nl n 2
t Jx\~x2
t-Table
A difference between two means is significant (at the given probability level) i f  the 
calculated t value is greater than the value given in this table. A probability o f p  = 
0.05 (95% probability o f making a correct statement) is usually acceptable for 
biological work.
When comparing two means, the number o f degrees of freedom is (ni + n2)-2, where 
ni is the number o f replicates o f treatment 1, and n2 is the number of replicates of 
treatment 2 (adapted from http://helios.bto.ed.ac.uk/bto/statistics/tress4a.html#Student,s%20t- 
test).
D e g r e e s  o f  
F r e e d o m
t-V A L U E
P-Value 0.1 0.05 0.01 0.001
1 6.31 12.71 63.66 636.62
2 2.92 4.30 9.93 31.60
3 2.35 3.18 5.84 12.92
4 2.13 2.78 4.60 8.61
5 2.02 2.57 4.03 6.87
6 1.94 2.45 3.71 5.96
7 1.89 2.37 3.50 5.41
8 1.86 2.31 3.36 5.04
9 1.83 2.26 3.25 4.78
10 1.81 2.23 3.17 4.59
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FI and F2 primers were used to sequence the proximal promoter region of the human 
C/EBP6 gene promoter insert in the plasmid vector pLUC. This plasmid is termed 
pHuC/EBP8[1.6kb]-Luc throughout this thesis.
F I  5 ’ - AGG AGCG AGG AGGTTCC AAG-3 ’
F 2  5 ’-TCCGAGGAGAGCAGCGAGAA-3 ’
GL1 and GL2 universal primers were used to sequence DNA inserts in the reporter 
vector pG12-Basic.
G L 1 5 ’-TGTATCTTATGGTACTGTAACTG-3 ’
G L 2  5 ’-CTTTATGTTTTTGGCGTCTTCCA-3 ’
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A p p e n d ix  V : T r a n s c r i p t i o n  f a c t o r  b in d in g
SITE SEARCHES OF THE HUMAN C/EBP8 GENE 
PROMOTER
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3 00000 USF 100292 (USF) 7 R 6
4 T00788 T-Ag
5 T00752 Sp1 
T00753 Sp1 
T00754 Sp1 
T00755 Sp1 
T00757 Sp1 
T00758 Sp1 
T00759 Sp1 
TQ1228 Sp1
6 J00033 AP- 
2alphaA 
T00Q34 AP-2 
100035 AP- 
2alphaA 
100952 AP-2 
101142 AP-2 
T02466 AP-
R01372 () 
R 0 2 2 4 5 0
R02121 ()
10 N 5
10 N 9
11 R 8
12 N 8
14 N 6
16 N 4
19 N 5
2alphaB 
7 T00821 TFIID R01943 ()
8 _00000 MIG1 100321 (MIG1)
9 T00302 GAL4 R00496 ()
10 _00000 H4TF2 100180 (H4TF2)
# Factor Model Beg Sns Len
11 T00392 H4TF- R00681 () 19 N 5
2
ACGTGG
TGGGC
KRGGCKRRK
SSSNKGGG
GGCTGGGG
CTGGGG
GGGG
GGTCC
Sequence
GGTCC
9 .6 7  1.61 1 .0 0 0  0 .0 0  8 2e-°2 1 .00  1 .00  0.0e+00 1 6e-0i
10.00 2.00 1.000 0.00 nc ? ? nc nc
1 2 .0 0  1 .33  1 .0 0 0  0 .0 0  nc ? ? nc nc
1 0 .00  1 .25  1 .0 0 0  0 .0 0  nc ? ? nc nc
1 6 .00  2 .0 0  1 .000  0 .0 0  nc ? ? nc nc
9 .7 9  1 .63  1 .000  0 .0 0  l-6e-0l 1 .00  1 .00  o.oe+oo 9.4e-i7
8.00 2.00 1.000 0.00 nc ? ? nc nc
7 .92  1 .58 1 .000  0 .0 0  2.9e-0i 1 .00  1 .00  0.0e+00 3 Oe-01
La Lai La Ld Lax m  S n  § 2 Y  Bsx
10.00 2.00 1.000 0.00 nc ? ? nc nc
379
A p p e n d ic e s
12 100033 AP- R05065 0 
2alphaA 
100034 AP-2 
J00035AP- 
2alphaA 
100952 AP-2 
T01142 AP-2 
102466AP- 
2alphaB
21 N 10 t c c c c m n s s s  14.00 1.40 1.000 0.00 nc nc nc
13 T00302 GAL4 R00496 0 22 R 4 cccc 8.00 2.00 1.000 0.00 nc ? ? nc
14 _00000 MIG1 100321 (MIG1) 22 R 6 CCCCAG 9.79 1.63 1.000 0.00 1 6e-01 1.00 1.00 0.0e+00
15 _00000 LBP-1 100191 (LBP-1) 24 R 5 CCAGG 7.52 1.50 1.000 0.00 2.9e-01 -J 00 1.000 0e+0°
16 T00320 GCF R02159 0 27 R 7 GSSSCGS 10.00 1.43 1.000 0.00 nc ? ? nc
17 T00302 GAL4 R00496 0 32 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc
18 T00759 Sd1 R01758 0 32 R 11 GGGGAGGGGGC 22.00 2.00 1.000 0.00 nc ? ? nc
19 T00490 MAZ R02306 0 33 N 7 GGGAGGG 14.00 2.00 1.000 0.00 nc ? ? nc
20 T00033 AP- R02121 0 33 R 8 SSSNKGGG 10.00 1.25 1.000 0.00 nc ? ? nc
2alphaA 
J00034 AP-2 
100035AP- 
2alphaA 
100952 AP-2 
101142 AP-2 
J02466 AP- 
2alphaB
# Factor Mode! Beq Sns Len Sequence 4a 4§/ La La 4 Pv Sm Spy
21 T00172 CTCF R02137 () 35 R 5 g ag g g  10.00 2.00 1.000 0.00
nc
9.4e-17
2.3e-02
nc
nc
nc
nc
nc
Em
nc nc nc
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22 T00302 GAL4 R00496 0 37 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc
23 T00788 T-Aa R013720 38 N 5 GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc
24 T00320 GCF R021590 41 R 7 GSSSCGS 10.00 1.43 1.000 0.00 nc ? ? nc
25 T00302 GAL4 R00496 0 42 R 4 CCCC 8.00 2.00 1.000 0.00 nc ? ? nc
26 T00033 AP- R02121 0 42 R 8 SSSNKGGG 10.00 1.25 1.000 0.00 nc ? ? nc
2alphaA
100034 AP-2
100035 AP- 
2alphaA 
100952 AP-2 
101142 AP-2 
102466 AP- 
2alphaB
27 T00302 GAL4 R00496 0 46 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc nc
28 _00000 PU.1 I00047 (PU.1) 49 R 6 GAGGAA 10.93 1.82 1.000 0.00 8.2e-02 1.00 1.00 8.2e-02 7.7e-02
29 T00702 PU.1 R04413 0 49 R 6 GAGGAA 12.00 2.00 1.000 0.00 nc ? ? nc nc
30 T00172 CTCF R02137 0 59 R 5 GAGGG 10.00 2.00 1.000 0.00 nc ? ? nc nc
# Factor Model Beq Sns Len Sequence La ^a/ Ld 4 ^  ! Sc Sm | lev E l P p v
31 T00302 GAL4 R004960 61 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc nc
32 T00788 T-Aa R01372 0 62 N 5 GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc nc
33 T00320 GCF R02159 0 62 R 7 GSSSCGS 10.00 1.43 1.000 0.00 nc ? ? nc nc
34 T02349 ZF5 R01772 0 64 N 6 GGCGCG 12.00 2.00 1.000 0.00 nc ? ? nc nc
35 T00788 T-Aa R01372 0 69 R 5 GCCCC 10.00 2.00 1.000 0.00 nc ? ? nc nc
36 T00320 GCF R02159 0 69 R 7 GSSSCGS 10.00 1.43 1.000 0.00 nc ? ? nc nc
37 T00302 GAL4 R004960 70 R 4 CCCC 8.00 2.00 1.000 0.00 nc ? ? nc nc
38 T00113 c-Ets- R043430 74 N 6 GGGAAG 12.00 2.00 1.000 0.00 nc ? ? nc nc
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2
39 T00302 GAL4 R004950 78 R 5 AGGCT 10.00 2.00 1.000 0.00 nc ? ? nc nc
40 T00714 RAF R00256 0 82 R 4 TCGG 8.00 2.00 1.000 0.00 nc ? ? nc nc
# Factor Model Beq Sns Len Sequence La Lai Lg Ld Ley Sc & 1 c fl■ hey 1 P  pv
41 T00302 GAL4 R00496 0 84 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc nc
42 T00788 T-Aa R01372 0 84 N 5 GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc nc
43 T00320 GCF R02159 0 84 R 7 GSSSCGS 10.00 1.43 1.000 0.00 nc ? ? nc nc
44 _00000 Sp1 I00295 (Sd1) 85 N 6 GGGCGG 8.19 1.36 1.000 0.00 1 6e-01 1 00 1.00 0.0e+00 1.7e-05
45 T00752 Sd1 
T00754 Sd1 
T00755 Sd1
R00017 0 
R00447 () 
R02891 0
85 R 6 GGGCGG 12.00 2.00 1.000 0.00 nc ? ? nc nc
46 T00270 ETF 
T00753 Sd1 
T00759 Sd1 
T01171 CP1
R013750 
R015450 
R030390 
R04790 0
85 N 6 GGGCGG 12.00 2.00 1.000 0.00 nc ? ? nc nc
47 T00788 T-Aa Q00168 (-) 87 N 5 GCGGC 6.50 1.30 1.000 0.00 2.9e-01 1 00 1.00 0.0e+00 2.2e-02
48 T00320 GCF R02159 0 93 N 7 SCGSSSC 10.00 1.43 1.000 0.00 nc ? ? nc nc
49 T00302 GAL4 R00496 0 95 N 4 GGGG 8.00 2.001.000 0.00 nc ? ? nc nc
50 T00788 T-Aa R01372 0 95 N 5 GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc nc
[1 ..50] o f 105 O  ©  ©  I I H I 21 | 31 | 41 | 51 | 61 | 71 | 81 | 91 | 101 | 111 I 121 I 131 I 141 I 151 I 161
# Factor Model Beq Sns Len Sequence La La/ Lg Ld Ley J§C §BY Ppy
3.0e-06
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52 _00000 EGR-1 100117 (EGR-1)
53 T0Q243 EGR3 R02147 () 
TQQ244 Egr-1
T00454 Krox-20
54 T01841 WT1-del2 R02262 () 
T01842WT1 l-del2
55 T00620 NGFI-C R03332 ()
T00759 Sp1 R03385 ()
T00899 WT1 R04861 0
T00900 WT1 I -
KTS
T01839 WT1 -KTS 
T01840WT1 I
56100788 T-Ag R01372 0
57 T00302 GAL4 R00496 ()
58 T00033 AP- R02121 ()
2alphaA
T00034 AP-2 
100035 AP- 
2alphaA 
100952 AP-2 
101142 AP-2 
102466 AP- 
2alphaB
59 T00714 RAF R00256 ()
60 T003Q2 GAL4 R00496 ()
99 N 
99 N
99 N 
99 R
100 R
101 R 
101 N
118 R 
120 N
g c g c c c c c g c  16.37 1.82 1.000 0.00 1 3e-°3 1.00 1.00 o.oe+oo 2.4e-03
9 c g c c c s c g c  17.00 1.89 1.000 0.00 nc ? ? nc nc
9 c g c c c c c g c  18.00 2.00 1.000 0.00 nc ? ? nc nc
9 c g c c c c c g c  18.00 2.00 1.000 0.00 nc ? ? nc nc
5  g c c c c  10.00 2.00 1.000 0.00 nc ? ? nc nc
4  cccc 8.00 2.00 1.000 0.00 nc ? ? nc nc
8 c c c m n s s s  10.00 1.25 1.000 0.00 nc ? ? nc nc
4  tc g g  8.00 2.00 1.000 0.00 nc ? ? nc nc
4  gggg  8.00 2.00 1.000 0.00 nc ? ? nc nc
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| # |  - Factor Model Beg Sns Len Sequence La La/ Lq Ld Lbl I s e &  S * Pp,
61 T00788 T-Aq R01372 0 120 N 5  GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc nc
62 T00320 GCF R02159 0 120 R 7 g s s s c g s  10.00 1.43 1.000 0.00 nc ? ? nc nc
63 T00753 Sd1 R02245 0 120 N g  KRGGCKRRK 12.00 1.33 1.000 0.00 nc ? ? nc nc
T00755 Sd1 
T00757 Sd1 
T00758 Sd1 
T01228 Sd1
64 _00000 Sp1 I00032 (Sp1) 120 N 1 o GGGGCGGGGC 16.91 1.69 1.000 0.00 3.3e-04 1 00 1.00 O.Oe+OO 4.2e-11
65 T00752 Sd1 
T00759 Sd1 
T00798 TBP
R00281 0 
R01764 0 
R02102 0
120 N 10 GGGGCGGGGC 20.00 2.00 1.000 0.00 nc ? ? nc nc
T00820 TFIID
66 T00754 Sd1 R02572 0 120| R 10 GGGGCGGGGC 20.00 2.00 1.000 0.00 nc ? ? nc nc
67 _00000 Sp1 I00295 (Sd1) 121 N 6 GGGCGG 8.19 1.36 1.000 0.00 1 6e-oi 1 .00  1 .00 O.Oe+OO 1.7e-05
68 T00270 ETF 
T01171 CP1
R01375 0 
R03039 0
121 N 6 GGGCGG 12.00 2.00 1.000 0.00 nc ? ? nc nc
69 T00033 AP- R02121 0 121 R 8 s s s n k g g g  1 o.oo 1.25 1.000 0.00 nc ? ? nc nc
2alphaA
T00034 AP-2 
100035 AP- 
2alphaA 
T00952 AP-2 
101142 AP-2 
102466 AP- 
2alphaB
70 T00261 ER R04883 0 122 N 6 gg c g g g  12.00 2.00 1.000 0.00 nc ? ? nc nc
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# Factor Model Beq Sns Len Sequence r r r r Lgy Sc Sm S p y Ppv
71 _00000 GCF 100152 (GCF) 123 N 8 GCGGGGCG 11.13 1.39 1.000 0.00 2 ie -02  1.00 1.00 O.Oe+OO 1.1e-21
72 T00302 GAL4 R00496 0 125 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc nc
73 T00788 T-Aq R01372 0 125 N 5 GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc nc
74 _00000 Sp1 I00295 (Sp1) 126 N 6 GGGCGT 8.19 1.36 1.000 0.00 1 6e-0 l 1.00 1.00 O.Oe+OO 1.7e-05
75 T00495 MBF-I R02198 0 128 R 7 GYGYGCA 12.00 1.71 1.000 0.00 nc ? ? nc nc
76 T00515 MTF-1 R02204 0 128 R 7 GNGYGCA 11.00 1.57 1.000 0.00 nc ? ? nc nc
77 T00752 Sp1 R01021 0 130 R 5 GTGCA 10.00 2.00 1.000 0.00 nc ? ? nc nc
78 T02789 bZIP910 R08444 0 133 R 7 CACGTCA 14.00 2.00 1.000 0.00 nc ? ? nc nc
79 _00000 ATF-1 100004 (ATF-1) 134 R 6 ACGTCA 10.21 1.70 1.000 0.00 8 2e-02 1.00 1.00 8 2e-02 8.9e-02
80 _00000 LRF-1 I00087 (LRF-1) 134 N 6 ACGTCA 9.51 1.58 1.000 0.00 8 2e-02 1.00 1.00 0 0e+00 8.9e-02
# Factor Model Beq Sns Len Sequence La La/ Lg Ld Lgv &  Srn Spy P p v
81 00000 ASF-1 
00000 MSN4 
_00000 deltaCREB
I00322 (MSN4)
100344 (ASF-1) 
100416 (deltaCREB)
134 R 6 ACGTCA 9.51 1.58 1.000 0.00 8 2e-02 1.00 1.00 00e+00 8.9e-02
82 00000 HBP-1 I00349 (HBP-1) 134 R 6 ACGTCA 9.67 1.61 1.000 0.00 8 2e-02 1 00 1.00 O.Oe+OO 1.7e-01
83 _00000 TREB-1 100410 (TREB-1) 134 N 6 ACGTCA 10.21 1.70 1.000 0.00 8 2e-02 1 00 1.00 8 2e-02 8 9e-02
84 T00968 ATF-1 Q00199 (-) 134 N 6 ACGTCA 10.90 1.82 1.000 0.00 8 2e-02 1.00 1.00 8 2e-02 8.9e-02
85 T00049 ATF 
T00050 ATF1
R00362 () 
R01492 ()
134 N 6 ACGTCA 12.00 2.00 1.000 0.00 nc ? ? nc nc
T00132 c-Jun
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100163 CREB
100164 CREB 
TO0166 deltaCREB 
T00167 CRE-BP1 
100846 TREB-1
T00942 EivF 
T01095 ATF-3
86 T00051 ATF 
TOO354 HBP-1 
T0Q937 HBP-1a 
T00938 HBP-1 b 
T01393 HBP- 
1b(c1)
101394 HBP-1 a(1) 
T01395 HBP- 
1a(c14)
R01562 () 
R01915 ()
134 R 6 a c g t c a  12.00 2.00 1.000 0.00 nc
2alpha
T00930 LEF-1
nc
87 T00605 NF-S R02219 0 135 N 7 YGTCAGC 13.00 1.86 1.000 0.00 nc ? ? nc
88 T00029 AP-1 R00368 0 136 R 4 GTCA 8.00 2.00 1.000 0.00 nc ? ? nc
89 T00320 GCF R021590 141 N 7 SCGSSSC 10.00 1.43 1.000 0.00 nc ? ? nc
90 T00302 GAL4 R00496 0 143 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc
# Factor Model Beq Sns Len Sequence La La/ Lg Ld Lgv Sc Sm Spy
91 T00788 T-Aa R01372 0 143 N 5 GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc
92 T00386 HSTF M00028 (mid c) 149 N 5 AG AAA 7.82 1.56 1.000 0.00 2 9e-01 1.00 1.00 2 9e-01
93 T00802 TCF- 
lalpha
T00803 TCF-
R02248 0 151 N 5 MAMAG 8.00 1.60 1.000 0.00 nc ? ? nc
nc
nc
nc
nc
nc
nc
3.0e-01
nc
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T00999 TCF-1A  
T010Q0 TCF-1B  
TQ1001 TCF-1C  
T 01002 TCF-1 
T01109 TCF-1 
T01979 TCF-1 E 
101981 TCF-1 F 
TQ1982 TCF-1 G
94 T01059 MNB1a 
T02690 Dof2 
T02691 Dof3 
T02692 PBF
R 0 8 4 4 0 0  
R08441 0  
R 08442ft 
R08443 ft
152 N 4 AAAG 8.00 2.00 1.000 0.00 nc ? ? nc nc
95 T00759 S d1 R02860 0 154 N 6 AGGCGG 12.00 2.00 1.000 0.00 nc ? ? nc nc
96 T00913 Yi R03154 0 154 R 10 AGNNNGNGGG 12.00 1.20 1.000 0.00 nc ? ? nc nc
97 T00788 T-Aa Q00168 (-) 156 N 5 GCGGC 6.501 .30  1.000 0.00 2 9e-01 1.00 1.00 O.Oe+OO 2.2e-02
98 T00320 GCF R02159 ft 156 R 7 GSSSCGS 10.00 1.43 1.000 0.00 nc ? ? nc nc
99 T00033 AP- R02121 ft 157 R 8 SSSNKGGG 10.00 1.25 1.000 0.00 nc ? ? nc nc
2alphaA 
T00034 AP-2 
100035 AP- 
2alphaA 
100952 AP-2 
101142 AP-2 
102466 AP- 
2alphaB
1 0 0 1 0 0 2 6 1 ER R04883 0  158 N 6 ggcggg  12.00 2.00 1.000 0.00 nc ? ? nc nc
Factor Model Beg Sns Len Sequence La L^ Lg k  k  &  &  I  &  5ev
101 00000 GCF 100152 (GCF) 159 N 8 g c g g g g c t  m 3 1.39 1.000 0.00 2 1e’ 1.00 1.00 o.oe+oo n e -21
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02
102 T00302 GAL4 R00496 0 161 N 4 GGGG 8.00 2.00 1.000 0.00 nc ? ? nc nc
103 T00788 T-Aq R01372 0 161 N 5 GGGGC 10.00 2.00 1.000 0.00 nc ? ? nc nc
104 T00752 Sd1 R022450 161 N 9 KRGGCKRRK 12.00 1.33 1.000 0.00 nc ? ? nc nc
T00753 Sp1 
T00754 Sp1 
T00755 Sp1 
TQ0757 Sp1 
T00758 Sp1 
T00759 Sp1 
T01228 Sp1
105 T00788 T-Ag R01372 () 166 N 5 tg g g c  10,00 2.00 1.000 0.00 nc ? ? nc nc
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GEMS Launcher Task: M atlnspector: Search for transcription factor binding sites 
working on Ali2hum andeltaprom oter.seq (1 8 3 0  bp)
Please be aware:
Indiv idual binding sites in a prom oter are NEVER suffic ient to  indicate transcrip tional function. Functional assessment of binding sites can be 
carried out by our o ther tools, e.g. M odellnspector. Com parative Genomics. Fram eW orker. BiblioSphere
I f  M atlnspector does not identify a known site, please send an email to  support@ aenom atix.de citing the corresponding paper!
Search Results ( 307 m atches)
M atlnspector Release professional 7 .4 .8 .2 , July 2007 Tue Aug 28 16:56:50  2007
Solution parameters:
Sequence file: Ali2hum andeltaprom oter.seq (1830 bp)
Family matches: yes
M atlnspector library: Matrix Family Library Version 6.3 (March 2007)
Selected groups • ALL vertebrates.lib  (0 .75/O ptim ized)
(core /m atrix  sim)
Inspecting sequence Ali2hum andeltaprom oter (1  - 1830):
Sequence
Fam ily /m atrix  Further Inform ation Opt. _ Str. (red: ci-value > 60
capitals: core sequence)
Position Core Matrix
from - sim. sim.
to
389
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|  VSGREF/PRE.01 Progesterone receptor binding site, IR3 sites 0.84 8 - 26 ( + ) 1.000 0.850 agaaatatgttTG TTcttt
|  V$HOXF/BARX2.01 Barx2, homeobox transcrip tion  factor tha t pre ferentia lly  binds to  paired TAAT m otifs 0.95 27 - 43 (-) 1.000 0.956 ta ttTAATaggtttcct
|  V$BRNF/BRN3.01 Brn-3, POU-IV protein class 0.78 31 - 49 ( + ) 0.750 0.809 aacctatta AAT Atcccat
■  V$HOXF/HOXC13.01 Flomeodomain transcrip tion  facto r HOXC13 0.91 31 - 47 (+ ) 1.000 0.914 aacctatTAAAtatccc
V iH O M F /E N l.O l Homeobox protein engrailed (en-1) 0.77 32 - 44 (-) 1.000 0 .775 ataTTTAataggt
- V$OCTP/OCT1P.01
O ctam er-binding facto r 1, POU-specific 
domain 0.86 38 - 50 ( + ) 1.000 0.864 taaATATcccata
|  V$STAF/STAF.02
Se-Cys tRNA gene transcrip tion activating 
factor 0.82
41 - 63 ( + ) 1.000 0.859 atatCCCAtagtgcaacgttaga
1 V$MYBL/VMYB.04 v-Myb, AMV v-m yb 0.85 51 - 63 (-) 1.000 0.879 tctAACGttgcac
|v$R X R F /R A R  RXR.01 Retinoic acid receptor / retinoid X receptor heterodim er, DR1 sites 0.78 58 - 82 (-) 1.000 0.793 gtcagttccagAGGTcatttctaac
V$NR2F/ARP1.01
Apolipoprotein AI regulatory protein 1, 
NR2F2, DR1 sites 0.82 60 - 84 (-) 1.000 0.898 cagtcagttccagaGGT Catttcta
V$TCFF/TCF11.01 T C F ll/L C R -F l/N r f l homodimers 1.00 63 - 69 (-) 1.000 1.000 GTCAttt
£  VSMYBL/CMYB.02
c-Myb, im portant in hematopoesis, cellu lar 
equiva lent to  avian myoblastosis virus 
oncogene v-m yb
0.96 94 - 106 (-) 1.000 0.971 acTAACtgctgtg
|  V$GREF/ARE.02 Androgene receptor binding site, IR3 sites 0.89 105 - 123 (+) 1.000 0.926 gtagagcttggtGTTCcga
I V$SRFF/SRF.02 Serum response factor 0.84 121 - 139 ( + ) 0.822 0.840 cgacgCAGAtctggtgaga
|  V$ETSF/ETS1.01 c-Ets-1 binding site 0.92 142 - 162 (+) 1.000 0.952 cctgcgcaGGAAgagactcga
V$ZF35/ZNF35.01 Human zinc finger protein ZNF35 0.96 146 - 158 ( + ) 1.000 0.963 cgcaggAAGAgac
f V$BRAC/TBX5.01 T-Box facto r 5 site (TBX5), m utations related to  Holt-Oram syndrome 0.99 162 - 182 ( + ) 1.000 0.995 acatggagcaGGTGtgactag
1 VSPAX3/PAX3.02 Pax-3 paired domain protein 0.85 164 - (-) 1.000 0.867 ctagT CACacctgctccat
390
a p p e n d i c e s
182
|  VSMYOD/E47.01 MyoD/E47 and MyoD/E12 dim ers 0.92 165 - 181 ( +  ) 1.000 0.968 tggaGCAGgtgtgacta
1  VSMEF2/SL1.01
Member of the RSRF (related to  serum 
response facto r) protein fam ily  from  
Xenopus laevis
0.84 173 - 195 (-) 1.000
■ ■ ■
0.848 taaatcaCTATcgctagtcacac
|  V$GATA/GATA1.06
Complex o f Lmo2 bound to  Tal-1, E2A 
proteins, and GATA-1, half-s ite  2 0.96
180 - 
192 ( + ) 1.000 0.960 tagcGATAgtgat
V$GFI1/GFI1.02 Growth facto r independence 1 0.90 182 - 196 (-) 1.000 0.916 ttaAATCactatcgc
VSPARF/TEF.Ol Thyrotroph ic em bryonic factor 0.85 184 - 200 ( +  ) 0.772 0.864 gatagtgatTTAAtgga
|v$H O XC /PBX HOXA9.01 PBX - HOXA9 binding site 0.79 185 - 201 (+ ) 1.000 0.838 atagTGATttaatggat
V$PARF/TEF HLF.01 Thyrotroph ic em bryonic factor /  hepatic leukemia facto r 0.78
185 - 
201 (-)
0.784 0.784 atccaTTAAatcactat
|  V$HOXF/HOXC13.01 Homeodomain transcrip tion factor HOXC13 0.91 186 - 202 (-) 1.000 0.945 aatccatTAAAtcacta
V$HOMF/EN1.01 Homeobox protein engrailed (en-1) 0.77 189 - 201 ( + ) 1.000 0.773 tgaTTTAatggat
J  V$HOXF/BARX2.01 Barx2, homeobox transcrip tion factor that pre ferentia lly  binds to paired TAAT m otifs 0.95
190 - 
206 ( + ) 1.000 0.960 gattTAATggatttggg
|  V$CLOX/CLOX.01 Cut-like homeo box 0.81 191 - 209 ( - ) 0.804 0.812 gggcccaaATCCattaaat
V$HNF6/HNF6.01 Liver enriched Cut - Homeodomain transcrip tion factor HNF6 (ONECUT) 0.82
192 - 
208 ( - ) 0.833 0.887 ggcccaaaTCCAttaaa
|  V$NKXH/HMX2.01 H m x2/N kx5-2 homeodomain transcrip tion factor 0.83 262 - 276 ( - ) 1.000 0.936 gggCTTAagagattc
|  V$NKXH/HMX2.01 Hm x2/Nkx5-2 homeodomain transcrip tion factor 0.83
265 - 
279 ( +  ) 1.000 0.913 tctCTTAagcccagg
|  V$CHRF/CHR.01 Cell cycle gene homology region (CDE/CHR tandem  elements regulate cell
279 -0 92 291 ( + ) 1.000 0.956
gagtTTGAaacca
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I cycle dependent repression) r
|  VSSORY/SOX5.01 Sox-5 0.87 293 - 309 ( + ) 1.000 0.871 cctggaCAATattgtga
f V$FKHD/FHXB.01 Fork head homologous X binds DNA w ith a dual sequence specific ity (FHXA and FHXB) 0.83
297 - 
313 (-) 0.909
L _ _ —
0.840 gatctcACAAtattgtc
|  V$OCT1/OCT1.05 O ctam er-binding facto r 1 0.89 313 - 327 ( + ) 0.950 0.910 ccCATCtcaattttt
|  V$SP1F/BTEB3.01 Basic transcrip tion  e lem ent (BTE) binding protein, BTEB3, FKLF-2 0.93
333 - 
347 ( + ) 1.000 0.934 gagatGGAGtctcgc
V$PAX5/PAX5.02 B-cell-specific activa to r protein 0.73 334 - 362 (-) 1.000 0.739 agcctgggcgacagAGCGagactccatct
V$AHRR/AHR.01 Aryl hydrocarbon /  d ioxin receptor 0.78 354 - 378 ( + ) 0.750 0.803 gcccaggctgGAGTgcaatggaacg
V$HEAT/HSF2.01 Heat shock factor 2 0.88 361 - 385 ( + ) 1.000 0.880 ctggagtgcaatgGAACgatctcgg
|  V$PURA/PURALPHA.01 Purine-rich element binding protein A 0.97 394 - 406 (-) 1.000 0.985 ggAGGCggaggtt
|  VSGZF1/GZF1.01 GDNF-inducible zinc finger protein 1 (ZNF336) 0.73
450 - 
462 ( ') 1.000 0.760 TGCGcctgtaatc
V$AHRR/AHRARNT.01 Aryl hydrocarbon receptor /  Arnt heterodim ers 0.92
451 - 
475 (-) 1.000 0.946 aagcgtagtggCGTGcgcctgtaat
V$ZF5F/ZF5.01 Zinc finger /  POZ domain transcrip tion facto r 0.95
455 - 
465 (-) 1.000 0.960 gcgtGCGCctg
|  VSHESF/HES1.01 Drosophila hairy and enhancer o f split homologue 1 (HES-1) 0.92
456 - 
470 (-) 1.000 0.932 tagtggcGTGCgcct
l  V$SORY/HMGIY.01
HMGI(Y) h igh-m ob ility-group protein I (Y), 
arch itectural transcrip tion factor 
organizing the fram ework of a nuclear 
protein-DNA transcrip tional complex
0.92 471 - 487 (-) 1.000 0.921 caaaAATTagccaagcg
|  V$CLOX/CUT2.01 Cut repeat I I 0.67 472 - 490 ( + ) 0.750 0.687
gcttggctaATTTttgtat
■  V&MEF2/MEF2.04 Myocyte-specific enhancer factor 2 0.80 481 - (-) 1.000 0.829 atttctactaaAAATacaaaaat
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I 5 0 3
I  V $ B C L 6 /B C L 6 .0 2
P O Z /z in c  f in g e r  p ro te in , t ra n s c r ip t io n a l 
re p re s s o r , t ra n s lo c a tio n s  o b s e rv e d  in 
d iffu s e  la rg e  cell ly m p h o m a
0 .7 7 4 9 0  '  ( +  ) 5 0 6  K } 1 .0 0 0 0 .8 3 5 t tt t ta g T A G A a a tg g g
j  V $ R U S H /S M A R C A 3 .0 1
S W I/S N F  re la te d , m a tr ix  a s s o c ia te d , a c tin  
d e p e n d e n t re g u la to r  o f c h ro m a tin ,  
s u b fa m ily  a , m e m b e r  3
0 .9 6 4 9 7  ’  ( - )  5 0 7  1 } 1 .0 0 0 0 .9 6 1 c c C C A T ttc ta
|v $ R X R F / V D R  R X R .0 4
B ip a r tite  b in d in g  s ite  o f V D R /R X R  
h e te ro d im e rs , D R 3  s ite s
0 .7 9
5 0 5  - 
5 2 9 ( - )
1 .0 0 0 0 .8 3 1 c a g c c tG G T C a a c a tg g tg a a a c c c
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V $ N R F 1 /N R F 1 .0 1
N u c le a r  re s p ira to ry  fa c to r  1 (N R F 1 ) , b Z IP  
tra n s c r ip tio n  fa c to r  th a t  ac ts  on n u c le a r  
g e n e s  e n c o d in g  m ito c h o n d r ia l p ro te in s
0 .7 8
9 4 3  -  
9 5 9 ( - )
1 .0 0 0 0 .8 2 9 cccG CG Cccg eg t t tc t
C o re  p ro m o te r-b in d in g  p ro te in  (C P B P ) w ith  
V $ Z B P F /Z F 9 ._ 0 1  3 Krueppe| .ty pe zin c  f in g e rs 0 .8 7
9 4 3  - 
9 6 5 ( - )
1 .0 0 0 0 .8 9 9 c c a g c tc C C G C g c c c g c g tttc t
V S N R F 1 /N R F 1 .0 1
N u c le a r re s p ira to ry  fa c to r  1 (N R F 1 ) , b Z IP  
tra n s c r ip tio n  fa c to r  th a t  ac ts  on n u c le a r  
g e n e s  e n c o d in g  m ito c h o n d r ia l p ro te in s
0 .7 8
9 4 4  - 
9 6 0 ( +  )
0 .7 5 0 0 .7 8 6 g aa A C G C g g g c g c g g g a
|  V & E 2 F F /E 2 F .0 3
E2F, in v o lv ed  in cell cyc le  re g u la tio n ,  
in te ra c ts  w ith  Rb p l0 7  p ro te in
0 .8 5
9 4 8  -  
9 6 4 ( +  )
1 .0 0 0 0 .9 1 6 c g c g g G C G C g g g a g c tg
V S N R F 1 /N R F 1 .0 1
N u c le a r re s p ira to ry  fa c to r  1 (N R F 1 ) , b Z IP  
tra n s c r ip tio n  fa c to r  th a t  ac ts  on n u c le a r  
g en e s  e n c o d in g  m ito c h o n d r ia l p ro te in s
0 .7 8
9 4 9  - 
9 6 5 ( - )
0 .7 5 0 0 .7 8 4 ccaG C TC ccgcgcccgc
V S Z F 5 F /Z F 5 .0 1
Z in c  f in g e r  /  PO Z d o m a in  tra n s c r ip tio n  
fa c to r
0 .9 5
9 4 9  - 
9 5 9 ( +  )
1 .0 0 0 0 .9 5 7 gcg g G C G C g g g
|  V S S T A F /Z N F 7 6  1 4 3 .0 1
Z N F 1 4 3  is th e  h u m a n  o rth o lo g  o f X e n o p u s  
S ta f, Z N F 7 6  is a D N A  b in d in g  p ro te in  
re la te d  to  Z N F 1 4 3  and  S ta f
0 .7 6
9 7 1  -  
9 9 3 ( - )
0 .8 0 9 0 .7 6 4 c c g a C C C C g c a g a c c c g g g c g tc
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|  V S E K L F /K K L F .O l K id n e y -e n r ic h e d  k ru p p e l- l ik e  fa c to r , K L F15 0 .9 1
9 8 6  - 
1 0 0 2 ( +  )
1 .0 0 0 0 .9 5 0 g g g g tc G G G G a g ta g c g
|  V $ D E A F /N U D R .0 1
N U D R  (n u c le a r  D E A F -1  re la te d  
t ra n s c r ip t io n a l re g u la to r  p ro te in )
0 .7 3
9 8 7  -  
1 0 0 5 ( +  )
1 .0 0 0 0 .7 3 1 g g g T C G G g g a g ta g c g tc c
|  V $ S P 1 F /B T E B 3 .0 1
B as ic  t ra n s c r ip t io n  e le m e n t  (B T E ) b in d in g  
p ro te in , B T E B 3 , F K L F -2
0 .9 3
9 8 9  -  
1 0 0 3 ( +  )
1 .0 0 0 0 .9 3 8 g tc g g G G A G ta g c g t
j V $ C R E B /T A X C R E B .0 2 T a x /C R E B  c o m p le x 0 .7 1
9 9 1  -  
1 0 1 1 ( - )
0 .7 5 0 0 .7 1 1 c c g g c cG G A C g ctac tccccg
|  V $ E T S F /C E T S 1 P 5 4 .0 1 c - E t s - l ( p 5 4 ) 0 .9 2
9 9 3  -  
1 0 1 3 ( - )
1 .0 0 0 0 .9 2 2 c tc c g g C C G G a c g c ta c tc c c
|  V $ W H N F /W H N .0 1
W in g e d  h e lix  p ro te in , in v o lv e d  in h a ir  
k e ra t in iz a tio n  and  th y m u s  e p ith e liu m  
d if fe re n t ia t io n
0 .9 5
9 9 6  -  
1 0 0 6 ( - )
1 .0 0 0 0 .9 7 5 c g g A C G C ta c t
V & Z B P F /Z F 9 .0 1
C o re  p ro m o te r-b in d in g  p ro te in  (C P B P ) w ith  
3 K ru e p p e l-ty p e  z in c  f in g e rs
0 .8 7
1 0 1 0  - 
1 0 3 2 ( +  )
1 .0 0 0 0 .9 1 5 g g a g a g c C C G C a c c tc g a g g a g c
|  V $ C D E F /C D E .0 1
C ell c y c le -d e p e n d e n t e le m e n t ,  C D F -1  
b in d in g  s ite  (C D E /C H R  ta n d e m  e le m e n ts  
re g u la te  cell cyc le  d e p e n d e n t re p re s s io n )
0 .8 7
1 0 3 9  - 
1 0 5 1 ( +  )
1 .0 0 0 0 .8 7 0 a g g a C G C G g tg tc
|  V $ W H N F /W H N .0 1
W in g e d  h e lix  p ro te in , in v o lv e d  in h a ir  
k e ra t in iz a tio n  and  th y m u s  e p ith e liu m  
d if fe re n t ia t io n
0 .9 5
1 0 3 9  -  
1 0 4 9 ( +  )
1 .0 0 0 0 .9 6 5 a g g A C G C g g tg
|  V $ W H N F /W H N .0 1
W in g e d  h e lix  p ro te in , in v o lv e d  in h a ir  
k e ra t in iz a tio n  and  th y m u s  e p ith e liu m  
d if fe re n t ia t io n
0 .9 5
1 0 5 4  -  
1 0 6 4 ( - )
1 .0 0 0 0 .9 5 5 g a g A C G C g g tc
V $ Z B P F /Z B P 8 9 .0 1 Z in c  f in g e r  tra n s c r ip tio n  fa c to r  Z B P -8 9
—
0 .9 3
1 0 5 4  - 
1 0 7 6 ( +  )
1 .0 0 0 0 .9 3 8 g a c c g c g tc tC C C C c a tc tg c tc
V $ Z B P F /Z N F 2 1 9 .0 1 K ru p p e l- lik e  z inc  f in g e r  p ro te in  2 1 9 0 .9 1
1 0 5 7  - 
1 0 7 9 ( + )
1 .0 0 0 0 .9 1 2 c g c g tc tC C C C c a tc tg c tc tg c
V $ A P 4 R /T A L 1 B E T A H E B .0 1 T a l - lb e t a /H E B  h e te ro d im e r 0 .8 6
1 0 6 2  - 
1 0 7 8 ( - )
1 .0 0 0 0 .8 9 9 c a g a g C A G A tg g g g g a g
V $ Y Y 1 F /Y Y 1 .0 1 Y in  and  Y ang  1 a c tiv a to r  s ites
r ...... .
0 .8 2
1 0 6 2  - 
1 0 8 0 ( +  )
1 .0 0 0 0 .8 3 8 ctcccC C A T c tg c tc tg c t
1  V S N E U R /N E U R O G .O l N e u ro g e n in  1 and  3 ( n g n l / 3 )  b in d in g  s ite s 0 .9 2 1 0 6 4  - ( +  ) 1 .0 0 0 0 .9 6 2 cccC C A Tctgctc
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1 0 7 6
V $ E 2 F F /E 2 F .0 2
I P
E 2F , in v o lv e d  in cell cy c le  re g u la t io n ,  
in te ra c ts  w ith  Rb p l 0 7  p ro te in
0 .8 4
1 0 7 7  -  
1 0 9 3 ( - )
1 .0 0 0 0 .8 8 6 c g c tg tc g c C A A A a g c a
V S E 2 F F /E 2 F 4  D P I . 01 E 2 F -4 /D P -1  h e te ro d im e r ic  c o m p le x 0 .8 4
1 0 7 8  - 
1 0 9 4 ( +  )
0 .7 6 9 0 .8 6 8 g c tt ttG G C G a c a g c g t
| V S E 2 F F /R B  E 2F 1  D P I . 0 1 R B /E 2 F -1 /D P -1  h e te ro tr im e r ic  c o m p le x 0 .7 1
1 0 8 0  - 
1 0 9 6 ( +  )
0 .7 6 5 0 .7 5 7 ttt tg G C G A c a g c g tc c
j V $ W H N F /W H N .0 1 W in g e d  h e lix  p ro te in , in v o lv e d  in h a ir  k e ra t in iz a t io n  a n d  th y m u s  e p ith e liu m  
d if fe re n t ia t io n
0 .9 5
1 0 8 7  -  
1 0 9 7 ( - )
1 .0 0 0 0 .9 8 3 g g g A C G C tg tc
V S N R 2 F /H N F 4 .0 2 H e p a tic  n u c le a r  fa c to r  4 ,  D R 2  s ites 0 .7 6
1 0 9 4  - 
1 1 1 8 ( ' )
1 .0 0 0 0 .8 0 0 c g tc c tg g c c g A A A G g c c g a c g g g a
V $ G L IF /G U 3 .0 1 G L I-K ru p p e l fa m ily  m e m b e r  G L I3 0 .8 6
1 1 6 5  - 
1 1 7 9 ( + )
0 .8 2 2 0 .8 6 6 g g g a C C T C c g a g g a g
|  V $ M A Z F /M A Z .0 1 M yc  a s s o c ia te d  z in c  f in g e r  p ro te in  (M A Z ) 0 .9 0
1 1 7 0  - 
1 1 8 2 ( +  )
1 .0 0 0 0 .9 3 0 c tc c G A G G a g a g c
|  V S D M T F /D M P 1 .0 1
C yc lin  D - in te ra c tin g  m y b -l ik e  p ro te in , 
D M T F 1  - cyc lin  D b in d in g  m y b -lik e  
t ra n s c r ip t io n  fa c to r  1
0 .8 2
1 1 9 3  - 
1 2 0 5 ( +  )
1 .0 0 0 0 .8 3 2 g g cccG G A T tccc
~ V $ N O L F /O L F 1 .0 1 O lfa c to ry  n e u ro n -s p e c if ic  fa c to r 0 .8 2
1 1 9 6  - 
1 2 1 8 ( +  )
1 .0 0 0 0 .8 4 6 c c g g a tT C C C c g a g g c g c cc g a g
V & A P 2 F /A P 2 .0 2 A c tiv a to r  p ro te in  2 a lp h a 0 .9 2
1 2 0 0  - 
1 2 1 4 ( - )
1 .0 0 0 0 .9 3 1 g g c G C C T c g g g g a a t
|  V $ D E A F /N U D R .0 1
N U D R  (n u c le a r  D E A F -1  re la te d  
t ra n s c r ip t io n a l re g u la to r  p ro te in )
0 .7 3
1 2 0 2  -  
1 2 2 0 ( - )
1 .0 0 0 0 .7 4 3 c a c T C G G g cg c c tc g g g g a
|  V $ H IC F /H IC 1 .0 1
H y p e r m e th y la te d  in c a n c e r 1, 
t ra n s c r ip t io n a l re p re s s o r c o n ta in in g  fiv e  
K ru p p e l- lik e  C 2 H 2  z in c  f in g e rs , fo r  o p t im a l 
b in d in g  m u lt ip le  b in d in g  s ites  a re  re q u ire d .
0 .9 3
1 2 2 4  -  
1 2 3 6 ( - )
1 .0 0 0 0 .9 8 5 ag g gc l"G C C cgca
V $ E G R F /C K R O X .0 1 C o lla g e n  k ro x  p ro te in  (z in c  f in g e r  p ro te in  
6 7  - z fp 6 7 )
0 .8 8
1 2 2 7  - 
1 2 4 3 ( - )
1 .0 0 0 0 .8 8 7 g g cg G G G A g g g c tg c cc
1 V $ S P 1 F /S P 1 .0 1 S tim u la tin g  p ro te in  1 , u b iq u ito u s  z inc  
f in g e r  tra n s c r ip t io n  fa c to r 0 .8 8
1 2 2 9  - 
1 2 4 3 ( - )
0 .8 0 7 0 .8 9 1 g g c g G G G A g g g c tg c
4 0 0
A P P E N D IC E S
|  V $ E K L F /K K L F .0 1 K id n e y -e n r ic h e d  k ru p p e l- l ik e  fa c to r , K L F 15 0 .9 1
1 2 3 0  -  
1 2 4 6 ( - )
1 .0 0 0 0 .9 3 3 g c a g g c G G G G a g g g c tg
|  V S M Y O D /M Y O D .O l M y o g e n ic  re g u la to ry  fa c to r  M y o D  ( m y f3 ) 0 .8 8
1 2 3 4  -  
1 2 5 0
( - ) 1 .0 0 0 0 .9 2 2 c c tG G C A g g c g g g g a g g
|  V S M Z F 1 /M Z F 1 .0 1 M y e lo id  z in c  f in g e r  p ro te in  M Z F 1 0 .9 9
1 2 3 4  - 
1 2 4 2
( - ) 1 .0 0 0 0 .9 9 1 g c G G G G a g g
: V $ A P 4 R /A P 4 .0 1 A c t iv a to r  p ro te in  4 0 .8 5
1 2 4 8  - 
1 2 6 4
( - ) 1 .0 0 0 0 .8 7 4 g g g g a C A G C g g c g g c c t
|  V $ C R E B /A T F 6 .0 2
A c tiv a tin g  tra n s c r ip t io n  fa c to r  6 , m e m b e r  
o f b -z ip  fa m ily , in d u c e d  by  ER s tre s s
0 .8 5
1 2 5 6  - 
1 2 7 6
( - ) 1 .0 0 0 0 .8 8 7 g g g a c c a G A C G tg g g g a c a g c
|  V $ M Z F 1 /M Z F 1 .0 1 M y e lo id  z in c  f in g e r  p ro te in  M Z F 1 0 .9 9
1 2 5 8  -  
1 2 6 6
( - ) 1 .0 0 0
■ ■ ■
1 .0 0 0 g tG G G G a c a
|  V S H IF F /H IF 1 .0 2
H y p o x ia  in d u c ib le  fa c to r , bH LH  /  PAS  
p ro te in  fa m ily
0 .9 3
1 2 6 2  -  
1 2 7 4
( - ) 1 .0 0 0 0 .9 6 2 g ac c a g a C G T G g g
|  V $ S M A D /S M A D 3 .0 1
S m a d 3  t ra n s c r ip t io n  fa c to r  in v o lv e d  in  
T G F -b e ta  s ig n a lin g
0 .9 9
1 2 6 7  -  
1 2 7 5
( +  ) 1 .0 0 0 0 .9 9 3 G T C T g g tc c
V & A H R R /N X F  A R N T .0 1
b H L H -P A S  ty p e  tra n s c r ip t io n  fa c to rs  
N X F /A R N T  h e te ro d im e r
0 .9 0
1 2 6 8  -  
1 2 9 2
( - ) 1 .0 0 0 0 .9 4 4 g c g g g a a g a g g C G T G g g g g a c c a g a
^ V S E G R F /W T 1 .0 1 W ilm s  T u m o r  S u p p re s s o r 0 .9 2
1 2 6 8  - 
1 2 8 4
( - ) 1 .0 0 0 0 .9 8 7 a g g c g T G G G g g a c c a g a
j; V $ E G R F /N G F IC .0 1 N e rv e  g ro w th  fa c to r - in d u c e d  p ro te in  C 0 .8 0
1 2 7 0  -  
1 2 8 6
( - ) 1 .0 0 0 0 .8 8 7 a g a g G C G T g g g g g a c c a
|  V $ E T S F /G A B P .0 1 G A B P: G A  b in d in g  p ro te in 0 .8 6
1 2 7 7  - 
1 2 9 7
( - ) 1 .0 0 0 0 .9 1 2 c a g a tg c g G G A A g a g g c g tg g
|  V $ S T A T /S T A T I .0 1
S ig n a l t ra n s d u c e r  and  a c t iv a to r  o f 
t ra n s c r ip tio n  1
0 .7 7
1 2 8 0  -  
1 2 9 8 ( - )
1 .0 0 0 0 .7 8 3 c c a g a tg c g G G A A g a g g c g
|  V S E 2 F F /E 2 F 1  D P I . 01 E 2 F -1 /D P -1  h e te ro d im e r ic  c o m p le x 0 .8 1
1 2 8 1  -  
1 2 9 7 ( - )
0 .7 8 2 0 .8 4 6 c a g a T G C G g g a a g a g g c
V $ Z F 3 5 /Z N F 3 5 .0 1 H u m a n  z in c  f in g e r  p ro te in  Z N F 3 5 0 .9 6
1 2 8 1  - 
1 2 9 3 ( - )
1 .0 0 0 0 .9 6 1 tg c g g g A A G A g g c
V $ P A X 6 /P A X 6 .0 1 P a x -6  p a ire d  d o m a in  b in d in g  s ite 0 .7 5
1 2 8 4  - 
1 3 0 2 ( +  )
0 .7 7 9 0 .7 5 3 tc ttc C C G C a tc tg g tc c c
4 0 1
A P P E N D IC E S
|  V S S R F F /S R F .0 3 5 e ru m  re s p o n s e  fa c to r 0 .7 9 1 2 8 5  - 1 3 0 3 ( +  ) 0 .8 0 3 0 .8 0 1 c ttc c c g c a tC T  G G tc c c a
V $ A P 4 R /P A R A X IS .0 1
P a ra x is  (T C F 1 5 ) ,  m e m b e r  o f  th e  T w is t  
s u b fa m ily  o f C lass  B b H LH  fa c to rs , fo rm s  
h e te ro d im e rs  w ith  E 1 2
0 .8 6
1 2 8 6  -  
1 3 0 2 ( - )
0 .8 8 2 0 .8 9 1 g g g A C C A g a tg c g g g a a
I  V S D M T F /D M P l.O l
I
C yclin  D - in te ra c t in g  m y b - l ik e  p ro te in ,  
D M T F 1  - cyc lin  D  b in d in g  m y b -l ik e  
t ra n s c r ip t io n  fa c to r  1
0 .8 2
1 2 8 6  - 
1 2 9 8 ( + ) 0 .8 0 1 0 .8 3 2 ttc c c G C A T c tg g
| V $ N E l)R /N E U R O G .0 1 IM eurogen in  1 an d  3 ( n g n l / 3 )  b in d in g  s ite s 0 .9 2 1 2 8 8  -  1 3 0 0 ( + ) 0 .8 3 3 0 .9 3 1 c c c G C A T c tg g tc
V & P A X 5 /P A X 5 .0 1 B -c e ll-s p e c ific  a c t iv a to r  p ro te in 0 .7 9
1 2 9 4  - 
1 3 2 2 ( +  ) 0 .8 5 7 0 .8 1 8 tc tg g tC C C A c g g tg g a g g c g c g g g g c g a
V S E G R F /E G R 1 .0 2 E G R 1 , e a r ly  g ro w th  re s p o n s e  1 0 .8 6
1 3 0 2  - 
1 3 1 8 ( +  ) 0 .8 4 2 0 .8 9 4 c a c g g tg g A G G C g c g g g
• V $ Z B P F /Z F 9 .0 1
C o re  p ro m o te r -b in d in g  p ro te in  (C P B P ) w ith  
3 K ru e p p e l-ty p e  z in c  f in g e rs
0 .8 7
1 3 0 2  - 
1 3 2 4 ( - )
1 .0 0 0 0 .8 8 4 cc tc g c cC C G C g c c tcc a c c g tg
|  V $ S P 1 F /S P 1 .0 2
S tim u la tin g  p ro te in  1 , u b iq u ito u s  z inc  
f in g e r  tra n s c r ip t io n  fa c to r
0 .8 5
1 3 0 8  - 
1 3 2 2 ( +  )
0 .7 5 0 0 .8 6 3 g g a g G C G C g g g g c g a
V $ P L A G /P L A G 1 .0 1
P le o m o rp h ic  a d e n o m a  g e n e  (P L A G ) 1, a 
d e v e lo p m e n ta l^  re g u la te d  C 2 H 2  z in c  
f in g e r  p ro te in
0 .8 8
1 3 0 9  - 
1 3 2 9 ( +  )
1 .0 0 0 0 .8 8 1 G A G G c g c g g g g c g a g g g c c tc
|  V $ E B O X /M Y C M A X .0 3 M Y C -M A X  b in d in g  s ites 0 .9 1
1 3 1 0  - 
1 3 2 2 (-) 1 .0 0 0 0 .9 1 9 tcg cc c C G C G cc t ....... I
|  V $ M A Z F /M A Z .0 1 M yc a s s o c ia te d  z in c  f in g e r  p ro te in  (M A Z ) 0 .9 0
1 3 1 0  - 
1 3 2 2 ( +  )
0 .8 6 6 0 .9 1 0 a g g c G C G G g g c g a
V $ A H R R /A H R A R N T .0 1
A ry l h y d ro c a rb o n  re c e p to r  /  A rn t  
h e te ro d im e rs
0 .9 2
1 3 2 4  - 
1 3 4 8 ( +  )
1 .0 0 0 0 .9 5 3 g g c c tc a c g c g C G T G c c c a c g g tc g
|  V S H E S F /H E L T .0 1 H e y - lik e  b H L H -tra n s c r ip t io n a l re p re s s o r 0 .9 1
1 3 2 5  - 
1 3 3 9 ( +  )
1 .0 0 0 0 .9 2 2 g cc tC A C G c g c g tg c
|  V S H E S F /H E L T .0 1 H e y -lik e  b H L H -tra n s c r ip t io n a l re p re s s o r 0 .9 1
1 3 2 8  - 
1 3 4 2 (-) 1 .0 0 0 0 .9 6 1 tg g g C A C G c g c g tg a
V $ N R F 1 /N R F 1 .0 1
N u c le a r  re s p ira to ry  fa c to r  1 (N R F 1 ) ,  b Z IP  
tra n s c r ip tio n  fa c to r  th a t  a c ts  on  n u c le a r
0 .7 8
1 3 2 8  - 
1 3 4 4 (-) 0 .7 5 0 0 .8 3 4 c g tG G G C a c g c g c g tg a
4 0 2
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fgenes encoding m itochondria l proteins
v' VSNRF1/NRF1.01
!
Nuclear resp ira tory fac to r 1 (NRF1), bZIP 
transcrip tion  fac to r th a t acts on nuclear 
genes encoding m itochondria l proteins
0.78 1329 - 1345 ( + ) 1.000 0.842 cacGCGCgtgcccacgg
|  V$EBOX/MYCMAX.03 MYC-MAX binding sites 0.91 1330 - 1342 (-) 1.000 0.921 tgggcaCGCGcgt
V$PAX5/PAX5.01 B-cell-specific activa to r protein 0.79
1333 - 
1361 ( + ) 0.857 0.804 cgcgtgCCCAcggtcggggggcgtccttg
V$ZBPF/ZNF219.01 Kruppel-like  zinc finger protein 219 0.91
1338 - 
1360 (-) 1.000 0.946 aaggacgCCCCccgaccgtgggc
! VSEGRF/EGR1.02 EGR1, early grow th response 1 0.86
1343 - 
1359 ( + ) 1.000 0.868 cggtcgggGGGCgtcct
|  VSWHNF/WHN.Ol
Winged helix protein, involved in hair 
kera tin iza tion and thym us epithelium  
d iffe ren tia tion
0.95 1349 - 1359 (-) 1.000 0.953 aggACGCcccc
|  V$SF1F/FTF.01
Alpha ( l) - fe to p ro te in  transcrip tion  facto r 
(FTF), liver receptor hom ologue-1 (LRH-1)
0.94 1353 - 
1365 (-) 1.000
0.951 cgtcCAAGgacgc
V$AHRR/NXF ARNT.01 bHLH-PAS type transcrip tion  factors NXF/ARNT heterodim er 0.90
1370 - 
1394 (-) 1.000 0.916 gggtggagaccCGTGggagaggacc
V$ZBPF/ZBP89.01 Zinc finger transcrip tion  facto r ZBP-89 0.93 1382 - 1404 ( + ) 1.000 0.968 cgggtctccaCCCCccgccctcc
|iV$ZBPF/ZN F219.01 Kruppel-like zinc finger protein 219 0.91 1385 - 1407 (+ ) 1.000
■■■■■I
0.986
■ ■ ■ ■
gtctccaCCCCccgccctccggc
|  VffcSPlF/TIEG.Ol
TGFbeta-inducible early gene (TIEG) /  
Early growth response gene alpha 
(EGRalpha)
0.83 1386 - 1400 (-) 1.000 0.858 ggcGGGGggtggaga
f  VSEGRF/WT1.01 Wilms Tum or Suppressor 0.92 1387 - 1403 (-) 0.953 0.963 gagggCGGGgggtggag
|  V$EKLF/KKLF.01 Kidney-enriched kruppel-like  factor, KLF15 0.91 1387 - 1403 (-) 1.000 0.945 gagggcGGGGggtggag
|  V$SP1F/SP1.01 Stim ula ting protein 1, ubiquitous zinc finger transcrip tion  factor 0.88
1391 - 
1405 (-) 1.000
0.934 cggaGGGCggggggt
4 0 3
A p p e n d ic e s
1  V$PURA/PURALPHA.01 Purine-rich e lem ent b inding protein A 0.97 1392 - 1404 (-) 1.000 0.974 ggAGGGcgggggg
|  V$AP2F/AP2.01 A ctiva tor pro tein  2 0.90 1396 - 1410 (-) 0.881 0.933 gtcGCCGgagggcgg
V$NRF1/NRF1.01
Nuclear resp ira tory fac to r 1 (NRF1), bZIP 
transcrip tion  fac to r th a t acts on nuclear 
genes encoding m itochondria l proteins
0.78 1422 - 1438 (-) 1.000 0.797 gcaGCGCgcgcgtccca
S VSNRF1/NRF1.01
Nuclear resp ira tory fac to r 1 (NRF1), bZIP 
transcrip tion  fac to r th a t acts on nuclear 
genes encoding m itochondria l proteins
0.78 1423 - 1439 ( + ) 0.750 0.788 gggACGCgcgcgctgcg
|  V$WHNF/WHN.01
Winged helix protein, involved in hair 
kera tin iza tion  and thym us epithelium  
d iffe ren tia tion
0.95 1423 - 
1433 ( + ) 1.000 0.952 gggACGCgcgc
VSZF5F/ZF5.01
Zinc finger /  POZ dom ain transcrip tion  
facto r 0.95
1425 - 
1435 (-) 1.000 0.966 gcgcGCGCgtc
|  VSHESF/HES1.01 Drosophila hairy and enhancer o f split homologue 1 (HES-1) 0.92
1426 - 
1440 (-) 0.944 0.924 ccgcagcGCGCgcgt
V$ZF5F/ZF5.01 Zinc finger /  POZ dom ain transcrip tion factor 0.95
1428 - 
1438 ( + ) 1.000 0.960 gcgcGCGCtgc
V$P53F/P53.05 Tum or suppressor p53 0.78 1438 - 1460 (-) 0 .800 0.799 aaatCAAAaccaggacttggccg
|  V$IRFF/IRF7.01 In te rfe ron  regula tory facto r 7 (IRF-7) 0.86 1445 - 1465 (-) 1.000 0.877 gagtGAAAtcaaaaccaggac
V$GFI1/GFI1.02 Growth facto r independence 1 0.90 1448 - 1462 (-) 1.000 0.906 tgaAATCaaaaccag
|  V$PRDF/PRDM1.01 PRDI binding facto r 1 0.81 1449 - 1467 (-) 1.000 0.835 gggagtGAAAtcaaaacca
I  V$IRFF/IRF4.01 In te rfe ron  regula tory facto r (IRF)-re lated 
protein (NF-EM5, PIP, LSIRF, ICSAT) 0.94
1451 - 
1471 (-) 1.000 0.959 ggttgggagtGAAAtcaaaac
I  V $ N F K B /N F K A P P A B 6 5 .0 1 NF-kappaB (p65) 0.87 1480 - 1492 ( + ) 1.000 0.902 cgaggaggTTCCa
|  V$ETSF/SPIB.01 Spi-B transcrip tion facto r (S p i- l/P U .l related) 0.88
1497 - 
1517 ( + ) 1.000 0.944 cacaaacaGGAAgaagagaag
4 0 4
a p p e n d i c e s
VSEVI1/EVI1.07 Evi-1 zinc finge r p ro te in , ca rboxy-te rm ina l zinc finger dom ain 0.90
1502 - 
1518 ( + ) 1.000 0.913 acaggAAGAagagaagg
V$MOKF/MOK2.02 R ibonucleoprotein associated zinc finger p ro tein  MOK-2 (hum an) 0.98
1511 - 
1531
1
(-) 1.000 0.984 cagcactccagggCCTTctct
V$THAP/THAP1.01 THAP dom ain conta in ing, apoptosis associated protein 0.90
1525 - 
1535 ( + ) 1.000 0.940 agtgctGGCAg
VSMYOD/MYOD.Ol Myogenic regu la tory fac to r MyoD (m yf3 ) 0.88 1528 - 1544 ( + ) 1.000 0.881 gctGGCAgagggagtgt
VSSP1F/BTEB3.01 Basic transcrip tion  e lem ent (BTE) binding pro te in , BTEB3, FKLF-2 0.93
1533 - 
1547 ( + ) 1.000 0.958 cagagGGAGtgtcat
V$TEAF/TEAD.01
TEA dom ain-conta in ing factors, 
transcrip tiona l enhancer factors 1 ,3,4,5 0.90
1542 - 
1554 ( + ) 1.000 0.921 tgtCATTcccagc
VSIKRS/IK1.01
Ikaros 1, potentia l regu la tor o f lym phocyte 
d iffe ren tia tion 0.92
1543 - 
1555 (-) 1.000 0.937 tgctGGGAatgac
V$EKLF/KKLF.01 Kidney-enriched kruppe l-like  facto r, KLF15 0.91 1574 - 1590 ( + ) 1.000 0.939 cgggccGGGGagggagc
V$EGRF/CKROX.01 Collagen krox protein (zinc finger protein 67 - zfp67) 0.88
1577 - 
1593 ( + ) 1.000 0.905 gccgGGGAgggagcagc
V$SP1F/SP1.01 S tim u la ting  protein 1, ubiquitous zinc finger transcrip tion  facto r 0.88
1577 - 
1591 ( + ) 0.807 0.887 gccgGGGAgggagca
V$NRSF/NRSF.01 N euron-restrictive  silencer facto r 0.69 1588 - 1608 (+) 1.000 0.744 agcAGCAgcgcgggcaccctc
VSNRF1/NRF1.01
Nuclear resp ira tory facto r 1 (NRF1), bZIP 
transcrip tion  facto r th a t acts on nuclear 
genes encoding m itochondria l proteins
0.78 1591 - 1607 (-) 0.750 0.788 aggGTGCccgcgctgct
1
VSCDEF/CDE.01
Cell cycle-dependent elem ent, CDF-1 
binding site (CDE/CHR tandem  elements 
regulate cell cycle dependent repression)
0.87 1592 - 1604 ( + ) 1.000 0.876 gcagCGCGggcac
V$HICF/HIC1.01
Hyperm ethylated in cancer 1, 
transcrip tional repressor containing five 
Kruppel-like C2H2 zinc fingers, fo r optim al 
binding m ultip le  binding sites are required.
0.93 1596 - 1608 (-) 1.000 0.992 gagggTGCCcgcg
1 V$HESF/HES1.01 Drosophila hairy and enhancer o f sp lit 0.92 1597 - (-) 1.000 0.962 caggaggGTGCccgc
405
A p p e n d ic e s
i l  Ih o m o lo g u e  1 (H E S -1 ) 1 6 1 1
1  fI  V $ C H R E /C H R E B P  M L X .0 1
:
C a rb o h y d ra te  re s p o n s e  e le m e n t  b in d in g  
p ro te in  (C H R E B P ) a n d  M a x - l ik e  p ro te in  X 
[M ix )  b in d  as  h e te ro d im e rs  to  g lu c o s e -  
re s p o n s iv e  p ro m o te rs
0 .8 3
1 6 0 2  -  
1 6 1 8 ( - )
1 .0 0 0 0 .8 5 5 C A C G ttg c a g g a g g g tg
V S B T B F /K A IS O .O l T ra n s c r ip tio n  fa c to r  K a is o , Z B T B 3 3 0 .9 2
1 6 0 5  -  
1 6 1 5 ( + ) 1 .0 0 0 0 .9 8 1 c c tc C T G C a a c
V $ Z B P F /Z N F 2 1 9 .0 1 K r u p p e l- lik e  z in c  f in g e r  p ro te in  2 1 9 0 .9 1
1 6 1 2  -  
1 6 3 4 (-) 1 .0 0 0 0 .9 2 0 c tg g g g a C C C C c a g c c c a c g ttg
I  V S N F K B /N F K A P P A B 5 0 .0 1 N F -k a p p a B  ( p 5 0 ) 0 .8 3
1 6 2 1  - 
1 6 3 3 ( + ) 0 .7 5 0 0 .8 7 6 c tg G G G G tc c c c a
I  V & N F K B /N F K A P P A B 5 0 .0 1 N F -k a p p a B  (p 5 0 ) 0 .8 3
1 6 2 2  -  
1 6 3 4 ( - )
1 .0 0 0 0 .9 3 4 ctg G G G A c c cc c a
1  V S N O L F /O L F l.O l O lfa c to ry  n e u ro n -s p e c if ic  fa c to r 0 .8 2
1 6 2 2  -  
1 6 4 4 ( +  ) 1 .0 0 0 0 .8 4 6 tg g g g g T C C C c a g g g c c g g g g a g
1  V $ E K L F /K K L F .0 1 K id n e y -e n r ic h e d  k ru p p e l- l ik e  fa c to r , K LF15 0 .9 1
1 6 3 3  -  
1 6 4 9 ( + )
1 .0 0 0 0 .9 4 7 a g g g c c G G G G a g g g g g c
V $ Z B P F /Z N F 2 1 9 .0 1 K ru p p e l- lik e  z in c  f in g e r  p ro te in  2 1 9 0 .9 1
1 6 3 3  - 
1 6 5 5 ( - )
1 .0 0 0 0 .9 2 5 cccg gg gC C C C ctccccg  gccct
I V $ E G R F /C K R O X .0 1 C o lla g e n  k ro x  p ro te in  (z in c  f in g e r  p ro te in  
6 7  - z fp 6 7 )
0 .8 8
1 6 3 6  -  
1 6 5 2 ( + )
1 .0 0 0 0 .9 2 0 g ccg G G G A g g g g g c c c c
I  V S S P 1 F /S P 1 .0 1
S tim u la tin g  p ro te in  1 , u b iq u ito u s  z inc  
f in g e r  tra n s c r ip t io n  fa c to r
0 .8 8
1 6 3 6  - 
1 6 5 0 ( +  )
0 .8 0 7 0 .9 1 1 g cc g G G G A g g g g g c c
I V $ E G R F /W T 1 .0 1 W ilm s  T u m o r  S u p p re s s o r 0 .9 2 1 6 3 8  - 
1 6 5 4 ( + ) 0 .8 3 7 0 .9 3 0 c g g g g A G G G g g ccccg g
|  V $ M A Z F /M A Z R .0 1 M Y C -a s s o c ia te d  z in c  f in g e r  p ro te in  re la te d  
t ra n s c r ip tio n  fa c to r
0 .8 8
1 6 3 8  - 
1 6 5 0 ( + ) 1 .0 0 0 0 .9 1 4 c g g g g a G G G G g c c
| v $ E T S F / S P I l  P U 1 .0 2
S p le e n  fo cu s  fo rm in g  v iru s  (S F F V ) p ro v ira l 
in te g ra tio n  o n c o g e n e  S p i l / t r a n s c r ip t io n  
fa c to r  P U . l
0 .9 6
1 6 5 0  - 
1 6 7 0 ( + ) 1 .0 0 0 0 .9 6 9 c c c g g g g a G G A A c tg a g a g g g
|  V $ M O K F /M O K 2 .0 1 R ib o n u c le o p ro te in  a s s o c ia te d  z in c  f in g e r  
p ro te in  M O K -2  (m o u s e )
0 .7 4
1 6 5 2  -  
1 6 7 2 (-) 0 .7 5 0 0 .7 5 2 c c c c c tc tc a g ttC C T  Ccccg
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V S P L A G /P L A G 1 .0 1
P le o m o rp h ic  a d e n o m a  g e n e  (PLAG) 1, a 
d e v e lo p m e n ta l^  re g u la te d  C2H2 z in c  
f in g e r p ro te in
0.88 1 6 5 6  -  
1 6 7 6 ( +  )
1 .0 0 0 0.908 G A G G a a c tg a g a g g g g g c g c g
|  V $ G A B F /G A G A .0 1 G A G A -B o x 0 .7 8
1 6 6 0  -  
1 6 8 4 ( +  ) 1 .0 0 0 0.780 a a c tg A G A G g g g g c g c g c c c c g g g a
' V 5 E G R F /W T 1 .0 1 W ilm s  T u m o r  S u p p re s s o r 0 .9 2
1 6 6 2  -  
1 6 7 8 ( + ) 0 .8 3 7 0.925 c tg a g A G G G g g c g c g c c
|  V S E K L F /K K L F .0 1 K id n e y -e n r ic h e d  k ru p p e l- l ik e  fa c to r ,  K L F15 0 .9 1
1 6 6 3  - 
1 6 7 9 ( +  ) 1 .0 0 0 0.912 tg a g a g G G G G c g c g c c c
■  |v$INSM/INSM1.01
Z in c  f in g e r  p ro te in  in s u lin o m a -a s s o c ia te d  1 
( IA - 1 )  fu n c tio n s  as  a t ra n s c r ip t io n a l  
re p re s s o r
0 .9 0
1 6 6 3  -  
1 6 7 5 ( + )
1 .0 0 0 0.936 tg a g a G G G G g c g c
|  V & E 2 F F /E 2 F .0 3
E 2F , in v o lv e d  in cell cy c le  re g u la t io n ,  
in te ra c ts  w ith  Rb p l0 7  p ro te in
0 .8 5
1 6 6 6  -  
1 6 8 2 (-) 1 .0 0 0 0.863 ccgg g G C G C g c c cc c tc
|  V $ E 2 F F /E 2 F .0 3
E 2F , in v o lv e d  in cell cy c le  re g u la t io n ,  
in te ra c ts  w ith  Rb p l0 7  p ro te in
0 .8 5
1 6 6 7  - 
1 6 8 3 ( +  )
1 .0 0 0 0.872 a g g g g G C G C g c c c c g g g
|  V 5 H E S F /H E S 1 .0 1
D ro s o p h ila  h a iry  and  e n h a n c e r  o f sp lit  
h o m o lo g u e  1 (H E S -1 )
0 .9 2
1 6 6 8  - 
1 6 8 2 ( - )
0 .9 4 4 0.943 ccgg gg cG C G C cccc
V 5 Z F 5 F /Z F 5 .0 1
Z in c  f in g e r  /  PO Z d o m a in  tra n s c r ip tio n  
fa c to r
0 .9 5
1 6 6 8  -  
1 6 7 8 ( +  )
1 .0 0 0 0.959 g g g g G C G C g cc
V & Z F 5 F /Z F 5 .0 1
Z in c  f in g e r  /  P O Z d o m a in  tra n s c r ip tio n  
fa c to r
0 .9 5
1 6 6 9  - 
1 6 7 9 (-) 1 .0 0 0 0.965 ggg cG C G C ccc
V $ H E A T /H S F 2 .0 1 H e a t  sh o ck  fa c to r  2 0.88 1 6 7 0  - 1 6 9 4 ( +  ) 1 .0 0 0 0.887 g g g cg c g c c c c g g G A A G g c tc g g g g
V $ Z F 5 F /Z F 5 .0 1
Z in c  f in g e r  /  PO Z d o m a in  tra n s c r ip tio n  
fa c to r
0 .9 5
1 6 7 0  - 
1 6 8 0 ( +  )
1 .0 0 0 0.965 g gg cG C G C ccc
V 5 Z B P F /Z F 9 .0 1
C o re  p ro m o te r-b in d in g  p ro te in  (C P B P ) w ith  
3 K ru e p p e l-ty p e  z in c  f in g e rs
0 .8 7
1 6 8 2  - 
1 7 0 4 ( - )
1 .0 0 0 0.934 cccgg ag C C G C c c c g a g c cttc c
|  V S S P 1 F /S P 1 .0 1
S tim u la tin g  p ro te in  1, u b iq u ito u s  z in c  
f in g e r  tra n s c r ip t io n  fa c to r
0.88 1 6 8 8  - 
1 7 0 2 ( +  )
1 .0 0 0 0.887 c tcg G G G C g g c tc c g
V $ P L A G /P L A G 1 .0 1
P le o m o rp h ic  a d e n o m a  g e n e  (P L A G ) 1, a 
d e v e lo p m e n ta lly  re g u la te d  C 2 H 2  z in c  
f in g e r  p ro te in
0.88 1 6 9 1  - 
1 7 1 1 ( + ) 0 .9 5 8 0.896 G G G G cg g c tc c g g g g g g c tc c
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|  V S N R S F /N R S E .O l N e u r a l- r e s tr ic t iv e -s i le n c e r -e le m e n t 0 .6 7
1 6 9 2  -  
1 7 1 2 (-) 1 .0 0 0 0.728 g gg ag c c c cc C G G A g c cg c c c
I I V $ G L IF /Z IC 2 .0 1
Z in c  f in g e r  tra n s c r ip t io n  fa c to r , Z ic  fa m ily  
m e m b e r  2 (o d d -p a ir e d  h o m o lo g ,  
D ro s o p h ila )
0 .8 9
1 6 9 8  -  
1 7 1 2 (-) 1 .0 0 0 0.899 g g g a g c c C C C C g g a g
|  V 4 N F K B /N F K A P P A B .0 1 N F -k a p p a B 0 .8 9
1 7 0 2  -  
1 7 1 4 (-) 1 .0 0 0 0.908 c tG G G A g cccccc
I V $ Z B P F /Z N F 2 1 9 .0 1 K ru p p e l- lik e  z in c  f in g e r  p ro te in  2 1 9 0 .9 1 1 7 1 2  -  
1 7 3 4 ( +  ) 1 .0 0 0 0.996 c a g g g c g C C C C c g c c c c ttc c c c
| V S E G R F /W T l .O l W ilm s  T u m o r  S u p p re s s o r 0 .9 2
1 7 1 3  -  
1 7 2 9 (-) 0 .9 5 3 0.980 a g g g g C G G G g g c g c c c t
V i N R F l / N R F l . 0 1
N u c le a r  re s p ira to ry  fa c to r  1 (N R F 1 ) ,  b Z IP  
t ra n s c r ip t io n  fa c to r  th a t  a c ts  on n u c le a r  
g e n e s  e n c o d in g  m ito c h o n d r ia l p ro te in s
0 .7 8
1 7 1 3  -  
1 7 2 9 ( +  ) 1 .0 0 0 0.797 agg G C G C c c cc g c c cc t
V 5 Z F 5 F /Z F 5 .0 1
Z in c  f in g e r  /  PO Z d o m a in  tra n s c r ip t io n  
fa c to r
0 .9 5
1 7 1 3  -  
1 7 2 3 ( - )
1.000 0.956 g g g g G C G C c c t
V 4 P L A G /P L A G 1 .0 1
P le o m o rp h ic  a d e n o m a  g e n e  (P L A G ) 1, a 
d e v e lo p m e n ta lly  re g u la te d  C 2 H 2  z in c  
f in g e r  p ro te in
0.88 1 7 1 5  -  
1 7 3 5 ( - )
0 .9 5 8 0.894 G G G G g a a g g g g c g g g g g c g c c
» V $ Z B P F /Z F 9 .0 1 C o re  p ro m o te r-b in d in g  p ro te in  (C P B P ) w ith  
3 K ru e p p e l-ty p e  z in c  f in g e rs
0 .8 7
1 7 1 5  - 
1 7 3 7 ( +  )
1.000 0.940 g g cgcccC C G C cccttcccccg c
I  V $ M A Z F /M A Z R .0 1
M Y C -a s s o c ia te d  z in c  f in g e r  p ro te in  re la te d  
t ra n s c r ip tio n  fa c to r
0.88 1 7 1 7  - 
1 7 2 9 (-) 1.000 0.902 a g g g g c G G G G g c g
|  V S S P 1 F /S P 1 .0 1
S t im u la tin g  p ro te in  1, u b iq u ito u s  z in c  
f in g e r  tra n s c r ip t io n  fa c to r
0.88 1 7 1 7  -  
1 7 3 1 ( - )
1.000 0.986 g a a g G G G C g g g g g c g
I  V $ E K L F /K K L F .0 1 K id n e y -e n r ic h e d  k ru p p e l- l ik e  fa c to r , K LF15 0 .9 1
1 7 1 8  - 
1 7 3 4 (-) 1 .0 0 0 0.945 g g g g a a G G G G c g g g g g c
I V $ E G R F /E G R 1 .0 2  
■
E G R 1, e a r ly  g ro w th  re s p o n s e  1 0.86 1 7 1 9  - 
1 7 3 5 ( - )
1 .0 0 0 0.911 g g g g g a a g G G G C g g g g g
|  V $ E T S F /S P I1  P U 1 .0 2
S p le e n  focu s  fo rm in g  v iru s  (S F F V ) p ro v ira l 
in te g ra tio n  o n c o g e n e  S p il / t r a n s c r ip t io n  
fa c to r  P U . l
0 .9 6
1 7 2 0  -  
1 7 4 0 ( - )
1 .0 0 0 0.960 g ccg cg g g G G A A g g g g c g g g g
■  V S S T A F /Z N F 7 6  1 4 3 .0 1 Z N F 1 4 3  is th e  h u m a n  o rth o lo g  o f X e n o p u s 0 .7 6 1 7 2 7  - ( +  ) 0 .8 0 9 0.817 ccttC C C C cg cgg ccccg gg gcg
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-
1  1
5 ta f ,  Z N F 7 6  is a D N A  b in d in g  p ro te in  
re la te d  to  Z N F 1 4 3  an d  S ta f
1 7 4 9
1
|  V t N R F l / N R F l . 0 1  1
N u c le a r  re s p ira to ry  fa c to r  1 (N R F 1 ) ,  b Z IP  
tra n s c r ip tio n  fa c to r  th a t  a c ts  on  n u c le a r  
g en e s  e n c o d in g  m ito c h o n d r ia l p ro te in s
0 .7 8
1 7 4 3  -  
1 7 5 9 ( - )
0 .7 5 0 0.847 a c c G C G G g g g c g c c c c g
? V S E G R F /E G R 1 .0 2 E G R 1 , e a r ly  g ro w th  re s p o n s e  1 0 .8 6
1 7 4 4  -  
1 7 6 0 ( - )
1 .0 0 0 0 .9 1 0 c a c c g c g g G G G C g c c c c
V S N R F 1 /N R F 1 .0 1
N u c le a r  re s p ira to ry  fa c to r  1 (N R F 1 ) ,  b Z IP  
t ra n s c r ip t io n  fa c to r  th a t  a c ts  on  n u c le a r  
g e n e s  e n c o d in g  m ito c h o n d r ia l p ro te in s
0 .7 8
1 7 4 4  -  
1 7 6 0 (+ ) 1 .0 0 0 0,733 g g g G C G C cc c c g cg g tg
V S Z F 5 F /Z F 5 .0 1
Z in c  f in g e r  /  P O Z d o m a in  t ra n s c r ip t io n  
fa c to r
0 .9 5
1 7 4 4  -  
1 7 5 4 (-) 1 .0 0 0 0 .9 5 6 g g g g G C G C c c c
|  V $ N R S F /N R S E .0 1  N e u r a l- r e s tr ic t iv e -s i le n c e r -e le m e n t 0 .6 7
1 7 4 5  -  
1 7 6 5 (-) 0 .7 8 2 0 .6 8 7 tcc g g c a c c g C G G G g g c g cc c
V S Z B P F /Z F 9 .0 1
C o re  p ro m o te r -b in d in g  p ro te in  (C P B P ) w ith  
3 K r u e p p e l- ty p e  z in c  f in g e rs
0 .8 7
1 7 6 0  - 
1 7 8 2 (-) 1 .0 0 0 0 .8 9 4 g cacg cc C C G C cc c g a c tc c g g c
|  V S E G R F /E G R 1 .0 2 E G R 1 , e a r ly  g ro w th  re s p o n s e  1 0 .8 6
1 7 6 2  - 
1 7 7 8 ( + ) 1 .0 0 0 0 .8 8 1 c g g a g tc g G G G C g g g g c
|  V $ E K L F /K K L F .0 1 K id n e y -e n r ic h e d  k ru p p e l- l ik e  fa c to r , K L F15 0 .9 1
1 7 6 3  -  
1 7 7 9 ( +  )
1 .0 0 0 0 .9 4 0 g g a g tc G G G G c g g g g c g
|  V $ S P 1 F /S P 1 .0 1
S tim u la tin g  p ro te in  1 , u b iq u ito u s  z in c  
f in g e r  t ra n s c r ip t io n  fa c to r
0 .8 8
1 7 6 6  -  
1 7 8 0 ( +  )
1 .0 0 0
■ ■ ■
1 .0 0 0 g tc g G G G C g g g g c g t
V S A H R R /A H R A R N T .O l
A ry l h y d ro c a rb o n  re c e p to r  /  A rn t  
h e te ro d im e rs
0 .9 2
1 7 6 7  - 
1 7 9 1 ( +  )
1 .0 0 0 0 .9 3 4 tc g g g g c g g g g C G T G c a c g tc a g c c
i V S E G R F /E G R 1 .0 2 E G R 1 , e a r ly  g ro w th  re s p o n s e  1 0 .8 6
1 7 6 7  -  
1 7 8 3 ( + ) 1 .0 0 0 0 .8 7 0 tc g g g g c g G G G C g tg c a
|  V $ E K L F /K K L F .0 1 K id n e y -e n r ic h e d  k ru p p e l- l ik e  fa c to r , K LF15 0 .9 1
1 7 6 8  - 
1 7 8 4 ( +  ) 1 .0 0 0 0 .9 7 2 c g g g g c G G G G c g tg c a c
|  V S M A Z F /M A Z .O l M yc a s s o c ia te d  z in c  f in g e r  p ro te in  (M A Z ) 0 .9 0
1 7 6 8  - 
1 7 8 0 ( +  ) 0 .8 6 6 0 .9 1 0 c g g g G C G G g g c g t
|  V $ S P 1 F /T IE G .0 1
T G F b e ta -in d u c ib le  e a r ly  g e n e  (T IE G )  /
E a r ly  g ro w th  re s p o n s e  g e n e  a lp h a  0 .8 3  
(E G R a lp h a )
1 7 7 1  -  
1 7 8 5 ( +  )
1.000 0 .8 5 9 g g c G G G G c g tg c a c g
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|  V $ H E S F /H E S 1 .0 1
D ro s o p h ila  h a iry  a n d  e n h a n c e r  o f  s p lit  
h o m o lo g u e  1 (H E S -1 )
0.92 1772 - 1786 ( +  ) 1 .0 0 0 0.920 g c g g g g c G T G C a c g t
|  V S C R E B /A T F 6 .0 2
A c tiv a t in g  tra n s c r ip t io n  fa c to r  6 , m e m b e r  
o f b -z ip  fa m ily ,  in d u c e d  by ER s tre s s
0.85 1774 - 1794 ( - ) 1 .0 0 0 0.990 c c c g g c tG A C G tg c a c g c c c c
|  V $ C R E B /C R E B .0 2 c A M P -re s p o n s iv e  e le m e n t  b in d in g  p ro te in 0.89 1777 - 1797 ( - ) 1 .0 0 0 0.975 a g c c c c g g c T G A C g tg c a c g c
|  V S H IF F /H IF 1 .0 2
H y p o x ia  in d u c ib le  fa c to r , b H LH  /  PAS  
p ro te in  fa m ily
0.93 1780 - 1792 ( - ) 1 .0 0 0 0.976 c g g c tg a C G T G c a
|  V & B A R B /B A R B IE .0 1 B a rb itu ra te - in d u c ib le  e le m e n t 0 .8 8
1797 - 
1811 ( +  ) 1 .0 0 0 0.887 ta g a A A A G g c g g c g g
|  V $ S P 1 F /G C .0 1 G C  b ox  e le m e n ts 0 .8 8
1802 - 
1816 ( +  ) 1.000 0.907 a a g g c G G C G g g g c tg
|  V S S P 1 F /S P 1 .0 1
S t im u la tin g  p ro te in  1, u b iq u ito u s  z in c  
f in g e r  tra n s c r ip t io n  fa c to r
0 .8 8
1807 - 
1821 ( + ) 1.000 0.898 g g c g G G G C tg g g c c c
3 0 7  m a tc h e s  fo u n d  in th is  s e q u e n c e .
 V *
Problems displaying the Java graphics? See our Technical FAQ
A total of 307 matches w ere found in 1 sequences!
Sequences searched: 1 (1 8 3 0  bp).
For c o m m e n ts , q u e s tio n s , o r  bug re p o rts , p le a s e  c o n ta c t s u p p o r t@ Q e n o m a tix .d e .
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TFSEARCH S earch  R esu lt
** TFSEARCH ver.1.3 ** (c)1995 Yutaka Akiyama (Kyoto Univ.)
This simple routine searches highly correlated sequence fragments 
versus TFMATRIX transcription factor binding site profile database 
by E.Wingender, R.Knueppel, P.Dietze, H.Karas (GBF-Braunschweig).
<Warning> Scoring scheme is so straightforward in this version.
score = 100.0 * ('weighted sum' - min) / (max - min)
The score does not properly reflect statistical significance!
Database: TRANSFAC MATRIX TABLE, Rel.3.3 06-01-1998
Query: delta promoter (1830 bases)
Taxonomy: ALL
Threshold: 85.0 point
TFMATRIX entries with High-scoring:
AATATGTTTG TTCTTTAGGA AACCTATTAA ATATCCCATA entry score
-> M00028 HSF 100.0
<----- M00029 HSF 100.0
--> M0 002 9 HSF 96.0
<----- M00101 CdxA 92.9
<------ M0014 3 SRY 90.9
--> M0014 8 SRY 90.0
------------ > M00131 HNF-3b 89.6
------------ > M00130 HFH-2 88.9
<----- M0002S HSF 88.5
<-■--------- MQ007 6 GATA-2 88.1
-----> M 0014 2 NIT2 87.5
-----> M 0 0 0 2  9 HSF 86.9
<------- M 0 0 1 4  8 SRY 86.4
-----> MOO0 2 8 HSF 85.9
------> MOO1 0 0 CdxA 85.9
M 0 0 1 3 1 HNF-3b 85.5
------------ > M 0 0 0 8 7 Ik-2 85.5
------> M 0 0 1 0 1 CdxA 85.0
4 1 1
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51  GTGCAACGTT AGAAATGACC TCTGGAACTG ACTGCAGAAA CTGCACAGCA e n t r y  s c o r e
 > M00028 HSF 100.0
 > M00028 HSF 100.0
 > MOO029 HSF 96.0
 > M00Q29 HSF 96.0
 <-------  MOO 101 CdxA 94.3
<--------  M002 5 3 cap 93.9
<------- M002 5? cap 91.0
 > M~0002° HSF 90.9
<--------  M00253 cap 89.0
-------  M00115 AP-4 87.5
< M0018 3 c-Myb 86.6
 <------- M00100 CdxA 85.9
<---------------- MOO 197 ABF1 85.4
<---------  M 00111 CF1 / 85.3
101 GTTAGTAGAG CTTGGTGTTC CGACGCAGAT CTGGTGAGAG GCCTGCGCAG entry score
<----- M00029 HSF 90.9
--> M001~5 AP-4 87.5
------ MOO IS 3 c-Myb 86.6
151 GAAGAGACTC GACATGGAGC AGGTGTGACT AGCGATAGTG ATTTAATGGA entry score
-------- > M0007 7 GATA-3 92.8
------ > MOOlOl CdxA 92.1
<--------  MG02 53 cap 91.6
<----- M00142 NIT2 91.2
--------- > M0007 5 GATA-1 90.6
---------------- M00018 Ubx 90.6
----------------> MOO002 E47 90.4
<------- M00253 cap 90.4
--------- > M0007 6 GATA-2 90.1
 > M00048 ADR1 89.2
<----------  M00184 MyoD 88.3
<-------- M00217 USF 85.5
201 TTTGGGCCCG ACATGGTGGC TCACGCCTGT AATCCCAGCA CTTTGGGAGG entry score
-------- > m 00141 Lyf-1 100.0
<  M00253 cap 96.2
 <--------  M00140 Bed 93.7
 > M00018 Ubx 90.6
<----------------- M00019 Dfd 89.4
 <  M000S7 Ik-2 87.3
4 1 2
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 > MOO0 48 ADR1 8 6 . 2
251 CTGAGGCCGG CGAATCTCTT AAGCCCAGGA GTTTGAAACC AGCCTGGACA entry score
  cap 96.2
------> y ADR1 89.2
<  d < cap 86.2
 > ' c HSF 85.4
301 ATATTGTGAG ATCCCATCTC AATTTTTTTT TTGAGATGGA GTCTCGCTCT entry score
------> '* * ADR1 93.8
<----------  Hb 92.0
<   Hb 91>1
<----------  v- Hb 88.4
------------ > - HFH-2 87.8
---------------- > c a p 87 .4
--------- > y, ' GATA-3 87.2
 <  , • GATA-3 86.2
 <----------  '3/ "i GATA-1 8 6.1
---------- > “Milol GATA-1 86.1
------------- > M0,1,: HFH-2 85.1
351 GTCGCCCAGG CTGGAGTGCA ATGGAACGAT CTCGGCTCAC TGCAACCTCC entry score
 > MOO048 ADR1 93.8
 > MO0029 HSF 90.9
<---- M00048 ADR1 90.8
---------- > M00141 HSF2 90.4
<----------  MOO075 GATA-1 89.4
4 01 GCCTCCCGGG TTCAAGCGAT TCTCCTGCCT CAGCCTCCCG AGTAGCTGGG entry score
-------- > M00253 cap 96.2
 <----- M00029 HSF 95.4
 <------------  M 0 0 0 2 8  HSF 94.3
  MQ0140 Bed 93.7
M0004 8 ADR1 90.8
------ M 0 0 0 1 9  Dfd 89.4
------- MO0O87 Ik-2 89.0
< ------------  M~00029  HSF 86.3
< ------------  M 0 0 0 4 8  ADR1 86.2
<----- M0004 5 ADR1 86.2
451 ATTACAGGCG CACGCCACTA CGCTTGGCTA ATTTTTGTAT TTTTAGTAGA entry score
  M 0 0 0 2 8  HSF 100.0
4 1 3
------  M 0 0 0 2 9 H SF 9 6 .  0
< ------ MOO 10 1 C dxA 94  . 3----- > M 0 0 1 40 B ed 9 3 . 7
--> M 0 0 0 1  9 D fd 89.4
----> ) r  - - Ik-2 89.0
---------> MC; 1 0 O' C dxA 87.2
<-- C dxA 85.9
< ------ ....... ...... C dxA 85.7
AATGGGGTTT CACCATGTTG ACCAGGCTGG TTTCAAACTC CTGACCTCAA entry score
-> HSF 100.0
-----> • ADR1 100.0
---- M! . : . Nkx-2. 100.0
-> ' HSF 96.0
-- ’ CdxA 94.3
<------ V  : . ' ] - ADR1 89.2
<----- ' AML-I a 88.7
<---- M;; L 2  2  2 SREBP- 88.7
< --------- CF1 / 88.2
------- > CRE-BP 87.5
-----> AML-la 87.4
-------> CREB 86.6
< ------- 'J v/ -t i CRE-BP 86.2
-------> M - cap 86.2
---- ' * CdxA 85.9
< ---------- i'31 ' j C ' '  ’ CREB 85. 6
<-------- m  r cap 85.3
GTGATCCGCC CACCTCAGCC TCCCAAAATG CTGGGATTAC CGGCATGAGC entry score
- - > iv] 1j  0 i  4 ;} Nkx-2. 100.0
< ------------- M 0 0 1 4 1 Lyf-1 100.0
------------> M 0 0 2 5 3 cap 96.2
------ > M 0 0 0 1 9 Dfd 93.9
---------- > M 0 0 1 4  0 Bed 93.7
< ----- MO0 2 7 1 AML-la 88.7
M 0 0 2 2  0 SREBP- 88.7
- > M 0 0 0 8 8 Ik-3 88.1
------------ > o o o CO Ik-2 87.3
----------- > MOO0 7 3 deltaE 87.0
< ------ 130004  8 ADRl 86.2
-> M 0 0 0 5 3 c-Rel 86.0
---- M 0 0 2 5 3 cap 85.3
4 1 4
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6 0 1  CACTGTGCTC GGCTGAAAAA A A C C ATA TTT TT A A TTTA A A  ATAATAAATG e n t r y  s c o r e
------- > M00101 CdxA 98.6
< M 0 0 2 5 3 cap 93.1
 <------ MOQiOi CdxA 90.0
 <------ MOO 100 CdxA 89.7
<--------  M002 -^3 cap 89.4
------ > 1_ “■ CdxA 88.5
------ > CdxA 86.4
------------> MG dl 86.0
---------- > » Hb 85.7
------------------- > „ y YI 85.7
<------- y . cdxA 85.7
< . Dfd 85.4
<------ ’I / /  CdxA 85.0
651 GGTCTGACCA GAAATGCCTG CCTCAAATTG CAGGACACAT GACAAAGCCC entry score
 > MGCto8 HSF 100.0
 > _• HSF 96.0
 <------- M CdxA 93.6
M002 5 5 cap 93.1
 <------- MOOIOQ CdxA 89.7
-- MOO253 cap 88.4
 > MOO 122 USF 88.0
<--------------  MOO 122 USF 88.0
<--------  M00009 Ttk 69 86.7
---------- > M00187 USF 85.5
M 0 0 0 1 9  Dfd 85.4
ATTCTTACTT AAGACATTTT CAGTGTGCGA TGGGTCTACC GGGATGTAAC entry score
<- M 0 0 0  4 8 ADRl 100.0
< M 0 0 0 7 5 GATA-1 95.5
<----- M 0 0 0 2 9 HSF 95.4
<--- M 0 0 0 2 8 HSF 94.3
---------- > M 0 0 0 7 5 GATA-1 91.0
------------> M 0 0 2 5 3 cap 89.2
< M 0 0 0 7  6 GATA-2 88.5
-----> M 0 0 2 5 3 cap 88.4
--------> M 0 0 0 4 0 CRE-BP 87.9
<- M 0 0 2 7 1 AML-la 87.4
c-------- M 0 0 0 4 0 CRE-BP 86.7---------------> M 0 0 0 7  6 GATA-2 86.6
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801 CTTACCTGTT TCCCAAAAAG GACCCAACTA CTTTAGGTTC AAGGCACTTT entry 
c-------------
 >
901 CAAGATGCCG CCACACGATG GCACTGCTTC CGTAGACCTG GAAGAAACGC entry
 >
 >
M 0 0 2 4 0 N k x - 2 . 8 6 . 0
M 0 0 0 7 7 G A T A -3 8 5 .  6
entry score
MO0 0 4 8 ADR1 100.
MO0 0 7  5 GATA-1 95.5
MOO0 7 5 GATA-1 92.2
M 0 0 0 7 6 GATA-2 88.5
MO 0 0  7 0 GATA-2 88.5
M 0 0 2 2 6 P 87.8
M 0 0 2 ~ i AML-la 87.4
M 0 0 0 7 7 GATA-3 85.6
score
M 0 0 1 4 1 Lyf-1 93.5
M 0 0 0 5 ~ Ik-2 89.9
M 0 0 2 2  3 STATx 88.5
MO0 0 2  9 HSF 86.9
M 0 0 0 2  9 HSF 86.3
M 0 0 2 5 3 cap 86.2
MO0 0 2 8 HSF 85.9
MOO I OO CdxA 85.9
MOO 1 5 9 C/EBP 85.4
entry score
MO0 0 2 9 HSF 90.9
M 0 0 0 2 9 HSF 86.9
M 0 0 0 2 9 HSF 86.3
M 0 0 2 5 3 cap 86.2
M 0 0 0 2 8 HSF 85.9
M 0 0 1 5 9 C/EBP 85.4
score
M 0 0 0 2 8 HSF 100.1
M 0 0 0 2 9 HSF 96.0
M 0 0 2  6 3 StuAp 90.8
M 0 0 0 7  5 GATA-1 89.0
M 0 0 0 7 5 GATA-1 88.2
M 0 0 0 7  6 GATA-2 87.0
M 0 0 0 7 6 GATA-2 85.8
M 0 Q 2 5 3 cap 85.2
416
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9 5 1  GGGCGCGGGA GCTGGCGGCG GACGCCCGGG TCTGCGGGGT CGGGGAGTAG e n t r y  s c o r e
------------ >  M 0 0 0 4 8  A D R 1  9 8 . 5
 > MOO0 4 Ji  A D R 1  9 2 . 3
 > MO0 2 6 3  S t u A p  9 0 . 8
 > M 0 0 Q4  8 A D R 1  8 7 . 7
< --------------------  M 0 0 2  5 3 cap 86.8
-------- > MQQOftl MZF1 86.1
<- M00032 c-Ets- 85.3
1001 CGTCCGGCCG GAGAGCCCGC ACCTCGAGGA GCCGGCGGAG GACGCGGTGT entry score
<----------  M002 63 StuAp 93.8
----------------> M ADR1 90.8
------ > M ADR1 86.2
--------  M c-Ets- 85.3
1051 CGTGACCGCG TCTCCCCCAT CTGCTCTGCT TTTGGCGACA GCGTCCCGTC entry score
<----- MOO 0 4 8 ADR1 98.5
 <----------  M'j'V-  GATA-1 95.5
 <----------  y j j  GATA-2 90.9
 <--------  CF1 / 90.8
---------- > StuAp 90.8
 <------- IIuCQH -i MZF1 89.6
 <---------  M0007 7 GATA-3 89.1
 <--------  M00112 CF1 / 87.9
 <----- M0004 6 ADRl 87.7
------- > M00050 E2F 87.4
---------- > M00154 MyoD 86.2
1101 GGCCTTTCGG CCAGGACGCA GCAGCCGCGT CTCTGGGCCT CGACCCCCAG entry score
<----- M00048 ADRl 98.5
< ------------  MOO04  3 ADRl 93.8
< ---------  M 0 0 0 2 8  HSF 91.1
------- > M 0 Q 2 5  3 cap 87.4
1151 GGCCGGCCGG ACCCGGGACC TCCGAGGAGA GCAGCGAGAA CCGGCCCGGA entry score
 >  M 0 0 0 2 9  HSF 100.0
< ------------------------------------------------------ M 0 0 0 4 8  ADRl 90.8
 >  M 0 0 0 2 8  HSF 88.5
<- MOO009 Ttk 69 86.7
< M00029 HSF 86.3
1201 TTCCCCGAGG CGCCCGAGTG CGGTGCGGGC AGCCCTCCCC GCCTGCCAGG entry score
4 1 7
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<----- M00083 MZF1 93.0
<----- M00048 ADRl 92.3
<------- M00048 ADRl 92.3
---- > M00271 AML-la 92.0
--------> M00253 cap 89.0
----- M00029 HSF 86.3
<------- M00048 ADRl 86.2
-> M00189 AP-2 85.0
CCGCCGCTGT CCCCACGTCT GGTCCCCCAC GCCTCTTCCC GCATCTGGTC entry score
<----- M00048 ADRl 98.5
<- M00083 MZF1 95.7
<- M00048 ADRl 93.8
<-- M00075 GATA-1 92.2
<---------- M00083 MZF1 87.8
<------- M00048 ADRl 87.7
----------> M00270 GCM 86.5
<-- M00076 GATA-2 86.2
CCACGGTGGA GGCGCGGGGC GAGGGCCTCA CGCGCGTGCC CACGGTCGGG entry score
----- M00048 ADRl 96.9
-------> M00048 ADRl 93.8
--> M00048 ADRl 92.3
---- M0004S ADRl 92.3
— M00048 ADRl 89.2
<-- M00067 Hairy 88.2
<-------- M00189 AP-2 87.0
GGGCGTCCTT GGACGCGCGG GTCCTCTCCC ACGGGTCTCC ACCCCCCGCC entry score
-> M00048 ADRl 96.9
<------- M00048 ADRl 96.9
----- M00189 AP-2 94.0
<------- M00048 ADRl 93.8
--> M00048 ADRl 92.3
<------- M00048 ADRl 92.3
< M00048 ADRl 90.8
<------------ MOO196 Spl 89.8
-- > M00048 ADRl 89.2
<---- M00048 ADRl 87.7
M00189 AP-2 87.0
c------- M00008 Spl 86.3
----------> M00187 USF 85.5
418
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-------------> M00055 N-Myc 85.5
1401 CTCCGGCGAC AGGAGCCGGC CTGGGACGCG CGCGCTGCGG CCAAGTCCTG entry score
------- > M0018 9 AP-2 94.0
  M00048 ADRl 90.8
  MOO 196 Spl 89.8
<----------  M00263 StuAp 87.7
M00008 Spl 86.3
---------- > M00263 StuAp 86.2
1451 GTTTTGATTT CACTCCCAAC CCCGAGGAGC GAGGAGGTTC CAAGCCCACA entry score
<------ M00048 ADRl 98.5
-------- > M00253 cap 94.9
<------ M00148 SRY 90.9
<----- M0002 9 HSF 90.9
<----- MOO048 ADRl 87.7
 > M0004 5 ADRl 87.7
- M00074 c-Ets- 87.0 
--------- > M00226 P 86.9
1501 AACAGGAAGA AGAGAAGGCC CTGGAGTGCT GGCAGAGGGA GTGTCATTCC entry score
 > M00028 HSF 95.3
 > M00028 HSF 95.3
-------  M0Q253 cap 94.8
 > M00048 ADRl 93.8
 > M00029 HSF 93.7
 > M00029 HSF 93.7
---------- > M00032 c-Ets- 89.2
------> M00048 ADRl 87.7
---------------> M00033 p300 87.1
------------ > M00074 c-Ets- 87.0
<-------MO0088 Ik-3 86.8
<------------ M00253 cap 86.7
<-----M00029 HSF 86.3
 > M00229 Skn-1 85.2
1551 CAGCAGCGCA GCGCAGGCCG GCCCGGGCCG GGGAGGGAGC AGCAGCGCGG entry score
>  M 0 Q 2 5 3  cap 94.8
------ > M00048 ADRl 92.3
  MQ0088 Ik-3 86.8
 > M00048 ADRl 86.2
-------- > M000S3 MZF1 85.2
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1601 GCACCCTCCT GCAACGTGGG CTGGGGGTCC CCAGGGCCGG GGAGGGGGCC entry score
 > M00048 ADRl 98.5
 > M0Q048 ADRl 93.8
 <  M00048 ADRl 93.8
 > MO0048 ADRl 93.8
<-- MO0048 ADRl 93.8
-------- > M0004 8 ADRl 92.3
 > M0004S ADRl 89.2
<  M00051 NF-kap 88.9
<-------------  M0018 2 GBP 88.4
---------- > m o o 051 NF-kap 88.3
 <-------- M0008 3 MZF1 87.8
<----- M00048 ADRl 87.7
------- > M0025? cap 86.7
------ > M000 4 8 ADRl 86.2
------- > MOO 154 STRE 85.8
------------- > M00064 PH04 85.5
----------------------->  M 00111 CF1 / 85.4
-------- > M0008 3 MZF1 85.2
<  MQ0189 AP-2 85.0
1651 CCGGGGAGGA ACTGAGAGGG GGCGCGCCCC GGGAAGGCTC GGGGCGGCTC entry score
<-------- M00253 cap 93.9
  M00048 ADRl 93.8
 > M00048 ADRl 93.8
<------ M00048 ADRl 93.8
------ > M00048 ADRl 93.8
 > M0004 8 ADRl 92.3
<-~ M00189 AP-2 91.0
 > M00029 HSF 90.9
------ > M00048 ADRl 89.2
 > M0014 7 HSF2 89.1
 > MOO154 STRE 87.7
<--  M000 4 8 ADRl 87.7
 > MO0048 ADRl 86.2
-------- MQ0189 AP-2 85.0
1701 CGGGGGGCTC CCAGGGCGCC CCCGCCCCTT CCCCCGCGGC CCCGGGGCGC entry score
 > M00048 ADRl 96.9
<------ M00048 ADRl 96.9
<----- MOO048 ADRl 96.9
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< M0004 8 ADRl 96.9
<------ MO004 9 ADRl 93.8
 > M0004 8 ADRl 93.8
<--------------  MO0255 GC box 92.5
 <-------------  MOO 196 Spl 92.4
> MO004 8 ADRl 92.3
<----------  MO0008 Spl 91.8
  M0018 9 AP-2 91.0
 <----- M000 4 8 ADRl 90.8
-> M0004J ADR1 89 -2
 <------ M00048 ADRl 89.2
<- M00048 ADRl 89.2
------------ > MOO 199 AP-2 89.0
 <--------  M00154 STRE 88.7
M0Q04 8 ADRl 87.7
 <------ MOO048 ADRl 87.7
<------------  MOO 189 AP-2 87.0
 <--------  M 0 0 0 8 3 MZF1 87.0
1751 CCCCGCGGTG CCGGAGTCGG GGCGGGGCGT GCACGTCAGC CGGGGCTAGA entry score
  MOOO^S HSF 100.0
  M0004 8 ADRl 96.9
  M00029 HSF 96.0
 > M00008 Spl 94.5
------ > MQ0048 ADRl 93.8
 > M00048 ADRl 93.8
 > M00048 ADRl 93.8
------------- > MOO 196 Spl 93.5
---------------> M00255 GC box 92.6
 > M0004 8 ADRl 92.3
<------------  MOO 113 CREB 91.8
 > MO0253 cap 90.0
  M00048 ADRl 89.2
< M 0 0101 CdxA 87.1
  M00252 TATA 86.1
---------- > MOO 17 5 AP-4 85.4
------ M0b216 TATA 85.4
1801 AAAGGCGGCG GGGCTGGGCC CAGCGAGGTG entry score
-> MOO028 HSF 100.0
-> M00029 HSF 96.0
------> M0004 8 ADRl 93.8
A p p e n d ic e s
Total 326 high-scoring sites found.
Max score: 100.0 point, Min score: 85.0 point
E TRANSFAC database document (Notice to users) 
yT F M A T R IX : binding site distribution matrix 
^ Parallel Application Tsukuba Laboratory Home Page
PAPIA system Top Page
M0Q255 GC box 91.3
M00008 Spl 89.0
MOO 196 Spl 8 8 . 6
M00008 Spl 87.7
M00101 CdxA 87.1
M00253 cap 8 6 . 6
M00252 TATA 86.1
M00196 Spl 85.4
M00216 TATA 85.4
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